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During bone marrow transplantation a conditioning regimen ablates endogenous
haematopoiesis. This is reconstituted by intravenous infusion of haematopoietic
progenitors (HPC) which home to and engraft the bone marrow, and are responsible
for long-term support of the haematopoietic and lymphoid systems. HPC are present
at low levels in the peripheral blood of normal individuals, but markedly raised
levels are found under a variety of circumstances which permit HPC harvest and
storage for future transplantation.
Elucidation of the mechanisms underlying the reciprocal phenomena ofHPC
homing and mobilisation is the objective of this thesis, and may allow the
development of novel approaches to mobilisation regimens and / or ex vivo HPC
manipulation.
Accurate and reproducible assays for quantitative and qualitative studies of HPC
were established. These included an immunocytometry based assay ofCD34 antigen
expression, dual colour immunocytometry studies of cell adhesion molecule, lineage
and activation marker expression by HPC derived from different sources, and three
colour immunocytometry of adhesion molecule expression within HPC subsets.
A 5Ichromium-labelling technique was developed as a functional assay with which
to examine the adhesion of haematopoietic cell lines to extracellular matrix
components, stromal and endothelial tissues in culture. A variety of techniques for
adhesion blockade were explored. A protocol for high-purity enrichment ofHPC
was developed, and the feasibility of applying the 5'chromium adhesion assay to
these cells was examined.
CD34 immunocytometry was confirmed as a valid method for defining HPC
populations. Marrow HPC were found to express nine adhesion molecules, two of
which were reduced by circulating cells. HPC derived from different sources
showed variation in lineage and activation marker expression, and HPC subsets
displayed differences in adhesion molecule expression. Haematopoietic cell lines
adhered to fibronectin and thrombospondin, but not to other extracellular matrix
components. Blockade of fibronectin adhesion was effected by divalent cation
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chelation, synthetic peptides and chondroitinase ABC. Cell line adhesion to stromal
and endothelial tissue cultures was demonstrated, but highly-enriched HPC labelled
poorly with 51chromium.
These studies have contributed to a better understanding of the pattern of cell
adhesion molecule expression by bone marrow and circulating HPC, and the
















CHAPTER 1. INTRODUCTION. p 21
1.1 Historical Background.
1.2 Haematopoietic Stem and Progenitor Cells.
1.3 Regulation of Haematopoiesis.
1.4 Haematopoietic Progenitor Transplantation.
1.5 Cell Adhesion and Position.
1.6 Haematopoietic Progenitor Cell Adhesion and Objectives of the Study.
CHAPTER 2. QUANTITATIVE DETERMINATION OF
2.1 Introduction.
2.2 General Methodology.
2.3 Standard methodology for the CFU-GM Assay.
2.4 Optimisation of CD34 Immunocytometry.
2.5 Determination of Resolution Limits of Immunocytometry.
2.6 Evaluation of Different Approaches to Data Analysis.
2.7 Study of the Overall Accuracy of CD34 Quantitation.
2.8 Establishment of a Correlation between CD34 and CFU-GM Assays.
2.9 Discussion.
HAEMATOPOIETIC PROGENITORS. p 63
6
CHAPTER 3. CHARACTERISATION OF HAEMATOPOIETIC
PROGENITOR PHENOTYPE. p 114
3.1 Introduction.
3.2 A Comparative Study of Haematopoietic Progenitor Cell Adhesion
Molecule Expression.
3.3 A Comparative Study of Haematopoietic Progenitor Expression of
Activation and Lineage Markers.
3.4 Characterisation of Cell Adhesion Molecule, Lineage and Activation
Marker Expression by Haematopoietic Cell Lines.
3.5 Development of Three-Colour Immunocytometry to Study Cell Adhesion
Molecule Expression within Haematopoietic Progenitor Subsets.
3.7 Discussion.
CHAPTER 4. DEVELOPMENT OF A 51CHROMIUM ADHESION ASSAY
TO STUDY FUNCTIONAL ADHESION OF HAEMATOPOIETIC CELL
LINES. p 176
4.1 Introduction.
4.2 Optimisation of "Chromium Radiolabelling.
4.3 Optimal Coating of the Carrier with Substrate.
4.4 Standardisation of the Adhesion Assay.
4.5 Discussion and Formulation of Results.
7
CHAPTER 5. APPLICATION OF THE 51CHROMIUM ADHESION ASSAY
TO THE STUDY OF HUMAN HAEMATOPOIETIC CELL LINE
ADHESION TO NON- CELLULAR SUBSTRATES. p 216
5.1 Introduction.
5.2 Study of the Adhesion of Human Haematopoietic Cell Lines to
Extracellular Matrix Components.
5.3 Effects ofActivating Agents on KGla adhesion to Extracellular Matrix
Components.
5.4 Studies of KGla Binding to Fibronectin.
5.5 Discussion.
CHAPTER 6. APPLICATION OF 51CHROMIUM ADHESION ASSAY TO
THE STUDY OF CELLULAR SUBSTRATES AND TO ENRICHED
POPULATIONS OF HAEMATOPOIETIC PROGENITORS. p 245
6.1 Introduction.
6.2 Preparation of in vitro Tissue Cultures.
6.3 Preparatory Experiments to Study the Adhesion of KGla to in vitro Tissue
Cultures.
6.4 Comparative Adhesion of Haematopoietic Cell Lines to M210-B4.
6.5 Blockade of KGla Adhesion to M210-B4.
6.6 Development of a Haematopoietic Progenitor Enrichment Protocol.




CHAPTER 7. GENERAL DISCUSSION. p 290
7.1 Definition and Analysis of the Haematopoietic Progenitor Population.
7.2 Phenotypic Studies on Haematopoietic Progenitors.
7.3 Functional Studies ofHaematopoietic Cell Line Adhesion.
7.4 Functional Assay of Haematopoietic Progenitor Adhesion.
7.5 The Limitations ofCurrent Adhesion Assays.




Appendix 1. Materials and Suppliers.
Appendix 2. Preparation of Solutions and Media.
Appendix 3. Additional Tables.






BSA bovine serum albumin
CAM cell adhesion molecule
CB umbilical cord blood
CD cluster designation
CD34%+ overall percentage CD34 positive cells
CD34%C CD34 positive cells as a percentage of CD45+ leucocytes
CD34" absolute number ofCD34 positive cells
CE cloning efficiency
CFU-GM colony forming unit - granulocyte-monocyte
51Cr chromium 51 (sodium chromate)
cv coefficient of variation
ECM extracellular matrix
EDTA ethylene diamine tetra-acetic acid
FACS fluorescence activated cell scanner
FACSort fluorescence activated cell sorter
FCS foetal calf serum
FITC fluorescein isothiocyanate
FL-1 fluorescence channel 1
FL-2 fluorescence channel 2
FL-3 fluorescence channel 3
FSC forward light scatter
GAM goat anti-mouse
HBSS Hanks' balanced salts solution
HPC haematopoietic progenitor cells
IMDM Iscove's modified Dulbecco's medium
LI labelling index
Lin lineage / activation marker
LP leucapheresis product
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LTBMC long-term bone marrow culture
mAb monoclonal antibody
mfi mean fluorescence intensity
MNC mononuclear cells
n number (of cells or experiments)
ns not significant
p pagination
p probability (Student's t test)
PB peripheral blood
PBm peripheral blood (mobilised)
PBS phosphate buffered saline
%fl+ percentage fluorescence positive
pFn plasma fibronectin
PMA phorbol myristate acetate
r correlation coefficient
RAM rat anti-mouse
RGDS arginine-glycine aspartic acid-serine
RGES arginine-glycine-glutamic acid-serine





SSC side light scatter
tFn tissue fibronectin
StandardSI units and abbreviations are used throughout.
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Our current conceptofa stem cellmodel ofhaematopoiesis dates to the seminal
observations ofPaul Ehrlich [Ehrlich, 1879; Lajtha, 1980]. Using newly developed
cytochemical stains he was able to distinguish several types ofcells within bone
marrow smears, including large basophilic cells, which he believed to be
developmental precursors ofgranulocytes. In 1898, Pappenheim developedmore
sensitive staining techniques which enabled him to distinguishmore closely related
cells, and to infer lineage relationships [Pappenheim, 1898]. He formulated the
hypothesis that rare populations ofimmature cells gave rise to large populations of
mature cells through sequential division and differentiation. He further suggested that
committedmyeloid and lymphoid progenitors were themselves derived from a
commonmultipotential progenitor.
Evidence to support this proposition did not come until the development ofmurine
bonemarrow transplantation experiments in the late 1950's [Ford, Hamerton, Barnes et
al. 1956], They demonstrated that transfused bonemarrow cells could rescuemice
whose haematopoietic and lymphoid systems had been ablated by irradiation. Using
thismodel, Till and McCulloch (1961) sacrificed irradiated, transplantedmice two
weeks aftermarrow infusion, and demonstrated the presence ofmacroscopic colonies
in the spleen, each ofwhich containedmany cells ofdifferent lineages. Furthermore,
cells from these splenic colonies, when pooled and injected into a second irradiated
mouse, were capable ofgenerating further splenic colonies, and rescued the mice from
bonemarrow failure. From these observations Till andMcCulloch drew three
conclusions: first, that each colony had arisen by repetitive division and differentiation
from a single cell (which they termed a spleen colony forming unit (CFU-S); second,
that at least some CFU-S gave rise to mature cells ofseveral different lineages; and
third, that the CFU-S pool was self-renewing and capable of long-term support of
haematopoiesis. Lajtha, Possi, Schofield etal [1969] used the pulsed incorporationof
toxic doses ofradioactiveDNA nucleotides to demonstrate that less than 5% ofCFU-S
were proliferating at any one time.
More recently, Lemischka, Rauletand Mulligan [1986] have used retroviral
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transfection ofmurine bonemarrow cellswith a genetic construct coding for
aminoglycoside resistance (which is randomly integrated into the genome), to
demonstrate that bothmyeloid and lymphoid cellsmay derive from the same precursor.
1.2 Haematopoietic Stem and Progenitor Cells.
1.2.1 Theoretical considerations.
The stem cellmodel ofhaematopoiesis is envisaged as ahierarchical scheme, in
which cellular proliferation and differentiation proceed through an arborescent series
ofevents, giving rise to at least 8 different cell lineages (Figure 1.1) [Spangrude, 1991],
Although the linear events ofthis process are recognised to form a continuum, different
stages are classified into functional compartments for convenience.
Stem cells are defined as undifferentiated cells capable ofself- renewal, multilineage
proliferation and differentiation, long- term regenerationoftissue, and flexibility in the
use ofthese options [Potten & Loeffler, 1990]. Haematopoietic stem cells are estimated
to comprise somewhere between 1/104andl/l 06 ofthe nucleated haematopoietic cells
in the bonemarrow, and the entire adult poolmay therefore comprise no more than 1 -
2x106 cells, 90-95% ofwhich are in quiescent phase at any one time [Lansdorp &
Dragowska, 1992]. Cycling haematopoietic stem cells generate a population of
committed haematopoietic progenitor cells with limited self-renewal capacity and
restricted lineage potential. Together, the haematopoietic stem and progenitor cells
(HPC) are termed the haematopoietic progenitor compartment, which comprises 1 -2%
ofnucleated bonemarrow cells. HPC undergo marked proliferation during the
generation ofprecursors and terminally-differentiated cells. The turnoverof
haematopoietic cells in a 70kgman is estimated to be in the order of200x109
erythrocytes, 10xl09neutrophilsand400xl09 platelets/day [Ogawa, 1993].
Many aspects ofthe stem cell model ofhaematopoiesis remainmoot. Two processes
may be used to explainmaintenance ofthe stem cell pool. First, stem cellsmay undergo
symmetric division, dividing to produce either two daughter stem cells or twomore
differentiated (precursor) cells. Alternatively, each stem cell divisionmay be
asymmetric, giving rise to a new stem cell and a single precursor [Holzer, Biehl, Antin
23





















Legend. The current model of haematopoiesis is based on experiments involving in
vivo transplantation and in vitro colony formation. Pluripotential haematopoietic
stem cells are thought to be capable of self-renewal and multilineage proliferation
and differentiation. At any one time the majority are quiescent, but proliferating
cells give rise to haematopoietic progenitors of progressively more restricted lineage
and proliferative potential. Morphologically identifiable precursor and terminally
differentiated cells comprise up to 99% of normal marrow and peripheral blood
cellularity. The marked amplification of cell numbers is a central feature of
haematopoiesis.
24
et al. 1983]. Kay proposed that very few stem cells contribute to haematopoiesis at
any one time, periodic activation and exhaustion of individual stem cells leading to
a process of clonal succession [Kay, 1965], Recent experimental evidence
demonstrating a decrease in telomeric length with advancing gestational age
suggests a finite potential for self-renewal in stem cells, and provides a rationale for
a strategy of clonal succession [Hayflick, 1965; Lansdorp, Dragowska & Mayani,
1993], Other groups have taken issue with this hypothesis and have provided
evidence suggesting that a relatively large proportion of stem cells are continuously
active in normal individuals [Brecher, Beal & Schneiderman, 1986; Harrison, Astle
& Lerner, 1988], McCulloch has suggested that several different differentiation
pathways to a given endpoint may coexist, perhaps with predominance ofmore
efficient or useful pathways at any one time, and variation in the blend of
differentiation pathways in response to abnormal circumstance [McCulloch, 1985],
Finally, themanner in which control is exerted over haematopoietic stem cell
quiescence / activation, proliferation and differentiation is unclear. Several authors
have proposed deterministicmodels inwhich stem cell regulation is directed through
adhesion to a specific anatomical niche (haematopoietic inductive microenvironment
[Trentin, 1971 & 1989]), or through competition between humoral factors for target
cells [van Zant & Goldwasser, 1979]. Ogawa has argued that the decision ofa stem cell
to self-renew or differentiate along a particular lineage is primarily stochastic and that
the haematopoietic microenvironment fulfils apermissive role in supporting cell
survival andproliferation [Nakahata, Gross & Ogawa, 1982; Ogawa, 1983 & 1993],
The manner in which the bone marrow stroma supports haematopoiesis at the
molecular and cellular level is returned to in Section 1.3.3, but the distinction
between a primarily instructive or a primarily selective role in control of
haematopoiesis must be considered at the level of the population dynamics of cell
collectives, and has important implications for interpretation of data on HPC
migration and mobilisation which is returned to in Section 1.6.
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1.2.2 Definition ofnomenclature.
The nomenclature in this field can give rise to problems and tomuch semantic
debate. I have elected to restrict the term "haematopoietic stem cell" to those
conceptual entities with the functional characteristics discussed in the preceding
section. The practical demonstration of "sternness" has proved elusive [Quesenberry,
1991], Potten and Loeffler [1990] have pointed out that the defined attributes ofstem
cells relate to their functional potential, and in order to testwhether a cell is a stem cell,
itmust be subj ected to an environment in which it expresses that potential. In so doing
the original cell is lost, and in addition, only a limited spectrum of the possible
functional repertoiremay be expressed.
The terms "haematopoietic progenitor compartment" and "haematopoietic
progenitor cells" (HPC) are used here as a broadly inclusive reference to stem cells,
multipotential progenitors and unipotential progenitors, to those cells expressing the
CD34 antigen, to those cells capable of in vitro haematopoietic colony formation, and
to those cells responsible for in vivomarrow repopulation in animals orman. The
mapping ofthese theoretical, in vitro and in vivo categories is not precise, and where
appropriate the limitations ofa particular assay as ameasure ofHPCwill be discussed.
1.2.2 Functional haematopoietic progenitor assays.
The murine spleen colony assay was the first quantitative haematopoietic progenitor
assay to be developed based on the observation that intravenous injection ofbone
marrow cells into irradiatedmice led tomarrow repopulation and the development of
multilineage colonies in the spleen [Till &McCulloch, 1961], These colonies are
considered to be the progeny ofsingle clonogenic cells, and can be harvested and
reinj ected into a second irradiatedmouse, wheremarrow repopulation and splenic
colonies again develop. Sequential repopulation has been taken to imply a capacity for
self-renewal (stem-ness), though splenic colonies have proved to be heterogeneous in
their ability to sustain long term haematopoiesis [Magli, Iscove & Odartchenko, 1982],
Splenic colonies generated at day 12-14 after infusion appear to represent proliferation
ofmore primitive colony forming cells than those generated earlier, and those cells that
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generate colonies in secondary recipientsmay bemore closely related to pluripotential
haematopoietic stem cells with long term repopulating ability [Ploemacher& Brons,
1989; Jones,Wagner, Celano etal. 1990]. Competitive repopulation assays may be the
only murine system in whichwe can clearly recognise and quantitatemarrow
repopulating cells [Harrison, Jordan, Zhong et al. 1993],
In 1965/66 two groups showed that it was possible to quantitate HPC by colony
formation in in vitro semisolid culture media [Ichikawa, Pluznick & Sachs, 1966;
Bradley & Metcalf, 1966]. Manipulation of the culture environment, and in
particular the cytokine support, can lead to the specific expansion and enumeration
of different multipotential and lineage-committed progenitors. The granulocyte-
monocyte colony-forming unit assay (CFU-GM) is in most widespread use [Wu,
Siminovitch, Till et al. 1968]. In addition, the erythroid burst-forming unit (BFU-E)
[Stephenson, Axelrad, McLeod et al. 1971], megakaryocyte colony- forming unit
(CFU-Meg) [Metcalf, MacDonald, Odartchenko et al. 1975], lymphoid colony-
forming unit (CFU-L) [Metcalf, Warner, Nossal et al. 1975; Sredni, Kalechman,
Michlin et al. 1976; Fibach, Gerassi & Sachs, 1976], and granulocyte-erythroid-
monocytic-megakaryocytic colony-forming unit (CFU-GEMM) [Fauser & Messner,
1979] have been defined. Studies on highly purified populations have suggested that
cells capable of long term repopulation in vivo are not detected by these kinds of
clonogenic assay [Miiller-Sieburg, Townsend, Weissman et al. 1988] and several
assays for more primitive progenitors have been developed [Visser & Van Bekkum,
1990]. These include the human blast-colony forming assay [Nakahata & Ogawa,
1982; Rowley, Sharkis, Hattenburg et al. 1987; Leary & Ogawa, 1987], the human
high proliferative potential colony forming assay [McNiece, Stewart, Deacon et al.
1989], the CFE1-A assay [Holyoake, Freshney, Konwalinka et al. 1993], and the
long term culture-initiating cell assay [Sutherland, Eaves, Eaves et al. 1989;
Sutherland, Lansdorp, Hemkelman et al. 1990; Eaves, Sutherland, Udomsakdi et al.
1992], The suggestion that quiescent progenitors capable of surviving in vitro
exposure to 5 fluorouracil or 4 hydroperoxycyclophosphamide may be closely
related to quiescent haematopoietic stem cells has been exploited by several groups
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in the design of the pre-CFU assay [Smith, Gasparetto, Collins et al. 1991] and the
delta assay [Rice, Boiron, Barbot et al. 1995], These various assays therefore
provide complementary information on HPC potentiality [Gordon, 1993a],
Xenogeneic murine bonemarrow transplantation has been used as an in vivomodel
ofhuman transplantation. Human bonemarrow administered by intravenous infusion
to irradiated, immunodeficient (scid or nod / scid) micewill engraft the bonemarrow,
and lead tomultilineage haematopoietic reconstitution ifother human tissues or
exogenous human haematopoietic cytokines are provided [Lapidot, Pflumio, Doedens
etal. 1992; Lapidot, Pflumio & Dick, 1993], Several other "humanised" animalmodels
have recently been developed whichmay prove useful in the exploration ofhuman
lymphohaematopoiesis [Srour, Hoffman &Zanjani, 1992],
1.2.4 Immunophenotypic haematopoietic progenitor assays.
The description ofCD34 antigen expression by haematopoietic stem and progenitor
cells [Katz, Tindle, Sutherland et al. 1985], has proved instrumental in permitting a
phenotypic approach to the quantitative and qualitative study ofHPC. The CD34
antigen is a heavily glycosylated type I integral membrane phosphoglycoprotein, with
a strong negative charge [Civin, 1992]. Sialic acid residues contribute to an anomalous
electrophoreticmobility,with an apparentmolecular weight of 105-120kD [Molgaard,
Brown, Simmons etal. 1989]. Themolecularweight ofthe CD34molecule predicted
from the sequences ofthe human andmurine CD34 cDNA is approximately 40kD. The
function ofthemolecule is uncertain. The genetic sequence is unique, with no close
homology to any other humanmolecule although there are some structural similarities
to the leukosialin (CD43) family ofcell surface mucins. The human gene is localised on
chromosome 1 q32, which is not a frequent breakpoint in haematological malignancies
[Molgaard, Brown, Simmons et al. 1989]. The intracellular tail is a substrate for protein
kinase C and otherprotein kinases, suggesting a role in signal transduction [Majdie,
Stockl, Pickl et al. 1994]. The highly sialated, negatively charged,N terminal
extracellular portion ofthe molecule adopts an extended configuration, proj ecting
45nm from the cellmembrane, and may prevent non-specific adhesion ofcells [Civin,
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1992; Greaves, Brown,Molgaard et al. 1992; Delia, Lampugnani, Resnati etal. 1993].
Alternatively, it has been suggested that the molecule acts as a scaffold to present cell-
type specific carbohydrate determinants to selectins [Williams, 1991], Recently it has
been shown that vascular endothelial CD34 acts a ligand for L-Selectin, though
apparently haematopoietic CD34 does not function in thisway [Baumhueter, Singer,
Henzel etal. 1993].
A large number ofmAbs to the CD34 antigen have nowbeen described [Civin,
Trischmann, Fackler etal. 1989; Egeland, Steen, Tjonnfjord etal. 1993], recognising
at least three discrete groups ofepitopes [Lansdorp, Dougherty & Humphries, 1989].
The epitopes recognised byMy10, BI-3C5,12-8 and ICH3 are dependent on
membrane-distal sialic acid residues, and are removed by Vibrio cholerae
neuraminidase and byPasteurella haemolytica O-sialoglycoprotease (Class I).
QBEND 10 binds to a distinct epitope which is not neuraminidase sensitive, but
remains O-sialoglycoprotease sensitive (Class II). The epitopes recognised by Tiik-3,
p 115.2 and 8G12 are resistant to both enzymes (Class III), and are thought to be
membrane-proximal [Sutherland& Keating, 1992; Sutherland, Marsh, Davidson etal.
1992]. Cross-linking ofCD34 by QBEND 10 but not bymAbs to proximal epitopes has
recently been demonstrated to induce homotypic aggregation ofthe cell line KG 1 a
through activation ofCD 18 [Majdic, Stockl,Pickleta/. 1994;Traore&Hirn, 1994],
The value ofCD34 to the investigator is as amarkerofprimitive differentiation
rather than of lineage specificity [Peschel & Koller, 1989; Holyoake&Alcorn, 1994].
Approximately 1.5% ofnucleated bonemarrow cells and 0.1% ofnucleated peripheral
blood cells are CD34+ [Civin, Trischmann, Fackler etal. 1989; Bender, Unverzagt &
Walker, 1991], and purified populations have a blast or early lymphoid cell
morphology. Virtually all in vitro colony forming cells are foundwithin this
population, including unipotent andmultipotent colony forming cells, blast colony
forming cells and long term culture- initiating cells. In vivo CD34+ populations have
proved capable oflong-term reconstitution ofhaematopoiesis and immunity in
primates andman [Berenson, Andrews, Bensinger etal. 1988; Berenson, Bensinger,
Hill etal. 1991; Shpall, Jones, Bearmanetal. 1994], Outwith the
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lymphohaematopoietic system, human CD34 expression is restricted tomicrovascular
endothelial cells, basementmembrane structures at a variety ofanatomical sites, and
stromal precursors [Simmons& Torok-Storb, 1991 a]. 40% ofacutemyeloid
leukaemias are CD34+, as are 60% ofB cell acute lymphoblastic leukaemias, and 1 -5%
ofT cell acute lymphoblastic leukaemia. Chronic myeloid leukaemia chronic phase
progenitor cells are also CD34+. Conversely chronic lymphatic leukaemias,
lymphomas, and non-haematolymphoid malignancies are CD34. The acute
myeloblastic cell lines KG and KG1 a are 70-90% CD34+ [Peschel & Koller, 1989], The
murine homologue ofCD34 has recently been described as showing a similar pattern of
tissue expression namely HPC, vascular endothelium and the budding edge ofnew
capillaries during angiogenesis [Baumhueter, Kyle, Dybdal et al, 1994], brain and
embryonic fibroblasts [Brown, Greaves &Molgaard, 1991; Young, Baumhueter&
Lasky, 1995].
The CD34+ cell population is heterogeneous. Dense CD34 expression occurs in the
earliest progenitors, with a progressive reductionwithmaturation, such that some of
the later progenitorsmay be operationally definedwithin the CD34 population during
immunocytometric analysis. Themost primitive HPC fall within the top 2% ofthe
CD34 fluorescence profile [Sutherland, Eaves, Eaves etal. 1989], In addition, this
populationpreferentially lacks expression ofCD3 8 [Terstappen, Huang, Safford et al.
1991] and/orHLA-DR [Civin& Loken, 1987; Srour, Brandt, Briddell etal, 1991],
Terstappen etal [ 1991 ] have usedmultiparameter flow cytometry to demonstrate that
CD34hl CD3 8" cells comprise 1 % ofHPC in the bonemarrow, lack differentiation
markers, and are ahomogeneous population ofprimitive blast cells bymorphology
with intermediate FSC and low SSC characteristics. Individual sorted cells gave rise to
primitive blast colonies [Leary & Ogawa, 1987] and could sustain repetitive replating,
implying a capacity for self-renewal. Expression ofthe CD3 8 antigen is an early event
in differentiation, and CD34+ CD3 8hl cells co-express early myeloid, erythroid, B or T
lymphoid lineage-associated antigens. CD34+ cells display low expressionofCD45
common determinants [Shah, Civin& Loken, 1988], CD45 isoforms are generated by
differentialmRNA splicing, though the biological functions are unknown [Thomas,
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1989; Caldwell, Patterson, Toalsoneta/. 1991]. Several groups have provided
evidence ofmutually exclusive sub-populations ofCD34+ cells defined by expression
ofthe CD45RO andCD45RA isoforms. CD45RO contain pluripotential and erythroid
precursors, CD45RAmyeloid and B lymphoid precursors. [Lansdorp, Sutherland&
Eaves, 1990; Fritsch, Buchinger, Printz etal. 1993b; Craig, Poppema, Little etal.
1994]. Primitive HPC also lack lineage specific markers [Andrews, Singer&
Bernstein, 1989and 1990; Smith, Gasparetto, Collins etal. 1991], but express the Thy-
1 antigen at low density [Baum, Weissman, Tsukamoto et al. 1992; Craig, Kay, Cutler
etal. 1993], The majority ofclonogenic cells have been shown to be present in the
CD34+ Thy-1" fraction, and the majority of long -term culture initiating cells (LTC-IC)
in the CD34+ Thy-1+fraction. In addition to these antigenic features, primitive HPC
display low retention ofthe supravital mitochondrial dye Rhodamine 123 [Bertoncello,
Bradley, Hodgson et al. 1991; Udomsakdi, Eaves, Sutherland et al. 1991], and ofthe
DNA-specific dye Hoechst 3 3 342 [Neben, Redfearn, Parra et al. 1991], It has been
suggested that the decreased accumulation ofRhodamine 123 and Hoechst 33342 in
primitive HPC is a reflection ofkinetic andmetabolic quiescence,with few, or largely
inactivemitochondria, and a condensed chromatin structure. However, Chaudhary and
Roninson [1991] have provided evidence ofhigh P-170 glycoprotein (P-gp) expression
and activity in these cells, and have proposed that active transmembrane efflux of
lipophilic compounds is responsible for this phenomenon. There is some evidence to
suggest that the coordinate expression ofCD34 and Pgp is restricted to quiescent stem
cells [Chaudhary & Roninson, 1991; List, Spier, Cline etal. 1991], Huang &
Terstappen [1992; 1994] have recently suggested that the CD34h'CD3 8" HLA-DR"
population in bonemarrow contains cells capable offibroblastic colony formation as
well as haematopoietic colony formation, implying that this phenotype includes an
antecedent commonmesenchymal stem cell.
The more common activated and lineage-committed HPC display higher
Rhodamine 123 retention, and coexpress CD38, HLA-DR and CD45RA, as well as
early markers of myeloid [CD33, CD13] [Andrews, Singer & Bernstein, 1989;
Terstappen, Safford & Loken, 1990], erythroid (CD71) [Loken, Shah, Dattilio et al.
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1987a], T lymphoid (TdT, CD7, CD5, CD2) [Gore, Kastan & Civin, 1991;
Terstappen, Huang & Picker, 1992], B cell (TdT, CD10+, CD19+) [Loken, Shah,
Dattilio et al. 1987b] or fibroblast (Stro-1) [Simmons & Torok Storb, 1991b;
Gronthos, Graves, Ohta et al. 1994] differentiation. It is possible to further dissect
HPC on the basis of cytokine receptor expression such as c-kit [Papayannopoulou,
Brice, Broudy et al. 1991; Briddell, Broudy, Bruno et al. 1992; Simmons, Aylett,
Niutta et al. 1994], enzymes such as myeloperoxidase [Strobl, Takimoto, Majdic et
al. 1993] or differential staining with lectins [Craig, Thomas & Lansdorp, 1992],
Caution should be exercised in the interpretationofexpression ofa particular antigen
as a lineage-specificmarker. For example, CD71 (transferrin receptor) is widely
expressed by proliferating cells, and is therefore only partially indicative oferythroid
commitment. Although several ofthe other antigens noted can be regarded as lineage-
specific post-commitment, uncertainty exists as to the pattern ofexpression on earlier
progenitors. Greaves has proposed that some observations of "lineage- infidelity" in
leukaemic phenotypes,may be representative ofaphase of "lineage-promiscuity"
amongstmultipotential cells, duringwhich lineage-specific antigens may be
coexpressed prior to irreversible commitment [Greaves, Chan, Furley et al. 1986].
Combinations ofantigenic markersmay prove to be amore accurate reflection ofHPC
subset commitment.
1.3 Regulation of Haematopoiesis.
1.3.1 Embryonic, foetal and adult haematopoiesis.
Haematopoietic stem cells are derived from haemangioblasts ofthe splanchnic
mesodermwhich forms on day 7 ofgestation in the regionofthe primitive streak and is
thought to give rise to both the vascular and haematopoietic systems [Broxmeyer,
1991; Tavassoli, 1994]. Between 7 and 8 days ofgestation these cells migrate along the
amniotic wall and visceral endoderm to form the yolk sac blood islands.
Extraembryonic blood islands support haematopoiesis from 15 days to 6 weeks of
gestation. The yolk sacmicroenvironment is selectively permissive for aprimitive
form oferythropoiesis inwhich cell differentiation is synchronous and the end
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products are nucleated red cells. These features ofprimitive erythropoiesis are
reminiscent ofthe intravascular form oferythropoiesis which occurs in amphibians and
birds, in which definitive adult haematopoiesis occurs in themesodermal region
containing the dorsal aorta [Tavassoli, 1991 ]. Medvinsky etal have recently
demonstrated that in embryonic mice, transitory yolk sac haematopoiesis is superseded
by intraembryonic haematopoiesis arising from the axial aorta-gonad-mesonephros
region,which is followed by foetal liver haematopoiesis [Medvinsky, Samoylina,
Muller et al. 1993]. Whether a similar intermediary step occurs inman is unknown, but
by 6 weeks gestation a definitive form ofextravascular haematopoiesis is established in
the liver and spleen. Although erythropoiesis still predominates, granulopoiesis also
occurs, and cells differentiate in a non-synchronousmanner. The end product of
erythropoiesis is an anucleate red cell.
The bonemarrow develops contemporaneously with ossification ofthemajor bones
from approximately 20 weeks onwards, and becomes themajor site from
approximately 2 weeks post-natal. During adult life, the bonemarrow supports
myeloid, erythroid,monocytic and megakaryocytic development, as well as B
lymphoid development, though granulopoiesis predominates. The spleen retains a
permissive haematopoietic microenvironment, and in pathological conditions such as
myelofibrosismay reassert this function, though, as in foetal life, erythropoiesis
predominates. In the normal adult, low levels ofHPC can be detected in the circulation,
and HPC migration occurs from the bonemarrow to the thymus (to support T lymphoid
development), and to areas in the stomach, caecum, mesentery and skin (to support
mast cell development) [Trentin, 1989].
1.3.2 The architecture ofthe bone marrow.
The principal haematopoietic tissue inman is the bonemarrow, and this is the site in
which themajority ofHPC reside.
Ultrastructural study ofhuman bonemarrow has proved difficult due to the problems
ofobtaining specimens without mechanical trauma, and the impediment that bone
provides to fixation for electronmicroscopy [Lichtman, 1991], Most data are therefore
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derived from rodent studies. The arterial supply comes from two sources.Nutrient
arteries enter themarrow cavity through the diaphysis, branch to formmedullary and
radial arteries, which penetrate the cortical endosteum and undergo arborisation to
form a canalicular system. Additional arterial blood enters the canalicular system from
periosteal arterioles arising frommuscular arteries. Cortical capillaries re-enter the
medullary cavity, draining into a highly branching network ofmedullary sinuses,
which themselves drain into a central sinus, and via emissary veins back into the
systemic circulation. It has been conjectured that the supply ofarterial blood to the
marrow via the bone cortex causes a drop in pO which augments haematopoiesis
[Bradley, Hodgson& Rosendaal, 1978; Roller, Bender, Miller etal. 1992],
Modulation ofthe vascular system through neural and humoral mechanismsmay
influence bonemarrow perfusion, oxygenation andpH.
The luminal aspect ofthe medullary sinuses are lined by a continuous layerof
endothelial cells, which are broad and flat, with overlapping edges but without tight
j unctions. The endothelial cells ofmarrow and liver sinusoids are actively endocytic,
and show areas ofmarked attenuation of cytoplasm, approaching the thickness ofa
double plasmamembrane (fenestraewith diaphragm). A fine basement membrane
underlies the endothelial cell layer, which consists ofa lattice ofcollagen type IV
containing various glycoproteins and proteoglycans [Yurchenko& Schnitty, 1990].
The basement membrane inmarrow sinuses is less complete than that at other vascular
sites. The outer (abluminal) surface ofthe sinus is enveloped by a discontinuous sheath
ofadventitial reticular cells. These cells are thought to be fibroblast derived, and
display extensive cytoplasmic processes which cover approximately 65% ofthe
abluminal surface, and extend into themarrow cavity. Adventitial reticular cells can
undergo maj or changes in cytoplasmic volume, and several forms ofstress such as
endotoxaemiaor increased erythropoietin have been shown tomarkedly reduce the
areaofthe abluminal surface covered by reticular cell processes [Lichtman, 1991],
Together, endothelial cells, basementmembrane and adventitial reticular cells form a
barrier between the blood and the extravascularhaematopoieticmarrow, which permits
regulation ofcell and macromolecular traffic between the two compartments
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[Lichtman, Packman& Constine, 1989; Irie & Tavassoli, 1991],
Transmigration ofthe blood-marrow barrier by haematopoietic cells requires
passage through a gap in the adventitial reticular cell layer, penetration ofthe basement
membrane, and formationofamigrationpore in the endothelial cell cytoplasm, often
close to a cell junction. Electronmicroscope studies reveal holes in endothelial cell
cytoplasm, though it is unclear whether these are artefactual, or sites ofcells in passage
which have been lost during preparation. Diaphragmatic fenestraemay also act as loci
ofminor resistance for cellmigration, ormay represent areas ofearly repair. Blood cell
release from themarrow is highly discriminatory, with a very highmarrowto blood
ratio ofimmature cells, and a lowmarrow to blood ratio ofmature cells. This is likely to
be partially due to alteration in cell adhesionmolecule expression or function during
cellular differentiation (vide infra), and partially due to increased cell motility and
deformabilitywithmaturation. The blood-marrowbarrier also plays an important role
in regulation ofcell transmigration.Marrow sinus endothelial cells show a luminal
surface charge distribution and sialic acid composition which is discontinuous and
non-random. Anionic charge is less dense around surface vesicles (pits), diaphragmatic
fenestrae, and cells in transit. Oligosaccharide groups (such as aD mannose, BD
galactose, N-acetylgalactosamine, andN-acetylglucosamine) are also highly
expressed overmost ofthe luminal surface ofthe cell, but are sparse on the abluminal
surface, and over the perinuclear zone and tapering ends ofthe endothelial cells, and
around vesicles and diaphragmatic fenestrae.
The cytoplasmic processes ofadventitial reticular cells provide much ofthe physical
support for developing haematopoietic cells, and are probably the principal fibroblast-
like cells in themarrow. Fibroblasts also occur in associationwith blood vessels,
nerves and bone, though it is unclear whether free-lying fibroblasts also occurwithin
themarrow space. Preadipocytes and adipocytes appear to be derived from adventitial
reticular cells, and are perisinusoidal.Marrow adipocytes differ from adipocytes in
other tissues [Tavassoli, 1989], in that they are smaller, with ahigh proportion of
neutral fats, little or no phospholipid, and a different fatty acid profile. They are
corticosteroid, but not insulin-dependent, and do not undergo involution in response to
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acute starvation. Intense haematopoiesis, however, engenders involution ofmarrow
adipocytes, withmetaplasia to adventitial reticular cells. Monocyte/macrophages and
T lymphocytes are haematopoietic cells in their own right, and provide amajor
regulatory component ofthe stroma [Emerson& Artin, 1989]. Nerves accompany
vascular structures,myelinated fibresmay affect vascular tone, whilst some authors
have suggested that non-myelinated fibres end in themarrow cavity, andmay affect
haematopoiesis by the release ofneurotransmitters.
The extracellularmatrix (ECM) is secreted by stromal cells, and consists principally
ofcollagen types I, III, IV and V (fibroblasts) [Bentley, 1982; Gay, Prince, Zuckerman
et al. 1989], fibronectin (fibroblasts and endothelial cells), laminin (endothelial cells),
and proteoglycans (in particular chondroitin sulphate and dermatan sulphate) [Keating,
Wright,Kinselletal. 1984; Zuckerman&Wicha, 1983; Gordon, 1988a; Zuckerman,
Prince& Gay, 1989; Clark, Gallagher& Dexter, 1992]
Haematopoietic cells develop in the extravascular space, normally in close
apposition to stromal cells and extracellularmatrix proteins and carbohydrates, which
provide a supportive haematopoietic micoenvironment. Thus granulopoiesis and B
lymphopoiesis occur in close associationwith the cytoplasmic processes ofadventitial
reticular cells, erythropoiesis around a central macrophage (the "erythroblastic islet"),
andmegakaryopoiesis adjacent to perivascular endothelial and reticular cells. Blazsek
et al. have identified multicellular aggregates (hematons) in bonemarrow aspirates
which contain the full range ofstromal and haematopoietic cells in the spatial
associations described above, andwhich they propose should be considered as a
fundamentalmorphogenetic unit inmammalian bonemarrow [Blazsek, Liu,Anjo et
al. 1995],
1.3.3 The haematopoietic microenvironment.
Control over proliferation, differentiation and survival ofhaematopoietic cells in
vivo is effected by a complex network ofstromal cells, extracellular matrix proteins and
carbohydrates, cell adhesion molecules, and through the secretion and presentation of
regulatory cytokines [Chabannon& Torok-Storb, 1992; Gordon& Greaves, 1989;
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Gordon, 1991 & 1994; Greenberger, 1986], Although there is continued debate as to
whether self-renewal and committment decisions by multipotential progenitors are
determined by themicroenvironmental or are predominantly stochastic events (vide
supra [Ogawa, Porter &Nakahata, 1983; Ogawa, 1993]), there is little dubiety that
continuedmaturation, proliferation and survival ofcommitted progenitors is
dependent on a supportive microenvironment.
It has proved difficult to examine the structural nature ofthe interaction between
haematopoietic and stromal cells in vivo. Studies of in vitro long-term bonemarrow
stromal cultures (LTBMC) have shown no clear evidence ofspecialisedmembrane
structures such as desmosomes, tightjunctions or gap junctions, between interacting
haematopoietic and stromal cells, thoughjunctional complexes are presentbetween
stromal cells [Dexter, Coutinho, Spooncereta/. 1990]. This suggests that intimate
haematopoietic-stromal cell contact is maintained by cell adhesionmolecules (CAMs)
and their ligands or counter-receptors (vide infra). Regulatory cytokines are not passed
directly to haematopoietic cells, but are presented to them in amembrane-bound form,
or are secreted in a soluble form into the localmicroenvironment, where theymay be
bound by extracellularmatrix proteoglycans - particularly heparan sulphate [Gordon,
Riley,Watt etal. 1987; Roberts, Gallagher, Spooncereia/. 1988; Dexter, Coutinho,
Spooncer etal. 1990; Gordon, 1991]. Presentation ofcytokines to haematopoietic cells
by stromal cells ormatrix componentsmay provide amechanism for spatial
containment ofthe signal. Cytokineswhich diffuse outside the immediate
microenvironment formed by the stromal cell-ECM-target cell complex are either
highly labile and rapidly degraded, or else form a background "soup" againstwhich
specific cytokine signalsmust be interpreted. Clearly some cytokines do act in an
endocrinemanner (such as erythropoietin) or can do so under iatrogenic circumstance
(e.g. G-CSF).
A partial list of the currently described regulatory cytokines, chemokines and
other factors is presented in Table 1.1 [Moore, 1991; Barrett & Gordon, 1993], In
addition, there are a number of humoral factors more properly classified as
endocrine, which have an important affect on haematopoiesis (Table 1.2). The
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Table 1.1 Regulatory Cytokines.
Growth factors.
granulocyte-monocyte colony stimulating factor (GM-CSF)
granulocyte colony stimulating factor (G-CSF)
monocyte colony stimulating factor (M-CSF, CSF-1)
erythropoietin (EPO)
thrombopoietin (TPO)
stem cell factor (SCF) (mast cell factor, c-kit ligand)
basic fibroblast growth factor (bFGF)
flk-2 / flt-3 ligand
Interleukins. Interferons.
Interleukin (IL) - la and - IB, 2 to 14. Interferon (IF) a, B and y.
Transforming Growth Factors.
transforming growth factor (TGF) B
tumour necrosis factor (TNF) a and B
Chemokines.
macrophage inflammatory protein (MIP) -1 and 2a and fi
platelet factor 4 (PF4)
macrophage chemotactic and activating factor (MACF)




insulin-like growth factors 1 and 2 (somatomedins).
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cytokines can be loosely classified into early, intermediate and late acting on the
basis of in vitro studies on HPC [Ogawa, 1993], Alhough it is clear that some do
have relatively well defined stimulatory or inhibitory effects on restricted
haematopoietic lineages, most have more complex functions. IL-4, for example,
demonstrates polyfunctional stimulatory and inhibitory activity on haematopoietic
proliferation [Peschel, Paul, Ohara et al. 1987], Other cytokines demonstrate
considerable pleiotropism outwith the haematopoietic system. For example, IL-6
activity has also been demonstrated in the immune, hepatic, nephritic and other
systems [Akira, Hirano, Taga et al. 1990]. Finally, it has become clear from work
on ex vivo cellular manipulation that combinations of cytokines have a much more
profound effect on haematopoietic proliferation than individual agents [Haylock,
To, Dowse et al. 1994], Considerable subtlety and some degree of redundancy
therefore exist within the microenvironmental systems which effect regulatory
control over haematopoiesis [Metcalf, 1993],
Although cytokines do not fall easily into a small number of families
[Groopman, Molina & Scadden, 1989; Moore, 1991], their receptors do appear to do
so (Table 1.3) [Barrett & Gordon, 1993; Cosman, Lyman, Idzerda et al. 1990], The
haematopoietin receptor superfamily are heterodimers, consisting of an a chain
displaying high ligand specificity but low binding affinity, which undergoes
conformational change on ligand binding allowing association with a 13 chain which
clamps the cytokine (forming a high affinity receptor) and mediates transmembrane
signalling. The GM-CSF, IL-3 and IL-5 receptor a chains associate with, and may
compete for, a common 13 chain. Different types of 13 chain are responsible for
different kinds of signalling. This flexibility of association provides a basis for
understanding the pleiotropic (association of a given a chain with several different 13
chains), and redundant (association of several different a chains with a 13 chain)
nature of cytokine activity. A cell may respond to several cytokines in a similar
manner or to the same cytokine in a different manner, dependent (in part) on the
relative affinity of a-13 binding.
Binding ofa cytokine to a cytokine receptor leads to internalisation and degradation
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Table 1.3 Haematopoietic Cytokine Receptors.
Immunoglobulin gene superfamily.
M-CSF receptor (c-fms) (CD115)
SCF receptor (c-kit) (CD117)
IL-1 receptor (CD121)
Haematopoietic receptor superfamily.
GM-CSF receptor* (CDwl 16) IL-2 receptor (CD122)
IL-3 receptor* (CD123) IL-4 receptor (CDwl24
IL-5 receptor* (CD 125) IL-7 receptor (CDwl 27)
EPO receptor IF receptors (CD118/ CD119)
Hybrid receptors.
G-CSF receptor
IL-6 receptor (CD 126 / CDwl 30)
Nerve growth factor receptor superfamily.
TNF receptor (CD 120)
Others.
IL-5 receptor a chain
IL-8 receptor (CDwl28)
TGFB receptor
Legend. For a key to the abbreviations please refer to the text and Table 1.1.
'independent a chains compete for a common 0 chain.
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of the complex. An equilibrium binding affinity assumes a steady state process, but
in fact constant removal of bound complex with replacement by fresh cytokine
receptor means that equilibrium is rarely achieved and actual binding affinity is
higher than equilibrium binding affinity. One may conclude that removal of bound
receptor forms a mechanism for temporal containment of the cytokine signal.
Given the abundance of factors which can be demonstrated to affect HPC
survival, proliferation and differentiation in vitro, it has proved remarkably difficult
to determine which may be of relevance in vivo. Results ofNorthern blot analyses,
reverse transcription - polymerase chain reaction analyses and bioassays in long-
term bone marrow cultures have demonstrated constitutive expression ofM-CSF,
G-CSF, IL-6, IL-3 and c-kit [Kittler, McGrath, Temeles et al. 1992], A dominant
negative regulatory effect appears to be provided by TGFP [Eaves, Cashman, Kay et
al. 1991],
1.4 Haematopoietic Progenitor Transplantation.
1.4.1 Clinical bone marrow transplantation.
In 1990 EDonnall Thomas was awarded aNobel Prize for his pioneering work on the
development ofhuman bonemarrow transplantation [Thomas, 1994]. During this
procedure autochthonous haematopoiesis is ablated by high dose chemotherapywith
orwithout radiotherapy. Intravenous infusion ofpreviously harvested autologous or
allogeneic bonemarrow, leads to reconstitution ofhaematopoietic and lymphoid
systems by exogenousHPC. Recovery ofperipheral blood erythrocytes, neutrophils
and platelets is normally complete within two to three weeks, though reconstitution of
the immune system can take up to 6-12 months [Atkinson, 1990; Lum, 1990], Prompt
lymphohaematopoietic recovery has been found to be related to the "dose" ofHPC
reinfused, with a threshold effect apparent at approximately 2x108 nucleated cells / kg,
2x 105 CFU-GM / kg, 2x 106 CD3 4+ cells / kg or 1.2x 106morphological blasts / kg
[Bender, To,Williams etal. 1992],
Over the past 20 years bonemarrow transplantation has come to fulfil an important
role in themanagement ofhaematological and solidmalignancies, bonemarrow
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Table 1.4 Current Clinical Indications for Bone Marrow Transplantation.
Haematological and solidmalignancies.




breast and germ cell tumours
Bone marrowfailure.
severe aplastic anaemia
Inborn errors ofhaematopoiesis, immunity andmetabolism.
haemoglobinopathies (e.g. sickle cell disease, B thalassaemia)
severe combined immune deficiency (e.g. adenosine deaminase deficiency)
lysosomal storage diseases (e.g. Gaucher's disease).
failure, and inborn errors ofhaematopoiesis, immunity and metabolism (Table 1.4).
The procedure is, however, associated with considerable short and long-term
morbidity and mortality, which arises from several sources. First, an intensive
chemo-radiotherapy conditioning regimen is required to treat endogenous disease
(in the case of neoplasia), to create "space" in the marrow for incoming HPC, and to
suppress the immune system which would normally reject allogeneic HPC. This
engenders an obligatory period of severe marrow hypoplasia during which the
patient requires intensive blood component support and protective isolation. Other
systems such as the gastrointestinal tract sustain collateral toxicity and transient
functional impairment. Methods of avoiding high-dose chemotherapy [Wu &
Keating, 1993] or reducing or eliminating the period ofmarrow hypoplasia would
markedly improve the safety of the procedure. Second, the use of autologous
transplantation permits higher doses of chemotherapy for treatment of neoplastic
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diseases, but has led to concern about the extent of neoplastic contamination in the
graft. Although the majority of patients probably undergo disease recurrence arising
from endogenous chemotherapy-resistant disease, reinfused cells can also contribute
[Brenner, Rill, Moen et al. 1994; Rill, Santana, Roberts et al. 1994], Methods of
utilising less contaminated source material, of high-grade HPC enrichment or of
neoplastic cell purging, may improve disease free survival in these patients (vide
infra). Third, allogeneic transplantation is used in the management of some
malignant diseases, but also in patients with marrow failure and inborn genetic
errors. The central problem is that of immune incompatibility between donor and
recipient leading to failure of engraftment or to graft versus host disease. Only 30%
of the Caucasian population in this country have an HLA-matched sibling donor.
The exceptional polymorphism of the HLA loci engenders great difficulty in finding
HLA-matched unrelated donors, and transplants are associated with particularly
high procedure-related morbidity and mortality due to graft failure and graft versus
host disease. The use of foetal haematopoietic tissue or more subtle immunological
modulation of the graft may mitigate these problems.
1.4.2 Alternative sources ofhaematopoietic progenitors.
AlthoughHPC circulate in the peripheral blood at low levels in the normal adult
[Chervenick& Boggs, 1971; Kurnick& Robinson, 1971], elevated levels occur under
a variety ofphysiological, pathological and iatrogenic circumstances (termed
mobilisation: Table 1.5).Minor and transient elevation ofHPC occurs following
exercise and physiological stress [Barrett, Longhurst, Sneath et al. 1978]. Muchmore
marked elevation in circulatingHPC occurs during the recovery phase following
marrow suppression by chemotherapy, usually just preceding recovery ofperipheral
blood neutrophils and platelets. The extent ofelevation is dependent on the nature of
the disease, the chemotherapeutic regimen, and the extentofprior exposure to
chemotherapy [Craig, Smith, Parker et al. 1992]. As a generalisation, themore
intensive the chemotherapeutic regimen, the greater the rebound. Peripheral blood
leucocytes can be harvested by apheresis and cryopreserved for future use [Henon,
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Table 1.5 Conditions Giving Rise to Elevation ofCirculating Haematopoietic
Progenitors.
foetal and neonatal life.
exercise, ACTH, hydrocortisone, endotoxin
dextran sulphate
recovery phase following chemotherapy,
haematopoietic cytokines: G-CSF, GM-CSF, IL-3.
Butturini & Gale, 1991; Craig, Turner & Parker, 1992; Henon, 1993; Holyoake &
Franklin, 1994], More recently it has been found that the administration of
recombinant human cytokines (in particular IL-3, GM- CSF and G-CSF) in vivo
leads to substantial elevation of circulating HPC. The use of both these modalities in
conjunction has a synergistic effect on circulating HPC levels, and has led to the
development of high dose chemotherapy and cytokine regimens with the express
intention ofmobilising HPC for leucapheretic harvest [Siena, Bregni, Brando et al.
1989; Craig, Anthony, Stewart et al. 1992], The use of circulating HPC for
transplantation has a number of potential and actual advantages over bone marrow
HPC. First, the range of patients amenable to harvest may be broadened, a general
anaesthetic is avoided, and patients with disease or fibrosis involving the pelvic
marrow may be harvested. Second, the rate of recovery of peripheral blood
neutrophil and platelet counts is more rapid, leading to reduced procedure-related
morbidity and mortality. Third, it is possible that peripheral blood harvests have less
neoplastic contamination than bone marrow harvests, though no clinical studies
have yet shown an advantage in terms of disease-free survival.
Peripheral blood also contains elevated levels ofHPC and immature cells at birth.
Fifty to 150mls ofblood can be salvaged from the placenta following delivery ofthe
child and clamping ofthe cord. There has been substantial recent interest in harvest and
storage ofumbilical cord blood, and around 50 cord blood HPC transplants have been
carried out, almost all to children [Broxmeyer, Douglas, Hangoc etal. 1989;
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Broxmeyer, Kurtzberg, Gluckman et al. 1991; Broxmeyer, Hangoc & Cooper, 1992;
Nicol, Hows & Bradley, 1994]. There are several arguments in favour ofthe
development ofumbilical cord blood banking for allogeneic HPC transplantation;
expansion ofallogeneic HPC availability, avoidance ofgeneral anaesthesia and bone
marrow aspiration ofthe donor, and the relative immaturity ofthe neonatal immune
system, which gives rise tominimal graft versus host disease - even following
transplantation betweenMHC incompatible individuals. Themajor concernwith
regard to umbilical cord blood transplantation is that theremay be insufficient HPC in
the harvest to effect long-term reconstitution in an adult recipient.
Some preliminary work has been done in the field of in utero transplantation. The
foetus is so immunologically immature that itwill acceptHPC introduced into the
umbilical cord or peritoneal cavitywithout a requirement for bonemarrow
conditioning [Touraine, Raudrant, Royo etal. 1991; Zanjani, Pallavicini, Ascensao et
al. 1992]. Although this is a potentially useful procedure in some genetic conditions,
adult derivedHPC harvests usually contain immunologically aggressive T
lymphocytes, which lead to fatal graft versus host disease iftransplanted into a foetus.
Several routes are available to reduce the immunological activity of the donor harvest
including ex vivo CD34 enrichment or T cell depletion, the use ofearly umbilical cord
blood, or the use ofhomogenised early foetal liver. Grafts derived from foetal liver are
rich in primitive HPC and contain immature T cells, and can be used for transplantation
both in utero and in the neonate. Successful foetal liver and / or thymic transplants have
been carried out in childrenwith severe congenital immunodeficiencies or congenital
enzyme deficiencies [Touraine, Raudrant, Royo etal. 1991], There is no convincing
evidence ofsuccessful engraftment in children and adults with aplastic anaemia and
leukaemia, probably due to themore intense immunosuppression required [Gale,
1992].
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1.4.3 Ex vivo manipulation ofhaematopoieticprogenitor grafts.
Until recently the extent ofex vivomanipulation ofthe HPC harvest has been limited
to separation ofthemononuclear cells (MNC) and cryopreservation ofthe product.
Routine assessment ofthe viability and HPC content ofthe harvest has utilised the
CFU-GM assay. Technological advances over the last fewyears promise arevolution
in assessment and ex vivomanipulation ofthe graft. In the first instance, CD34
immunocytometry has been shown to correlate withCFU-GM, and to be an effective
method ofmonitoringHPC in the bonemarrowand in the peripheral blood following
recovery from chemotherapy. This is amore global, rapid and reproducible assay for
HPC enumeration thanCFU-GM, and has superseded the latter in the clinical practice
ofsome groups [Siena, Bregni, Brando etal. 1991a; Siena, Bregni, Belli etal. 1992], It
is possibile that increasing sophistication in immunocytometry technique will allow
more detailedmonitoring ofCD34 subsets, proliferation and apoptosis.
Expression ofthe CD34 antigen has also been used extensively as a vehicle for HPC
enrichment. Several approaches to positive selection have been developed and these
are discussed inmore depth in Chapter 6.6 [Visser& Van Bekkum, 1990; Wunder & de
Wynter, 1994]. Studies by Berenson etal have shown that CD34+ purified cells
successfully engraft bonemarrow in both primates andman [Berenson, Andrews,
Bensinger etal. 1988; Berenson, Bensinger, Hill et al. 1991], The systemsmarketed by
CellPro, Baxter (Immunex) and Applied Immune Sciences are currently licensed for
clinical use. It is claimed that these systems yield aproduct which has 50 to 90% CD34+
purity, though this level ofenrichment has proved difficult to achieve in independent
laboratories [Wunder & deWynter, 1994]. Potential advantages ofusing enriched
products are a reduction in the volume ofcells stored (with reduced storage costs and
recipient cryoprotectant exposure), reduction in T cell content ofthe graft (vide infra)
and purging ofCD34" neoplastic cells. The predominant drawbacks are the open nature
ofcurrently available enrichment systems, poor characterisation ofthe effect ofthe
enrichment onHPC subset balance and long-term viability, and expense.
Interest in the field ofautologous transplantation for haematological and solid
malignancies has focused on the issue ofneoplastic cells contaminating the graft.
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Impetus has been added to the field by the discovery that in somemyeloid and
lymphoid malignancies neoplastic contamination can be detected in autologous grafts
by the polymerase chain reaction (though not necessarily by less sensitivemethods
such as SouthernBlot) [Craig, Langlands, Parker et al. 1994; Cole-Sinclair, Foroni,
Wright etal. 1993], and the demonstration by Brenner etal. that neoplastic
contamination can give rise to patient relapse in acute leukaemia [Brenner, Rill,Moen
etal. 1994] and solid tumours [Rill, Santana, Roberts etal. 1994]. Several approaches
have been explored in attempts to purge the graft, including CD34 positive selection,
negative selection ofneoplastic cells usingmAbs or lectins to tumour-specific
antigens, incubation ofthe graft with stromal layers, incubation with chemotherapeutic
agents, activation ofT andNK cells with interleukin 2, and latterly attempts to induce
neoplastic cell apoptosis using antisense oligonucleotides. Experimental work has
shown variable degrees ofsuccesswith thesemethods, but none has yet translated into
an improvement in clinically relevant end-points.
Allogeneic transplantation is associated with a very high procedure-related
morbidity and mortality, dependent on the extent of immune incompatibility between
donor and recipient. Clinically, this presents as a primary failure ofengraftment (host
rej ection ofthe graft), or as acute or chronic graft versus host disease. It has been shown
that T cell depletion ofthe graft virtually eliminates graft versus host disease, but
unfortunately the potential clinical benefit is offset by increased incidence ofgraft
failure, and increased relapse ofneoplastic (particularly leukaemic) disease. Two
approaches bear promise for the future. First, itmay be possible to selectively and
quantitatively deplete T cell subsets from the allogeneic graft, with the aim of
modifying the intensity ofthe graft versus host disease, or discriminating graft versus
host from a graft versus leukaemia effect. Second, itmay be possible tomimic a graft
versus leukaemia effect in the autologous setting through activation ofT andNK cells
by immune cytokines such as interleukin 2. Current experiencewith IL-2 suggests that
immunotherapy ismore likely to be effective in the setting ofminimal residual disease
than in themanagementofbulk disease. Themost promising current approach
combines high dosage chemo-radiotherapy and autologous bonemarrow rescuewith
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administration of IL-2 either to the graft ex vivo, or to the patient post-transplant, or
both [Heslop, Duncombe, Reittie et al. 1991],
The availability ofrecombinant human cytokines has created the possibility ofex
vivo expansion ofthe HPC population. Current experimental data suggests that the use
ofcombinations ofbetween 4 and 6 cytokines effectmarked expansion in the CD34+
population, and inmoremature precursors and terminally differentiated cells [Moore,
1991; Haylock, To, Dowse et al. 1994]. The hope is that ex vivo HPC expansionwill
allow transplantation from relatively small numbers ofHPC (e.g. from an umbilical
cord harvest), orwill improve the rapidity ofengraftment, allowing reduction or
elimination ofthe pancytopenic period. A theoretical concern is that the
haematopoietic stem cell pool in the graftmay be exhausted through cytokine-driven
proliferation and differentiation, leading to long-term graft failure [Moore, 1992], To
date, expanded HPC populations have not been transplanted into patients, though this
development seems imminent.
Finally, HPC form an attractive target for gene transduction, for the correction ofa
wide range ofgenetic and acquired diseases ofhaematopoiesis, immunity and
metabolism (Table 1.6) [Miller, 1990;Larrick&Burck, 1991;Karlsson 1991].
Successful transduction and transplantationofHPCmay theoretically lead to long-
term expression ofa construct by derivative progeny belonging to several lineages. The
problems are several fold. First, current approaches to gene transduction are non-
targeted, and therefore require highly enriched HPC populations to achieve
satisfactory vector to target cell ratios. At present, themostwidely used transduction
vehicles are retroviral which have a high transfection efficiency, but are limited in the
size ofpassenger construct and to transfection ofactively replicating cells. There are
associated risks ofgeneration ofreplication-competent retrovirus by recombination,
and of insertionalmutagenesis due to random insertion ofthe construct into the
genome. Alternative methods using other viruses (such as adenoviruses and adeno-
associated virus) or physical transfection vectors (such as electroporation, liposomes
ormacromolecular complexes) are under scrutiny. The priorities are to achieve high
efficiency transfectionofrare, quiescent haematopoietic stem cells, with larger genetic
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Table 1.6 Candidate Diseases forCorrection by Gene Transfer into
Haematopoietic Progenitors.
Class I: expression of the genetic defect restricted to lymphoid cells e.g. non-ADA
deficient severe combined immune deficiency, X-linked agammaglobulinaemia.
Class II: expression restricted to haematopoietic and lymphoid cells
e.g. Wiskott-Aldrich syndrome, Chediak-Higashi syndrome.
Class III: expression restricted to haematopoietic cells e.g. a and B thalassaemia,
sickle cell disease and other haemoglobinopathies, chronic granulomatous disease,
platelet storage pool disorders, osteopetrosis.
Class IV: generalised expression of the genetic defect, clinical manifestations
restricted to lymphohaematopoietic cells e.g. adenosine deaminase deficiency,
purine nucleoside deficiency, Fanconi's anaemia.
Class V: generalised expression with generalised clinical manifestations e.g.
Lesch-Nyhan syndrome, mucopolysaccharidoses, mucolipidoses, lysosomal storage
disorders such as Gaucher's disease and Niemann Pick disease.
Class VI: defective gene not normally expressed by lymphohaematopoietic cells e.g.
haemophilia A and B, von Willebrand's disease, antitrypsin deficiency.
constructs which may need to contain regulatory sequences for appropriate
expression, and genome targeting sequences for homologous recombination.
Finally, it should be clear that successful HPC gene transfection ex vivo may not
translate into stable morphological reconstitution in vivo. Primary failure of the
transfected HPC graft may occur if the cells have entered apoptosis. Secondary
failure may occur ifprimitive quiescent stem cells have not been transduced, or if
there is successful competition from autochthonous HPC. Indeed expression of a
neoantigen by the transduced population may lead to immunological rejection of the
graft. The manner in which HPC are manipulated ex vivo may prove equally as
important as the structure of the genetic construct and the nature of the vector in
achieving successful HPC gene therapy.
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1.4.4 Haematopoietic progenitor transplantation as aproblem in cellposition.
Much of the focus of academic and clinical research over the past 20-30 years
has reflected on the nature and identification of haematopoietic stem cells, and
latterly on the control ofproliferation and differentiation by soluble cytokines. It is
clear that HPC physiology is dependent on context, provided in vivo predominantly
by the bone marrow microenvironment. As discussed above HPC are not merely
sessile but are capable of ontogenic and adult migration, selective homing to the
bone marrow and mobilisation to the peripheral blood under a variety of
physiological, pathological and iatrogenic circumstances. The determinants ofHPC
position are therefore not simply of cursory interest, but are likely to prove of
central importance to a fuller understanding of HPC physiology, and are of
relevance to clinical HPC transplantation and ex vivo manipulation.
1.5 Cell Adhesion and Position.
1.5.1 Cell adhesion molecules as determinants ofposition.
Close cell-cell contact between mammalian cells is opposed by mutual repulsion
thought to be conveyed by negatively charged sialic acid residues of molecules
such as leukosialin and CD34 [Bell, Dembo & Bongrand, 1984; Greaves, Brown,
Molgaard et al. 1992], Cell-cell and cell-matrix adhesion are active functional
processes involving membrane expression of cell adhesion molecules (CAMs).
Individual CAMs demonstrate high specificity in the cognate ligands or counter-
receptors to which they bind.
Three types of CAM-ligand binding have been described [Alberts, Bray, Lewis,
et al. 1989]. Homophilic binding involves binding of a cell surface molecule to a
similar molecule on an apposing cell (trans-binding), or sometimes on the adjacent
membrane of the same cell (cis-binding). Members of the cadherin family (Table
1.7) involved in the assembly of adherins and desmosomal junctions in epithelial
sheets, and the immunoglobulin gene superfamily members NCAM and PECAM-1
can bind in this way.
Most cell adhesion molecules, such as integrin family members, are involved in
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Table 1.7 Families of Cell Adhesion Molecules.
cadherin superfamily.
immunoglobulin gene superfamily (Table 1.8)
integrin superfamily (Table 1.9)
selectin family (Table 1.10)
proteoglycan analogues (Table 1.11)
CD36 / LIMP II family (Table 1.11)
heterophilic binding, i.e. bind to a counter-receptor of different structure on another
cell, or to an extracellular ligand such as collagen or fibronectin. Members of the
selectin family and HCAM bind to carbohydrate moieties on other cells or within
the extracellular matrix.
Occasionally, cell adhesion molecules bind via a multivalent link molecule, for
example, the binding of platelet gpIIb/IIIa complex to dimeric fibrinogen, or the
binding of CD36 to thrombospondin.
Most cell adhesion molecules are transmembrane proteins, consisting of an
extracellular domain which is involved in ligand or counter-receptor binding, a
hydrophobic transmembrane domain, and an intracellular domain which is often
linked to the cytoskeleton. Bidirectional signal transduction can therefore occur
through many of these molecules. Changes in CAM expression are achieved
through alteration in local density or overall surface expression, or modulation of
the binding affinity of the molecule by modification of its chemical structure and /
or electrical charge in situ.
1.5.2 Molecular biology ofcell adhesion molecules.
There are at least five families of cell surface proteins involved in cell adhesion
(Table 1.7) [Long, 1992], These are reviewed in more depth in an appended paper
(Appendix 5). The cadherin family includes at least three related molecules involved
in calcium dependent, cell-cell homophilic binding E- cadherin (uvomorulin),
P-cadherin, and N-cadherin [Takeichi, 1988; Takeichi, 1990; Flemming, 1990;
Hynes 1992a]. Cadherins are fundamental in establishing and maintaining
boundaries between multicellular structures during embryogenesis and in
maintaining cellular cohesion in epithelial derived tissues. There is no evidence that
Cadherins are expressed by haematopoietic tissues.
Members of the immunoglobulin gene superfamily [Williams, 1987; Williams
& Barclay, 1988] include adhesion molecules which bind counter-receptors or
structural ligands, antigen-specific receptors such as the T cell receptor and surface
immunoglobulin, major histocompatibility complex molecules, neurologic-
expressed antigens, and cytokine receptors (Table 1.8). The molecules of this family
are characterised by variable numbers of immunoglobulin domains, consisting of
two sheets of anti-parallel B pleated strands, each containing 90-100 amino acids,
and an interdomain disulphide bond. Most members of the immunoglobulin gene
superfamily are involved in calcium independent heterophilic binding. The
prototypic molecule of this family is NCAM (CD56) [Edelman, 1987 and 1988],
expression of which has not, however, been observed in HPC [Saeland, Duvert,
Caux el al. 1992; Bender, Unverzagt, Walker et al. 1991].
Intercellular cell adhesion molecule, ICAM-1 (CD54), has five immunoglobulin
domains, and is expressed by a wide variety of cells, including HPC [Arkin,
Naprstek, Guarini et al. 1991; Saeland, Duvert, Caux et al. 1992], ICAM-1 and two
closely related immunoglobulin family genes ICAM-2 (CD 102) and ICAM-3
(CD50), bind to the leukocyte B integrin LFA-1. HPC expression of PECAM-1
(CD31) expression has been described by Simmons et al [Simmons, Niutta, Ashman
et al. 1992; Watt, Williamson, Genevier et al. 1993], with homophilic affinity for
PECAM-1, and heterophilic affinity for sulphated glycosaminoglycans such as
heparin and heparan sulphate [De Lisser, Newman & Albelda, 1994],
HPC expression of LFA-3 (CD58) has also been described [Saeland, Duvert,
Caux et al 1992] and is a counter-receptor to LFA-2 (CD2) expressed almost
exclusively by T cells. The majority of HPC also express HLA-DR [Srour, Brandt,
Briddell et al. 1991], Whether these molecules are involved in antigen presentation
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Table 1.8 Members of the Immunoglobulin Gene Superfamily.
Cell adhesion molecules. Nervous system.















platelet-derived growth factor receptor
carcinoembryonic antigen (CD66e)
SCF receptor (c-kit)




Legend. " expressed by both immune and neurologic cells.
or in regulation of HPC proliferation by T lymphocytes (or both) is unclear [Pantel
& Nakeff, 1993],
Two members of the immunoglobulin gene superfamily are expressed by
endothelial cells: ICAM-2 (CD102), which is constitutively expressed, and VCAM-
1 (CD 106), which is expressed in response to inflammatory stimuli, and binds the
B] integrin, VLA-4 (CD49d/CD29).
The integrins comprise a large family of transmembrane sialoglycoproteins with
widespread tissue distribution, and involvement in both cell-cell and cell-matrix
interaction (Table 1.9) [Hynes, 1987; Hemler, 1988; Albelda& Buck, 1990;
Ruoslahti, 1991; Hynes, 1992]. Molecules of this family are membrane-spanning
heterodimers, with unique a subunits, and a small number of B subunits from which
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Table 1.9 Members of the Integrin Family.
fii (CD29): VLA Family,

















a&2 LFA-1 (CD 11 a/CD 1.8)
afi2 MAC-1 (CD1 lb/CD 18)
aBopl50,95 (CD1 lc/CD18)
(CD61) Cytoadhesion Family.
an B3 GPIIa/IIIb (CD41/CD61)
ayBi VNR (CD51/CD61)
Legend. The complexity of the family has been increased by the discovery of novel
B subunits which can form alternative complexes with a , a and a .
subfamilies are defined. Subunits are M 100-200,OOOkD in size, and considerable
r
structural homology is evident; the various a chains are 25-65% homologous, and
the B chains 37-45% homologous. The a and B chains of a molecule are non-
covalently bound, and both contribute to ligand specificity, a chains demonstrate a
highly conserved binding domain to the amino-acid sequence arginine-glycine-
aspargine (RGD) [Ruoslahti & Pierschbacher, 1986 & 1987] which allows many of
this family to bind to extracellular matrix proteins such as collagen type I,
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fibronectin, laminin and vitronectin [Hynes, 1987 and 1992; Buck & Horowitz,
1987; Humphries, 1990]. In addition, the a chain contains 3-4 repeats of a divalent
cation binding site (Ca2+ or Mg2+). Changes in extracellular divalent cation
concentration and temperature affect the topology and functional activity of the in
situ molecule [Graham & Brown, 1991],
The B chains are common to subfamilies of receptors, and are bound to the
actin-based intracellular cytoskeleton by a series of link proteins which include
talin, vinculin and a-actinin [Alberts, Bray, Lewis et al. 1989]. Subfamilies are
differentiated on the basis of a common B chain (Table 1.9).
The Bi subfamily [Hemler, 1990] is widely expressed, and mainly involved in
binding to ECM proteins. Two members are reported to be expressed by HPC:
VLA-4 (CD49d/CD29), which has dual specificity to the heparin binding domain of
fibronectin and to VCAM-1 (CD106), and VLA-5 (CD49e/CD29), which recognises
the cell binding domain of fibronectin [Soligo, Schiro, Luksch et al. 1990; Saeland,
Duvert, Caux et al. 1992; Liesveld, Winslow, Frediani et al. 1993], The VLA-
4:VCAM-1 adhesion system appears to be of particular importance in the adhesion
of HPC to stroma in vitro [Miyake, Weissman, Greenberger et al. 1991; Miyake,
Medina, Ishihara et al. 1991; Miyake, Hasunuma, Yagita et al. 1992; Simmons,
Masinovsky, Longenecker et al. 1992],
The B subfamily [Larson & Springer, 1990; Arnaout, 1990] are termed
leucocyte cell adhesion molecules, and comprise three members with a common B
chain (CD18). LFA-1 (CD1 la/CD18) is expressed by all leucocytes including HPC,
and is a counter- receptor for ICAM-1 and -2 as previously discussed [Soligo,
Schiro, Luksch et al. 1990; Kansas, Muirhead & Dailey, 1990; Saeland, Duvert,
Caux et al. 1992; Liesveld, Winslow, Frediani et al. 1993].
The B; (cytoadhesin) subfamily comprises gpIIb/IIIa (CD41a/CD61), an
important platelet adhesion molecule for fibrinogen, fibronectin, and von
Willebrand Factor (vWF); and the vitronectin receptor (VNR) (CD51/CD61).
Under normal physiological conditions, integrins largely exist in an inactive
form. A variety of physiological stimuli such as cytokines or cell adhesion, or
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Table 1.10 Members of the Selectin Family.
L-Selectin (LECAM-1, MEL-14, LAM-1) (CD62L)
E-Selectin (LECAM-2, ELAM-1) (CD62E)
P-Selectin (LECAM-3, GMP-140, PADGEM) (CD62P)
chemical substances such as phorbol myristate acetate (PMA) or calcium ionophore,
can lead to rapid activation of integrin binding through conformational changes
mediated through the cytoskeleton [Makgoba & Bernard, 1993].
The selectin family are C-type lectins i.e. carbohydrate-binding proteins (Table
1.10) [Rosen, 1990; Watson, Kingsmore, Johnston, et al. 1990; Springer & Lasky,
1991; Lasky, 1991 & 1992; Bevilacqua & Nelson, 1993]. The N terminal domain is
homologous with a variety of animal lectins, including hepatic galactose receptors,
soluble mannose binding lectins, invertebrate lectins, and also the low affinity
receptor for IgE (CD23). They are temperature insensitive, and Ca2+ dependent,
though Mg2+ independent. There are three members of the family. L-selectin
(CD62L) (LECAM-1, MEL-14, LAM-1) plays a central role in the regulation of
lymphocyte traffic, and has been shown to be expressed by HPC by Simmons,
Niutta, Ashman et al [1992]. E-selectin (CD62E) (LECAM-2, ELAM-1) is
expressed by endothelial cells in response to inflammatory stimuli. P-selectin
(CD62P) (LECAM-3/GMP-140/PADGEM), is stored in the a granules of
megakaryocytes and platelets, and in Weibel-Palade bodies in endothelial cells.
Current evidence suggests that selectins mediate leukocyte rolling on inflamed
endothelium, by recognition and presentation of oligosaccharide ligands such as
Lewis" (CD15), sialyl Lewis" (CD15s), and VIM2 (CDw65) [Lawrence & Springer,
1991; Pickler, Warnock, Burns et al. 1991; Foxwall, Watson, Dowbenko et al.
1992; von Andrian, Chambers, Berg et al. 1993; Kuijpers, 1993] and CD34
[Baumhueter, Singer, Henzel et al. 1993],
The homing-associated cell adhesion molecule HCAM (CD44) (Table 1.11)
[Haynes, Telen, Hale et al. 1989; Lewisohn, Nagler, Ginzton et al. 1989] represents
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GPIIIb or IV (CD36).
a family of cell surface glycoproteins ranging from 80 to 200kD, most of which
have hyaluronan binding affinity (Haynes, Liao & Patton, 1991; Underhill, 1992).
Tissue expression is widespread on both leucocytes and epithelial cells: the
molecule has been identified as of key importance in the recirculation of
lymphocytes between blood and lymphoid organs, from which it derives its name.
The distal portion of the CD44 extracellular domain has significant homology with
cartilage-link and proteoglycan core proteins. Cartilage-link proteins stabilise large
aggregates of proteoglycan core proteins by binding proteoglycan monomers to
hyaluronic acid or collagen. CD44 is the principal cell surface receptor for
hyaluronic acid [Miyake, Underhill, Lesley et al. 1990], and binds additional
extracellular matrix components including fibronectin, collagen types I and VI, and
a vascular endothelial molecule. At least 12 different isoforms are generated by
alternative splicing leading to the addition of variable numbers of exons to the
membrane proximal extracellular domain. The haematopoietic isoform (CD44H)
has no additional exons, whilst the epithelial isoform (CD44E) has additional
isoforms and a reduced affinity for hyaluronic acid [Dougherty, Cooper, Memory et
al. 1994]. The products of CD44 gene activity appear to exercise many diverse
functions in the cell, and at the cell surface, and disturbances in gene activity arising
from derangement in the control of alternative splicing occur early in the natural
history ofmany malignancies [Dougherty, Lansdorp, Cooper et al. 1991;
Stamenkovic, Aruffo, Amiot et al. 1991; Screaton, Bell, Jackson et al. 1992;
Matsumura & Tarin, 1993]. Monoclonal antibodies to CD44 have been shown to
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blockade lymphohaematopoiesis in bone marrow stromal cultures [Miyake, Medina,
Hayashi etal. 1990].
CD36 (GPIIIb or IV) (Table 1.11) is an 88kD transmembrane glycoprotein, with
substantial homology to a rat lysosomal integral membrane protein (LIMP II).
CD36 acts as a cellular receptor for oxidised low density lipoprotein, for collagen
and for thrombospondin [Asch, Barnwell, Silverstein et al. 1987; Asch, Tepler,
Silbiger et al. 1991; Greenwalt, Lipsky, Ockenhouse et al. 1992]. In addition, there
is evidence that CD36 is expressed by erythrocytes infected with the human malarial
parasite Plasmodium falciparum. CD36 displays a unique structure in which both
amino and carboxyl termini are intracellular, and the central region of the molecule
is extracellular. The intracellular domains contain protein tyrosine kinase activity
and are thought to be involved in signal transduction [Greenwalt, Lipsky,
Ockenhouse etal. 1992],
1.5.3 Conceptualproblems: cell identity andposition.
It will be understood from the foregoing discussion that there is categorical
overlap between cytokines and their receptors, and cell adhesion molecules and their
ligands. For example M-CSF receptor (c-fms, CD115) and SCF receptor (c-kit,
CD 117) are classified as cytokine receptors, but are structural members of the
immunoglobulin gene superfamily of cell adhesion molecules. Presentation of
cytokines on the cell membrane or bound to extracellular matrix proteoglycans may
principally provide a mechanism for spatial containment or modulation of the signal
[Ruoslahti & Yamaguchi, 1991], but could also be conceived as a functional cell
adhesion system [Nathan & Sporn, 1991]. Conversely, members of the integrin
family of cell adhesion molecules are bidirectional signal transducers, and binding
to a ligand may effect changes in cellular phenotype, morphology, functional
activity and survival [Ruoslahti & Reed, 1994].
Moreover, both cytokines and cell adhesion molecules show evidence of
pleiotropism (i.e. ligands expressed by multiple targets) and polyfunctionality (i.e.
multiple functional changes effected by ligand binding). Indeed, the targets
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themselves may express multiple ligands for different cytokines, cell adhesion
molecules, or ECM components. Cell adhesion behaviour is likely to be determined
by the composite action of a mosaic of cell adhesion molecules, expressed at
variable density, distribution and activation status on the cell membrane.
Contemplating such complexity from a homeostatic view point [Bernard, 1865]
gives the appearance ofmarked redundancy within the system. It may be more
productive to view such a system as a highly interconnected network of exceptional
depth and subtlety [Metcalf, 1993]. Whichever paradigm is preferred, a reductionist
approach to analysing the determinants of cell adhesion may run in to difficulties
with this general property of functional overlap.
Finally, the dependence of adhesion on cell phenotype, ofmicroenvironmental
signalling on adhesion and of differential gene expression on signalling, suggests a
very high degree on interdependence of cell identity, function and position
[Wolpert, 1969; Edelman, 1988; Dainiak, 1991; Greenwald & Rubin, 1992],
1.6 Haematopoietic Progenitor Cell Adhesion: The Objectives of the Study.
HPC interact with bone marrow in three generic ways: (1) circulating HPC
recognise and transmigrate the sinusoidal endothelium (homing); (2) HPC adhere to
marrow stromal cells or ECM components (engraftment); and (3) HPC
communicate with regulatory cells (such as T lymphocytes and monocytes) through
a variety ofmethods including adhesion (regulation).
Although it is recognised that these processesmust be mediated inprinciple through
HPC cell adhesionmolecule recognition of ligands or counter-receptors expressed by
bonemarrow sinusoidal endothelium, stromal cells and extracellularmatrix
components, the cell adhesionmolecules involved and their functional roles are poorly
defined. Expression of numerous CAM belonging to several molecular families has
been described by various groups. These include immunoglobulin gene superfamily
members ICAM-1 (CD54) [Arkin, Naprstek, Guarini et al, 1991; Saeland, Duvert,
Caux et al, 1992], PECAM-1 (CD31) [Simmons, Niutta, Ashman et al, 1992; Watt,
Williamson, Genevier et al, 1993; Lund-Johansen & Terstappen, 1993] and LFA-3
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(CD58) [Saeland, Duvert, Caux et al, 1992], the B( integrins VLA-4 (CD49d/CD29)
and VLA-5 (CD49e/CD29) [Soligo, Schiro, Luksch et al, 1990; Rosemblatt,
Vuillet-Gaugler, Leroy et al. 1991; Saeland, Duvert, Caux et al, 1992; Teixido,
Hemler, Greenberger et al. 1992; Liesveld, Winslow, Frediani et al, 1993; Lund-
Johansen & Terstappen, 1993], the B2 integrin LFA-1 (CD1 la/CD18) [Soligo,
Schiro, Luksch et al, 1990; Teixido, Hemler, Greenberger et al. 1992; Saeland,
Duvert, Caux et al, 1992; Liesveld, Winslow, Frediani et al, 1993; Kansas,
Muirhead & Dailey, 1990; Papayannopoulou & Brice, 1992], L-Selectin (CD62L)
[Simmons, Niutta, Ashman et al, 1992; Lund-Johansen & Terstappen, 1993], the
HCAM (CD44) family [Lewinsohn, Nagler, Ginzton et al, 1990; Kansas, Muirhead
& Dailey, 1990; Saeland, Duvert, Caux et al, 1992; Lund-Johansen & Terstappen,
1993] and CD36 [Long & Dixit, 1990; Greenwalt, Lipsky, Ockenhouse et al, 1992]
(Table 3.1). In addition to these, CD34 may itself act as a ligand for L-Selectin
[Baumhueter, Singer, Henzel et al, 1993], CD43 may bind ICAM-1 (CD54) [Moore,
Huang, Terstappen et al. 1994] and Sialyl Lewis" is known to be a ligand for P- and
E-selectins [Lund-Johansen & Terstappen, 1993; Karakantza, Gibson, Cavenagh et
al. 1994], CD45 and Thy-1 are known to mediate adhesion to heparan sulphate
[Parish, Hogarth & McKenzie, 1988], HLA-DR may mediate adhesion to CD4+ T
lymphocytes and CD4 may mediate adhesion to HLA Class II receptors on other
regulatory cells such as monocytes [Zauli, Furlini, Vitale et al, 1994; Louache,
Debili, Marandin et al. 1994], Finally, cell membrane-associated proteoglycans may
mediate adhesion to fibronectin [Minguell, Hardy & Tavassoli, 1992; Verfaillie,
Benis, Iida et al, 1994], Other potential cell adhesion molecules remain poorly
defined [Aizawa & Tavassoli, 1987 & 1988; Tavassoli & Hardy, 1990; Hardy,
Matsuoka & Tavassoli, 1991; Tavassoli & Minguell, 1991], or are of uncertain
adhesive import e.g. the interaction of cytokine receptors such as c-kit with their
membrane- or proteoglycan-bound ligands [Reisbach, Bartke, Kempkes et al. 1993].
The system displays a further level of complexity. Most CAMs display both
pleiotropism and polyfunctionality due to the presence ofmultiple structural
domains within CAMs and their ligands, and diverse secondary messenger systems.
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There exist, therefore, multiple potential HPC adhesive pathways, any or all of
which may participate in cell homing, engraftment and regulation. This diversity
may reflect heterogeneity within the CD34+ population, the variety of cellular and
extracellular matrix elements with which HPC engage, or the manner in which
HPC-stromal adhesion is initiated and stabilised. Finally, the possibility that real
functional redundancy exists within the system must be considered.
Thefirst objective ofthis studywas to establish an optimalmethodwith which to
define the humanHPCpopulation and to characterise thepatternofcell adhesion
molecule expression within thatpopulation.
The mechanisms underlying HPC release from the marrow during mobilisation
are unknown, and may or may not resemble the physiological release of HPC which
must occur during migration. Three hypotheses were considered: first that alteration
or blockade ofHPC cell adhesion molecule expression occurs, either as a direct
affect of the mobilising agent, or as an indirect response to humoral feedback from
other cells or tissues. Second that damage to the sinusoidal endothelium occurs,
leading to loss of control over cell traffic across the blood / marrow interface. Third
that perturbation of HPC population dynamics as a result of increased cell
proliferation or survival leads to "spill-over" of excess HPC from the marrow into
the peripheral blood (Appendix 5). These possibilities are not necessarily mutually
exclusive, and different mechanisms may predominate under different
circumstances (Table 1.5).
Ifthe first proposition is correct onemight expect differences inCAM expression
between sessile and circulating HPC, whereas ifthe second or third are correct one
might not.
The second objective was to determine whether differences in CAM expression
could be detected between sessile and circulating HPC and ifso, whether such
differences could be responsible for HPC mobilisation or simply reflect more
general differences in the heterogeneity ofthe study population.
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Phenotypic information provides, at best, circumstantial evidence for the
involvement of specific cell adhesion pathways in HPC homing, engraftment and
mobilisation. Semisolid clonogenic assays have been used by several groups to
investigate HPC adhesion. Selective localisation of primitive HPC in stromal
cultures is recognised [Coulombel, Eaves, Eaves et al, 1983; Gordon, Clarke,
Atkinson et al, 1990; Liesveld, Abboud, Duerst et al. 1989]. Differential binding of
erythroid and myeloid progenitors to collagen type I [Koenigsmann, Griffin, DiCarlo
et al, 1992], to fibroblasts and fibronectin [Tsai, Patel, Beaumont etal, 1987;
Coulombel, Vuillet-Gaugler, Leroy et al, 1988 & 1991; Verfaillie, McCarthy &
McGlave, 1990] and to hemonectin [Campbell, Long & Wicha, 1990], have been
described. One ofthe key issues is the extent towhich a causal link can be drawn
between the expression of a given CAM and cellular adhesion behaviour.
The third objective was the development ofan assay system which would allow
the correlation ofcellular CAMphenotype with functional adhesion to a variety of
substrates, and which wouldpermit analysis ofthe adhesion pathways involved
through through selective activation and blockade.
62
CHAPTER 2. QUANTITATIVE DETERMINATION OF
HAEMATOPOIETIC PROGENITORS.
2.1 Introduction. p 64
2.2 General Methodology.
. 1 Sources ofhuman material, p 65.
.2 Culture and storage ofcell lines, p 66.
.3 Enumeration ofnucleated cells and assessment ofviability, p 68.
p 65
2.3 Standard Methodology for the CFU-GM Assay. p 68
2.4 Optimisation of CD34 Immunocytometry. p 69
.1 Backgound. p 69.
.2 Titration and handling ofmonoclonal antibodies, p 76.
.3 Optimisation of immunofluorescence labelling, p 80.
.4 Effects oferythrocyte lysis and cellfixation on the physical andfluorescence
characteristics ofthe study population, p 82.
.5 Set-up ofthe flow cytometer. p 84.
. 6 Comparative study ofavailable anti-CD34 monoclonal antibodies and
direct / indirect systems of labelling, p 88.
2.5 Determination of Resolution Limits of Immunocytometry. p 94
2.6 Evaluation of Different Approaches to Data Analysis. p 96
2.7 Study of the Overall Accuracy of CD34 Quantitation. p 101
2.8 Establishment of a Correlation between CD34 and CFU-GM Assays.
p 103
.1 Standardisation and reproducibility of the CFU-GM assay, p 105.
.2 Standardisation and reproducibility ofCD34* quantitation, p 107.
.3 Theoretical considerations in the definition ofthe CD34+ population, p 109.
2.9 Discussion. p 105
63
2.1 Introduction.
The starting point for study of haematopoietic progenitor cells (HPC) was the
development of accurate and reproducible assays. For many years the granulocyte /
monocyte colony-forming unit assay (CFU-GM) [Pluznick & Sachs, 1965; Bradley
& Metcalf, 1966] has been regarded as the gold standard for clinical HPC
quantitation of bone marrow and peripheral blood harvests, and for many research
purposes. This is a functional assay in which the study population is incubated for 7-
14 days in culture medium, serum and a cytokine source, in a support matrix of agar
or methylcellulose. HPC proliferate to form colonies which are held together by the
support matrix, and can be enumerated by light microscopy against a backgound of
individual cells or precursors with very restricted proliferative capacity. In man,
CFU-GM have been shown to correlate well with neutrophil recovery after bone
marrow transplantation, but to a lesser degree with platelet recovery.
Clonogenic assays suffer from several limitations for routine clinical and
research use, namely a high degree of dependence on the culture conditions,
difficulty in achieving standardisation between laboratories, a 14 day delay in
awaiting a read-out and representation of only a subset of the HPC population
(namely committed myeloid progenitors). Their central strength is that they provide
direct functional evidence of the presence of haematopoietic progenitors. A standard
form of the CFU-GM assay was used to validate an immunocytometry assay as
described below. The culture methodology is discussed in Section 2.3.
The search for a more global, rapid and standardised HPC assay has directed
attention to immunocytometry. The fluorescence activated cell scanner (FACS)
combines multiparameter measurements of physical properties and fluorescence on
large numbers of cells, allowing greater accuracy in the enumeration and phenotypic
characterisation of cell populations [Parks, Lanier & Herzenberg, 1986], As
discussed above (Section 1.2.4), the majority of human HPC express the CD34
antigen, which may justifiably be used as a broad indicator of this compartment.
Here again important problems exist, this time due to the small size of the study
population and low expression of the CD34 antigen, and methodological problems
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such as the choice ofmonoclonal antibody and fluorochrome. Much care was taken
to optimise and standardise CD34 immunocytometry methodology which was
critical to the accuracy of the further studies, and this is detailed in Sections 2.4 to
2.6. The overall accuracy ofCD34 quantitation was studied in Section 2.7 and a
linear relationship between CD34+ cell numbers and CFU-GM colony formation
established in Section 2.8. Finally, the methodological limitations ofHPC assays,
and attempts to achieve reproducibility and standardisation between different
European laboratories, are discussed in Section 2.9.
2.2 General Methodology.
2.2.1 Sources ofhuman material
Sources of human material included (1) peripheral blood samples from normal
volunteers (PB); (2) peripheral blood (PBm) and leucapheresis product (LP) from
patients with Hodgkin's disease, non- Hodgkin's lymphoma, or stage III / IV breast
carcinoma, undergoing peripheral blood leucocyte harvest during the recovery phase
following high dose cyclophosphamide (4g/m2 iv) and recombinant human
granulocyte colony stimulating factor (rhuG-CSF) (5pg/kg/day sc); (3) normal bone
marrow (BM) initially obtained from the sternum of patients undergoing
cardiothoracic surgery or from pelvic bone fragments from patients undergoing
prosthetic hip replacement. These sources proved entirely unsatisfactory however,
and for the work described bone marrow aspirates had to be obtained from the
posterior iliac crest of normal volunteers under local anaesthetic, or of patients
undergoing general anaesthetic for non-malignant surgical procedures; (4) Placental
umbilical cord blood samples after Caesarean section (CB).
Bone marrow and blood samples were judged "normal" on the strength of a
normal peripheral blood count and the absence of relevant disease in the donor.
10ml samples were collected in a syringe pre-flushed with heparin, and were held in
a sterile universal container containing 10ml Hanks' balanced salts solution (HBSS)
with lOmM ethylenediaminetetra-acetic acid (EDTA), so that original cell counts
could be calculated from actual counts made on the diluted samples. Latterly, the
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anticoagulation was changed to 500iu (4mg) lithium heparin in a 20ml universal
container, which was found to be more satisfactory for BM and CB samples.
The use of human material for this study was approved by Lothian Health
Board, Ethics ofMedical Research Sub-Committee for Medicine and Clinical
Oncology under submission numbers MCO/58/91, MCO/98/91, and MCO/47/92.
All samples were taken and used with the informed consent of the patient or
volunteer. Personal medical information was treated as confidential, and complied
with the guidelines set out by the Data Protection Act 1984.
2.2.2 Culture and storage ofcell lines.
The cell lines used during these studies are listed in Table 2.1. Imported cell
lines were expanded in culture to establish a master cell bank, which was stored in
aliquots at -160°C in liquid Nitrogen. Aliquots were thawed for use as required to
maintain a working cell bank.
Suspension cell lines were maintained in Iscove's modified Dulbecco's medium
(IMDM), 10% foetal calf serum (FCS) with 1% antibiotic stock (standard tissue
culture medium. Appendix 2) at a concentration of lxlO6 cells/ml. FCS was heat
inactivated by incubation at 56°C for 30min. The medium was changed and cell
concentration adjusted, once or twice a week as necessary. Cell manipulation was
carried out using sterile technique in a laminar flow cabinet. All tissue culture media
were filtered prior to use, stored at +4°C in sterile glassware, and discarded after one
week. In view of recurrent problems with fungal contamination of the cultures, 50
and 250ml canted-neck tissue culture flasks were used with a vented cap
incorporating a hydrophobic membrane filter, allowing continuous gaseous
exchange with the incubator environment whilst maintaining a hermetic seal. The
incubator was maintained at 37°C, 5% C02 and 100% humidity.
Adherent cell lines were also maintained in standard tissue culture medium and
the same incubator environment, but were passaged once a week by discarding the
medium, washing once in anticoagulant medium, and incubating with sufficient
trypsin / EDTA to cover the surface of the plate (l-2ml in a 50ml 25cm2 flask, 5ml
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Table 2.1 Human Haematopoietic Cell Lines Studied.
KGla acute myelogenous leukaemia cell line [Koeffler, Biling, Lusis et al. 1980].
K562. chronic myelogenous leukaemia. [Lozzio & Lozzio, 1975].
HL60 acute promyelocytic leukaemia.[Collins, Gallo & Gallagher, 1977].
CEM T lymphoblastic leukaemia (Sangster, Minowada, Suciu-Foca et al. 1986).
NALM-6 B cell lymphoma line.
in a 250ml 75cm2 flask). Some adherent lines such as M210-B4 detach from the
surface quite easily, but remain aggregated as sheets in suspension which required
further trypsin exposure. Others, such as 5637 required prolonged trypsin incubation
at 37°C along with considerable shaking to detach them from the plastic surface, but
achieved a single cell suspension. Satisfactory dispersion was assessed using an
inverted microscope. The action of the trypsin was arrested by adding 5ml FCS,
followed by centrifugation and resuspension in fresh culture medium.
Surplus cells were cryopreserved in FCS, 10% dimethylsulfoxide (DMSO) using
a programmed cell freezer, and stored at -160°C in liquid nitrogen. For recovery,
cells were defrosted rapidly in a 37°C waterbath, and mixed with 1ml FCS
containing lOOpl magnesium sulphate, lOOpl DNAse, and lOOpl preservative-free
heparin. They were allowed to equilibrate at ambient temperature for 5 min,
subjected to centrifugation, and re-suspended in culture medium for 30 min. The
cells were resuspended in fresh culture medium before transfer to tissue culture
flasks.
Unless otherwise stated, all centrifugation was carried out at 20Og for 5 min, and
the supernatant removed by tube inversion or by aspiration.
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2.2.3 Enumeration ofnucleated cells and assessment ofviability.
Enumeration of nucleated cells was carried out using a Coulter ZF cell counter,
following lysis of red cells by lyzerglobin, or latterly by direct analysis using a
Coulter T-890. Cell concentration could be related to differential cell counts in the
original specimen because a standard amount of diluent (10ml of anticoagulant
medium) was used.
Original cell concentration = measured cell concentration x final volume
original volume
The later use of lithium heparin as an anticoagulant obviated the need for this
calculation.
Enumeration of cell lines was carried out using a Neubauer haemocytometer.
This proved more useful than the automated counters in that it allowed exclusion of
cell debris and non-viable cells, and an assessment of homotypic aggregation. To
maintain maximal reproducibility all cell counting was carried out by the same
observer.
Cell viability was assessed by trypan blue dye exclusion, a measure of
membrane integrity. 50pl of cells were incubated with an equal volume of trypan
blue for 5 minutes (final concentration 0.2%), and examined in a Neubauer
haemocytometer using an inverted microscope. Clear cells were considered viable,
dark blue cells were considered non-viable. Of importance is the observation that
trypan blue exclusion will not detect the early stages of apoptosis, and is therefore a
relatively crude measure of cell survival [Koury, 1992].
2.3 Standard Methodology for the CFU-GM Assay.
A standard method was adopted for the CFU-GM assay. A mononuclear cell
suspension was prepared over Ficoll-Hypaque (density 1.077g/dl). 10ml of the
sample in anticoagulant medium (1:2 dilution) was layered carefully over 4ml of
Ficoll-Hypaque, and centrifuged at 500g for 15min. The mononuclear cells were
recovered from the plasma / Ficoll interface using a disposable Pasteur pipette, and
the cell concentration adjusted to 2x106 cells/ml in standard tissue culture medium.
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200pl of medium containing 4x105 cells was added to 800pl methylcellulose, 600pl
FCS, 200pl of 5637 conditioned medium, 170pl IMDM, and 30pl of antibiotic
stock (total 2ml) (CFU-GM assay medium Appendix 2).
Methylcellulose was made up in the following manner: 18g ofmethylcellulose
was autoclaved, and 450ml distilled water was filtered into a sterile bottle. The latter
was heated to boiling point, the methylcellulose added, and the solution allowed to
simmer for a further lOmin. The temperature was allowed to drop to 37°C with
magnetic stirring, and 50ml of 10 x IMDM was added. The solution was stirred for
a further 15-30min at +4°C until it thickened, and was left overnight to settle
[Freshney, Pragnell & Freshney, 1994], New batches of FCS were bought in on a 6-
12 monthly basis and compared for overall CFU-GM formation against each other
and against previous batches. It was stored at -20°C prior to use. Conditioned
medium was prepared by culture of the 5637 human bladder carcinoma-derived cell
line in standard tissue culture medium to produce an adherent layer. The media was
removed at weekly intervals, clarified of debris by centrifugation, and stored frozen
at -70°C until required. 0.5ml ofCFU-GM culture medium containing lxl 05 cells
was added to each of 3 wells of a 24 well tissue culture cluster dish, each with an
approximate surface area of 2cm2. Cultures were incubated at 37°C, 5%C02, 100%
humidity for 14 days. Clusters of 10-50 cells, and colonies of greater than 50 cells
were enumerated using an inverted microscope, and the mean of the triplicate assays
quoted as the result. CFU-GM clusters and colonies are illustrated in Figure 2.1.
2.4 Optimisation of CD34 Immunocytometry.
2.4.1 Background.
When highly purified antigens began to be used for immunisation in the 1930s
and 40s it was recognised that the antibody response to a single antigen was
heterogeneous i.e. involved the formation of complex populations of antibodies to
various epitopes. Recognition of the existence of homogeneous antibody
populations arose out of studies of the occurrence of Bence Jones proteinuria and
serum monoclonal immunoglobulins in patients with myeloma. Kohler and Milstein
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Figure 2.1 CFU-GM Colony Assays.
A
Legend. Cluster (A) and colony (B) formation in a day +14 CFU-GM assay
(magnification xlO).
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[1975] were instrumental in the development of the hybridoma technique for
producing monoclonal antibodies (mAbs), whereby antibody-forming spleen or
lymph node cells from a mouse immunised with known antigens are fused with
murine plasmacytoma cells, and the resultant clones screened for the production of
antibodies of useful specificity. MAbs have provided a highly specific tool for the
analysis of antigen structure and expression, and latterly a series of international
workshops has established a system whereby mAbs from different sources are
classified according to their antigenic specificity (cluster designation CD) [Golding,
1983],
Fluorochrome dyes which absorb light at a specific wavelength and emit light at
a higher wavelength have proved useful as detector systems. Fluorescein
isothiocyanate (FITC) can be readily conjugated to mAbs without loss of antibody
specificity or avidity, or dye quenching. It absorbs light at 488nm and emits at
around 520nm. A group of natural fluorochromes, the phycobiliproteins (which
include phycoerythrin (RPE), phycocyanin and allophycocyanin), are derived from
red algae and photosynthetic cyanobacteria. RPE absorbs maximum light at 505nm
and 75% ofmaximum at 488nm, emitting at 578nm. Because of their similar
excitation wavelength but discrete emission wavelengths FITC and RPE can be used
together in dual immunofluorescence studies. Initially, three colour
immunocytometry was only possible using fluorochromes with higher excitation
and emission wavelengths, necessitating the use of a dual laser instrument. Latterly,
a number of tandem dyes have been developed for single laser three colour work
{e.g. Red613 and Quantum Red) containing a donor fluorochrome (usually RPE)
which emits light within the excitation wavelength of an acceptor fluorochrome,
which emits light at a higher wavelength {e.g. Cy5 in Quantum Red) [Glazer &
Stryer, 1983]. The combination emits light at a higher wavelength (630-670nm).
Very recently a new dye, peridinin chlorophyll protein (PerCP) has been developed
which absorbs light at 488nm and emits at 675nm, bringing the potential advantages
of a simpler labelling protocol and less fluorescence overlap (Chapter 3.5.1).
Cellular autofluorescence, a product of normal cell constituents such as flavins
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and cytochromes, provides the background against which a specific fluorescence
label must be detected. Moreover, many cells express Fc gamma receptors which
bind mAbs through the Fc arm of the antibody, leading to false interpretation of
those cells as antigen positive. Where possible fluorochrome-conjugated antibody
fragments (Fab or F(ab')2) adsorbed with human serum proteins were used in order
to reduce non-specific uptake and cross-linking of antigenic sites which can
precipitate cell aggregation. To achieve accurate information by
immunofluorescence considerable care must be devoted to the choice ofmAb and
fluorochrome dye, optimal cell preparation and labelling technique.
Flow cytometry provides multiparameter measurements on large numbers of
cells in suspension, allowing characterisation of cell populations and the
identification of component subpopulations. The fluorescence activated cell scanner
(FACS) is equipped with an argon laser tuned at 488nm, power 14.8mW. It
combines measurements of intrinsic cell properties (forward and side light scatter),
with quantitative assessment of fluorescence [Parks, Lanier & Herzenberg, 1986].
Cells in suspension pass from a reservoir into the centre of a nozzle, where they are
surrounded by cell free sheath fluid which confines the cells to the centre of a liquid
jet. The laser emits light which is of single wavelength (monochromatic), in phase
(coherent), and unidirectional with all rays parallel (collimated). As cells pass
through the focused laser beam they scatter laser light, and fluorescent molecules
that they contain or carry, are excited and fluoresce. A forward light scatter (FSC)
detector detects light scattered at small angles from the axis of the laser, and
converts it to an electronic signal. A side light scatter (SSC) detector detects light
perpendicular to the axis. Fluorescent light is directed to separate photomultiplier
detectors by a dichroic reflector. Optical filters reject scattered light, and help to
define the acceptance wavelengths for each detector (Figure 2.2). Light scatter and
fluorescence detector signals are amplified and digitised and stored by computer.
Light scatter analysis provides information about relative cell size and internal
complexity, which proves useful for discrimination of cell types in heterogeneous
populations (Figure 2.3). Light scatter is most proportional to overall cell size at
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Legend. Monochromatic collimated light (480nm) from an argon ion laser
illuminates the stream of individual cells (a). Light reflected due to the size and
granularity of the cell is detected by the forward (b) and orthogonal side (c) scatter
detectors respectively. Cellular and membrane-bound fluorochromes absorb incident
light and emit light at a higher wavelength (d). The dichroic reflector (e) reflects
light of lower wavelength and allows light of higher wavelength to pass through.
Further refinement is achieved by the band pass filters if) which permit passage of a
very restricted range of light wavelengths. The photomultiplier tubes (PMT) (g)
convert light intensity into electrical voltage, which is then digitalised and analysed
by computer.
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Figure 2.3 FSC / SSC Characteristics ofMature Cell Populations.
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Legend. Forward and side scatter characteristics of leukocyte populations in lysed
peripheral blood: unlabelled (A); CD 16" neutrophils and natural killer cells (B);
CD 14* monocytes (C); CD3" T lymphocytes (D); CD19+ B lymphocytes (E); CD45
leucocytes (F).
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smallest angles from the laser axis (FSC). At large angles (in the 90° range), light
scatter is significantly affected by internal structure, granularity and nuclear shape
(SSC). Back angles (180°) show weak signals, similar in informational content to
the corresponding forward angles. Light scatter from non-spherical cells can be
affected by cell orientation. The measurement of fluorescent light requires that
several criteria be fulfilled, namely that fluorescence signals should be proportional
to the amount of dye in or on the cell, that there should be sufficient signal for
analysis and that there is a high signal to noise ratio. Signal / dye proportionality can
be degraded if the laser illumination is not sufficiently high or if there is non-
linearity in the electronics due to photomultiplier detector or amplifier saturation.
Fluorescence signals from a particular dye are passed through a system of optical
filters to discriminate against light from other sources - for example the exciting
laser beam, stray room light, cellular autofluorescence or fluorescent light from
other dyes. Since laser light is several orders ofmagnitude brighter than
fluorescence, the filters must have an attenuation approaching 6 orders ofmagnitude
at the laser wavelength. Optical filtering is achieved in two ways. Firstly by use of a
dichroic reflector which reflects shorter wavelengths, whilst allowing longer
wavelengths to pass. These are useful for separating signals when several dyes are
excited by one laser. Secondly, by use of selected band pass filters which will only
transmit light within a narrow band of wavelengths (usually in the order of 30nm)
(see Figure 2.2). Photomultiplier detectors are used for low level fluorescence
detection because they offer high gain / low noise amplification of the
photoelectronic signal produced by the fluorescent light, and good linearity over a
wide range of signal levels. The relationship between the intensity of detected light
and the electronic signal generated is dependent on the voltage of photomultiplier
detector (gain), and the mode of amplification. The choice between linear and
logarithmic amplification depends on the range of signals to be measured, and the
type of distribution expected. Linear amplification is appropriate for signals that
vary over a small range, such as light scatter. Logarithmic amplification is
particularly useful for immunofluorescence, where a single sample may contain
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autofluorescent cells, stained cells several times as bright, and stained cells tens or
hundreds as times as bright. Logarithmic amplification was used during the
acquisition and visualisation of fluorescence data, but the data was converted to
linear values by the software prior to mathematical analysis.
The detector voltages and signal amplification on the flow cytometer are
adjusted for each series of experiments using negative control (irrelevant-
specificity, isotype-specific) and positive control (anti-CD45) stained samples for
each fluorescence parameter to be measured. The study population needs to be
evenly distributed on the FSC / SSC dot-plot, and the negative control cell
population should fall on the left of the fluorescence histograms. If the histogram is
too far to the left, however, low fluorescence cells will summate in the 0 column
and undermine the validity of the measurements ofmean fluorescence intensity
(mfi) vide infra. Spectral overlap occurs in systems in which more than one
fluorescent dye is in use. Compensation is achieved by running positive control
samples stained with one dye and adjusting the signal output from the
complementary detector such that the histogram is the same as that of the negative
control (Figure 2.4). This is carried out by adjustment of the linear amplifier (the
photomultiplier detector voltage should remain constant).
Once the cytometer was set-up for a particular series of experiments, the
parameters were not changed, so that data were comparable between experiments.
2.4.2 Titration and handling ofmonoclonal antibodies.
MAbs were purchased from a commercial source (Appendix 1), reconstituted
according to manufacturers' instructions, aliquoted and stored frozen (-70°C) if non-
conjugated, or at +4°C if conjugated. Prior to use mAbs were spun at 16,000# for
30min at +4°C using an Eppendorf centrifuge in a cold room, to remove aggregates.
This manoeuver was repeated on a weekly basis for the directly conjugated mAbs
and sheep anti-mouse (SAM) FITC and RPE conjugates. Each mAb was titrated
prior to routine use on an appropriate cell population. Table 2.2 shows the data from
a representative experiment in which the anti-CD34 mAb 8G12-RPE was titrated on
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Figure 2.4 Negative and Positive Controls and Compensation.
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Legend. Negative and single stained CD45-FITC and CD45 SAM-RPE positive
controls were used to establish satisfactory fluorescence gains and compensation,
(A) Negative control (B) CD45-FITC control (C) CD45 SAM-RPE control.
Compensation ensures that fluorescence in the unstained channel of the stained
positive controls (i.e. FL-2 in B and FL-1 in C) is similar to that in the negative
controls (i.e. A).
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20pl 98.7% 1181 ±530 2.23
10pl*# 98.4% 1068 ± 504 2.12
5 pi 98.7% 1076 ±503 2.14
lpl 97.9% 618 ±529 1.17
0.5pl 87.4% 176±145 1.21
O.lpl 5.1% 25 ±34 0.74
0.05pl 6.8% 30 ±24 1.25
O.Olpl 0.04% 3 ± 1 1.48
negative
control
0.01% 1.2 ± 1.5
Legend. A range of volumes of 8G12-RPE were used to label 5x105 KGla in order
to establish the optimum titration for routine use. Percentage positive fluorescence
(%fT), mean fluorescence intensity (mfi) and resolution index (RI) were calculated.
The mAb may be used down to a concentration of 5pl / 5xl05 cells.
* manufacturers recommendation. # volume used.
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the KGla cell line. A range of volumes of the mAb were used to stain 5xl05 KGla,
though equally serial dilutions of the same volume could have been used. In this
case 5-10pl is adequate to achieve saturation of available epitopes. Below this, the
mean fluorescence intensity (mfi) and the percentage positive fluorescence (%fl+)
begin to fall because the quantity ofmAb is inadequate. Above this the amount of
non-specific binding and low-affinity Fc receptor uptake ofmAb is increased.
The negative controls should be used at a similar volume and concentration to
the test mAbs. This allows calculation of a resolution index (RI) for the mAb
defined as: RI = mfi+ - mfi-
jSD+2 + SD-2
where mfi+ and SD+ represent the mean fluorescence intensity and standard
deviation of the positive population, and mfi- and SD- represent the mean
fluorescence and standard deviation of the negative control population [Martini,
D'Hautcourt, Brando et al. 1989],
The peak resolution index represents the optimal mAb concentration, because
below this the mfi of the positive population will be low, and above this the mfi of
the negative population will be high (due to non-specific uptake). The standard
deviations give a measure of the distribution of fluorescence such that a mAb giving
a consistent fluorescence intensity will have a higher RI than one with a similar mfi
but more diffuse or patchy staining. The use of a standard deviation assumes a
normal distribution of fluorescence which clearly does not pertain under most
circumstances. It is often more convenient to titrate a mAb against a homogeneous
cell line, but the target population may have a different level of antigen expression
or level of Fc receptor uptake compared to the cell line, and hence the optimal titre
may differ. Optimally, each batch of each mAb would be re-titrated against all
possible targets. In practice, each batch ofmAb was titrated against the most
convenient target, i.e. cell line and / or leucapheresis product. The majority of
commercial mAbs were found to lie within their optimal resolution indices at 10pl /
5x105 cells - as recommended by the manufacturers. A standardised volume was
used wherever possible.
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2.4.3 Optimisation of immunofluorescence labelling.
Human blood or bone marrow cells were enumerated using an automated
counter, and aliquots containing 5x105 leucocytes were used for each test and
control sample. Cells were handled in a medium consisting of isosmotic phosphate
buffered saline (PBS), containing 1% bovine serum albumin (BSA) to prevent cell
death, 0.1% sodium azide to inhibit modulation and capping of surface antigens, and
0.02% EDTA to prevent cell clumping (handling medium Appendix 2). Test
samples were routinely processed in parallel with negative control samples stained
with mAbs of irrelevant specificity but of the same isotype as the experimental
antibody. Wherever possible IgGl mAbs were used, because IgG2a and IgM
isotypes are reported to show higher non-specific binding and therefore a lower
resoluton index (vide infra). Directly conjugated, irrelevant-specificity mAbs were
used as controls for directly conjugated mAbs, whilst purified irrelevant mAbs were
used for indirect systems along with the appropriate second stage reagent. The
routine test panel for single and dual colour labelling is outlined in Table 2.3.
The cells were washed twice in the handling medium, pelleted each time by
centrifugation at 200g for 5min prior to removal of the supernatant. Preliminary
tests showed that this centrifuge time and speed was sufficient to achieve a pellet,
with negligible cell loss due to buoyancy or traumatic fragmentation. Cells were
resuspended by gentle shaking by hand rather than vortex, again to minimise cell
trauma. Cells were incubated with 0.5% solution of human gamma globulin in PBS
for 15 minutes to reduce non-specific and Fc receptor-mediated uptake of antibody
on the cell surface (human gamma globulin solution Appendix 2). Using the direct
system, the cells were incubated with the primary murine mAb directly conjugated
to a fluorochrome for 15 min. Using the indirect system, the cells were incubated
with the primary murine mAb for 15 min, washed twice in handling medium, and
incubated with a sheep anti-mouse antibody (SAM)-fluorochrome conjugate, again
for 15 min. A further wash was carried out prior to red cell lysis and fixation. All
washing, centrifugation and incubation was carried out at +4°C to reduce antigen
capping.
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Table 2.3 Test Panels for CD34 Quantitation.
#1: CD34 + SAM-FITC.
#2: CD45 + SAM-FITC.








#1: CD34-RPE + CD45-FITC.
#2: IgGl-RPE + IgGl-FITC.
Legend. CD34: purified mAb. SAM-FITC: sheep anti-mouse antbody conjugated to
FITC. CD34-FITC: anti-CD34 mAb directly conjugated with FITC. The same
abbreviations apply to the CD45 and IgGl (negative control) mAbs, and the RPE
conjugates. Within each test protocol the labelled samples were compared with
similarly conjugated mAbs of the same isotype but irrelevant specificity.
Some authors have advocated shortening the preparatory procedure by omitting
most of the washing steps [Caldwell & Taylor,1986], pointing to advantages in
preparation time and reduction in selective cell losses due to osmotic and traumatic
fragility, and the higher buoyant density of activated and malignant cells and cell
lines. This approach was not adopted because of the higher background fluorescence
incurred, leading to higher thresholds on the negative controls and obscuration of
small cell populations with low positive fluorescence.
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2.4.4 Effect oferythrocyte lysis and cellfixation on the physical andfluorescence
characteristics ofthe study population.
High erythrocyte contamination in the sample leads to a low leucocyte
percentage in the acquired population and exacerbates the difficulty in studying the
CD34+ population. Two general approaches were taken to remove erythrocytes from
the study population. Ficoll discontinuous density centrifugation is highly effective,
but has been reported to lead to HPC loss [Wunder, Sovalat, Fritsch el al. 1992], an
observation which was confirmed in a later study (Chapter 6.6.3).
As an alternative, erythrocytes were lysed by incubation with 0.5ml of a solution
containing 8.29g/l ammonium chloride, 37mg/l EDTA and 0.84g/l sodium hydrogen
carbonate in distilled water, adjusted to a pH of 7.3-7.5 using a pH meter [Hoffman
& Hansen, 1981], The osmolarity of the solution was checked using a Micro-
Osmometer and found to be in the order of 298mOsm (erythrocyte lysis solution
Appendix 2).
An experiment was carried out to determine whether erythrocyte lysis induced
alteration in the physical or fluorescence characteristics of the study population. A
sample of leucapheresis product (LP) was stained with CD34-RPE and CD45-FITC,
and, along with the relevant negative controls, was subjected to no-lysis, a lysis
wash, or 15, 30, 45 or 60 min exposure to the lysis solution at ambient temperature.
The results are summarised in Table 2.4. The whole blood sample (no lysis) has
been swamped with erythrocytes, leading to very low CD45+ and CD34+
percentages. On the LP, a threshold change in all parameters can be seen between
no-lysis and lysis wash, corresponding to the elimination of contaminating
erythrocytes (note that the CD45+% rises from 27% to 95% and CD34+ from 0.6% to
2.1%). No changes occurred thereafter despite up to lhr incubation. The conclusion
is therefore that satisfactory erythrocyte lysis can be achieved with this reagent,
without progressive alteration in physical or fluorescent characteristics of the
leucocytes.
For standard purposes, the incubation in lysis solution was carried out for 5 min
at ambient temperature, after immunofluorescence staining was completed. The
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Table 2.4 Effects of Erythrocyte Lysis on Physical and Fluorescence
Characteristics of CD34 and CD45 Labelled Leucocytes.
Sample FSC ssc FL-1 FL-2
IgGl CD45 IgGl CD34
u>hole blood 3% (2) 0.1%(9)
leucapheresis
product
no lysis 98 34 0.05% (4) 27% (5) 0.05% (3) 0.6% (3)
wash 132 33 0.66% (9) 95% (15) 0.52% (10) 2.1% (10)
15min 131 42 0.69% (9) 94% (15) 0.46% (10) 2.5% (10)
30min 123 44 0.53% (7) 91% (13) 0.51% (7) 1.5% (7)
45min 128 42 0.82% (7) 95% (13) 0.62% (6) 2.4% (6)
60min 123 55 0.85% (6) 93% (15) 0.64% (7) 2.2% (7)
Legend. Results are expressed as the mean of 3 experiments. Physical characteristics
are expressed as a mean value, fluorescence characteristics as % fluorescence
positivity (%fT) and as mean fluorescence intensity (in parenthesis). High levels of
erythrocyte contamination lead to low CD34 and CD45 percentages in non-lysed
whole blood and (to a lesser extent) leucapheresis product. No progression occurs in
the physical or fluorescence characteristics of the study population with prolonged
incubation in the lysis solution.
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cells were washed in handling medium, and if red cell contamination was still
judged to be too high, these steps were repeated. In practice, it was found that
samples of LP or BM mononuclear cells required only a single lysis step, whilst
whole blood or marrow often required two steps.
The flow cytometer was not on site, and therefore samples required fixation and
storage in 2% paraformaldehyde prior to analysis. The distribution and intensity of
immunofluorescence on human and murine cells fixed in paraformaldehyde is
reported to be identical to that of fresh, unfixed cells. Cells can be stored at +4°C in
the dark, for up to two weeks without difficulty, though after several weeks
auto fluorescence does increase [Lanier & Warner, 1981; Lai, Edison & Chused,
1988], Samples of peripheral blood mononuclear cells were analysed with and
without paraformaldehyde, and following 14 days storage (Table 2.5). Minor
changes in the physical and fluorescence characteristics of the population occurred
over this period, which could largely be compensated by adjustment of the
cytometer. Samples were analysed within a few days of preparation where possible.
Some groups mix the test cells with propidium iodide prior to flow cytometry as
a measure of viability. The stain is taken up by non-viable cells which fluoresce
brightly in FL-2 and can be excluded during data acquisition.Unfortunately this was
not a practical option because fixed cells stain uniformly with this dye. Fresh cells
were used for staining wherever possible, and trypan blue dye exclusion was used to
assess viability where necessary.
2.4.5 Set-up ofthe flow cytometer.
Samples were acquired and analysed using a FACScan flow cytometer (FACS),
with an 488nm Argon ion laser emitting light at 14.7 millivolts. Optimal cytometry
settings were established using a series of test samples, and maintained throughout
the duration of the study unless otherwise indicated. The routine cytometer settings
are detailed in Table 2.6.
For routine CD34+ enumeration an acquisition gate was established on the FSC /
SSC dot-plot by a process of back-gating on the CD45+ control (Figure 2.5). In an
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Table 2.5 Effects of Paraformaldehyde Storage on Physical and Fluorescence
Characteristics of CD34 and CD45 Labelled Cells.
Parameter PBS Para Para day +14 cf: Para cf: Para
day +14
FSC 102 + 2 103 + 2 96 + 5 ns p<0.05
ssc 69+13 63 + 12 59 + 9 ns p<0.05
FL-1 (CD45+) 93.8 + 0.7 89.3 + 3.0 77.0 + 23.0 ns ns
(347 ± 55) (266 + 71) (212 + 46) (ns) (p<0.05)
FL-2 (CD34+) 0.23 + 0.13 0.18 + 0.10 0.46 + 0.59 ns ns
(18 + 5) (13 + 2) (30 ± 4) (ns) (p<0.05)
Legend. Peripheral blood mononuclear cells prepared over Ficoll-Hypaque density
gradient were labelled with CD34-RPE and CD45-FITC. Results are expressed as
the mean ± standard deviation of 4 experiments. Physical characteristics are
expressed as a mean value, fluorescence characteristics as percentage fluorescence
positivity (%fT) and as mean fluorescence intensity (in parenthesis). Results in PBS
are compared to those in paraformaldehyde and to those after 14 days storage in
paraformaldehyde by paired t test. Minor changes in the physical characteristics of
the cells occurred which were easily compensated by adjusting the acquisition gate.
A significantly lower FL-1 mfi and higher FL-2 mfi at day +14 was demonstrated.
This was compensated during setting of the thresholds on the negative controls such
that no significant difference in%ff existed. Samples were analysed as soon after
staining as reasonably possible.
PBS: phosphate buffered saline. Para: paraformaldehyde.
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Table 2.6 Flow Cytometry Settings for Single and Dual Colour
Immunocytometry of Leucocytes.
Parameter Detector Amplification Threshold





FL-1 - %FL-2 1.7
FL-2 - %FL-1 42.0
Legend. Flow cytometer settings and compensation established for single and dual
colour immunocytometry on positive and negative control samples. Once
established, the settings were not changed during a series of experiments in order to
maintain comparability of data.
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Figure 2.5 Backgating on the CD45+ Population to Define Acquisition Gates for
CD34" Enumeration.
Legend. Lysed peripheral blood leukocytes acquired on an open gate (A) are
contaminated by a variable number of residual erythocytes and debris: negative
control Ml: 0.71% (B), CD45* Ml: 92.54% (C). A gate (R2) established on the
CD45+ population allows these cells to be projected on the FSC / SSC dot-plot and
an acquisition gate (Rl) to be drawn such as to exclude most of the CD45" debris
and high FSC cell aggregates (D). Negative control Ml on the Rl population is now
0.15% (E) and CD45*Ml: 98.79% (F).
a -00 100 150 208
FSC-H\FSC-Heigint -
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adaptation of the method described by Loken [Loken, Brosnan, Bach et al. 1990;
Stelzer, Shults & Loken, 1993], negative and positive control cells were acquired
ungated, and the CD45+ population was defined on the appropriate fluorescence
histogram (FL-1). The software program (Lysis II) was used to superimpose the
CD45+ cells on the FSC / SSC dot-plot, and an acquisition gate was set to exclude
CD45" erythrocytes and debris, and cell aggregates. It is important when setting an
acquisition gate to achieve the right balance between a gate which is too permissive
- in which the leucocytes may be swamped by erythrocytes and debris, and too
restrictive - in which one risks excluding CD34+ cells with low FSC. The process of
backgating allows one to place the acquisition gate more accurately, and to
compensate for inter-sample variation. 10-50,000 events were acquired in list mode
for each analysis. Data were analysed using the Lysis II software.
2.4.6 Comparative study ofthe efficacy ofavailable anti-CD34 monoclonal
antibodies and direct / indirect systems oflabelling.
A comparative study was carried out of the efficacy of available anti-CD34
mAbs, in both indirect and direct labelling systems. The human myeloblasts cell
line KG la was used for this study, because the high constitutive expression of the
CD34 antigen allows unimpeded analysis of the monoclonal antibodies [Civin,
Strauss, Brovall et al. 1984]. Preliminary study revealed that KG la were large cells,
with high FSC and medium-high SSC profile, though a significant population of
smaller cells / cell fragments were also present, presumably due to the persistence of
effete and dead cells in the culture media and / or traumatic fragmentation during
the preparatory procedure. The FSC amplification was reduced to 1.00 in order to
bring the singlet population on scale, but other than this the flow cytometry settings
did not need to be altered from those established on normal leucocytes (Table 2.6).
Approximately 87 ± 3% KGla in healthy liquid culture expressed the CD34 antigen
and backgating revealed that these were predominantly within the singlet cell
population. Acquisition gates set around this population displayed a maximum
CD34 expression of 98 ± 1% with a mfi of 1181 ± 530 (Figure 2.6, Tables 2.7 - 2.9).
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Figure 2.6 CD34 -Labelling ofKGla With and Without Gating.
Legend. KGla acquired on an open gate (A) include a significant amount of CD34"
debris: negative control Ml 0.2% (B), CD34" Ml 91.5% (C). Acquisition on a
narrow gate around the singlet population (D) reduces the negative tail (fluorescence
summated in the 0 column): negative control M2 0.2% (E), CD34+ M2 98.7% (F).
























Table 2.7 Evaluation of anti-CD34 (FITC) Monoclonal Antibodies on KGla.
antibody %/r mfi RI
QBEND10 SAM-FITC 99 ± 0.9% 1385 ± 214 1.46 ±0.09
My10 SAM-FITC 98 ± 1.8% 1025 ±59 1.30 ± 0.12
BI-3C5 SAM-FITC 87 ± 13.6% 561 ±85 0.96 ±0.02
TuK 3 SAM-FITC 94 ± 6.2% 425 ±110
12-8 SAM-FITC 97 ± 1.1% 1780 ±374 1.10 ± 0.06
IgGl SAM-FITC 0.5% 7 ± 2
IgM SAM-FITC 0.5% 7 ± 2
QBEND10-FITC 58 ± 11% 197 ±44 1.74 ±0.47
8G12-FITC 86 ± 5% 334 ± 13 1.80 ±0.06
IgGl-FITC 0.5% 7 ± 3
Legend. Results reported are the mean ± standard deviation of 3 replicate
experiments. The best mAbs over all parameters were the IgGl isotypes QBEND10
and My10, and the IgM 12-8 using an indirect sheep anti-mouse FITC conjugate
(SAM-FITC). Purified 8G12 was not available for evaluation. The RI for TuK 3
could not be calculated because no IgG3 negative control was available. Direct
conjugates QBEND10-FITC and 8G12-FITC demonstrated satisfactory RI but less
%fl+.
Abbreviations. %fl+ percentage fluorescence positivity. mfi. mean fluorescence
intensity. RI. resolution index. SAM-FITC: sheep anti-mouse FITC conjugate.
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Table 2.8 Evaluation of anti-CD34 (RPE) Monoclonal Antibodies on KGla.
antibody %fl+ mfi RI
QBEND 10 SAM-RPE 97 ± 1.9% 536 ±337 1.18 ± 0.28
My10 SAM-RPE 89 ± 7% 356 ±296 0.96 ±0.24
BI-3C5 SAM-RPE 83 ± 10% 217 ± 80 0.82 ±0.15
TtiK 3 SAM-RPE 42 ± 17% 107 ±96
12-8 SAM-RPE 68 ± 22% 367 ±509 0.46 ±0.38
IgGl SAM-RPE 0.5% 5 ± 3
IgM SAM-RPE 0.5% 4 ± 3
QBEND 10-RPE 3 ± 3% 61 ±37 0.35 ± 0.11
8G12-RPE 99 ± 0.2% 1,108 ±63 2.16 ±0.06
IgGl-RPE 0.5% 1 ± 1
Legend. Results reported are the mean ± standard deviation of 3 replicate
experiments. The SAM-RPE indirect label was not as satisfactory as the SAM-FITC
(Table 2.7). 8G12-RPE proved to offer a superior RI compared to the indirect labels.
Abbreviations. %jt percentage fluorescence positivity. mfi mean fluorescence
intensity. RI resolution index. SAM-RPE sheep anti-mouse RPE conjugate.
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Table 2.9 Evaluation ofNegative Control Antibodies on KGla.
FL-1 FL-2
antibodies %fl+ mfi antibodies %fi+ mfi
auto 0.5 ± 0% 6.1 ± 1.3 auto 0.5 ± 0% 3.1 ±0.9
IgGl
SAM-FITC
1.1 ±0% 7.1 ±2.2 IgGl
SAM-RPE
1.1 ±0.5% 4.5 ±2.8
IgM
SAM-FITC
0.8 ± 0.3% 6.6 ±2.3 IgM
SAM-RPE
0.9 ± 0.7% 4.1 ±2.7
IgGl-FITC 1.5 ±0.6% 6.7 ±3.2
Legend. Data represents the mean ± standard deviation of 3 replicate experiments.
Abbreviations. %ft: percentage fluorescence positivity. mfi: mean fluorescence
intensity.
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of 149 ± 3 (within the CD34+ population) of a representative normal human bone
marrow aspirate (see Chapter 3.5.2).
Isotype-specific irrelevant mAbs and second step reagents were evaluated as
negative controls against autofluorescent KGla with a marker set at 0.5% (0.5x10s
cells / test, 20pl neat mAb), and acquisition gates set around the main KGla
population as detailed above. The SAM-FITC and SAM-RPE were F(ab)2 fragments
in order to minimise uptake by Fc receptors, and were used at a titration of 1:20.
The comparative %fT and mfi of unstained (autofluorescent) cells and negative
controls is documented in Table 2.9. The percentage of cells binding mAb in a non¬
specific manner (after subtraction of the autofluorescent population) can be
summarised as: IgM 0.35% < IgGl 0.6% < IgGl-FITC 1.0%. Little difference was
demonstrated between the use of SAM-FITC and SAM-RPE.
The currently available mAb to CD34 were evaluated for comparative efficacy
by percentage ofKGla displaying positive fluorescence, mfi of the positive
population and resolution index (RI) comparative to the appropriate isotype-specific
negative control. No IgG3 control was available for Tuk 3. Direct and indirect
reagents were used as appropriate. 10,000 events were collected within an
acquisition gate set around the singlet KGla population. Results quoted are the
mean of 3 replicate experiments (Tables 2.7, 2.8 & 2.9). The variation in the
fluorescence characteristics of the KGla (expressed as the standard deviation, SD),
is a reflection of variability in experimental technique, in particular in cellular
autofluorescence and nonspecific mAb binding, and in cell size and acquisition
gates. The best mAbs over all parameters (Tables 2.7 & 2.8) were the IgGl isotypes
QBEND10 and My10, and the IgM 12-8. Purified 8G12 was not available for
evaluation. Using an indirect technique and SAM-FITC up to 98% of gated KGla
were CD34+, with an mfi of>1000, and resolution indices greater than 1.3. BI-3C5
and Tuk 3 proved inferior by most criteria, though a correct negative control for Tuk
3 was not available and the RI was therefore not calculated. Indirect labelling with
SAM-RPE proved inferior to SAM-FITC with almost all mAbs. The direct
conjugates 8G12-FITC and QBEND10-FITC, proved inferior in terms of%fl+ and
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mfi, but superior in terms ofRI. 8G12-FITC was superior to QBEND10-FITC by all
criteria (Table 2.7). 8G12-RPE became available in mid-1993, and proved
equivalent to the indirect labels in terms of %+ and mfi, but markedly superior in
terms ofRI (Table 2.8). The superior resolution with direct conjugates is explained
by the reduced intra-experimental variability in fluorescence (z'.e. the standard
deviation of the mfi) allowing greater discrimination between positive and negative
populations.
The optimal immunofluorescence labelling protocol for CD34 quantitation drawn
from the studies detailed in this section is summarised in Table 2.10 and the test panel
noted in Table 2.3.This protocol is similar to that recommended by the 1st and 2nd
European workshops on HPC determination [Wunder, Sovalat, Fritsch et al. 1992;
Wunder, Sovalat Elenon etal. 1994],
2.5 Determination of the Resolution Limits of Immunocytometry.
It was clearly desirable to attempt to determine the resolution limits of the
immunocytometry technique which are dependent on the accuracy of the flow
cytometer, variation in the properties of the cells and an acceptable coefficient of
variation (cv).
In a preliminary experiment, a peripheral blood mononuclear preparation
(unstained) was put through the flow cytometer in a series of 10 acquisitions of
10,000 events, and a further 10 acquisitions of 50,000 events. On the 10,000 event
acquisition, a marker set at 0.5% positive fluorescence demonstrated an actual %fT
of 0.45 ± 0.06% (cv=12.9%), and a marker set at 0.05% demonstrated an actual
%fT of 0.04 ± 0.02% (cv=39.9%) (Results quoted as mean ± standard deviation of 10
replicate experiments). Similar markers set on the 50,000 event acquisition
demonstrated actual %fT of 0.50 ± 0.06% (cv=12.1%) and 0.04 ± 0.03%
(cv=96.3%) respectively. The cv using a higher %fT marker was clearly more
satisfactory, though there was no significant difference between 10 and 50,000 event
acquisitions (p=ns, non-paired t test).
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Table 2.10 Synopsis of the Labelling Protocol for Single Colour
Immunocytometry.
5x105 cells / test.
washed twice in 0.5ml of handling medium.
incubated for 15min in 0.5% human gamma globulin solution.
incubated for 15min with 10pl mAb (See Table 2.3).
washed twice in handling medium*.
incubated for 15min with 10pl 2nd step reagent*.
washed once in handling medium.
incubated for 5-10min in erythrocyte lysis solution (until clarification)5
washed once in handling medium5,
resuspended in 0.5ml paraformaldehyde.
Legend. The formulation of the solutions used is described in the text and in
Appendix 2. Reagents were maintained and all centrifugation, incubation and
storage carried out at +4°C. "indirect labelling techniques only. somitted for cell
lines, samples prepared over Ficoll-Hypaque and some leucapheresis products.
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A series of experiments was carried out using serial dilution ofKGla in
peripheral blood MNC in order to establish correlation between expected CD34+
counts and measured counts, and to establish the range of the cv - especially at the
lower limits of resolution. Peripheral blood MNC were spiked with KG la at a range
of relevant concentrations, and were labelled with QBEND10 and SAM-FITC using
standard technique. Cells were acquired ungated, and analysed relative to a 0.5%
marker established on the FL-1 histogram of non-spiked (but labelled) PB-MNC.
The results are presented in Table 2.11. The correlation coefficient between
predicted and measured CD34%+ was highly significant (r=0.98, p<0.001). As can
be seen, the KG la population was 86.4% CD34+ and a CD34+ KGla% corrected for
this factor is quoted in column 2 of Table 2.11. There was a persistent shortfall in
the proportion of CD34+ KGla detected compared to that predicted, though whether
this was due to a technical artefact such as inaccuracy in the dilution technique, or to
interaction between KGla and the mononuclear cell population, was unclear. The cv
lies between 3 and 15% over a wide range of concentrations, until the %ff falls
below 1% where the cv deteriorates.
2.6 Evaluation of Different Approaches to Data Analysis.
An experiment was carried out to establish the optimum method of quantitating
the CD34+ population within a given sample. PB and LP samples were studied from
10 patients undergoing mobilisation with cyclophosphamide and rhuG-CSF. Each
sample was labelled with 8G12-RPE and CD45-FITC, with appropriate negative
controls. 30-50,000 events were acquired through a permissive gate established on
the CD45+ backgated FSC / SSC dot-plot, set to exclude debris and aggregates only.
Although this leads to a lower overall CD45%+ than a more restrictive gate, it
prevents exclusion of small CD34+ cells. Data was analysed using three markers on
the negative control FL-2 histogram, 0.01%, 0.05%, and a marker at the point of
minimum inflection (Figure 2.7). Regions were established on the correlative dot-
plot of SSC / FL2, to include 0.01-0.05% of the low side scatter cells of the negative
control. In addition, the CD34+ population could be backgated onto the correlative
96
Table 2.11 Serial Dilution of KGla in Peripheral Blood Mononuclear Cells.
KGla dilution corrected CD34%f observed CD34%+ ± SD (cv)
100% 86.4% 86.4 ± 11.1% (12.8%)
75% 64.8% 50.1 ± 1.7% (3.4%)
50% 43.2% 30.9 ± 3.0% (9.6%)
25% 21.6% 12.1 ± 1.7% (14.0%)
12.5% 14.5% 6.5 ±0.7% (10.8%)
6.25% 7.23% 3.3 ±0.5% (14.7%)
3.12% 2.69% 1.8 ±0.1% (3.4%)
1.56% 1.35% 1.1 ±0.1% (5.3%)
0.78% 0.67% 0.6 ±0.15% (26.3%)
0.39% 0.34% 0.5 ± 0.00%
0.195% 0.168% 0.47 ±0.15% (31.9%)
0.00% 0.00% 0.47 ±0.06% (12.8%)
Legend. In the second column the CD34%+ is corrected for the fact that 86.4% of
KGla are CD34+. Results in the third column are the mean ± standard deviation of 3
replicate experiments. The coefficient of variation is quoted in parentheses. The
coefficient of variation was satisfactory above approximately 1% CD34+.
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Figure 2.7 Comparative Approaches to CD34 Enumeration.
Legend. Several approaches to enumeration of the CD34+ population were
examined. Markers established on the FL-2 negative control (A) at M2 0.01%, M3
0.05% and M4 (point ofminimal inflection) 0.1%, revealed CD34%T of 0.04%,
2.21% and 2.34% respectively (B). A region established on the SSC / FL-2 dot-plot
demonstrated a negative control (R2) of 0.01% (C) and a CD34%~ of 2.12% (D).
Backgating the CD34+ population (defined on M4) onto the SSC / FL-1 dot-plot
demonstrates that the CD34" cells are predominantly CD45'° and SSC'°: negative
control (R3) 0.02% (E), CD34%T 2.00% (F).
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dot plot of SSC / FL-1 (CD45) , and a region established to include 0.01-0.05% of
the CD45" SSC'° cells on the negative control.
Paired t tests were carried out to establish whether significant differences existed
between the CD34+ counts determined by different analytical methods. The CD34+
counts determined on the histograms were significantly different such that those
calculated on a 0.01% marker were less than those calculated on a 0.05% marker
(p<0.001), which in their turn were less than those calculated on a variable marker
(p<0.001). Clearly, some CD34+ cells have low fluorescence, are obscured by the
background population, and are ignored when a stringent analytical marker is
employed. The background fluorescence achieved on the dot-plots was less than that
on the 0.05% histogram, but there was no significant difference between the two
dot-plot analyses, indicating that the exclusion of SSChl cells was the critical factor,
and that CD45" cells do not contribute significantly to the backgound. There was no
significant difference between the CD34%+ on the 0.05% histogram and the 2 dot-
plot analyses.
In conclusion there is probably no unequivocally "correct" method of
establishing positive CD34 fluorescence. A variable marker on the histogram gives
a higher overall CD34+ count due to the inclusion of CD34'0 cells, but produces a
high background and is difficult to standardise. Although there was no difference
between the 0.05% histogram marker and the two dot-plots, the latter display a
lower false positive background. Use of a very high marker (0.01%) on the
histogram alone, leads to underestimation of the CD34 count. Several authors have
argued that true CD34+ cells show low side scatter, and are CD45'nt, and that these
characteristics can be used to discriminate true CD34+ cells from false uptake by
neutrophils (SSChi, CD45inl or CD45hi), monocytes (SSCin"hi, CD45hi) and
lymphocytes (SSC'°, CD45h') [Trischmann, Schepers & Civin, 1993; Sutherland,
Keating, Nayar et al. 1994]. A proportion of CD34+ cells are CD45hl (Figure 2.8),
and there seems no reason apriori to dismiss these as false positive staining
lymphocytes. In fact, no particular advantage to backgating the CD34+ population
onto a SSC / FL-1 dot-plot prior to quantitation was demonstrated in this study. The
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Figure 2.8 CD45* Fluorescence of Various Populations of Leucocytes.
Legend. Leucocyte populations were dual stained with Lin SAM-RPE and CD45-
FITC. (A) All cells; (B) CD16+ gated neutrophils and NK cells; (C) CD14+ gated
monocytes; (D) CD3+ gated T lymphocytes; (E) CD19+ gated B lymphocytes; (F)
CD34+ gated HPC. Although all leucocytes are >97.5% CD45+ (Ml), they can be
subdivided into CD45hl and CD45'° populations (M2 & M3) (A). T and B
lymphocytes fall predominantly into a CD451" subpopulation (M3) (D & E), whilst
neutrophils and monocytes demonstrate a broad spectrum of CD45 fluorescence (B
& C). HPC are predominantly CD45'0 (M2) (F). Several groups have recommended
exclusion of CD45hl SSC1" cells during CD34 enumeration, though overlap in the
properties of different populations does occur and this strategy does lead to
ignorance of a CD34+ subset.
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more contentious issue as to whether CD34+ high side scattering cells should be
dismissed as false positive is returned to in Section 2.9.3 and Chapter 3.5.4.
The variable contamination of the study sample with erythrocytes presents a
problem in achieving accurate CD34+ enumeration. Samples were routinely run in
tandem, i.e. one stained with anti-CD34 and anti-CD45 mAbs, and the other with
the appropriate negative controls. The measured CD34%+ was corrected for
erythrocyte contamination by division with the CD45%+
i. e. CD34%C = CD34% - Neg control%+ x 100
CD45%+ - Neg control%+
The absolute number of CD34+ cells in the sample (CD34n) can be calculated by
interpreting the CD34%C as a percentage of the absolute leucocyte count measured
by a cell counter. This calculation is dependent on the assumption that all
leukocytes are CD45+. Nucleated erythroid precursors are CD45", and although the
Coulter ZF and T-890 instruments were satisfactory for analysing peripheral blood
samples, microscopic examination of the film was required to obtain a differential
count of nucleated erythrocytes from other nucleated cells in bone marrow samples.
2.7 Study of the Overall Accuracy of CD34 Quantitation.
In order to establish the overall accuracy with which CD34+ populations can be
defined and quantitated a series of experiments was carried out in which samples of
BM, PBm, LP and CB were stained in four separate experiments with 8G12-RPE and
CD45-FITC using standard labelling protocol, acquired through a CD45-backgated
FSC / SSC gate, and analysed on the basis of overall CD45 positivity and CD34
positivity on the FL-2 / SSC dot plot.
The mean CD34%C, SD and cv of the four replicate experiments / sample were
calculated for a total of 15 samples, the results ofwhich are presented in Figure 2.9.
The median CD34%C was 1.08% (range 0.14 - 6.70) and the median cv 14.8%
(range 1.4 - 43.5). There was a weak negative correlation between CD34%C and cv
(r= -0.42) with a regression line described by the formula: y = 21.2 - 2.86.x. The
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Figure 2.9 Overall Accuracy of CD34+ Quantitation.
Legend. CD34%+ was analysed on 4 aliquots from each of 15 samples from BM,
PBm, LP and CB and the mean, standard deviation and coefficient of variation of the
replicate assays was calculated for each sample. There was a weak negative
correlation between CD34%C and cv (r= -0.42) with a regression line described by
the formula: y = 21.2 - 2.86.x. Abscissa: CD34%+, Ordinate: coefficient of
variation. Solid data points are observed results. The results are tabulated in
Appendix 3 Table A.l.
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bone marrow samples demonstrated a CD34%C of 0.63 ± 0.64% (n=4), PBm of 2.26
± 2.20% (n=8) and CB of 0.69 ± 0.52% (n=4).
2.8 Establishment of a Correlation between CD34+ and CFU-GM Assays.
A direct correlation has been reported between the concentration of CD34+ cells
and CFU-GM in normal human marrow, and in mobilised peripheral blood [Fritsch,
Emminger, Buchinger et al. 1991; Serke, Sauberlich & Huhn, 1991]. The CFU-GM
cloning efficiency (CE) of an HPC population is defined as the percentage of CD34+
cells giving rise to colonies [Wunder, Sovalat, Fritsch et al. 1992]
i. e. CFU-GM CE = number ofCFU-GM (>50 cells) x 100
number ofCD34+ cells
A series of 14 LP samples were analysed by CFU-GM and CD34 immunocytometry
in order to assess whether the two assays provided comparable results. The data are
presented in Figure 2.10, and give a correlation coefficient of r = +0.90, with a
regression line formularised as y = - 41.69 + 217.77.x. The cloning efficiency varies
substantially from 0.4 to 32.5%. The correlation degrades below approximately
0.5% CD34+ or 10 CFU-GM/105 cells. In fact, when the 10 samples in this subgroup
were analysed separately, no correlation could be demonstrated (r=+0.06).
Similarly, no correlation could be demonstrated between CD34 and CFU-GM in 10
samples from the blood of normal individuals (r= -0.11) (Table A3).
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Figure 2.10 Correlation between CFU-GM and CD34+ Cells in 14
Leucapheresis Product Samples.
Legend. CD34%+ and CFU-GM were analysed from 14 samples of LP. There is a
strong positive correlation coefficient of r = +0.90 with the regression line
formularised as y = - 41.69 + 217.77.x, but this degrades below approximately 0.5%
CD34+ or 10 CFU-GM/105 cells (r = +0.06). Abscissa: CD34%+, Ordinate:
CFU-GM/105 leucocytes., Solid data points are observed results. Some data points




The objective of the initial phase of this study was to establish an accurate
and reproducible method with which to define the haematopoietic progenitor cell
population and to validate the optimised immunocytometry system through
comparison with an alternative (clonogenic) assay system and by collaboration with
other research groups (vide infra).
2.9.1 Standardisation and reproducibility ofthe CFU-GM assay.
There are a number of factors which contribute to the difficulty in achieving
standardisation and reproducibility of semi-solid clonogenic assays, and in achiev¬
ing comparability of data between sources.
Firstly, cell survival and proliferation is dependent on the culture environment,
including base medium, serum source, cytokines, humidity, oxygen and carbon
dioxide tension (and pH), and presence of infection. Clonogenic assays are
particularly dependent on the nature of the serum source and cytokine stimulation.
There is considerable batch-to-batch variation in colony growth in FCS, though
whether this is a reflection of the protein / lipid content, cytokine content or other
factors, is unclear. Culture conditions can be standardised by use of commercial
culture media (such as those marketed by Gibco BRL, Paisley or by Stem Cell Inc.,
Vancouver), or by the use of serum-free culture conditions and defined cytokine
cocktails.
Secondly, the number and dispersion of colonies in the assay may be an
important source of error during enumeration. The accuracy of clonogenic assays is
fundamentally limited by the statistical accuracy inherent in counting a small
number of colonies. In a group of x assays with a total of n colonies, the mean
number of colonies per assay is n/x with a standard deviation jn/x due to the Poisson
distribution [Blackett, 1974]. Therefore in a triplicate assay with a total of 3
colonies the SD is 0.58 and the cv is 58%, with a total of 30 colonies the SD is 1.83
and the cv is 18.25% and with a total of 300 colonies the SD is 5.77 and the cv is
5.8%. In addition to inherent statistical variation, considerable variation is added by
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the observer. Accurate colony enumeration must be carried out carefully by a
dedicated observer. A highly cellular backgound, clumping of nucleated cells,
erythrocyte contamination or infection, can all give rise to considerable "noise"
against which it proves impossible to enumerate colonies. Inadequate dispersion of
cells in the culture media can lead to clumps or swathes of cells which may be
mistaken for colonies. In addition, colonies can occur at any depth within the culture
matrix (l-2mm) and may be missed if outwith the plane of focus. The formation of
very high numbers of colonies (>l-200/assay) or very low numbers (<10/assay) is
particularly problematic due to colony overlap and observer fatigue in the first
instance and the high coefficient of varation in the second. A range of assays at
different cell concentrations may need to be established.
Finally, the nature of the cell population under investigation may be an
important determinant of the cloning efficiency of the HPC population. Not all
CD34+ cells form colonies, as can be seen from the data in Section 2.8. There are
several reasons for this. Not all CD34+ cells are necessarily HPC, for example in
bone marrow CD34+ endothelial cells may be present. In addition, only a proportion
of HPC form colonies under a given set of conditions. Colony formation is a
composite product ofHPC proliferation, differentiation and survival, and the
cloning efficiency is as much a function of the culture conditions as it is of the HPC
present. One can talk (for example) about the CFU-GM cloning efficiency and the
BFU-E cloning efficiency of a given population, and although it is assumed that the
cells which form CFU-GM under a given set of culture conditions are different to
those which form BFU-E under a different set of conditions, this is not necessarily
so. Adding to the complexity, Gordon et al [Lewis, Blackett & Gordon, 1994] have
shown temporal succession ofCFU-GM colony formation such that CFU-GM
present at day +7 are mainly different colonies from those present at day +14 or at
+21. Furthermore, it is likely that cloning efficiency is source dependent i.e. varies
with the proportion ofmyeloid progenitors in the CD34+ population, and the
presence and activation of accessory cells. Positive and negative cytokines are not
only provided from exogenous sources (such as serum and conditioned medium),
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but also from T lymphocytes and monocytes. The numbers and activation of
accessory cells may vary substantially dependent on the source and in vivo cytokine
exposure of the study population. In addition, the exogenous cytokines may act on
accessory cells, leading to a secondary effect on HPC proliferation in vitro [Wunder,
Bacrenzung, Sovalat et al. 1992]. Comparability of clonogenic assays between
different source materials may therefore only really be achievable by the study of
highly purified CD34+ populations, and even then is only informative about a subset
of the HPC population.
2.9.2 Standardisation and reproducibility ofCD34+ quantitation.
Two factors are of critical importance to the accurate resolution of HPC using
CD34 immunocytometry, the choice ofmAb-fluorochrome labelling system and
adequate control over non-specific binding. MylO, 8G12 and QBEND10 are the
best current mAbs to the CD34 antigen. In the main, an indirect labelling system
with SAM-FITC gives rise to brighter fluorescence than the direct conjugates, but at
the cost of higher background fluorescence. 8G12-RPE proved satisfactory in terms
of fluorescence intensity, with a low background and high resolution index allowing
superior resolution of the CD34+ population (Section 2.4.6). These results are
broadly comparable with those published by the groups in Vancouver [Lansdorp,
Sutherland & Eaves, 1990] and Milan [Ravagnani, Siena, Bregni et al. 1991; Siena,
Bregni, Brando et al. 1991b]. Prior to 1992, QBEND10 was acceptable for indirect
labelling, and was the only CD34 mAb available in a FITC-conjugated form. 8G12-
FITC became available in this country in April 1992, and 8G12-RPE in mid 1993,
and the latter was used in later studies. The optimised labelling and analytical
protocol (Table 2.10) was not dissimilar to that arrived at by others [Siena, Bregni,
Gianni et al. 1993; Siena, Bregni, Di Nicola et al. 1994; Bender, Unverzagt &
Walker, 1994; Sauberlich, Kirsch & Serke, 1994; Gee & Lamb, 1994; Roscoe,
Rybka, Winkelstein et al. 1994], Detailed attention to technique is important to the
validity of the results. The correlation demonstrated between CD34%+ and CFU-
GM (Section 2.8) is similar to that reported by several other groups [Siena, Bregni,
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Brando et al. 1991a; Serke, Saubelich & Huhn, 1991; Bender, Williams, Myers et
al. 1992; Fritsch, Buchinger & Printz, 1993c; Bender, Lum, Unverzagt et al, 1994],
Many groups now use CD34 quantitation as a real-time marker for assessing the
viability of a harvest, or to monitor peripheral blood stem HPC rebound following
chemotherapy [Siena, Bregni, Belli et al. 1992].
Caution needs to be exercised in that the accuracy and reproducibility of CD34+
counts remains dependent on careful methodology, and degrades at low percentages
of CD34 positivity (Section 2.7). The correlation between CD34 positivity and
CFU-GM also deteriorates below a level of about 0.5% CD34+ (Section 2.8).
Data was contributed to two European workshops on F1PC quantitation held in
Mulhouse, France in 1992 and 1993 [Wunder, Sovalat, Fritsch et al, 1992; Wunder,
Sovalat, Henon et al, 1994], which attempted to achieve a consensus between field
workers on optimal techniques for CD34 quantitation for both clinical and research
use. As a study in standardisation, 22 European clinical and research laboratories
conducted an experiment in which samples of a LP harvested from a normal adult
volunteer in Berlin were assayed by each laboratory, using aliquots of the same
staining reagents, and a commonly agreed technical and analytical protocol. Flow
cytometers from five different companies were used, and cytometer set-up and
acquisition gates could not be standardised. The percentage of non-viable cells as
determined by dye-exclusion varied between 0 and 42%. False positive rates on the
negative controls varied between 0.01 and 0.5%. Results obtained with the CD34-
FITC conjugates were highly variable, with CD34+ percentages determined by
8G12-FITC ranging from 0.00 to 1.29%, and those determined by QBEND10-FITC
ranging from 0.17 to 17.8% with 5 failures. Results obtained in Berlin immediately
after harvest revealed a percentage CD34+ of 0.24 (8G12-RPE, mean of a
quadruplicate determination on 50,000 cells). In summary, even a highly motivated
group of experienced cytometry laboratories with an agreed protocol have difficulty
establishing reproducibility [Sovalat, Wunder, Zimmermann et al, 1994], This is
perhaps not particularly suprising in view of the high cv associated with replicate
experiments in a single laboratory (Section 2.7).
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2.9.3 Theoretical considerations in the definition ofCD34+ populations.
The definition of positive fluorescence is such a fundamental issue in the
interpretation of CD34 immunocytometry data, that it is discussed in some depth
here. Negative control samples are established using the study sample, irrelevant-
specificity isotype-specific mAbs, and identical technique. There are several schools
of thought as to how the criteria for discrimination ofpositive and negative
populations should be established [Martini, D'Hautcourt, Brando et al. 1990], The
first advocates that a marker should be set either at the point at which the number of
false positives on the negative control equals the number of false negatives on the
positive control (the point of zero differential), or just after the peak on the negative
control, (the point of minimal inflection) (Figure 2.11). These approaches lead to a
variable background level of false positive cells, which (particularly in the former)
may be up to 20-25%. The advantage of this kind of approach is that it allows low
intensity stained cells in the test sample to be included in the analysis.
The second school of thought sets a marker at a fixed percentage of false
positive cells on the negative control (Figure 2.11), classically at 0.5-2%, - though
much more stringent criteria can be used. This has the advantage that the extent of
contamination of the positive population with false positives is quantifiable, but has
the disadvantages that low intensity staining positive cells are operationally
considered negative and that a few highly fluorescent cells in the negative control
can cause a significant shift in the discriminatory marker to the right (the problem
is compounded because the flow cytometer determines fluorescence on a cell by cell
basis, rather than presenting a fluorescence profile of the whole population). The use
of a discriminatory region on a fluorescence / SSC dot plot as discussed in Section
2.6 eases the problem since most false positive cells are high SSC neutrophils and
monocytes, but is based on the assumption that CD34+ HPC are never high
scattering.
The third school of thought eschews the definition of positive and negative
populations of cells in favour of direct comparison ofmean fluorescence of negative
control and labelled populations. This is very helpful where the study population is
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Figure 2.11 Methods of Discrimination of Positive and Negative Populations.
Legend. Unstained (A) and CD34-RPE labelled (B) KG la are used for illustration.
Several methods may be used to discriminate fluorescence positive and negative
populations. Fixed markers can be established at various levels of stringency on the
negative control (A) Ml 0.00%, M2 0.05%, leading to CD34%+ (B) ofMl 77.55%
or M2 88.88% respectively. Variable markers can be established at the point of
minimal inflection M3 (A) 0.38% (B) 92.47% or at the point of zero differential on
the overlay histogram (C) where the percentage false+ on the negative control (M4
4.33%) roughly equals the percentage false" on the labelled sample (M4 95.22%).
Where (as here) there is a homogeneous fluorescence positive population (as averse
to generation of a single or complex subpopulations), the mean fluorescence
intensity (A 11, B 1102)/or the peak channel number (modal fluorescence) (A 8, B
1197) may prove a more useful measure.
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more or less homogeneous (e.g. a cell line), but may be inappropriate where discrete
or complex populations exist. A small shift in the mean fluorescence of a
homogeneous population may be impossible to discriminate from a larger shift in
the fluorescence of a discrete subpopulation, without direct inspection of the
histogram. There are particular problems with the use of the standard deviation,
which assumes a normal distribution of data around the mean. This is valid only
under strictly defined circumstances, namely a cell population which is
homogeneous in its expression of the antigen. The standard deviation was found to
be useful in titration and comparative assessment ofmAbs against cell lines, where
a resolution index was calculated (Section 2.4.2 and 2.4.6).
These problems are particularly acute when studying small cell populations with
low density antigen expression - such as CD34+ HPC.
In this study the criteria employed to define the CD34+ population and measure
fluorescence within it, has been adapted to the purpose in hand. In defining the
CD34+ population for enumeration, the priority was seen as including most potential
CD34+ cells even at the cost of a higher false positive background (which can then
be subtracted), i.e. high sensitivity with lower specificity. CD34 / CD45 stained
cells were therefore acquired through a permissive gate and quantified on a 0.05%
histogram marker or FL-2 / SSC dot plot as described above (Section 2.6). The risk
of ignoring CD34+ SSChl cells on the latter was considered to be offset by the
possible detection of CD34'0 cells.
During 2 or 3 colour immunocytometry (Chapter 3) or FACS-based enrichment
Chapter 6.6), the priority is to achieve minimal contamination of the study
population with false positive cells, even at the price of ignoring CD34'° cells (i.e.
high specificity but low sensitivity). The threshold markers need to be highly
discriminatory because when one comes to analyse the dual fluorescence data it is
not possible to separate the true positive population from the false positive because
the dispersal of the false positive fluorescence intensity is unknown. The problem is
most acute when small levels of true positivity are under study. An increase in the
false positivity rate (by lowering the discrimatory threshold) leads to increased
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contamination of the positive population, especially at low percentage true
positivity. If, for example, the negative control marker was set at 0.5% positive, and
the test sample was 1% positive, one could deduce that 0.5% of the cells in the test
sample were true positive, but one could not ascertain which these were. If, on dual
immunofluorescence studies, the 1% apparent positive cells (0.5% false and 0.5%
true) show 50% positive expression of a second antigen, it becomes impossible to
deduce whether all the true positive cells (and none of the false positive) are
coexpressing the second antigen, or none of the true positive but all of the false
positive, or some proportion of each. Cells for dual colour immunofluorescence
studies were acquired through a fairly restricted lymphoblastoid gate, judged by
backgating the CD34+ population onto the FSC / SSC dot plot (Chapters 3.2 and
3.3). In some of the studies using triple colour immunofluorescence, cells were
acquired through a gate established on the FSC / FL-2 dot plot (Chapter 3.5). Here,
a control acquisition was carried out through an open gate to provide an estimate of
the contamination of the study population with false positive events. It should be
reiterated that use of stringent criteria such as these biases the data in favour ofmore
primitive, CD34hi HPC.
In the circumstance of analysing overall expression of an antigen on a cell line,
or coexpression within a defined CD34+ population, a less stringent indicative
threshold marker ofpositivity (such as the point of minimal inflection), and / or the
mean fluorescence intensity of the study population were found to be more useful
(Chapter 3). This is because low intensity fluorescence may be missed by highly
stringent markers, and sensitivity is of much more importance than specificity.
A final problem is the question of whether the false positive percentage should
be subtracted from the actual positive percentage to reveal the "true positive"
percentage. In my opinion the answer is no, because the term "false positive"
assumes that these highly fluorescent cells are antigen negative, when in fact these
are highly autofluorescent cells or those to which mAb has become inappropriately
bound, and their antigenic status is indeterminate. In a population of cells in which
99% are CD44+, for example, it is unjustifiable to assume that a 5% "false positive"
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population are CD44". If the false positive population are a random selection of the
background population, then the same proportion of these cells would be
fluorescence positive as in the general population, and one could correct for the
error. However, the assumption is not necessarily valid. In the analyses that follow,
the actual measured percentage positivity is quoted, along with the percentage
positivity in the negative controls. The use of discriminatory or indicative markers
is stated overtly. Where appropriate, a two-tailed paired or non-paired t test has been
carried out on the results of a series of experiments to compare a particular
percentage positivity (%fl+) or mean fluorescence intensity (mfi) with negative
controls or a parallel series of experiments respectively (discussed further in
Chapter 3.2.1).
This extended analysis focuses on the issue of what is meant by the statement
that particular cell or cell population is "positive". A final point should be
emphasised: that fluorescence positivity referenced to an indicative or
discriminatory threshold marker, cannot be interpreted as synonymous with the
presence or absence of a given antigen on the cell surface. It is to be hoped that the
correlation between antigen density and fluorescence intensity is linear, and the
relationship may be quantitated by a reference titration based on standardised beads
(Chapter 3.5.2). However, a given cell expressing the antigen at low density can
quite clearly fall within the fluorescence negative population, especially if it starts
from a low base (i.e. has lower than average autofluorescence).
This somewhat complex combination of approaches, then, was found to be most
informative in analysing fluorescence structure in Chapter 3, where the initial
objective was to examine cell adhesion molecule expression within CD34+
populations from different sources.
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CHAPTER 3. CHARACTERISATION OF HAEMATOPOIETIC
PROGENITOR PHENOTYPE.
3.1 Introduction. />115
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3.1 Introduction.
The development ofsatisfactory immunocytometry methodology detailed in
Chapter 2 permitted the use ofmulticolour immunocytometry for phenotypic
haematopoietic progenitor (HPC) analyses. In an initial study ofHPC cell adhesion
molecule (CAM) expression, HPC were labelledwith the directly conjugated anti-
CD34mAbQBEND10-FITC and cell adhesionmolecules by purifiedmAbs with a
sheep anti-murine R-phycoerythrin (SAM-RPE) second step reagent. FL-1
discriminators were set at a 0.5% false positivity rate and samples ofless than 1 %
measured positivity (0.5% true positivity) were not studied on the grounds thatmore
than 50% ofthe study population would not, in fact, be HPC (Chapter 2.9.3). This
initial study suggested that significant differences do exist between sessile and
circulating HPC (Section 3.2), but also that methodological weaknesses needed
attention. The biological significance ofthe observations remained unclear for several
reasons. In particular, it was uncertain whether differences in CAM expression
reflected differences in the heterogeneity ofthe CD34+ population or the effects of
supraphysiological cytokine exposure, and whether phenotypic differences could be
directly translated into differences in functional binding behaviour. Itwas therefore
decided to study the pattern oflineage and activationmarkers in HPC derived from
different sources (Section 3.3). Between 1992 and 1993 8G12-RPE became available
and the superior resolution index ofthis mAb-conjugate (Chapter 2.4.6 and 2.9.2),
along with improvements in the staining and analytical techniques, allowed a
reduction in the false positive rate to 0.05% ofthe negative control. The implications in
terms of improved precision, accuracy and comparability ofthe results are discussed in
Section 3.3. The question as to whether differentHPC subsets express different
patterns ofCAM was addressed first using a representative panel ofhuman
haematopoietic cell lines (Section 3.4), and later through development ofthree-colour
immunocytometry (Section 3.5). The latter represented a considerablemethodological
challenge in viewofthe small numbers ofcells under examination. The composite
results ofthis series ofexperiments is discussed in Section 3.6. The development ofan
in vitro assaywithwhich to study functional cell binding is discussed in Chapters 4-6.
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3.2 A Comparative Study of Haematopoietic Progenitor Cell Adhesion
Molecule Expression.
A dual immunocytometry study was designed to look at the coexpression ofthe
CD34 antigen and a panel ofcell adhesionmolecules demonstrated by other groups to
be expressed by bonemarrowHPC, orwhichwere thought likely to be expressed on the
basis ofknown bonemarrow stromal and endothelial stucture (Table 3.1) [Gordon,
1988a & b; Soligo, Schiro, Luksch et al. 1990; Kansas, Muirhead& Dailey, 1990;
Lewinsohn,Nagler, Ginzton etal. 1990; Long &Dixit, 1990; Arkin, Naprstek, Guarini
et al. 1991; Papayannopoulou& Brice, 1992; Clark, Gallagher& Dexter, 1992;
Saeland, Duvert, C&uxetal. 1992; Simmons, Niutta, Ashman etal. 1992; Greenwait
Lipsly, Ockenhouse etal. 1992; Teixido, Hemler, Greenberger et al. 1992; Liesveld,
Winslow, Frediani etal. 1993; Lund-Johansen& Terstappen, 1993; Kobayashi,
Imamura, IJede etal. 1994],
3.2.1 Study design and general methodology.
Five groups ofsamples were studied: peripheral blood from normal volunteers
(n=12) (PB), bonemarrow from normal volunteers (n=8) (BM); normal umbilical cord
blood (n=8) (CB), and peripheral blood from patients following 4g/m2
cyclophosphamide and 5 pg/kg rhuG-CSF (n=8) (PBm), taken at two time points during
the recovery phase following hypoplasia: as the peripheral blood leucocyte count rose
above 1 x 109/l (PBm# 1), and 48hr later(PBm#2), corresponding to the rise and fall of
circulating progenitors in the peripheral blood [Craig, Anthony, Stewarteitf/. 1993],
These sources are discussed in Section 2.2.1.
Dual immunofluorescence was carried out using a technique similar to that used for
labelling cells with a single fluorochrome. Sampleswere prepared by discontinuous
density centrifugation overFicoll Hypaque. Mononuclear cells from the interface were
collected, counted, and the viability assessed by trypan blue exclusion. Cells were
washed thrice in handling medium, and 5x 105 cells/testwere incubated with rabbit
serum for 15min (to block Fc receptor uptake ofmAbs) and re-washed. Theywere
incubated for 3 0minwith 1Opl ofa pretitred purifiedmAb addressed to a cell adhesion
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molecule (Table 3.1). After incubation the cells were washed thrice, and incubated
with SAM- RPE pre-titred to 1/40, for 30 min. The cells were again washed thrice,
incubated for 15 min with mouse serum to block uptake of the secondary mAb by
unbound active sites on the SAM. The mouse serum was removed, and the cells
washed and incubated for 30 min with lOpl ofQBEND10-FITC. The cells were
washed and resuspended in 1% paraformaldehyde. Positive controls were
established using purified and FITC-conjugated mAbs addressed to CD45. Negative
controls were established using irrelevant isotype-specific purified and conjugated
mAbs as appropriate. All incubation, washing, centrifugation and storage, was
carried out at +4°C. The routine method for dual immunofluorescence labelling is
documented in Table 3.2, and the test and control panel in Table 3.3.
Compensation was set in the two fluorescence channels using the positive controls as
previously detailed in Chapter 2.4.1 and Figure 2.4. Data acquisitionwas carried out
withConsort 30 DataManagement System. For clinical samples, 10,000 cells were
acquired through a lymphoblastoid acquisition gate set to include cells ofmedium-high
FSC and low SSC. This windowhas been shown to include the vastmajority ofcolony-
forming cells (CFU-GEMM, CFU-GM and BFU-E) and long term culture - initiating
cells (LTC-IC) [Andrews, Singer& Bernstein, 1989]. The gate reduced background
autofluorescence ofmyeloid cells and partially enriched for HPC, permitting better
definition ofthe CD34+ population [Civin, Banquerigo, Strauss et al. 1987]. FSC, SSC
and two fluorescence signals were determined for each cell and stored in list mode data
files. The analysis ofthe four dimensional datawas performedwith Consort 3 0
software. Discriminatorymarkers were established using the negative controls at 0.5%
on the FL-1 and at the point ofminimal inflection on the FL-2 histogram. A dual
parameter contourmap displaying FL-1 against FL-2 was used to define four cell
populations, namely CD34" CAM+ (#1), CD34+ CAM+ (#2), CD34"CAM" (#3) and
CD34+CAM" (#4) (Figure 3.1). The percentage ofevents in quadrants 2 and 4 defined
the percentage ofCD34+ HPC in the acquired sample, and allowed a statement ofthe
percentage ofCD34+ cells coexpressing the CAM ofinterest. The arithmeticmean
fluorescence intensity (mfi) ofthe CAM, SAM- RPE on the CD34+ populationwas
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Table 3.2. Dual Immunofluorescence Labelling for the Cell Adhesion Molecule
Study.
low density mononuclear cells (5x105 cells / test)
wash thrice in 0.5ml handling medium
incubated with 20jal rabbit serum for 15min (Fc receptor blockade)
wash once in 0.5ml handling medium
incubated with lOpl ofpurified anti-CAM mAb for 30min
washed thrice in handling medium
incubated with lOpl of SAM-RPE for 30min
washed thrice in handling medium
incubated with 20pi ofmouse serum for 15min
wash once in handling medium
incubated with lOpl of QBEND10-FITC for 30min
washed once in handling medium
resuspended in 1% paraformaldehyde
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Legend. QBEND10-FITC: anti-CD34 mAb directly conjugated to FITC.
CD**: purified mAb addressed to the appropriate antigen. SAM-RPE: sheep anti-
mouse antbody conjugated to RPE. The labelled samples were compared with
similarly conjugated mAbs of the same isotype but irrelevant specificity.
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calculated by summating RPE fluorescence intensity of the two CD34+ quadrants.
On the assumption that the percentage positive fluorescence (%fT) or the mean
fluorescence intensity (mfi) of CD34+ expression of a particular CAM would be
normally distributed continuous variables over a series of experiments, results were
quoted as mean ± standard deviation (SD) of several replicate experiments (n). A
two-tailed paired Student's t test was used to assess whether %fl+ or mfi was
significantly different from control, and a two-tailed non-paired t test was used to
assess the significance of differences between sources (Table 3.4). The p value so
derived provides a measure of the probability of obtaining the observed data if the
null hypothesis is true i.e. if there is (in fact) no difference in the fluorescence of the
two populations under comparison. The t tests have not been formally modified to
correct for the effects ofmultiple comparisons [Altman, 1994], but in view of the
fact that four sets of comparisons were intended for each CAM, the cut-off for
statistical significance was considered to be p<0.01.
3.2.2 Analysis ofnormalperipheral blood samples at rest, andfollowing exercise.
Peripheral blood samples were taken from normalmale and female volunteers, prior
to exercise (steady state), and immediately following vigorous exercise. Vigorous
exercise is known to transiently mobiliseHPC, probably by displacing them from a
marginated population. The volunteers exercised on a static bike for 10 minutes, at
30km/h andmaximum toleratedwork load. Fivemen and fivewomen (median age
31.5; range 25-38) achieved amedian heart rate of 155bpm (range 130-180), which
represented 70-95% ofmaximal heart rate (calculated as 220-age). A1.5 ± 0.2 fold
increase in peripheral blood leucocytes occurred. CD34+ levels were below threshold
levels prior to (0.28 ± 0.17), and following (0.22 ±0.19) exercise (threshold 0.5%).
Bender, Unverzagt,Walker etal [1991 ] have reported comparable steady state
peripheral blood CD34+ levels of0.2 ± 0.1%, and felt sufficiently confident to study
antigen expressionwithin this population. The immunocytometry systemwas not
considered sufficiently sensitive to permit valid study ofCD34+ HPC at this order of
concentration.
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3.2.3 Analysis ofsamplesfrom normal bone marrow, mobilisedperipheral blood
and umbilical cord blood.
CD34+ HPC comprised 5.1 ± 4.8% ofcells within the lymphoblastoid acquisition
gate from bonemarrow (n=8). Adult peripheral blood taken at day 10 ± 1 post
cyclophosphamide (PBm#l), showed a white count of 1.9 ± 0.6x109/l, and contained
6.8 ± 4.3% CD34+cells (n=7). Paired sampleswere taken at day 12± 1 (PBm#2),
showed awhite count of 16.7 ± 3.1x1071, and contained 5.3 ±5.3% CD34+ cells (n=8).
Umbilical cord blood samples studied contained 2.0 ± 1.9% CD34+ cells (n=8), though
this is not a representative group because cord blood samples with very lowCD34+
counts were discarded. The relative numbers ofCD34+ cells acquiredwere therefore
510 ± 480 from BM, 680 ±430 from PBra#l, 530 ± 530 from PBm#2, and 200 ± 190 from
CB. Clearly, less CD34+ cells were analysed from cord blood samples, though this
difference was not found to be statistically significant (Table 3.4). The contamination
ofthe study population with non-specific labelled cells can be calculated from the ratio
ofthemean false %+ in the negative control to themean%CD34+ (xl 00). The respective
contamination percentageswere 9.5% (BM), 7.9% (PBm#l), 8.2% (PBm#2) and20.6%
(CB). Overall CD34%+ cells are comparable with those reported by Bender forBM
(1.8%) and PBm (0.6-5%), allowing for the effect ofthe lymphoblastoid gate [Bender,
Unverzagt,Walker etal. 1991; Bender, Williams,Myers etal. 1992],
The results ofCAM expression within these populations are summarised in Figures
3.1,3.2 & 3.3 and Table 3.4. BM HPC expressed ICAM-1 (CD54), PECAM-1 (CD31),
LFA-3 (CD58), VLA-4 (CD49d), VLA-5 (CD49e), LFA-1 (CD 11 a), L-Selectin
(CD62L), HCAM (CD44) and CD36, but notVNR (CD51). Analysis ofthe mfi
demonstrated very highHPC CD44 expression, with intermediate expression ofthe
otherCAMswith the exception ofCD51. PBm #1 and #2 HPC display significantly less
expression ofCD58 and CD49e comparative to BM HPC, when analysed according to
mean%fl+ but no significant difference in the expressionofother antigens. This
difference was not detected by mfi, andmay reflect reduced expression by, or reduced
representationofaCD34+ subpopulation. There was no significant difference in cell
adhesionmolecule expression by PBml andPBm2HPC.
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Figure 3.1 Dual Immunocytometry Studies of Cell Adhesion Molecule
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Legend. CD34 (FL-1) on the abscissa, CAMs (FL-2) on the ordinate. Quadrant 1:
CD34' lin; Q2: CD34+ lin+; Q3: CD34" lin; Q4: CD34+ lin. (A) ICAM-1 (CD54);
(B) PECAM-1 (CD31); (C) LFA-3 (CD58); (D) VLA-4 (CD49d); (E) VLA-5
(CD49e); (F) LFA-1 (CD1 la); (G) VNR (CD51); (H) L-Selectin (CD62L); (I)
HCAM (CD44); (J) CD36; (K) CD45 positive control; (L) IgG negative control.
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Figure 3.2 Percentage Positivity Cell Adhesion Molecule Expression within
CD34+ Populations from Bone Marrow, Mobilised Peripheral Blood and
Umbilical Cord Blood.
13 bone marrow
■ peripheral blood day +10
£3 peripheral blood day +12
H cord blood
CD54 CD31 CD49e CD11a CD51 CD62L CD44 CD36 lgG1 lgG2a CD45
Legend. Relative percentage positivity of cell adhesion molecule expression within
the CD34" population from bone marrow, mobilised peripheral blood and cord
blood. Results are reported as the mean ± standard deviation of 7 or 8 replicate
experiments. Detailed results are documented in Appendix 3 Table A4.
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Figure 3.3 Mean Fluorescence Intensity of Cell Adhesion Molecule Expression
within CD34+ Populations from Bone Marrow, Mobilised Peripheral Blood and
Umbilical Cord Blood.
Legend. Relative mean fluorescence intensity of cell adhesion molecule expression
within the CD34+ population from bone marrow, mobilised peripheral blood and
cord blood. Results are reported as the mean ± standard deviation of 7 or 8 replicate
experiments. Detailed results are documented in Appendix 3 Table A5.
Legend. Table 3.4 (overpage). Bone marrow (BM) CD34+ CAM expression is
compared to that ofmobilised peripheral blood at 2 time points (PBm#l and PBra#2),
and to that of cord blood (CB) by non-paired t test. PBm#l and PBm#2 are compared
by paired t test. Both percentage positivity and mean fluorescence intensity (mfi) in
parentheses have been analysed. Differential expression of LFA-3 (CD58) and
VLA-5 (CD49e) was the most consistent finding (see text for discussion).
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Table 3.4 Comparative Statistics on CD34+ Cell Adhesion Molecule Expression.
CD BM:PBT#1 BM:PBm#2 BM:CB PBm#l:PBm#2
CD34 ns ns ns ns
CD54% (mfi) ns (ns) ns (ns) p<0.01 (ns) ns (ns)
CD31% (mfi) ns (ns) ns (ns) ns (ns)
CD58% (mfi) p<0.01 (ns) p<0.01 (ns) p<0.01 (P<0.05) ns (ns)
CD49d% (mfi) ns (ns) ns (ns) p<0.05 (ns) ns (ns)
CD49e% (mfi) p<0.05 (ns) p<0.01 (ns) p<0.01 (ns) ns (ns)
CD1 la% (mfi) ns (ns) ns (ns) p<0.01 (ns) ns (ns)
CD51% (mfi) ns (ns) ns (ns) ns (p<0.01) ns (ns)
CD62L% (mfi) ns (ns) ns (ns) p<0.001 (ns) ns (ns)
CD44% (mfi) ns (ns) ns (ns) p<0.05 (ns) ns (ns)
CD36% (mfi) ns (ns) ns (ns) ns (ns) p<0.05 (ns)
FITC control
IgGl% ns ns ns ns
CD45% ns p<0.05 p<0.01 ns
RPE control
IgGl% (mfi) p<0.05 (ns) ns (ns) ns (p<0.05) p<0.05 (ns)
IgG2a% (mfi) ns (ns) ns (ns) ns (p<0.01) ns (ns)
CD45% ns p<0.05 p<0.05 ns
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CB HPC display significantly less expression of CD54, CD58, CD49e, CD1 la
and CD62L when analysed by %fT but not by mfi. A central concern in the
interpretation of this data was that the CB IgGl and IgG2a SAM-RPE negative
controls demonstrated significantly increased backgound binding compared to BM
and PB samples (Figure 3.2 & 3.3, Table 3.4). In contrast the IgGl-FITC direct
conjugate negative control showed little difference between these sources,
suggesting that the major problem was overbinding of the second step reagent.
3.2.4 Effects ofmouse serum on binding ofsecond-step reagent.
A concern was raised that the use ofmouse serum to blockade SAM-RPE uptake of
QBEND10-FITC may reduce antibody binding, in particular ofthe SAM-RPE to the
purifiedmAb. An experiment was carried out by dual labelling normal peripheral
bloodMNCwithCD34-FITC and CD45, SAM-RPE. Omittingmouse serum from the
protocol led tomarked binding ofthe CD34mAb by the second step reagent (Table
3.5). A triplicate experiment confirmed thatmouse serum had no significant effect on
CD45 SAM-RPE labelling ofPB-MNC (Table 3.6).
3.2.5 Comparability ofdata, andmethodological problems.
An important issue was considered to be the comparability ofthe data between
different samples, linked to differences in fluorescence ofthe negative control, and
variability in the size ofthe study population. A specific source ofconcern was that
variation in auto fluorescence or non-specific binding ofantibodies, reflected by
differences in the mfi ofthe negative controls, would lead to artefactual differences in
% binding between sources due to shift in the discriminatorymarker. Marker position
(fluorescence channel) for each ofthe sources is documented in Table 3.7. Significance
ofdifferences betweenmarker positions was calculated by non-paired t test. There was
no significant difference betweenmarker positions on FL-1, implying that CD34
definition is directly comparable. In FL-2, PB andBMmarkers were comparable, but
themarkers on CB were positioned significantly higher. This was not related to
increased autofluorescence in this population, and reflected non-specific
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Table 3.5 Effects of Incubation with and without Mouse Serum.
Mouse serum CD34+ 0.46% IgGl-FITC 0.46%
CD45+ 94.87% IgGl SAM-RPE 0.81%
No serum CD34+ 55.64% IgGl-FITC 1.43%
CD45+ 88.20% IgGl SAM-RPE 1.08%
Legend. Data from a representative experiment demonstrating that omission of
mouse serum from the labelling protocol leads to marked uptake of the CD34 mAb
by the SAM-RPE second step reagent.
Table 3.6 Effect ofMouse Serum on CD45 SAM-RPE Labelling of Peripheral
Blood Mononuclear Cells.
mouse serum CD45+ 56.2 ± 15.1% P<0.05 IgGl SAM-RPE 3.6 ± 1.1%
no serum CD45+ 71.8 ± 13.5% P<0.05 IgGl SAM-RPE 6.3 ± 2.5%
Legend. Data presented is the mean ± standard deviation of 3 replicate experiments.
Paired t test revealed no significant difference between CD45%+ or negative binding
with orwithoutmouse serum.
These two experiments demonstrated the general utility of mouse serum as a
blockading agent in dual colourwork.
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Table 3.7 Marker Channel for Each of the Sources.
fluorescence BM (n=7) PB"#1 (n=5) PBT#2 (n=5) CB (n=7)
FL-1 auto 38± 10 25 ± 10 ns 18 ± 6 P<0.01 32 ± 25 ns
IgGl-FITC 59± 19 50 ± 9 ns 46 ± 17 ns 68 ± 17 ns
FL-2 auto 24 ±6 15 ± 7 P<0.05 12 ±3 P<0.01 25 ± 22 ns
IgGl
SAM-RPE




22 ±7 29 ± 7 ns 33 ± 14 ns 59 ±23
P<0.01
Legend. Data presented is the mean channel position ± standard deviation for each
source, autofluorescence and negative controls. The marker position used in PBm#l,
PBm#2 and CB are compared to that used on BM by non-paired t test. There are few
differences in the marker positions used on BM and PBm, but those used on CB
samples were placed significantly higher due to higher non-specific uptake of the
second step reagent.
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binding of the purified mAb and / or second step reagent despite equivalent
handling to that of other samples. Whether this is due to higher Fc receptor
expression on the background population [Anderson & Looney, 1986], or the
presence of unusual contaminants such as Wharton's Jelly in the cord blood samples
is unclear [Flanagan & Mitoma, 1958], Comparability of the CB data with BM and
PBm data is therefore confounded by a smaller CD34+ population, with greater
false-positive contamination, and higher non-specific binding of the reagents in FL-
2. The observations on BM and PB samples were therefore held to be valid, but the
observations on CB were considered more difficult to interpret, especially in the
presence of a generalised reduction in CAM expression, but significantly higher
CD45 expression.
The biological significance of the observed differences between BM and PBm
samples was considered to be uncertain for two reasons. First, differences in the
nature of the source material including exposure to chemotherapy and supra-
physiological levels of rhuG-CSF may engender differences in HPC heterogeneity
between study groups. If HPC subsets express different levels of CAMs this could
explain the observed differences in CAM expression between groups. Second, the
functional role of the observed CAM expression in HPC-stromal and endothelial
adhesion is poorly understood. This study was therefore instrumental in formulating
both the objectives and the methodological design of further experiments.
3.3 Haematopoietic Progenitor Cell Expression of Lineage and Activation
Markers.
The pattern ofactivation and lineage-associated antigen expression within HPC has
been discussed in Section 1.2.4. The panel of antigens used to discriminate HPC
subsets is detailed in Table 3.8. The earliest identified lineage-associated antigens
were used as markers for lineage committment along with HLA-DR and CD38 as
markers of HPC activation [Fraser, Leahy & Berridge, 1986; Loken, Shah, Dattilio
et al. 1987a & b; Civin & Loken, 1987; Terstappen, Hollander, Meiners et al. 1990;
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Table 3.8 Lineage and Activation Markers Studied.
CD Lineage mAb, isotype (species) Source
CD33 myeloid D3HL60.251 IgGl (murine) Immunotech
CD7 T lymphoid 8H8 IgGl (murine) Immunotech
CD 19 B lymphoid J4.119 IgGl (murine) Immunotech
CD71 erythroid YDJ1.2.2 IgGl (murine) Immunotech
CD41a megakaryocytic P2 IgGl (murine) Immunotech
CD38 activation T16 IgGl (murine) Immunotech
HLA-DR activation B8.12.2 IgG2b (murine) Immunotech
Terstappen & Loken 1990; Terstappen, Safford & Loken, 1990; Srour, Brandt,
Briddell et al. 1991; Terstappen, Huang, Safford et al. 1991; Terstappen, Huang &
Pickler, 1992], The limitations of this selection are discussed in Section 3.6.2.
3.3.1 Modifications in dual immunocytometry methodology.
The methodological problems associated with the cell adhesion molecule study
(Section 3.2.5) stimulated a number ofmodifications to the dual immunocytometry
protocol aimed at reduction in procedure-related cell loss or ignorance, reduction in
non-specific binding of labelling reagents, more stringent definition of a larger
study population and more informative analysis of that population.
The immunocytometry protocol (Table 3.2) was modified in the following ways:
(1) Contemporaneous whole blood and leucapheresis products were examined from
the same patient, in case the leucapheresis procedure had selectively depleted a
CD34+ subpopulation. (2) A whole-sample labelling technique was used with red
cell lysis, in order to reduce Ficoll-related cell losses (Chapters 2.4.4 and 6.6.3).
(3) 0.5% human gamma globulin solution was used instead of rabbit serum, to
improve Fc receptor blockade. (4) The number of washes was reduced, but the
volume of each wash increased (to reduce preparation time and cell trauma).
(5) 8G12-RPE was used instead ofQBEND-FITC as the anti-CD34 label because of
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its superior resolution index, allowing a more stringent marker to be set (0.05%),
with consequent reduction in contamination of the study population (Chapter 2.4.6
and 2.9.3). (6) Directly conjugated mAbs were used as lineage markers, to reduce
non-specific binding. (7) All mAb incubation steps were reduced to 15min at +4°C
to improve the ratio of specific to non-specific binding. (8) The Lysis II software
was used rather than Consort 30 software, because of added flexibility.
(9) The lymphoblastoid acquisition gate was established by backgating the CD34+
population onto the SSC / FSC dot plot, to allow more accurate placement (Figure
3.4). (10) 30,000 cells were acquired per analysis to allow a larger study population
(the low frequency of a cell population leads to a high cv which may skew the mean
[Terstappen, Buescher, Nguyen et al. 1993]). (11) Additional negative and positive
controls were established (i.e. CD34-RPE, IgGl-FITC and CD34-RPE, CD45-
FITC) in order to allow more accurate determination ofmfi within the CD34+ popu¬
lation. (12) A marker was established at the point ofminimal inflexion on the FITC
histogram, to establish greater flexibility and sensitivity in detecting lineage marker
expression.
The modified protocol and test system are summarised in Table 3.9 and 3.10.
3.3.2 Results.
The results of this series of experiments is presented in Figures 3.5, 3.6 & 3.7
and Table 3.11. Improvements in assay technique led to improvements in the
number of CD34+ cells examined, and a reduction in the false-positive
contamination of the study population. Whole blood samples (PBm and CB) were
not as easy to study as BM or LP because the red cell burden was greater and
interfered with both the staining and the analytical technique. The modifications in
technique allowed better standardisation ofmarker position, but CB samples still
demonstrated a significantly smaller CD34+ study population and significantly
greater contamination compared to other sources. Under global analysis no
significant expression ofCD33, CD7, CD19 or CD41a by CD34+ HPC from any
source was detected (Appendix 3 Tables A6 & A7). However, direct inspection of
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Table 3.9 Modified Dual Immunofluorescence Labelling Protocol used for the
Analysis of Lineage-Marker Expression.
Immunofluorescence labelling.
whole product (in anticoagulant medium)
5x105 nucleated cells / test,
wash x2 in 1ml handling medium
incubate with 0.5ml of 0.5% human gamma globulin for 15min
incubate with 10pl 8G12-RPE + 10pl mAb-FITC for 15min at +4°c
wash xl in 1ml of handling medium
incubate in 2ml of erythrocyte lysis solution for 15min
resuspend in 0.5ml 1% paraformaldehyde
Flow cytometry.
Standard cytometer set up used (Table 2.6).
A test sample of cells was acquired ungated in SetUp. The CD34+ population was
defined on the FL2 histogram, and highlighted on the FSC / SSC dot-plot. A
lymphoblastoid acquisition gate was established on the FSC / SSC dot-plot using
the CD34+ population as a whole.
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Legend. 8G12-RPE: anti-CD34 mAb directly conjugated with RPE.
CD**-FITC: mAb to a lineage or activation marker directly conjugated to FITC.
Labelled samples were compared with similarly conjugated mAbs of the same
isotype but irrelevant specificity.
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Figure 3.4 Backgating of the CD34~ Population on the FSC / SSC Dot-Plot.
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Legend. Lysed peripheral blood leukocytes acquired on an open gate (A)
demonstrated negative control fluorescence (M2) of 0.05% (B), CD34" 1.67% (C).
A gate (R2) established on the CD34T population allows these cells to be projected
on the FSC / SSC dot-plot and an acquisition gate (Rl) to be drawn around the
lymphoblastoid population (D). Negative control fluorescence (M3) on the Rl
population is now 0.00% (E) and CD34" 3.25% (F).
Figure 3.5 Representative Experiment Demonstrating Lineage Marker
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Legend. Cells were acquired and the CD34+ population identified as described in
Figure 3.4. Cells gated on the CD34" population (M2 Figure 3.4F) were projected
onto the FL-1 histogram. (A) negative control %ff 3.1% mfi 10. (B) CD45 %ff
99.6% mfl 95. (C) CD33 %ff 10.3% mfi 14. (D) CD7 %fT 6.8% mfi 14.(E) CD19
%ff 4.2% mfi 10. (F) CD71 %ff 50.0% mfi 26.(G) CD41a%ff 5.8% mfi 15. (H)
CD38 %ff 66.2% mfi 30.(1) HLA-DR%ff 82.4% mfi 44.
Figure 3.6 Percentage Positive Lineage Marker Expression within the CD34+











■ peripheral blood (mobilised)
H leucapheresis product
E cord blood
CD33 CD7 CD19 CD71 CD41a CD38 HLA-DR lgG1 CD45
Legend. Relative percentage positivity of lineage and activation marker expression
within the CD34+ population from bone marrow, mobilised peripheral blood and
cord blood. Results are reported as the mean ± standard deviation of 4 replicate
experiments. Detailed results are documented in Appendix 3 Table A6.
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Figure 3.7 Mean Fluorescence Intensity of Lineage Marker Expression within
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Legend. Relative percentage positivity of lineage and activation marker expression
within the CD34+ population from bone marrow, mobilised peripheral blood and
cord blood. Results are reported as the mean ± standard deviation of 4 replicate
experiments. Detailed results are documented in Appendix 3 Table A7.
Legend. Table 3.11 (overpage). Bonemarrow (BM) CD34" lineage and activation
marker expression is compared to that ofmobilised peripheral blood (PBm),
leucapheresis product (LP) and cord blood (CB) by non-paired t test. PBm and LP
are compared by paired t test. Both percentage positivity and mean fluorescence
intensity (mfl) in parentheses, have been analysed. See text for discussion.
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Table 3.11 Comparative Statistics on Lineage Marker Expression by CD34+
Cells from Bone Marrow, Mobilised Peripheral Blood and Matched
Leucapheresis Product and Cord Blood.
CD BM:PBT BM:LP PBT:LP' BM.CB
CD34 ns ns p<0.05 p<0.01
Events p<0.05 ns p<0.05 p<0.01
IgGl-RPE p<0.05 ns ns ns
Contamination. ns ns ns p<0.05
CD33% (mfi) ns (ns) ns (ns) ns (ns) ns (ns)
CD7% (mfi) ns (ns) ns (ns) ns (ns) ns (ns)
CD 19% (mfi) ns (ns) ns (ns) p<0.05 (ns) ns (ns)
CD71% (mfi) ns (ns) ns (P<0.05) ns (ns) ns (ns)
CD41a% (mfi) ns (ns) ns (ns) ns (ns) ns (ns)
CD38% (mfi) ns (p<0.001) ns (p<0.001) ns (p<0.05) p<0.05 (p<0.001)
HLADR (mfi) ns (p<0.02) ns (p<0.001) ns (ns) ns (p<0.05)
IgGl% (mfi) ns (ns) ns (ns) ns (ns) ns (ns)
CD45% (mfi) ns (ns) ns (ns) ns (ns) ns (ns)
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the relevant fluorescence histograms (Figures 3.5 - 3.7) suggest that CD33 and
CD 19 are expressed by subpopulations ofCD34+ cells within BM from at least
some individuals, but not by circulating populations. This information is masked by
the high variance between samples and the relatively low power of the study (n=4).
CD71 is expressed by 40% ofBM HPC and somewhat fewer circulating cells.
CD38 and HLA-DR are expressed by the majority of HPC, but at higher antigen
density in BM compared to PB populations. There is a particularly marker
difference in the expression of CD38 between CB and other populations. There are
therefore detectable differences in the expression of lineage and activation markers
between normal bone marrow and circulating HPC (Table 3.11).
3.4 Characterisation of Cell Adhesion Molecule, Lineage and Activation
Marker Expression by Human Haematopoietic Cell Lines.
In view of the difficulties inherent in studying CAM expression within HPC
subsets {vide infra), it was decided to study a panel of human haematopoietic cell
lines to ascertain whether differences in lineage or activation markers were
associated with differences in CAM expression. The cell lines KGla, K562, HL-60,
NALM-6 and CEM were used for this study. Their characteristics are listed in Table
2.1 and culture and storage discussed in Section 2.2.2.
Single colour immunofluorescence was used to characterise the pattern of
expression ofCAMs using purified mAbs and a SAM-FITC second step reagent
(Section 3.2), and of lineage / activation markers using directly FITC conjugated
mAbs (Section 3.3). Standard immunocytometry labelling technique was used with
the omission of erythrocyte lysis (Chapter 2.4 and Table 2.10). The settings on the
flow cytometer were adjusted to compensate for the larger size and greater
autofluorescence of the cell lines compared to normal human cells (Table 3.12).
10,000 events were acquired through an acquisition gate set on the FSC / SSC dot-
plot to include the singlet population, but to exclude cellular aggregates and debris
(Figure 2.6).
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The results of this work are summarised in Figures 3.8 to 3.12 inclusive. KGla
is a human acute myelogenous leukaemia cell line. The cells are CD34+ and
coexpress CD7 and CD71, though not CD38, HLA-DR or CD33. In addition they
express the CAMs CD54, CD31, CD58, CD49d, CD49e, CD1 la, CD44 and CD36.
K562 is a human chronic myelogenous leukaemia cell line. The cells are CD34,
CD19+ and CD71+. They co-express CD54, CD58, CD49d, CD49e and CD51.
HL-60 is a human promyelocytic leukaemia cell line. They are CD34", HLA-DR7,
and co-express CD54, CD58, CD49d, CD49e, CD1 la and CD44. NALM-6 is a
human B lymphoid cell line, which is CD34", CD19+, CD71+, CD38+ and HLA-DR7.
Interestingly, this line is CD45". The cells coexpress CD54, CD58, CD49d and
CD49e. Finally, CEM is a human acute T lymphoblastic leukaemia cell line, CD34",
CD7+, CD71+ and CD38+. The cell coexpress CD54, CD49d, CD49e and CD44.
L-Selectin (CD62L) is thought to be shed from activated leucocytes by proteolytic
cleavage, and perhaps it is not suprising, therefore, that itwas not found to be expressed
by any ofthe cell lines.
This study supported the generalisation that differences in CAM expression do
occur in association with differences in activation and lineage commitment. For
example, the composite data shows that CD54, CD49d and 49e were expressed by
all cell lines, whereas CD1 la and CD44 were not expressed by CD19+ cell lines
(K562 and NALM-6), and CD31 and CD36 expression was restricted to the CD34+
cell line KGla. Unfortunately, it is difficult to know the extent to which cell lines
can be considered representative ofHPC subsets [Akiyama, Larjava, Yamada et al.
1990],
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Table 3.12 Flow Cytometry Settings for the Cell Line Studies.
Parameter Detector Amplification Threshold





FL1 - %FL2 1.8%
FL2 - %FL1 42.0%
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Figure 3.8 Representative Experiment Demonstrating Single Colour
Immunofluorescence of Cell Adhesion Molecule Expression by KGla.
Legend. KGla labelled with purified mAbs to CAMs and sheep anti-mouse FI1C.
(A) negative control %fl+ 4.5% mfi 12. (B) CD45 %fT 96.6% mfi 150. (C) ICAM-1
(CD54) %fl+ 97.4% mfi 104. (D) PECAM-1 (CD31) %ff 69.8% mfi 44. (E) LFA-3
%fT 94.7% mfi 73. (F) VLA-4 (CD49d) %fl+ 96.3% mfi 95. (G) VLA-5 (CD49e)
%fT 91.0% mfi 64. (H) LFA-1 (CD1 la) %fT 99.6% mfi 274. (I) VNR (CD51) %fT
91.4% mfi 66. (J) L-Selecfin (CD62L) %fT 77.3% mfi 48. (K) HCAM (CD44) %ff
98.5% mfi 679. (L) CD36 %fT 92.5% mfi 80.
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Legend. Relative percentage positivity of cell adhesion molecule expression by
KG la, K562, HL-60, NALM-6 and CEM. Results are reported as the mean ±
standard deviation of 4 replicate experiments. Detailed results are documented in
Appendix 3 Table A8-12.
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Figure 3.10 Mean Fluorescence Intensity of Cell Adhesion Molecule Expression
by Haematopoietic Cell Lines.
Legend. Relative mean fluorescence intensity of cell adhesion molecule expression
by KGla, K562, HL-60, NALM-6 and CEM. Results are reported as the mean ±
standard deviation of 4 replicate experiments. Detailed results are documented in
Appendix 3 Table A8-12.
145
Figure 3.11 Percentage Positive Lineage and Activation Marker Expression by
Haematopoietic Cell Lines.
Legend. Relative percentage positivity of lineage and activation marker expression
by KG la, K562, HL-60, NALM-6 and CEM. Results are reported as the mean ±
standard deviation of 4 replicate experiments. Detailed results are documented m
Appendix 3 Table A8-12.
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Figure 3.12 Mean Fluorescence Intensity of Lineage and Activation Marker
Expression by Haematopoietic Cell Lines.





Legend. Relative mean fluorescence intensity of lineage marker expression by
KGla, K562, HL-60, NALM-6 and CEM. Results are reported as the mean ±
standard deviation of 4 replicate experiments. Detailed results are documented in
Appendix 3 Table A8-12.
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3.5 Development of Three Colour Immunocytometry to Study Cell Adhesion
Molecule Expression within Haematopoietic Progenitor Subsets.
It was clear, therefore, that the pattern ofCAM expression within CD34+ lineage
subsets would have to be defined using three-colour immunocytometry. This
provided a particularly difficult technical and analytical challenge.
The immunofluorescence labelling protocol was fairly standard. 8G12-RPE was
used to label the CD34+ population on the grounds that the antigen present in the
lowest density generally should be stained with the brightest fluorochrome. Directly
FITC conjugated mAbs addressed to the lineage-associated antigens were used.
Commercial availability dictated the use of anti-CAM mAbs in purified form, with
an anti-murine third colour reagent. Binding of the directly conjugated reagents by
the second-step (third colour) reagent was blocked with mouse serum as previously.
The labelling protocol is summarised in Table 3.13. Up to 10,000 events were
acquired through a gate defined on the CD34+ / FSC dot plot (Lysis II software).
This was necessary in order to substantially increase the number of cells under
analysis, to include cells of high side scatter in the analysis, and in order to be able
to carry out the nested analysis ofCAM expression within lineage subsets which
was not otherwise possible on the Lysis II software. The Paint-A-Gate software can
carry out a nested analysis, but requires transfer ofmarkers between programmes
which is unsatisfactory, and provides inadequate statistical information.
Several technical problems required solution, the choice of third colour reagent
and establishment of a satisfactory compensation network, the use of beads to
calibrate the intensity of antigen expression, a more detailed estimation of the level
of contamination of the study (CD34+) population, and an evaluation of the
distribution ofCD34+ cells on the FSC / SSC dot plot.
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Table 3.13 Three Colour Immunofluorescence Labelling Protocol.
lxlO6 leucocytes (whole blood)
washed twice in 1ml handling medium
incubated for 15min in 0.5% human immunoglobulin in PBS
incubated for 15min with 20pl anti-CAM mAb (purified)
washed twice in 1ml handling medium
incubated for 15min with 20pl of 2nd stage reagent
washed twice in 1ml handling medium
incubated for 15min with 20pl of 3rd stage reagent (Quantum Red only)
washed twice in handling medium (Quantum Red only)
incubated for 15min with 20pi murine serum
incubated for 15min with 20pl 8G12-RPE and 20pl Lin-FITC
washed once in 1ml handling medium
incubated for 5-10min with 0.5ml erythrocyte lysis solution (until clarification),
washed once in handling medium
stored in 1ml 1% paraformaldehyde.
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3.5.1 Evaluation ofpotential third colour reagents.
Three reagents were assessed for their utility as 3rd colour reagents: GAM-Red
613, streptavidin-Quantum Red, and RAM-PerCP. Whereas GAM-Red 613 and
RAM-PerCP could be used by a classical two-step indirect labelling technique, a
three step labelling procedure had to be adopted with Quantum Red whereby the
purified mAb was labelled with a RAM-biotinylated second step, and the
streptavidin-Quantum Red was used as a third step reagent. The 8G12-RPE and
lineage-FITC mAbs were then added as a fourth step. Both the second and third step
reagents had to be independently titrated.
The three reagents were evaluated by staining KG la with the anti-CD44 mAb
and with the appropriate second (and third) step reagent.CD44 was chosen as it was
the most densely expressed of the CAMs (and therefore gave rise to the brightest
fluorescence likely to be confronted), and because it was an IgG2a isotype mAb -
like the LFA-3 and VLA-5 mAbs which were the ultimate target of the study.
Negative controls were established with purified IgG2a of irrelevant specificity and
the appropriate reagents as detailed above. Red 613 proved very bright (Figure 3.13,
A & D), and engendered a high degree of fluorescence in FL-2 despite maximum
compensation (G). In experiments on LP the shift in the FL-2 negative control
completely obscured the RPE-labelled CD34+ population. Both Quantum Red and
PerCP provided acceptable fluorescence overlap (H & I), the FL-2 histograms
differed little from those of the negative controls (not shown). Although the mfi of
the Quantum Red negative control (E) was higher than that of PerCP (F), the
combination of a higher mfi on the positive population (B cf: C) and a cleaner
discrimination (probably due to the specificity of the strepavidin-biotin system),
meant that the percentage positivity was greater with Quantum Red.
3.5.2 Use ofcalibration beads to assess the intensity ofantigen expression.
Quantum simply cellular calibration microbeads were used to provide
calibration of antigen density. The beads are a mixture of five populations of
microbeads, four with defined antibody binding capacity and one non-binding. The
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Figure 3.13 Spectral Overlap of the Third Colour Reagents.
Legend. Sample of KG la was labelled with CD44 and Red 613 (A, D & G),
Quantum Red (B, E & H) or PerCp (C, F & I) as described in the text.
A, B & C represent the positively stained samples (FL-3) and D, E & F their
respective negative controls. Ml is a fixed marker, and M2 is set on 0.5% of the
negative controls. G, H & I are the FL-2 histograms of the respective FL-3 labelled
samples (A, B & C). Once again M3 is a fixed marker and M4 is set on 0.5% of the
FL-2 histogram from the FL-3 negative controls (not shown). See main text for
discussion of results.
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antibody binding capacity is derived from covalently bound goat anti-mouse
immunoglobulin on the microbead. 50pl of solution containing approximately
100,000 microbeads were dispensed and labelled with directly conjugated 8G12-
RPE using the standard protocol, with the exception that the incubation step with
human gamma globulin was omitted (Table 3.13), and the mAb incubation was
prolonged to lhr (as recommended by the manufacturer). Similar amounts ofmAb
were used for microbead labelling as for cell labelling in order to ensure that
saturation of binding sites occurred. Contemporaneous KGla samples were stained
with 8G12-RPE and IgGl-RPE. Acquisition was carried out with the same
cytometer set-up (Table 3.12). Microbeads are approximately the size of
lymphocytes, and were acquired through gating on the singlet population (Figure
3.14), whilst KGla were acquired through their usual gate. The peak arithmetic
channel numbers for each of the five microbead populations were recorded, a
correlation coefficient and regression line was calculated, and a calibration curve of
the arithmetic histogram channel (abscissa) against the antibody binding capacity
(ordinate) was plotted (Figure 3.15). In this experiment the correlation coefficient
was r = +1.00, and the regression line was described by the formula y = -1,798 +
618.x. The mean fluorescence intensity of 8G12-RPE staining ofKGla could then
be used to estimate the mean number of antibody binding sites present on KGla by
calculation from the regression equation or by extrapolation from the calibration
graph. Mean KGla fluorescence in the negative control was 2.46, equating to an
antibody binding capacity of -277 (an artefact of the formula), whilst mean
fluorescence in the positive control was 1,596, equating to an antibody binding
capacity of 984,530. This is equivalent to the number of cognate epitopes expressed
by KGla. A Coulter Channalyser 256 measured a KGla diameter of 10.8pm, giving
a calculated surface area of 366.4pm2 (based on the inaccurate assumption that cells
are spherical) and an epitope density of 2,687/pm2.
A second experiment was carried out in which microbeads were again labelled
with 8G12-RPE, whilst a normal bone marrow sample was labelled with 8G12-RPE
and a CD45-FITC conjugate. The samples were acquired using the normal
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Figure 3.14 Physical Characteristics and Fluorescence of Microbeads.
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Legend. An acquisition gate was established on the singlet population of 8G12-RPE
labelled microbeads on the FSC / SSC dot-plot (A & B), allowing discrimination of
five discrete populations on the FL-2 histogram (C). These demonstrated peak
channel numbers ofMl: 2.21, M2: 15.26, M3: 50.94, M4: 113 and M5: 375
respectively (C). This data was used to construct a calibration curve of peak channel
number against antibody binding sites as demonstrated in Figure 3.15 and discussed
in the main text.
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Legend. The peak channel numbers for each of the 5 populations of 8G12-RPE
labelled microbeads were recorded (Figure 3.14) and plotted against the known
mAb binding capacity. The correlation coefficient was r = +1.00 and the regression
line was described by the formula y = -1,798 + 618.x. Abscissa: mAb binding
capacity. Ordinate: peak channel number. The solid data points are those observed.
Too a large extent these overlap. Data is tabulated in Appendix 3 Table A13.
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cytometer set-up (Table 2.6). Microbeads were acquired through a gate on the
singlet population as previously, whilst the bone marrow samples were acquired
through a FSC / SSC gate excluding debris and aggregates. In this experiment the
correlation coefficient was (once again) r = +1.00, and the regression line was
described by the formula y = -2,452 + 362.x . The peak channel number for 8G12-
RPE staining of the CD34+ population was 152, corresponding to an antibody
binding capacity of 52,588. An average lymphocyte diameter of 7.2pm, gives a
calculated surface area of 162.9pm2 and an estimated epitope density of 323/pm2.
This study does not prove that CD34 antigen density is greater on KGla than HPC.
It is possible that KGla express a different form of CD34 with more epitopes per
molecule, or that the structure of the membrane is different and provides a greater
effective surface area (cells are not spheres). Nevertheless this kind of calculation is
useful in providing a measure of antigen density on comparable cells, and
demonstrates one of the reasons why CD34+ HPC are more difficult to define than
CD34+ KGla.
A third series of experiments were carried out in which KGla and microbeads
were stained with anti-CD44 mAb and with RAM-PerCP as a second step reagent.
A control set of beads was stained with the second step reagent alone. Unfortunately
discrimination of the separate populations of beads was poor using this indirect
technique. This is perhaps not suprising because the variable orientation of the
primary mAb on the surface of the beads, binding of the second step reagent directly
by the beads and the variable number of RAM-PerCP molecules which may bind to
an individual primary mAb, all conspire to degrade the linearity of the relationship
between the number of binding sites presented and the intensity of fluorescence.
3.5.3 Contamination ofthe study population with variation in the discriminatory
marker.
If cells were to be acquired on the basis of CD34+, it was important that the
acquisition was carried out in such a way as to provide a measure of the level of
contamination. In an initial series of experiments HPC were acquired on the basis of
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CD34+ alone, defined on the basis of the FL-2 negative control acquired through an
open gate. The acquired cells proved to give rise to considerable spectral overlap
into both FL-1 and FL-3. On closer examination it was found that highly FL-2
autofluorescent cells, which provided the main false positive contamination of the
study population, also provided most of the spectral overlap in the other channels.
Furthermore, much of the autofluorescent contamination was found to be arising
from the debris and cell aggregates. It was clear, therefore, that the study population
would have to be acquired through a more complex gate on FSC and FL-2. A
somewhat involved set-up procedure was adopted: CD34-RPE / CD45-FITC
labelled cells and the appropriate negative controls were used to establish an
acquisition gate by CD45 backgating as described in Chapter 2.4.5, except that
debris and cell aggregates were excluded on the FSC alone rather than on the FSC-
SSC dot-plot. A series ofmarkers were established on the negative control acquired
through this gate, and the percentages compared with those on the CD34+ sample in
order to define the placement of the discriminatory marker. This analysis was quite
informative in that it demonstrated that the higher the discriminatory marker the
lower the contamination of the CD34+ population (as expected), but also that the
CD34+ population itself has a broader range of fluorescence than suspected (Figure
3.16). 0.05% was chosen as the discriminatory marker because a higher marker
engenders greater contamination of the study population (as discussed in Chapter
2.9.3) and also therefore obscuration of the analysis of the study population due to
greater spectral overlap, but it has to be acknowledged that this biases the data in
favour of the more primitive CD34hl population. A similar type of problem arises
when enrichment ofHPC is carried out on the basis of CD34 positivity (Chapter
6.6). A 0.05% discriminatory marker defined on analysis of the negative control
gated on FSC alone was therefore used to backgate the CD34+ population onto the
FSC / FL-2 dot-plot such that an acquisition gate could be established on these two
parameters (Figure 3.17). A minor adjustment to the compensation in FL-1 and FL3
was then necessary (Table 3.14).
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Figure 3.16 Range of Fluorescence of the CD34+ Population and Dependence of
Contamination of the Study Population on the Discriminatory Marker.
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Legend. A series ofmarkers were established on the negative control (A, B & C)
and on PBm labelled with CD45-FITC and CD34-RPE (D, E & F).
FL-1 Ml: (A) 1.0% (D) 61.6%. FL-2 M2: (B) 0.00% (E) 0.08% contamination
<12.5%. FL-2 M3: (B) 0.01% (E) 0.12% contamination 8.3%. FL-2 M4 (B) 0.05%
(E) 0.44% contamination 11.4%. FL-2 M5: (B) 0.10% (E) 0.65% contamination
16.7%. FL-2 M6: (B) 0.20% (E) 0.81% contamination 24.7%. FL-2 M7: (B) 0.50%
(E) 1.43% contamination 36.4%. FL-2 M8: (B) 0.94% (E) 2.05% contamination
45.8%. It is clear that CD34+ cells overlap with the negative population over a wide
range of fluorescence. The maximal CD34" count (after subtraction of false
positivity) is achieved at M8 (1.11%) and minimal contamination at M2 or M3. The
use of the SSC / FL-2 dot-plot allows better discrimination of false positives R2 (C)
0.01% from CD34+ cells R2 (F) 0.83%. Contamination was 1.2% due to exclusion
of high side scatter cells.
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Figure 3.17 Establishment of an Acquisition Gate on the FSC / FL-2 Dot-Plot.
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Legend. Negative control and CD45-FITC, CD34-RPE labelled samples from PBra
were acquired through an open gate (A) and used to establish a marker on FL-1:
negative control (B) Ml: 1.44%, CD45-FITC labelled sample (C) Ml: 73.97%. The
CD45+ cells were backgated through region R2 (=M1) onto the FSC / FL-2 dot-plot
(D), and a region R1 was defined to exclude FSC'° CD45" debris and FSChl
aggregates. Cells acquired through this gate were used to establish a marker on FL-2
negative control (E) M2: 0.05% and CD34-RPE labelled sample (F) M2: 3.08%.
The CD34+ cells were backgated through region R3 (=M2) onto the FSC / FL-2 dot-
plot (G) allowing adjustment of the acquisition gate Rl. Cells acquired through the
adjusted Rl gate demonstrated a CD45+ of 96.8% (H) and a CD34+ of 100% (I). Test
samples acquired through an open gate demonstrated that 0.02% of the negative
control (J) and 1.94% of the CD34+ labelled sample (K) would fall into Rl, leading
to a calculated contamination of 1%.
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Table 3.14 Flow Cytometer Settings for Three-Colour Immunocytometry.
Parameter Detector Amplification Threshold






FL1 - %FL2 1.7%
FL2 - %FL 1 42.6%
FL2 - %FL3 0.0%
FL3 - %FL2 10.0%
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3.5.4 Discrimination ofCD34+ lineage subsets by light-scatter.
Since, the intention of this study was to quantify the differences in CAM
expression between HPC subsets, it was thought valuable to determine whether
CD34+ subsets could be resolved on the basis of light scatter as well as antigen
expression. Samples stained for anti-CD34 and lineage markers were acquired
using the CD45 backgating technique described above (Chapter 2.4.5). During
analysis a discriminatory marker established on the CD34+ IgG-FITC was used to
discriminate fluorescence positive and negative subpopulations and to project these
back onto the FSC / SSC dot-plot. It became obvious that there were simply too few
CD34+ CD33+, CD34+ CD7+, CD34+ CD19+ or CD34+ CD41a+ cells available to
achieve useful information on distribution. In general, the CD34+ CD71+, CD34+
HLA-DR7 and (to a lesser extent) CD34+ CD38+ subpopulations appeared to contain
more high forward and side scattering cells than their respective negative
populations (Figure 3.18). These light scatter characteristics are consistent with
studies using counterflow elutriation which demonstrate that CD34hI HLA-DR" and
CD38" populations consist of small, low density early progeniors and stem cells,
whilst CD34'0 HLA-DR7 and CD38+ cells are larger, denser, committed HPC
[Herbein, Sovalat, Wunder et al. 1994].
Terstappen et al have demonstrated that the physical characteristics of granular
and non-granular lymphocytes cannot be resolved using standard linear or
logarithmic functions, but can be separated easily if the side scatter data is
transformed by a polynomial function so as to increase the resolution in the middle
of the SSC range [Terstappen, Mickaels, Dost et al, 1990]. A similar analytical
programme applied to data on HPC subset distribution may be more informative
than the standard software. Nevertheless this information provided a further
argument for acquiring data on the basis of a FSC / CD34+ gate, and not excluding
CD34+ SSChl cells from the analysis.
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Legend. Cells from a leucapheresis product were acquired on a gate (Rl) established
on CD34" alone. Negative (M2 = R3) and positive (Ml = R2) markers and gates
were established on the negative control (not shown) and were used to backgate the
CD34" Marker and CD34+ Marker" populations onto the FSC / SSC dot-plots.
(A) CD34" CD71 (FL-1) histogram. (B) CD34" CD7F FSC / SSC dot-plot
(C) CD34" CD71" FSC / SSC dot-plot (D) CD34" HLA-DR (FL-1) histogram.
(E) CD34" HLA-DR FSC / SSC dot-plot (F) CD34" HLA-DR" FSC / SSC dot-plot.
(G) CD34" CD38 (FL-1) histogram. (H) CD34" CD38' FSC / SSC dot-plot
(I) CD34" CD38" FSC / SSC dot-plot.
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3.5.5 Three colour analysis ofadhesion molecule expression within bone marrow
HPC subsets.
In view of the difficulties encountered in resolving CD34+ lineage subsets
described above it was decided that a more modest objective would be established:
to determine whether LFA-3 and VLA-5 expression varied with CD71, HLA-DR
and CD38 expression. This seemed reasonable in that it was unlikely that the
presence or absence of minor subpopulations would contribute to significant shifts
in CAM expression, and because all three of the activation markers demonstrated
higher expression in sessile compared to circulating HPC (Section 3.3.2).
The labelling protocol is described in Table 3.13, the cytometer set-up in Table 3.14
and the panel of assays in Table 3.15. An IgG2a mAb to CD44 and an irrelevant-
specificity IgG2a were used as positive and negative controls respectively because
the LFA-3 and VLA-5 mAbs were IgG2a isotypes. A FSC / FL-2 acquisition gate
was established using the negative control (sample #15) and a positive control
(sample #13) as previously described (Section 3.5.3 and 3.5.4). Under an open gate
10,000 events were acquired in order to establish the CD34%+ and the %fl+ of the
negative control, from which the level of contamination of the study population
could be estimated. The acquisition gate was further adjusted to ensure there was no
negative tail on the study population (Section 3.5.3). A target of 2,000 events was
acquired through this gate, necessitating evaluation of up to 500,000 cells per
sample. Discrimination of activation positive and negative CD34+ cells was carried
out by analysis of the CD34+ FL-1 histogram on samples #13 and #14 as previously
described (Section 3.3). Analysis ofCAM expression within CD34+ lin+ and lin"
subpopulations was carried out by establishing discriminatory markers on the FL-3
histogram using the relevant positive and negative controls (e.g. #3 and #4 for the
CD34+ CD71-labelled samples) and the mfi of FL-3 antigen expression (Figure
3.19) [Terstappen, Hollander, Meiners et al, 1990]. Antigen quantitation could not
be carried out because of the failure of the calibration beads with indirect technique
as described above (Section 3.5.2). The results were compared to the relevant
negative controls and to each other using paired t tests (Tables 3.16-3.18).
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Table 3.15 Test Panel for the Th
#1. CD58 RAM-Biotin Strep-QR
#2 CD49d RAM-Biotin Strep-QR
#3 CD44 RAM-Biotin Strep-QR






#5. CD58 RAM-Biotin Strep-QR
#6 CD49d RAM-Biotin Strep-QR
#7 CD44 RAM-Biotin Strep-QR





#9. CD58 RAM-Biotin Strep-QR
#10 CD49d RAM-Biotin Strep-QR
#11 .CD44 RAM-Biotin Strep-QR









Legend. CD34-RPE: anti-CD34 mAb directly conjugated with RPE.
CD**-FITC: mAb addressed to a lineage or activation marker directly conjugated to
FITC. SAM-FITC: sheep anti-mouse antbody conjugated to FITC. CD**: purified
anti-cell adhesion molecule mAb. RAM-Biotin Strep-QR: biotinylated rat anti-
mouse and strepavidin-linked Quantum Red. Labelled samples were compared with
similarly conjugated mAbs of the same isotype but irrelevant specificity.
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There were found to be two problems in the interpretation of the results: First, a
relatively wide standard deviation such that it was difficult to statistically
discriminate LFA-3 (CD58) and VLA-5 (CD49e) expression from the negative
control (CD44 expression could be statistically discriminated in the main) (Tables
3.16 & 3.17). Second, there was a clear difference in negative control fluorescence
between lineage subsets with increasing background in the general order CD34+ lin"
< CD34+ global < CD34+ lin+ (Figure 3.19 & Table 3.18). Allowing for these
limitations, LFA-3 (CD58) did not vary significantly between subsets whilst VLA-5
(CD49e) expression did appear to be greater in the CD34+ CD71+ and CD34+
CD38+ subpopulations compared to their activation negative counterparts (Table 3.18).
3.6 Discussion.
The work described in this Chapter aimed to clarify the pattern of cell adhesion
molecule expression by HPC and demonstrated that differences occur between
sessile and circulating populations. The observation that there are source dependent
differences in HPC lineage and activation subsets was confirmed. Although cell line
studies suggest that differences in CAM expression and lineage commitment may be
linked, it proved very difficult to test this proposition on HPC because of the small
size of the study population and a wide standard deviation ofmost measurements of
antigen expression. The precision and accuracy of the immunocytometry technique
improved over the series of studies detailed as a reflection of improvements in
reagents and labelling and in analytical methodology. Nevertheless, some important
problems remain.
3.6.1 Problems associated with the interpretation ofadhesion molecule expression.
The data on HPC adhesion molecule expression was summarised in Section
3.2.3 and Figures 3.2 and 3.3, and the problems associated with interpreting the
validity of comparative data or the physiological relevance of the observations is
discussed in Section 3.2.5. The results on BM CD34+ adhesion molecule expression
are broadly comparable with those of other groups [Lewinsohn, Nagler, Ginzton et
165
Figure 3.19 Analysis of Cell Adhesion Molecule Expression within
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Legend. Cells were acquired through an acquisition gate (Rl) established on the
FSC / FL-2 dot-plot (A) as previously described (Figure 3.17). The study population
was CD34+ on FL-2 (B>and CD71" (M2 = R2) and CD7T (Ml - R3) populations
were defined on the FL-1 histogram (C) using the appropriate negative controls
(Figure 3.5). CD34+ IgG2a (D) and CD34+ CD44+ (G) were used to define positivity
in FL-3. Expression of the third antigen within the CD34* CD71" (R2) population
(E & H) and the CD34+ CD7T (R3) population (F & I) could then be compared to
that within the CD34T population as a whole (D & G) using percentage positivity
and mean fluorscence intensity.
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Table 3.16 Percentage Positive CAM Fluorescence within CD34+ Lin+ and Lin
Subsets.
phenotype CD34+ FL-3+ CD3F FL-r FL-3+ CD34* FL-F FL-3+
CD34 71 58. 13.8 ± 9.5% ns 0.7 ± 0.7% ns 31.8 ± 24.3% ns
CD34 71 49e. 24.7 ± 21.7% ns 18.9 ± 19.1% ns 35.9 ± 26.2% ns
CD34 71 IgG. 7.7 ± 4.2% 0.16 ±0.17% 18.6 ± 12.5%






CD34 38 58. 7.1 ±4.8% ns 0.8 ± 0.9% ns 10.6 ± 7.8% ns
CD34 38 49e. 23.7 ± 20.1% ns 12.6 ± 17.4% ns 29.8 ± 21.8% ns
CD34 38 IgG. 6.6 ± 4.6% 0.85 ± 1.25% 9.9 ± 7.0%






CD34 HLADR 58. 7.2 ± 4.3% ns 1.1 ±0.9% ns 9.2 ± 6.2% ns
CD34 HLADR 49e. 22.0 ± 18.8% ns 13.6 ± 11.5% ns 26.6 ± 22.3% ns
CD34 HLADR IgG. 5.7 ±3.3% 0.8 ± 0.2% 7.3 ± 4.4%







Table 3.17 Mean Fluorescence Intensity of CAM Expression within CD34+ Lin+
and Lin Subsets.
phenotype CD34+ FL-3+ CD34+ FL-L FL-3+ CD34* FL-F FL-3+
CD34 71 58. 86 ± 29 ns 36 ± 21 ns 162 ± 120 ns
CD34 71 49e. 93 ± 36 ns 75 ±31 ns 117 ± 39 ns
CD34 71 IgG. 61 ±31 29 ±26 100 ±31
CD34 71 CD44. 250 ± 69 p<0.05 210 ±52 p<0.02 301 ± 103 p<0.05
CD34 38 58. 58 ± 31 ns 34 ± 20 ns 70 ± 32 ns
CD34 38 49e. 89 ± 28 ns 67 ± 22 ns 101 ±24 ns
CD34 38 IgG. 56 ±21 34 ±20 68 ±22
CD34, 38 44. 256 ± 83 p<0.05 256 ± 83 p<0.05 312 ± 145 p<0.05
CD34 HLADR 58. 57 ± 26 ns 49 ± 54 ns 64 ± 25 ns
CD34 HLADR 49e. 79 ± 24 ns 62 ± 24 ns 85 ± 25 ns
CD34 HLADR IgG. 48 ±28 30 ±21 52 ±27
CD34 HLADR 44. 276 ± 142 ns 260 ± 99 p<0.05 288 ± 165 ns
Legend. In the preceding tables results of%fT and mfi ofCAM expression within
the CD34+ population as a whole and within the CD34+ lin" and lin+ populations are
reported as the mean ± standard deviation of 4 experiments, and are compared to the
relevant negative controls by paired t test. Discussion of results - see main text.
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Table 3.18 Statistical Analysis of CAM Expression within CD34+ Lin and Lin+
Subsets.
phenotype global: lin global: lin lin: lin*
%fl+ mfi %fl+ mfi %fi+ mfi
CD34 71 58. ns ns ns ns ns ns
CD34 71 49e. p<0.05 p<0.01 p<0.05 ns p<0.05 p<0.02
CD34 71 IgG. ns p<0.01 ns ns ns p<0.05
CD34 71 CD44. ns ns p<0.05 ns ns ns
CD34 38 58. ns ns ns ns ns ns
CD34 38 49e. p<0.01 ns ns ns p<0.01 ns
CD34 38 IgG. p<0.05 p<0.02 ns ns ns p<0.05
CD34 38 44. ns ns p<0.05 ns ns ns
CD34 HLADR 58. ns ns ns ns ns ns
CD34 HLADR 49e. ns ns ns ns ns ns
CD34 HLADR IgG. p<0.05 ns ns ns ns p<0.05
CD34 HLADR 44. ns ns p<0.02 ns ns ns
Legend. Results of%fl+ and mfi ofCAM expression are compared using paired t
tests: CD34+ population with CD34+ lin" population (global:liri ), CD34+ population
with CD34+ lin+ population (global:lin ) and CD34+ lin" population with CD34+ lin+
population (lin: lin). For discussion of results - see main text.
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al. 1990; Long & Dixit, 1990; Soligo, Schiro, Luksch et al. 1990; Arkin, Naprstek,
Guarini et al. 1991; Saeland, Duvert, Caux et al. 1992; Greenwalt, Lipsky,
Ockenhouse et al. 1992; Simmons, Niutta, Ashman et al. 1992; Watt, Williamson,
Genevier et al. 1993; Liesveld, Winslow, Frediani et al. 1993], and the implications
for a model ofHPC homing and engraftment are discussed in Chapter 7.2.
There are few studies which directly compare CAM expression between BM and
circulating CD34+ cells. Mohle, Haas & Hunstein, [1993] reported LFA-1 to be
significantly reduced in LP HPC from 23 patients, 15 mobilised with cytotoxic
chemotherapy and rhu-G- CSF, and 8 with a combination of rhuIL-3 and rhuGM-
CSF. No difference in ICAM-1 or CD44 expression was demonstrated, and no other
CAMs were studied. Leavesley, Oliver, Swart et al [1994], have reported reduced
expression of LFA-1 and VLA-4, but not PECAM-1 in cryopreserved LP HPC from
3 patients following chemotherapy and rhuG-CSF. Again no other CAMs were
studied. Saeland, Duvert, Caux et al [1992], found no difference in the expression of
adhesion molecules between BM and UCB CD34+ cells using a semiquantitative
reporting system.
The discordance between the findings in these studies and those in the present
study may relate to several factors including differences in the study population
(e.g. cytokine exposure or cryopreservation), variation in immunofluorescence
labelling and cytometry technique (discussed further below in Section 3.7.2), and
stochastic variation between studies.
The power of a study is dependent on the size of the study population, the
variation in the data (SD), the size of difference sought, and the level of statistical
significance demanded [Altman, 1994], For example, calculating from the data
presented in Table A4, the power of this study to detect a difference of 15% in LFA-
1 expression between BM and LP CD34+ cells, given a SD of 12.5% (a calculated
standard difference of 1.2) and n=8, was approximately 0.20 for a p value of <0.01,
and 0.40 for a p value of <0.05. In other words, there was an 80% chance of
obtaining a non-significant result when a 15% difference in LFA-1 expression
between BM and LP CD34+ cells did in fact exist (a type II error) allowing for a p
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value of <0.01, and a 60% chance allowing for a p value of <0.05. In the study by
Mohle, Haas & Hunstein [1993], a 15% difference in LFA-1 expression between
BM and LP CD34+ cells was detected at a p<0.001 (my calculation based on their
published data), though the power of their study is difficult to estimate because of
inequality in the size of the study populations (BM n=6, LP n=23). In general, the
larger the comparative study population, and the smaller the variation in expression
of the antigen of interest, the greater the power of the study. There is a strong
argument therefore for carrying out highly focused studies with large study
populations. Given an SD of 12.5%, in order to achieve a 95% chance of detecting a
difference of 10% between BM and LP CD34+ CAM expression (at a p value of
<0.01), it would be necessary to study at least 100 paired samples.
3.6.2 Problems associated with the definition ofHPC-subsets.
Caution was exercised in the interpretation of antigen expression as a marker of
lineage-committment. First, quantitative multifactorial analysis of peripheral blood
leucocyte populations has illustrated that antigen expression is rarely lineage-
restricted and is better described as lineage- associated [Terstappen, Hollander,
Meiners et al, 1990], In particular, considerable uncertainty exists as to the pattern
of expression of lineage-associated antigens on earlier progenitors. It has been
proposed that some observations of "lineage- infidelity" in leukaemic phenotypes,
may be representative of a general phase of "lineage-promiscuity" amongst
multipotential cells, during which lineage-specific antigens may be coexpressed
prior to irreversible committment [Greaves, Chan, Furley et al. 1986; McCulloch,
1987], Recent advances in immunocytometric technique provide support for this
thesis [Hurwitz, Gore, Stone et al. 1992], Second, considerable variability exists
between the reports from different groups on the levels of antigen positivity or
expression. This is related to two phenomena: first, an absence of standardisation
between research groups with regard to the nature of the study populations, the
preparatory handling (including enrichment techniques), the epitope specificity and
fluorescence intensity of the mAb-fluorochrome conjugates (see for example
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Chapter 2.4.6), labelling technique, cytometer set-up and acquisition gates (Chapter
2.6), and analytical criteria including definition of the CD34+ population and of
lineage marker positivity (Chapter 2.9.3). Second, stochastic variation occurs
between studies and this is particularly marked if the study population is small
(Chapters 2.7 and 2.9.2).
CD33 expression is thought to be restricted to myeloid lineage cells [Andrews,
Singer & Bernstein, 1990; Terstappen, Hollander, Meiners et al, 1990; Terstappen
& Loken, 1990], Overall, CD34+ CD33 expression was very low in this study
despite detection of the antigen in the BM CD34" population (Figure 3.5 - 3.7).
These results are comparable with those of Fritsch, Buchinger, Printz et al.
[1993a], who found CD34+ cells to be predominantly CD33 orl0. In contrast many
groups have described significant CD34+ CD33 expression: Bender et al reported
higher levels of CD33 expression by PBm (73.5%) and PBS (84%) CD34+ cells
compared to those in BM (43%) [Bender, Unverzagt, Walker et al. 1991; Bender,
Williams, Myers et al, 1992], CD33 antigen density was however described as low
with some patients (30%) predominantly negative. Saeland, Duvert, Caux et al.
[1992] reported CD34+ CD33 expression at low antigen density and with
considerable heterogeneity, leading to substantial overlap with the negative
population. Mohle, Haas & Hunstein [1993] reported that 80% of PBm CD34+ were
CD33+ albeit with substantial inter-individual variability. The consensus therefore
seems to be that CD33 antigen expression within the CD34+ population is low
density and highly variable, leading to a wide variation in reported positivity. It is
also possible that differences in epitope affinity or resolution index between mAbs
are contributing to the problem. CD13 may be used as a marker ofmyeloid
committment, but Saeland, Duvert, Caux et al [1992] have reported broad
expression of this antigen within the CD34+ population including cells expressing
lymphoid markers CD10+ and CD19+.
Several groups have reported the presence of a significant CD34+ subpopulation
expressing B-lymphoid associated antigens (CD10, CD 19 and CD20) in BM (6.5-
10%) but not in CB or PB cells [Ryan, Kossover, Mitchell et al. 1986; Loken, Shah,
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Dattilio et al, 1987b; Bender, Unverzagt, Walker et al. 1991; Bender, Williams,
Myers et al. 1992; Saeland, Duvert, Caux et al. 1992; Bender, Unverzagt, Walker et
al. 1994; To, Haylock, Dowse et al. 1994], CD19 displays exceptional B lineage-
specificity, is amongst the earliest B-lymphoid antigens expressed, and is
coexpressed with CD10, intranuclear TdT, and HLA-DR [Loken, Shah, Dattilio et
al. 1987b; Serke, Sauberlich, Abe et al. 1991].
Terstappen, Huang & Pickler [1992] have demonstrated that CD34+ thymocyte
subsets in human thymus are HLA-DR, CD44 and CD54 low, CD38, CD7, CD49d
and CD62L high. The same group were able to clearly demonstrate a CD34+ CD7+
population in foetal but not in adult BM. Saeland, Duvert, Caux et al. [1992] have
confirmed virtually no expression of T-lymphoid associated antigens CD2, CD3,
CD4, CD7 or CD8 on BM or CB HPC. Bender et al have reported low level CD34+
CD7 expression in BM (2.7%) and PB (7%), but not PBm [Bender, Unverzagt,
Walker et al. 1991; Bender, Williams, Myers et al. 1992],
CD41a was not expressed by CD34+ cells in this study, nor in that of Saeland,
Duvert, Caux et al [1992], In comparison Bender, Williams, Myers et al. [1992]
have reported high (81%) though heterogeneous expression of CD41 by PBm CD34+
cells.
CD71 (transferrin receptor) was used as a marker of erythroid committment in
these studies, but is expressed by other proliferating cells [Loken, Shah, Dattilio et
al. 1987a]. Expression of CD71 occurs in a subpopulation consisting of 40% of
CD34+ cells in BM, and slightly fewer in PBm. This result is similar to that of To,
Haylock, Dowse et al. [1994], though Bender et al. [Bender, Unverzagt, Walker et
al. 1991; Bender, Williams, Myers et al. 1992] reported a more polarised difference
in CD71 expression between BM (94%) and PB (17%) and PBm (16%). Glycophorin
A is widely used as a marker of erythroid differentiation, but is not expressed by
HPC [Loken, Shah, Dattilio et al, 1987a; Saeland, Duvert, Caux et al. 1992]. It may
be better to use a mAb to the CD45RO isoform as a marker ofprimitive and
erythroid HPC [Lansdorp, Sutherland & Eaves, 1990].
Both CD38 and HLA-DR are expressed by the majority ofCD34+ cells in a
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homogeneous fashion (Figure 3.5-3.7 and Table 3.11), at significantly greatermfi
in BM than in blood derived HPC, concordant with the observations of To, Haylock,
Dowse et al. [1994]. Terstappen et al have reported that less than 1% ofCD34+ cells
are CD38, and that there is an inverse relationship between CD34 antigen intensity
and CD38 antigen intensity, with the latter coexpressed with lineage- associated
antigens CD71, CD33, CD10 or CD7 [Terstappen, Huang, Safford et al. 1991]. This
group suggest that CD34hl CD38" lin" cells are a primitive blast population with
characteristic intermediate FSC and low SSC, and that activation and lineage
commitment is accompanied by decreasing CD34 expression, increasing CD38 and
lineage-related antigen expression, and an increase in heterogeneity in the FSC and
SSC characteristics of the population (Chapter 1.2.4 7 Section 3.5.4). HLA-DR is
also expressed on the majority ofCD34+ cells, HLA-DR" populations being
regarded as particularly primitive at least in adult bone marrow [Civin & Loken,
1987; Sutherland, Eaves, Eaves et al. 1989; Verfaillie, Blakholmer & McGlave,
1990; Srour, Brandt, Briddell et al. 1991; Huang & Terstappen, 1994] (Chapter
1.2.4).
In summary, differences in the state of activation / lineage committment clearly
do exist between BM-derived and PB-derived HPC, particularly with regard to the
presence of a CD19+ subset and a larger CD71+ subset within BM, and greater
homogeneous expression ofCD38 and HLA-DR compared to PB, suggesting the
presence ofmore activated CD34+ population within the BM, with more erythroid
and B-lymphoid precursors. Combination of lineage and activation markers using
three colour immunocytometry may provide more accurate discrimination of CD34+
subsets in the future.
3.6.3 Problems with three-colour immunocytometry ofHPC subsets.
The difficulties in defining CD34+ populations, quantitating CAM expression
and identifying lineage subsets discussed in the preceding two chapters reach their
apotheosis when attempting three-colour analysis. The central problem was to
acquire sufficient cells to make an analysis meaningful. This was achieved by
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acquiring through a gate established on FSC and CD34 positivity and analysing
activation markers which showed a reasonable balance between positive and
negative subpopulations. Fortuitously these markers were also those which showed
differences between sessile and circulating CD34+ populations i.e. CD71, CD38 and
HLA-DR. In view of the extended nature of the labelling and analytical procedures
it was decided to focus on the two CAMs which showed the most clear cut
difference in expression between sessile and circulating HPC. Statistical variation
between samples and a higher background fluorescence in the CD34+ lin+
subpopulation compared to the CD34+ lin", made interpretation very difficult.
Allowing for this proviso, no difference in LFA-3 expression could be demonstrated
between "activated" and "non-activated" CD34+ populations, whilst higher
expression ofVLA-5 appeared to occur in the CD34+ CD71+ and CD34+ CD38+
subpopulations compared to the relevant CD34+ lin" cells. Since CD71 and CD38 are
more highly expressed by BM CD34+ HPC than PBm CD34+ HPC, this observation
supports the proposition that differences in VLA-5 expression between sessile and
circulating populations are at least linked to generic changes in the activation status
of the study population.
LFA-3 is a counter-receptor for T-lymphocyte expressed LFA-2 and is more
likely to play a role in HPC than in primary anchorage. VLA-5 mediates binding to
fibronectin, an important constituent of the extracellular matrix of bone marrow
stroma. It was therefore considered necessary to develop an assay with which to
examine the potential functional role ofCAM in general, and VLA-5 in particular,
in HPC-stromal adhesion.
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4.1 Introduction.
Although immunocytometry provides valuable information about the pattern of
HPC adhesion molecule expression, it does not provide information on the
functional status of those molecules, nor on the role various cell adhesion molecule
- ligand systems play in the processes of endothelial homing and stromal
engraftment. In order to explore these issues, it was necessary to develop an in vitro
assay with which to study cellular adhesion to a range of substrates. Several criteria
were considered to be of importance in the design of the assay: firstly, it should
allow study of cell adhesion to both cellular and non-cellular substrates; secondly, it
should allow correlation of adhesive behaviour with cellular phenotype - especially
cell adhesion molecule expression; thirdly, both adherent and non-adherent
populations should be assayed in order to reduce sampling errors; fourthly,
relatively large numbers of cells should be enumerated, in order to improve the
statistical power of the assay; finally, parameters should be chosen which would
allow the assay to focus on the affinity of a given cell-substrate interaction (i.e.
other variable factors such as the temporal kinetics of the interaction, or the maxi¬
mal binding capacity of a substrate would be controlled at optimal levels).
Several approaches were considered. Direct visualisation of adherent cells using
light / phase or fluoresence microscopy is fairly straightforward, but small numbers
of cells must be used (1-200/well) or a selected microsopic field enumerated for
larger cell numbers. The variation in the number of cells between wells, or between
similar sized areas in the same well, is irregular even in a perfectly mixed sample,
and conforms to a Poisson distribution [Dacie and Lewis, 1975]. The standard
deviation (SD) of the distribution of cell numbers has been shown to be equal to jm,
where m is the mean of the number of cells counted. Thus the inherent coefficient of
variation (cv) of counts on 100 cells is 10%, on 200 cells is 7.1%, and on 1,000 cells
is 3.2%. The situation is compounded by technical and observer variation. It is
necessary to introduce 104 to 10s cells per well in order to achieve an acceptable cv,
and it is clearly not possible to enumerate these by eye.
Semisolid clonogenic assays have been used by several groups to study HPC
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adhesion. Gordon,Clark, Atkinson et al. [1990] used the CFU-blast assay and
Liesveld, Abboud, Duerst et al [1989] the CFU-GM assay as their primary read¬
out. This kind of assay yields information on adhesive behaviour of a functionally
defined subpopulation of HPC, and may be applied to cell lines. There are three
important limitations which follow on from those discussed in Chapters 2.1 and
2.9.1: first, the phenotypic identity of the cell giving rise to a particular colony is
unknown, making it difficult to directly correlate the behaviour of the adhesive
cells with their cell adhesion molecule expression; secondly, the intrinsic
dependence of clonogenic assays on the culture environment leads to problems of
assessing the potential effect of the substrate on the cloning efficiency (leading to
concern about the comparability of adherent and non- adherent F1PC counts in the
adhesion assay); thirdly, 1-200 colonies per assay are required to avoid problems
with statistical accuracy and observer error similar to those encountered in the direct
visualisation methods discussed above [Blackett, 1974],
Vital stains can be used to quantitate adherent cell populations, these include
methylene blue [Rahilly & Fleming, 1993], or 3- (4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) [Mosmann, 1983], crystal violet [Wilkins,
Stupack, Stewart et al, 1991] and rose bengal [Gamble & Vadas, 1988]. These are
not easily applicable to the study of cell adhesion to cellular substrates, because
both test and substrate cells are stained by the detector system.
A radiolabelling approach was considered because it promised accurate and
sensitive quantitation of large cell numbers against both cellular and non-cellular
substrates, allowed cell phenotype and functional adhesion to be related, and was
potentially applicable to enriched HPC populations and haematopoietic cell lines.
The radiolabel should have an appropriate energy and half life and should remain
cell-associated for the duration of the experiment, without impairment of cellular
function. Chromium-51 (5ICr), technetium 99m and indium 111 or 113m are
gamma-emitters, and all can be used for cell labelling. 51Cr produces a high energy,
low abundance gamma-ray, and has a longer half life than the other elements
(27.7d). On cellular uptake it is reduced from the hexavalent to the trivalent form,
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and binds to intracellular proteins [Danpure & Osman, 1990], The specific activity
of an element is the radioactivity per unit mass. One becquerel is defined as one
disintegration / second, and 1 kilobecquerel (kBq) is equivalent to 27 nanocuries
(nCi) (37kBq=lpCi). 51Cr sodium chromate was available with a specific activity of
13-22 GBq/mg at a reference date. The problem of identifying a specific weight and
activity of sodium chromate was circumvented by using a fixed radioactivity for cell
incubation. The sodium chromate was supplied as a stock solution by the
radiopharmacy at the Royal Infirmary of Edinburgh at 2 weekly intervals, such that
the radioactivity after one week (mid-point) was predicted to be 200kBq/80pl. Some
degree of variability in the labelling index of the cells (see below) therefore arose
from the age of the salt.
Critical aspects of the assay were considered to be labelling intensity (which
would determine sensitivity) and uniformity, potential for functional alteration in
cell adhesion, cell toxicity, leakage of 5,Cr label into the supernatant (with potential
redistribution to cellular substrate) and the reproducibility of the assay.
It was decided to develop the 5lCr adhesion assay using human haematopoietic
cell lines in the first instance. These provided the practical advantages of ready
availability of large numbers of cells, consistency and homogeneity of the study
population within which lineage differentiation and adhesion molecule expression
could be relatively closely defined. This strategy avoided confronting the problems
associated with enrichment, heterogeneity and characterisation ofHPC populations
during establishment of the assay system, issues which could be returned to at a
later date.
Adhesion of the leukaemic cell line KG la to plasma fibronectin (pFn) and
denatured bovine serum albumin (dBSA) was used as a test system to optimise the
chromium labelling (Section 4.2), assess substrate preparation (Section 4.3) and
standardise the adhesion assay (Section 4.4). The most informative way of analysing
the results is discussed in Section 4.5. Later the assay was extended to the study of
other purified extracellular matrix components (Chapter 5) and to in vitro stromal
cultures (Chapter 6).
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Storage, handling and disposal of radioactive materials was carried out in
accordance with national and institutional guidelines, and was overseen by the local
radiation protection supervisor.
4.2 Optimisation of''Chromium Radiolabelling.
4.2.1 Cell radiolabelling.
51Cr radiolabelling was carried out a modification of the technique described by
Gallin, Clark & Kimball [1972] and Butcher & Ford [1986]. lxlO7 KGla were
removed from culture, washed in FCS, and cell viability checked by trypan blue dye
exclusion. The cells were incubated with 51Cr in lOOpl PBS + 20% FCS for 1 hour
at 37°C in an incubator with gentle occasional mixing by hand. Hardy & Minguell
[1992] demonstrated that optimal 51Cr binding occurs when serum is a component of
both the radiolabelling medium and the assay medium. The cells were pelleted by
centrifugation at 200g for 5 min, and the supernatant removed. The cells were
washed twice in 2ml culture medium, with removal of the supernatant following
centrifugation each time. The supernatant and washes were pooled (total discard
count). The cells were resuspended in the adhesion medium, which for most
purposes was IMDM + 10% FCS (i.e. standard tissue culture medium) The cells
were recounted and viability checked. The concentration was adjusted to lxl06/ml.
10% of the cells + medium were removed (10% of the total cell count), and the
remaining cells were pelleted and 10% of the supernatant removed (10% of the total
supernatant count).
The following parameters were defined:
global count: total cell count + total discard count.
5lCr uptake: total cell count / global count (%).
labelling index (LI): total cell count / 103 cells.
supernatant contamination: total supernatant count / total cell count (%).
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4.2.2 Definition ofthe resolution limits ofthe gamma counter.
The gamma counter was set up to detect gamma irradiation in the spectrum 240-
400, and the peak 5lCr gamma emission was adjusted to fall within the centre of that
range, as recommended by the manufacturer. 200kBq gave a count in the order of
800,000cpm, suggesting a detection efficiency of 6.7%, and a comparable count was
obtained on a second gamma counter. The accuracy of the gamma counter improves
with the total number of events counted, and is therefore directly related to the
radioactivity of the sample, and the time spent counting. In practice, 15min was the
maximum tolerable time per sample, if a single experiment was to be analysed over
24hrs. A radioactive decay of approximately 2% may be expected over a period of
24 hours, and therefore paired samples were analysed sequentially (i. e. the
supernatant and adherent counts from each experiment and control grouped
together), as averse to batched (all the supernatants counted first, followed by all the
adherent layers).
An experiment was carried out to determine the variability of the count under
these circumstances. Serial dilutions of "Cr were made up and counted six times in
succession (Table 4.1). The mean and standard deviation of serial counts on the
same sample, and the coefficient of variation (cv) were calculated. 51Cr undergoes
exponential decay with a half life of 27.7 days, predicting a deterioration of
approximately 0.3% over the expected period of the experiment (4hrs). The absolute
floor of detection is determined by background radiation (40cpm). The relative floor
depends on the cv one is prepared to accept. A cv of less than 10% is probably
acceptable for accurate quantitation, suggesting that this is not an important
limitation (Table 4.1).
4.2.3 Definition of the resolution limits ofcell numbers.
The floor of detection in terms of cells numbers is dependent upon the maximal
achievable labelling index, which is itself dependent on the sodium chromate uptake
by the cells, and on the specific activity of the chromate salt. Unfortunately sodium
chromate is toxic, leading to cell death and leakage into the supernatant. The 5lCr
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Table 4.1 Resolution Limits of the Gamma Counter using Serial Dilutions of
51Chromium.
target cpm measured cpm coefficient of
variation
105 101,392 ±433 0.43%
104 10,199 ±71 0.70%
103 1.076 ±9 0.83%
500 533 ±6 1.13%
250 228 ± 4 1.86%
100 101± 2 2.31%
50 46 ± 1 3.20%
Blank 42 ±2 5.14%
Legend. Serial dilutions of 51Cr were made up and counted 6 times in succession.
Result are quoted as mean ± standard deviation of 6 sequential analyses of the same
sample. Abbreviations, cpm: counts per minute, cv: coefficient of variation, target
cpm: the estimated number of counts that would be expected from the dilutions
made. The gamma counter is capable of detecting radioactivity just above
background with an acceptable degree of accuracy.
182
incubation is therefore a trade-off between adequate labelling and cell toxicity. Cell
death and 5lCr elution manifest as elevated supernatant radioactivity, falsely
allocated to the non-adherent fraction.
Several concentrations of 51Cr were compared for their effect on cell labelling
(Table 4.2), number and viability: lOOkBq/lOOpl, 200kBq/100pl, 400kBq/200pl,
and a control incubation in FCS only. 20-60% FCS was added to adjust the
concentration, and to maintain cell viability. Cell recovery and viability was similar
in all 3 concentrations and control, suggesting that cell loss was predominantly due
to loss of low buoyant density cells and debris during the washing / centrifugation
steps, rather than cell toxicity. An adequate labelling index and acceptable
supernatant contamination was achieved at 200kBq/107 cells/1 OOpl. Although the
total chromium dose was less than that used by other groups, the sodium chromate
and cell concentrations were at the upper limits of the range 400-2,OOOkBq /
107-108cells/ml (lOpCi / 107-108cells/ml = LI:2cpm / 103 human lymphocytes
[Butcher & Ford, 1986]; 20pCi / 2xl07cells/ml [Gallin, Clark & Kimball, 1972];
50pCi / 2-4xl07 cells/ml = LI:300cpm/103 murine cell line [Hardy & Minguell,
1993]). Butcher comments that although doses as high as 100-200pCi (3,700-
7,400kBq) can be used, these lead to significant radiocytotoxicity [Butcher & Ford,
1986],
With a LI of 40cpm/103cells, an adhesion assay using 105 cells per well will
resolve cell counts in the middle of the range with a cv of approximately 1%, and
detect a floor of approximately 1% of the population with a cv of between 2 and 3%
(Table 4.1).
4.2.4 Reduction ofsupernatant contamination.
The optimal number ofwashes post-incubation was assessed by serial
centrifugation / washing steps in a single experiment (Table 4.3). Removal of the
supernatant and 2 subsequent washes were sufficient to remove most discard 51Cr
without subjecting the cells to excessive time or trauma. In subsequent experiments
it was found that larger volume washes (approximately 2ml) allowed a
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Table 4.2 Effect of "Chromium Concentration on Labelling Index and Cell
Viability.
Parameters 400kBq/200jul 200kBq/200jul lOOkBq/lOOjul
Total count* 1,284 ± 124 700 ± 68 208 ± 97
"Cr uptake 8.6 ± 4.4% 35.0 ± 7.0% 55.7 ± 7.2%
Labelling Index
(LI)$
23.0 ±6.8 44.0 ± 13.4 12.0 ±7.3
Supernatant
contamination
4.4 ± 1.2% 2.5 ± 2.8% 1.9 ±0.7%
cell recovery® 51.1 ± 14.6% 56.4 ±4.1% 47.8 ± 17.1%
cell viability® >99% >99% >99%
Legend. Various concentrations of "Cr compared for their effect on cell labelling.
Results quoted as mean ± standard deviation of 3 experiments. Total count* quoted
as thousands of counts per minute. Labelling index (LI)$ defined as counts per
minute / 103 cells. Cell recovery® counted by Neubauer chamber, and viability
assessed by trypan blue dye exclusion. Parallel samples subjected to washing only
showed a cell recovery of 59.0 ± 9.5% and viability >99%. Satisfactory labelling
and supernatant contamination was achieved at a concentration of 200kBq/200pl.
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Table 4.3 Effect of Serial Washing on the Supernatant Contamination.
cell count 70,032
discard 365,572
wash 1 35,849 (51%)*
wash 2 9,263 (12%)
wash 3 10,172(13%)
wash 4 10,167(13%)
wash 5 5,555 (7%)
wash 6 3,073 (4%)
wash 7 1,952 (3%)
wash 8 2,469 (3%)
Legend. lxlO7 KGla were incubated with 200kBq 5lCr in lOOpl for lhr for cell
labelling. Serial washes were carried out and the residual supernatant contamination
calculated at each step. Two washes were felt to be sufficient to remove most
contamination. During subsequent studies it was found that increasing the wash
volume to 2-4mls reduced contamination after two washes to approximately 2%.
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reduction in the supernatant contamination to approximately 2% with two washes
only.
4.2.5 Estimation ofrates ofcell toxicity and51chromium elution.
A further study was carried out to assess the likely decline in cell numbers and
viability, and resulting increase in supernatant contamination over the experimental
period (4hrs). lxlO7 KGla were labelled with 200kBq of 5lCr using the standardised
technique. Five aliquots were made, and cells / supernatant separated by
centrifugation at time 0, and at hourly intervals over 4hrs. Though cell numbers and
viability remained remarkably constant, an approximate doubling of supernatant
contamination was observed over this period, presumably due to leakage of 5lCr
from the cells (Table 4.4). Where possible, the supernatant contamination was
assayed on a 10% aliquot set aside and separated at the end of the experimental
period. In practice, the supernatant contamination was rarely greater than 1-2% and
never greater than 5%.
4.2.6 Correlation of 51chromium-labelling with actual cell numbers.
A series of experiments was carried out to determine how well actual cell
numbers correlated with cell number estimated by "Cr-labelling. KGla were
labelled using standardised technique, and a target range of concentrations was
established by serial dilution. The volume of each assay was normalised to 500pl,
and the actual cell number counted by Neubauer haemocytometer. The radioactivity
of the assays was counted by gamma counter, and a predicted cell number was
calculated based on the assay count and the LI for the experiment. Four experiments
were carried out, and the results are tabulated (Table 4.5). A two-tailed paired t test
showed no significant difference between actual and estimated cell numbers through
the range 2.5xl03 to lxlO6 cells. At lxlO3 the predicted count was significantly
greater than the actual count. This is not suprising because blank count for these
four experiments was 39 ± 2cpm, and blank and cellular counts are additive.
Therefore if, for example, the blank count is subtracted from the measured count for
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viability cell count supernatant
count'
total count
Ohrs 2.3xl06 >99% 172,767 2,753 (1.6%) 175,520
lhr 2.7xl06 >99% 175,623 4,823 (2.7%) 180,466
2hrs 2.3xl06 >99% 170,187 4,250 (2.4%) 174,437
3hrs 2.3xl06 >99% 157,013 4,780 (2.9%) 161,793
4hrs 2.3xl06 >99% 166,689 5,817(3.4%) 172,504
Legend. There was a slight diminution of the cell counts over 4hrs. Supernatant
counts expressed as a percentage of the cell count*, showed a progressive increase
(correlation coefficient r=+0.90, regression analysis y = 1.46 + 0.38. x).
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lxlO6 86 ± 16xl04 18,635 ±7,442 80±16x104 ns (3)
5x10s 46 ± 12x104 11,393 ±5,738 39 ± 7xl04 ns (4)
1x10s 8 ± 2x104 1,980 ±800 7 ± lxlO4 ns (4)
5xl04 4 ±lxlO4 1,030 ±659 4± lxlO4 ns (4)
lxlO4 1 ±0.25xl04 299±199 1 ±0.6x104 ns (4)
5xl03 5 ± lxlO3 117 ± 17 7 ± 3xl03 ns (3)
2.5xl03 2.7 ± 0.6xl03 87 ± 13 4.6 ± 2.0xl03 ns (5)
lxlO3 0.6 ± 0.4xl03 58 ±8 2.6 ± 1.6xl03 P<0.05 (4)
Legend. Results are quoted as the mean ± standard deviation of (n) experiments. A
paired t test showed no significant differences between actual and estimated cell
numbers (labelling index 27 ± 10 cpm/103 cells). "Cr count is an accurate reflection
of cell numbers throughout the range 5xl03 to 1x10s cells. Below this, background
radiation makes a significant contribution to the "Cr count, giving rise to an
overestimate of cell numbers.
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the lxlO3 series of assays, the corrected 51Cr count is 19 ± 7cpm and the corrected
predicted cell count is 1.1 ± 0.4x103, which is not significantly different from the
actual count (p=ns). The correlation coefficient calculated for mean data r = +1.00
(n=8), with a regression line described by the formula y = -0.36 + 0.91 .x where x
represents actual cell numbers and y represents predicted cell numbers (Figure 4.1).
It was concluded, therefore, that s'Cr-labelling is an accurate representation of
actual cell numbers over the range studied, though clearly accuracy does begin to
degrade as the cell count approaches the absolute limit of detection at 103.
4.3 Optimal Coating of the Carrier with Substrate.
4.3.1 KGla incubation with substrate.
The adhesion assay was standardised using 51Cr-labelled KGla, and pFn and
dBSA-coated 12 (4cm2) or 24 well (2cm2) tissue culture clusters. Triplicate wells
within each tissue culture plate were incubated with 200 or lOOpl (respectively) of
PBS containing 0.05mg/ml of pFN, or 1% BSA denatured by boiling for 5min.
These were allowed to dry completely at 37°C over lhr. The coating concentration
of pFN was therefore 2.5pg/cm2, consistent with that recommended by other groups
[Giancotti, Comoglio & Tarone, 1986], 2-4xl05 5lCr-labelled KGla were added to
each well, and the volume of assay medium was adjusted to 200-400pl. This gave a
working cell concentration of lxl05/100pl/cm2. Cells were incubated with the
substrate for 2hrs at 37°C, and the supernatant was removed by pipette. The wells
were washed twice with assay medium with gentle agitation of the plate by hand to
remove loose and non-adherent cells. The supernatant and washes were pooled
(supernatant count) in a scintillation tube. The adherent cells were incubated for
15min with 0.1% Non-Idet in distilled water to lyse adherent cells, and removed by
pipette (adherent count). The supernatant and adherent counts were measured by
gamma counter as previously described. The total count (supernatant + adherent
count) and % adherence (adherent count x 100 / total count) were calculated.
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Figure 4.1 Regression Analysis Relating Actual and Predicted Cell Numbers
Over the Target Range 103 to 10" Cells.
Legend. Regression analysis relating actual to predicted cell numbers over the
working range 103 to 106 cells. Abscissa: actual cell number x 103. Ordinate:
Predicted ceil number x 103. Solid data points are observed values. The correlation
coefficient r = +1.00 with a regression line described by the formula
y = -0.36 + 0.91.x. The full range of data is documented in Table 4.5.
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4.3.2 Coating of tissue culture wells with fibronectin.
A series of experiments was carried out to determine the conditions under which
optimal discrimination between specific (fibronectin) and control (albumin)
adhesion could be achieved.
An important initial consideration was the nature and characteristics of the
carrier. Most plastics will adsorb protein from solution, though the avidity and
capacity with which they do so may vary considerably. Coating of a plastic in
excess of its capacity may lead to lower avidity binding of the protein to itself, with
resultant instability or desorption of bound protein (prozone effect). In addition, the
integrity of the protein may be compromised by binding, or the orientation /
presentation may be inadequate, leading to reduced functional activity. It has been
shown, for example, that when the surface chemistry of glass is modified by
derivatization with alkyl chains containing end-groups of different polarities, there
is little variation in the amount of fibronectin which adsorbs to the carrier, but
dramatic variation in the adhesive behaviour of cells, presumably due to differences
in protein conformation [Lewandowska, Balachander, Sukenik el al. 1989], Finally,
the carrier itselfmay bind cells, leading to difficulty in discrimination of specific
binding against background. Twelve and 24 well polystyrene plates were used
which had been prepared by the company by an electrical charging technique termed
Corona discharge. This breaks the structure of the styrene ring and allows
hydrophobic and ionic interaction with macromolecules and cells [personal
communication: Costar UK Ltd.],
A study was carried out to assess optimal coating of the surface of the tissue
culture wells. Parallel sets of triplicate wells in 2 separate polystyrene tissue culture
plates were incubated with lOOpl of 50pg/ml pFn in PBS, or lOOpl of 1% dBSA in
PBS. One plate was allowed to dry at 37°C for lhr, whilst the other was simply
incubated on the bench at ambient temperature. Both plates were then washed twice
with 500pl IMDM 10% FCS per well, and the adhesion of 1x10s KGla / well
studied in the manner described below. A paired t test carried out on the results of
three replicate experiments, showed no significant difference between KGla
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adhesion to pFn under the two different coating conditions described, or similarly to
dBSA . This suggests that the pFn is adsorbed onto the surface of the plastic from
solution and maintained in a functional configuration (Table 4.6).
A group of experiments were carried out to assess optimal coating concentration
of pFn, using the surrogate indicator of percentage KGla adherence. Wells were
incubated with lOOpl of pFn in distilled water at a range of concentrations between
1 and 500pg/ml. It was confirmed that KGla adherence rose to a plateau at
50pg/ml, corresponding to a maximal adsorption of between 0.5 and 2.5pg pFn /
cm2 (Table 4.7). This is comparable with the data of Giancotti, Comoglio & Tarone
[1986], who showed that binding ofmurine cell lines to pFn in vitro achieved
plateau at a fibronectin concentration of 25pg/ml, corresponding to adsorption of
0.5pg/cm2 of the protein.
Experiments looking at KGla adhesion to the plastic carrier (Section 4.3.3 and
Table 4.8 vide infra), demonstrated very substantial background binding, which was
markedly reduced by a coating step (with dBSA), and also by the presence of FCS
in the assay medium. The presence of a surfeit of denatured protein is clearly a
prerequisite for the discrimination of specific from background binding, though
there is a risk that serum proteins may compete with the purified substrate protein
for space on the carrier.
4.3.3. Effects ofthe assay medium on carrier and substrate adhesion.
The influence of the assay medium on substrate adhesion was examined. KGla
were 51Cr labelled using standard technique, and thereafter washed and handled in
IMDM, IMDM + 10% FCS, or HBSS containing lOmM (0.4g/l) EDTA. The effects
of these assay media on KGla adhesion to tissue culture plastic, pFn and denatured
BSA, was studied, and the results are summarised in Table 4.8. KGla adhesion was
significantly greater to pFn than to dBSA in IMDM (p<0.01) and IMDM + 10%
FCS (p<0.01), but not in HBSS + EDTA. There was no significant difference in
binding to pFn using IMDM or IMDM + 10% FCS as the assay medium, suggesting
that FCS was not competing with the pFn for carrier space - at least at this
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Table 4.6 Effects of Coating Conditions on KGla Adherence to Fibronectin
and Albumin Coated Tissue Culture Wells.
substrate wet coating dry coating significance
fibronectin 71.7± 8.6% (3) 65.5± 8.4% (3) ns




Legend. Results are quoted as mean % adherence ± standard deviation (number of
experiments). Statistical significance of the difference between wet and dry coating
conditions was determined by paired Student's t test. Adherence to naked tissue
culture plastic and fibronectin-coated wells was significantly greater than that to
albumin-coated wells (p<0.001 and p<0.01 respectively), but there was no
significant difference between plastic and fibronectin adherence, indicating the need
for a blocking agent to enable discrimination of specific binding against
background.
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1 pg/ml 16.8 ± 12.9% (4)
5 pg/ml 24.3 ± 12.9% (4)
10 pg/ml 33.5 ± 15.7% (4)
50 pg/ml 49.4 ± 16.0% (4)
100 pg/ml 45.6 ± 16.3% (4)
500 pg/ml 49.1 ± 16.4% (4)
Legend. A group of experiments was carried out to assess optimal coating
concentration with pFn using KGla adherence as a surrogate indicator. Results are
quoted as mean % adherence ± standard deviation (n = number of experiments).
KGla adherence rose to a plateau at 50pg/ml.
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Table 4.8 Effects ofAssay Medium on KGla Adhesion to Various Substrates.






pFn 66.2 ± 15.9% 61.1 ±5.9% 48.2 ± 6.0% 16.3 ± 12.2%
dBSA 15.9 ±6.7% 10.1 ±4.8% 15.2 ± 10.5% 20.9 ± 11.3%
plastic 69.1 ±2.5% 13.2 ±6.2%
Legend. Result are quoted as mean % adherence ± standard deviation of 4 replicate
experiments. The pFn and dBSA data is from a different set of experiments than the
tissue plastic data. Paired t test was used to compare data from concomitant
experiments. Non-paired t test was used to compare data from separate series of
experiments in IMDM and RPMI. HBSS + EDTA*: refer to Chapter 5.4.1.
concentration. pFn binding in these media was superior to that in HBSS + EDTA
(p<0.01 and p<0.01 respectively) suggesting that divalent cations are essential for
pFn-specific binding (Chapter 5.4.1). There was no significant difference in binding
to dBSA between the 3 assay media. Adherence to tissue culture grade plastic was
substantial, and was markedly reduced in the presence of FCS (p<0.001). Routine
assays were therefore carried out in IMDM + 10% FCS (assay medium). At a later
date it became more attractive on financial grounds to use RPMI as the base
medium. KGla binding to pFn in RPMI and RPMI + 10% FCS was significantly
greater than that to dBSA (p<0.02 and p<0.01 respectively: paired t test), and
showed no significant difference between the two media (p=ns: paired t test). Non
paired t tests showed no significant difference in KGla binding to pFn between
IMDM and RPMI (p=ns), though binding in IMDM + 10% FCS was slightly
superior to that in RPMI + 10% FCS (p<0.05). Again dBSA binding showed no
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dependence on the type ofmedium. Some authors have claimed that FCS enhances
cell adhesion through the presence of a serum-spreading factor (probably
vitronectin) and other plasma glycoproteins such as fibronectin. This was not
confirmed in these experiments, and there may be several explanations for the
discrepancy: that FCS does vary considerably from batch to batch, that heat
inactivation of the FCS denatures structural proteins or that haematopoietic cell
lines may not adhere to the putative serum spreading factor (see Chapter 5.2).
Overall, the data for sections 4.3.2 and 4.3.3 support the validity of using Costar
tissue culture plates as a satisfactory protein carrier for adhesion experiments,
provided backgound cellular adhesion to the plastic is adequately blocked by the test
protein and / or FCS in the assay medium.
4.4 Standardisation of the Adhesion Assay.
4.4.1. Pre-incubation with denatured BSA, washing and shaking.
The extent of specific adhesion of cells to substrate is dependent on whether
complete blockade of backgound adhesion has been achieved, and the stringency of
the washing and shaking steps, i.e. the distractive phase of the assay. Since these
factors are compound in their effect on cell-substrate adherence in the experimental
system, they were examined in tandem. Parallel triplicate wells were coated with
pFn or dBSA. In one plate, each well was further incubated with 0.5ml of 1%
dBSA in PBS for 15min, which was then removed by pipette just prior to
introduction of 51Cr-labelled KGla. Wells in the other plate were not subjected to
this step. In each plate, non-adherent KGla in parallel triplicate wells were removed
with the supernatant, and the adherent KGla then subjected to none, one or two
washes with 200pl of assay medium. Washes were added by tipping the plates
slightly, and adding the media down the side of the well from a 200pl pipette. The
plates were swirled a few times by hand, and the supernatant / wash removed after
tipping the plate in the opposite direction. This approach reduced the possibility of
directly dislodging or aspirating adherent cells with the stream from the pipette. A
total of 6 triplicate assays was therefore carried out, in each of 2 experiments.
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As expected, both pFn and dBSA binding were highest when the supernatant
was removed without washing, but the differential between dBSA and pFn binding
improved with washing, both with and without dBSA preincubation. pFn adhesion
was significantly impaired by dBSA preincubation afer 2 washes (p<0.001), whilst
this made no difference to background (dBSA) adhesion (Table 4.9).
In a separate experiment the effect of tipping the plate twice in both directions
by hand ("shaking") before removing each wash was compared with not doing so
(i.e. simply removing the supernatant). The results of this simple experiment are
detailed in Table 4.10, and demonstrated that non-shaken cultures gave rise to
significantly greater binding, and less discrimination between pFn and dBSA
adhesion.
In summary of this composite data, it was found that removing the supernatant
and washing the substrate twice, with gentle shaking of the plate by hand each time,
gave the best discrimination between KGla adhesion to pFn and dBSA. A dBSA
pre-incubation step was considered unnecessary in an assay medium containing
FCS, provided that adequate washing of loosely adherent cells was carried out.
4.4.2 Investigation ofthe temporal kinetics and temperature-dependence ofthe
assay system.
A study was made of the temperature dependence of the assay, by incubating
KGla with pFN and BSA substrates at 4°C, ambient temperature (approximately
20°C), and at 37°C in separate tissue culture plates. The results are summarised in
Table 4.11. Background adherence was not affected by temperature, but pFn binding
was abrogated at 4°C. There were no significant differences between binding
activity at ambient temperature and at 37°C.
A study of the temporal dependence of the incubation was also made (Table
4.12). Radiolabelled KGla were incubated with pFN and BSA substrates for 0 min
(added and then immediately removed), 15min, 30min, lhr, 2hrs and 4hrs.
Background adherence remained relatively constant, with a floor even following
negligible incubation time (sample 0). Fibronectin-specific adhesion rose from this
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Table 4.9 Effects of Pre-Incubation with 1% Denatured BSA and Number of
Washes on KGla Adherence to Fibronectin and Albumin.
substrate no wash one wash two washes
albumin pre¬
incubation
fibronectin 32.8 ± 6.2% 11.8 ± 1.6% 16.6 ±0.1%*
albumin 8.5 ±0.1% 2.0 ± 0.6% 1.2 ±0.1%~
significance p<0.05 p<0.02 p<0.001
no albumin pre¬
incubation
fibronectin 41.8 ±4.6% 34.1 ±2.3% 21.2 ±0.1%
albumin 16.4 ±3.8% 3.4 ±0% 1.1 ±0.3%~
significance p<0.05 p<0.01 pO.001
Legend. Results are quoted as mean % adherence ± standard deviation (n=2).
Significance levels are those of the difference between fibronectin and albumin
adherence under the conditions specified (paired Student's t test). Following 2
washes, the difference between fibronectin adherence with and without an albumin
pre-incubation step is highly significant (p<0.001)*, whilst that between albumin
adherence with and without an albumin pre-incubation step is nof.
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Table 4.10 Effects of "Shaking" or "Not-Shaking" the Plate between Washes.
substrate shakenplates non-shaken
pFn 38.4 ± 11.8% (4) 63.4 ± 6.2% (4)
dBSA 8.9 ± 4.8% (3) 48.6 ± 16.7% (4)
Legend. Mean % adherence ± standard deviation of (n) replicate experiments. Paired
t tests demonstrated pFn and dBSA adhesion to be significantly higher under non-
shaken conditions compared to shaken (both p<0.01). Moreover, the difference
between pFn and dBSA adhesion was significant in the shaken plates (p<0.02), but
not in the non-shaken plates (p=ns).
Table 4.11 Temperature Dependence of the Assay System.
Substrate +4°C AT 37°C
pFn 23.0 ±5.8% 52.3 ±2.1% 51.0 ± 1.9%
dBSA 21.0 ±4.2% 22.9 ±3.6% 19.1 ±0.5%
Legend. Results are presented as mean % adherence ± standard deviation of 4
replicate experiments. Background adherence was not affected by temperature, but
pFn adherence was reduced at +4°C. There was no significant difference between
adhesion at ambient tempertaure (AT) and 37°C.
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Table 4.12 Temporal Dependence of the Assay System.
substrate Omin 15min 3Omin
pFn 2.6 ± 1.1% 16.9 ±8.6% 21.5 ± 13.5%
dBSA 4.4 ±2.1% 14.7 ± 8.7% 8.8 ± 6.2%
substrate lhr 2hrs 4hrs
pFn 36.2 ± 20.3% 27.8 ± 34.6% 32.0 ± 22.8%
dBSA 6.5 ± 5.7% 4.8 ± 2.7% 5.1 ± 1.2%
Legend. Data is presented as the mean % adherence ± standard deviation of 4
replicate experiments. Background adherence remained relatively constant
throughout, pFn adherence rose to a plateau at lhr.
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floor to a plateau following lhr incubation (Table 4.12). The kinetics of attachment
are similar to reported rates for other cell types [Jauregui, McMillan, Driscoll et al.
1986; Hardy & Minguell, 1993],
It seems unlikely that the assay will be useful in studying adhesive phenomena
as they evolve because of the inherent delay in sedimentation of the leucocytes to
the substrate surface. 400pl ofmedium occupies a depth of 2mm over a 2cm2
surface area. Calculations based on a leucocyte sedimentation index (in plasma) of
13.6mm/hr (95% range 3.7 - 23.4mm/hr) [Diem & Lentner, 1970] suggest that the
cells should settle to the adhesive surface within 8.8min (95% range 32.3 - 5.1min).
In addition, there appears to be a residual floor of 2-5% of cells in the adherent
fraction even after negligible incubation.
4.4.3 Dispersion andmorphology ofcells on the well surface.
The dispersion of the cells on the well surface was examined by inverted
microscopy. In initial experiments it was found that cells tended to be concentrated
around the perimeter of the circular well, despite thorough mixing by hand. A series
of experiments revealed that the ratio of cells / high-power field in the periphery
compared to the centre of the assay dish was between 4:1 and 7:1. It was found that
increasing the volume of the suspension medium to 400pl eliminated this problem,
giving rise to a uniform cell distribution. The reason for this phenomenon may be
that the depth of suspension medium is less in the centre of the well than towards
the periphery due to convexity of the centre of the well base or formation of a
meniscus due to surface tension at the periphery, or may relate to the pattern of
convection currents within the well. At an incubating volume of 400pl / 2cm2 well,
distribution of KGla within the culture well was found to be uniform both during
the adhesion phase, and following removal of the supernatant (Figure 4.2). An
experiment carried out to determine whether the suspension volume made any
difference to the %KG1 a binding to pFn, failed to show any such difference (Table
4.13).
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Figure 4.2 Adhesion of KG la to Plasma Fibronectin.
Legend. Uniform dispersion ofKG la adherent to the surface of a pFn-coated well,
lhr following suspension in 400pl of assay medium. No change in the morphology
of the adherent cells was apparent, (magnification xlO).
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Table 4.13 Effects of Variation in Suspension Medium on KGla Adhesion to
Fibronectin.
200gl medium 400iul medium significance
% adherence 58.3 ± 12.5% 48.2 ± 6.0% ns
Legend. Data is presented as the mean % adherence ± standard deviation of 4
replicate experiments. There was no significant difference in the adherence ofKGla
to pFn in the 2 volumes studied (paired t test).
A second consideration pertained to the distribution of adherent cells in the
wells following removal of the supernatant and non-adherent cells. Microscopic
examination revealed that vigorous washing led to an uneven distribution due to
dislodgement of some adherent cells. Careful removal and addition of fluid by
pipette from the side of the tilted culture dish avoided the problem.
The question of whether the reproducibility of the assay could be improved by
centrifugation of the plate at the beginning of the incubation was explored. Parallel
experiments were carried out to compare KGla adhesion to pFN and BSA, with and
without centrifugation of the plate for lOmin at 500g. The results showed no
significant difference between adhesion to either substrate under these
circumstances (Table 4.14), confirming that apposition of cells and substrate was
not a limiting factor in the assay, and demonstrating that centrifugation was not
effective in reducing inter-experimental variability. Microscopic examination of the
plates revealed that non-centrifuged plates showed an even dispersion of cells over
the test surface, whilst those which had been centrifuged showed concentration of
cells at the periphery of the plate, with a predominance at the dependent side. Since
a horizontal plate centifuge was not available, this avenue was not explored further.
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Table 4.14 Effect of Centrifugation on Overall Cell Adhesion.
substrate centrifugation no centrifugation
pFn 29.6 ± 16.0% 34.1 ±22.7%
dBSA 19.6 ± 15.8% 22.8 ± 20.4%
Legend. Data is presented as the mean % adherence ± standard deviation of 3
replicate experiments. No significant difference could be demonstrated between
adherence with or without centrifugation (non-paired t test).
4.4.4 Concentration dependence ofthe assay.
There are two relevant cell concentrations, the volumetric concentration and the
two-dimensional surface concentration. The volumetric concentration is important
because adhesion may be inhibited by cell-secreted proteins [Gjessing & Seglen,
1980], The surface concentration is important because it reflects the degree to which
cells may physically interact or compete for available sites at the adhesive surface.
For leucocytes approximately 20pm in diameter, total surface coverage with spheres
corresponds to 2.5x10s cells / cm2.
The dependence of backgound and specific adherence on concentration was
studied using standard technique, and 24 well pFn and dBSA coated tissue culture
plates (surface area 2cm2). Adhesion of radiolabelled KGla were studied at
concentrations between lxlO4 and lxl07/well. No cell-cell aggregation was
observed microscopically even at higher volumetric concentrations. The results of 3
experiments are summarised in Table 4.15. At low levels ofKGla (l-2xl04),
background albumin adherence was higher than expected. However, it should be
recalled that the LI for these 3 experiments was 36 ± 7 cpm /103 cells set against a
standard backgound of 41 ± lcpm. The absolute floor is therefore 10% of lxlO4
cells and 5% of 2xl04 cells, but only 1% of 1x10s cells. Apart from this anomaly,
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Table 4.15 Concentration Dependence of the Assay System.
cell (n) pFn dBSA
lxlO4 41.2 ± 13.6% (4,120) 13.8 ±2.4% (1,380)
2x104 42.3 ± 14.8% (8,460) 14.2 ± 1.9% (2,840)
1x10s 38.9 ± 9.2% (38,000) 5.4 ± 2.8% (5,400)
2xl05 36.0 ± 10.5% (72,000) 5.3 ±3.9% (10,400)
1x10s 41.2 ± 19.5% (412,000) 5.6 ± 1.7% (56,000)
2x10s 43.2 ±2.9% (864,000) 6.0 ± 1.4% (120,000)
lxlO7 8.6 ± 2.7% (860,000) 1.5 ±0.8% (150,000)
Legend, cell(n) represents the number of 51Cr-labelled KG la added to each 2cm2
well of a 24 well plate. Data is presented as the mean % adherence ± standard
deviation of 3 replicate experiments, with the calculated absolute adherent cell
numbers in parentheses.
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percentage adherence remained remarkably constant over the range of lxl04 to
2x106 cells / well, for both pFn and BSA adherence. This implied that a fixed
proportion ofKGla were capable of adherence to these substrates. At lxlO7 cells /
well, the percentage adherence fell sharply, and when absolute adherent cell
numbers were calculated, a ceiling of 8.6xl05 KGla / pFn-coated well, and 1,5x10 s
KG la / BSA-coated well were defined. Total well surface coverage is calculated to
be achieved at 5x10s cells. These figures are highly dependent on the defined
experimental conditions, but do suggest that a reproducible maximal binding
capacity exists, though whether due to occupation of a finite number of binding
sites, or steric hindrance at the highest density is not discriminated.
4.4.5 Replating efficiency ofthe non-adherent population.
A series of experiments was carried out to establish the extent to which non¬
adherent and loosely-adherent cells present in the supernatant were capable of
binding to the test substrate in a second assay. Triplicate assays were established at
a concentration of 4x10s cells / 2cm2 well, against substrates of pFn and dBSA,
using the standardised protocol. The supernatant removed after 2hrs was
immediately transferred to a second series ofwells containing the same test
substrate, and incubated for a second 2hrs. The supernatant and adherent fractions
from the second phase were considered to equate to the supernatant from the first.
Percentage adherences were established for both phases, and the results are shown
in Table 4.16. Binding to pFn fell significantly on replating (p<0.05, paired t test),
whereas the fall in dBSA binding fell short of significance on the paired t test. There
was no significant difference between pFn and dBSA adhesion during secondary
adhesion, though this may reflect the high variablitity of the pFn adhesion. The
lower proportion of dBSA-adherent cells following replating is difficult to
rationalise. It is possible that background binding is partially dependent on physical
characteristics of the cells such as size or ionic charge.
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pFn 34 ± 4% 13 ±9% p<0.05
dBSA 7 ± 0.6% 4 ± 1% ns
Legend. Results quoted as mean ± standard deviation of 3 experiments. pFn is
significantly greater than dBSA during primary adhesion (p<0.01) but not during
secondary adhesion (ns) (paired t test). Percentage adhesion to pFn fell significantly
on replating whereas that to dBSA did not.
4.4.6 Reproducibility and quality control.
To achieve maximum reproducibility, each assay was carried out in triplicate
within a single tissue culture plate, in tandem with triplicate internal positive and
negative controls. In addition, the labelling parameters and control assays were
monitored over the period of research to establish the mean and coefficient of
variation of the experimental system, and to ensure that there was no drift in the
controls due to, for example, change in operator technique. The stability of the
labelling indices and control adhesion indices is documented in Table 4.17. The
labelling indices were considered to be satisfactory, with no evidence of drift.
A key problem was found to be the variability of dBSA as a negative control. A
meta-analysis of 23 experiments carried out over a 6 month period showed
considerable variation in percentage binding to pFn and to dBSA. An analysis of the
differences between pFn and dBSA binding showed an overall 30.6% difference
which was significant at p<0.001 (Table 4.18). Further analysis of this data with
correction for the level of dBSA binding showed that the assay remained valid at all
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Table 4.17 Stability of the Labelling Indices.
Labelling indices
global count 627 ±151 (22)
51Cr uptake 0.40 ± 0.14 (22)
Labelling Index 34 ± 12 (21)
Supernatant contamination 2.8 =± 2.1% (19)
adherence indices
pFn 47.6 ± 19.7% cv 41.4 (23)
dBSA 17.1 ± 11.3% cv 66.1 (23)
Legend. Results quoted as mean ± standard deviation of n experiments, cv.
coefficient of variation.
Table 4.18 Subanalysis of Fibronectin and dBSA Adhesion.
dBSA
adherence
mean difference ± SD
pFn% - dBSA%
significance (n)
global 30.6 ± 18.4% p<0.001 (23)
<10% 33.2 ±20.5% p<0.01 (7)
10-20% 33.5 ± 18.9% p<0.01 (8)
>20% 25.3 ± 17.2% p<0.01 (8)
Legend. Mean difference between pFn and dBSA binding ± standard deviation is
quoted for a series of experiments, and sub-analysed for experiments in which
background (dBSA) binding was <10%, 10-20%, and >20%. Significance levels
(paired t test) and number of experiments analysed (n) are documented.
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Table 4.19 Background Adhesion ofKGla to Different Batches of BSA.
batch #1 dBSA 44.8 ± 25.9% (4)
batch #2 dBSA 47.2 ±23.5%
BSA (not denatured) 43.8 ±21.3%
Legend. Results quoted as mean ± standard deviation of 4 experiments. A paired t
test failed to show any significant differences between these substrates.
levels of background binding.
A series of experiments was carried out to determine whether control binding
was dependent on the extent of denaturation or age of the dBSA. A low stringency
wash was used so that differences in dBSA adhesion would be detectable if present.
No batch effect could be demonstrated (Table 4.19).
4.5 Discussion and Formulation of Results.
The objective of the work discussed in this Chapter was to establish an assay
system with which to study functional HPC adhesion. A standardised methodology
was developed and optimised, and its reproducibility demonstrated. The potential
strengths and limitations of the assay system were also explored.
slCr was used to label human haematopoietic cell lines with minimal cell
toxicity or chromium leakage. The labelling index is sufficient to resolve 1% of a
population, provided a minimum of 10s cells are used per test. There is a theoretical
concern that chromium could induce intracellular protein changes and lead to
abnormal adherence within the test system. Hardy & Minguell (1993) have carried
out parallel studies with 5lCr and 35S-methionine metabolic labelling on murine cell
lines, and found no difference in their adhesion to a variety of substrates.
Costar tissue culture grade plastics proved to be a satisfactory carrier, providing
adequate adsorption of protein from solution and maintaining functional orientation.
Cellular adherence to tissue culture plastics is marked, but is effectively blocked by
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coating with protein, and additionally by FCS in the assay medium. The presence of
FCS does not affect pFn binding, and therefore permits differentiation of specific
binding from background. An additional incubation step with dBSA appears
unnecessary, and may compete with substrate for carrier binding, or inhibit specific
cell binding.
The most important determinant of cellular adherence within the assay system is
the technique used to remove the non-adherent and loosely adherent cells during the
distractive phase of the experiment. Removal of the supernatant and 2 washes, with
gentle mixing by hand, provided the greatest discrimination between substrate and
background binding, but also proved the greatest source of inter-experimental
variability. Percentage binding is highly dependent on the experimental conditions,
especially stringency ofwashing, and should be seen as an indicative measure of
the adhesive affinity of the test population as a whole for the test substrate.
Replating experiments suggest that the primary non- / loosely-adherent population
does have less binding affinity than the primary adherent population. The data
derived from the concentration dependence of the assay suggests that a reproducible
maximal binding capacity can be established for a given cell population and
substrate under defined experimental conditions.
Taken overall, these data suggest the presence, in an apparently homogeneous
population, of cells with varied but continuously distributed affinity for a given
substrate, rather than the presence of two discrete populations (adhesive and non-
adhesive). Cellular binding affinity is likely to depend on the density of expression
and the activation state of one or more cell adhesion molecules. At the same time,
an apparently homogeneous substrate is likely to display a distribution of binding
domains which differ in affinity due to variation in accessibility and conformation.
Percentage adherence and maximal binding capacity are therefore highly dependent
on the technique used to distract the non-adherent population. Too little or too much
washing stringency is likely to lead to loss of discriminatory power of the assay.
Optimisation and standardisation of the distractive technique was therefore a key
element in the development of the assay.
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The question arose as to whether dBSA was the best "negative control" for these
experiments. It became clear from studies on other extracellular matrix (ECM)
components (Chapter 5.2) that the absolute floor of adhesion was less than that
observed in the dBSA-coated wells. It is unclear whether this was due to a specific
inhibitory feature of some ECM components (for example the negative charge
associated with sulphated proteoglycans), an inherent (but non-specific) "stickiness"
of denatured proteins or inadequate coverage of plastic. Given that different batches
of dBSA showed little difference in backgound binding, it was thought that
variability in the assay was primarily dependent on technical variation such as
washing stringency, which reinforced the importance of the internal negative
controls.
Three approaches to the formulation of the results were considered. The most
comprehensive approach is to carry out each assay at a series of concentrations, in
order to establish a maximal binding capacity (Section 4.4.4). To carry this out in
triplicate within each experiment, with an internal negative control would require in
the order of 108 51Cr-labelled cells per experiment. This was regarded as unfeasible
for routine use given the time and resources available. Adhesion was assayed at a
single concentration at 1-2x10s cells / 2cm2 representing 20-40% of total surface
coverage, and allowing a single experiment to be completed with around 106 cells.
The results from such an experiment can be quoted "as seen", with no attempt to
correct for inter-experimental variability. Some groups have considered albumin
adherence to be non-specific, and that the test substrate-specific adherence should
be calculated by subtraction of albumin adherence from test substrate adherence.
There are both theoretical and practical problems with this approach. The
conceptual problem is similar to that discussed in the interpretation of dual
immunofluorescence data, i.e. that since the character of the cells adherent to
albumin is indeterminate, and may or may not be representative of the population as
a whole, they may not be legitimately subtracted from the cells which adhere to the
test substrate. Indeed the nomenclature of specific and non-specific adherence
contains a mechanisitic implication which is not warranted by the informative
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content of the assay. For example, adherence to plastic is greater than that to
albumin, but is not mediated by plastic-specific cell adhesion molecules.
Conversely, adhesion to pFN can only be said to be "specific" if it can be
demonstrated to be mediated by a unique adhesion pathway, which is not involved
(for example) in adhesion to other ECM components. There are also practical
difficulties with this approach where substrate adherence is less than that to dBSA
(Chapter 5.2). Some groups have quoted results as a binding index, defined as the
ratio of percentage substrate adherence (numerator) to percentage albumin
adherence (denominator) [Hardy & Minguell, 1993]. This approach normalises the
substrate adherence to that of the neutral background substrate, and goes some way
towards reducing inter-experimental variability due to washing and shaking
technique. The weakness of formularising results in this way is the somewhat
arbitrary nature of the calculation, and rigidity in practical application. I elected to
evaluate the statistical significance of results using a two-tailed paired t test to
compare substrate binding with concurrent controls over 4 replicate experiments.
Where binding results were compared with those from a different series of
experiments, a two-tailed, non-paired t test was used. The use of these statistical
tests is based on the assumption that variation in cell binding between similar
experiments is a normally distributed continuous variable. Two-tailed tests are used
because substrate binding may be higher or lower than control. This approach
allowed flexibility in comparing substrate to control adherence, evaluating
adherence to different substrates, and examining the effects of activation or
blockade on specific interactions. However it should be noted that the criteria for a
given p value in a paired t test are more stringent than those in a non-paired because
of the lower number of degrees of freedom allowed when entering the table of the t
distribution. The presentation of the analysis as a test with 2 possible outcomes
(significant or non-significant) does over-simplify the interpretation of the results.
The choice of a particular cut-off for statistical significance is somewhat arbitrary,
and depends on the probability of a Type I error one is prepared to accept (the
chance that an apparently "significant" result is, in fact, normal). In view of the
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multiple comparisons made during some experiments (e.g. Chapter 5.2), and with
the tacit support of convention, the term "statistical significance" was reserved for p
values of <0.01. Adhesive interactions of biological significance may fail to achieve
statisitical significance due to inadequate power of the study, a reflection of small
number of experiments and / or high inter-experimental variability. Stringent
criteria for statistical significance increase the risk of a Type II error (i.e. that a
biologically significant difference is missed) [Altman, 1994].
In summary, unless otherwise stated, results are quoted as the mean % adherence
(m) ± the standard deviation (SD) of several replicate experiments, which gives an
indicative measure of the overall binding affinity between the cell population and
the substrate under the defined experimental conditions. The result of a two-tailed
paired or non-paired t test is quoted in parenthesis as a p value, and is used to
compare test data with internal controls or with an external set of experiments
respectively. The p value provides a measure of the probability of obtaining the
observed result if there is (in fact) no difference in the adhesive behaviour of the
two populations under comparison. Because of the somewhat arbitrary nature of the
conventional cut-off. p values of >0.05 are considered non-significant, and those
<0.01 are considered significant, and those between 0.01 and 0.05 are considered
borderline. The standardised cell labelling, substrate preparation and adhesion
protocol is summarised in Table 4.20.
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Table 4.20 Summary of the Standardised Cell Adhesion Assay.
Cell labelling procedure.
lxlO7 cells incubated with 200kBq 5lCr in lOOpl for Ihr at 37°C
washed twice in 2ml assay medium (IMDM + 10% FCS)
10% aliquot retained for total discard count.
Resuspended in 2ml assay medium, cell count and viability checked by Neubauer
chamber and trypan blue exclusion.
10% aliquot (200pl) is set aside (reserve)
Substrate preparation.
Stock solutions established: O.lmg/ml collagens, 0.05mg/ml pFn and other
glycoproteins / proteoglycans, 1% BSA.
lOOpl aliqouts of stock incubated in each test well (24 well plate) for lhr at room
temperature.
Wells are washed with assay medium before use.
Each assay and control is carried out in triplicate wells.
Adhesive phase.
Aliquots of l-2xl05 cells in 400pl of assay medium are introduced to each test and
control well.
Incubation for 2hrs at 37°C. Plates are wrapped in cellophane to prevent
dehydration of the wells.
Distractive phase.
Supernatant is removed to an assay tube, and wells are washed twice with 200pi
assay medium, with gentle shaking of the plate by hand each time. Addition and
removal ofmedia is carried out by 200pi pipette down the side of the well.
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Results.
Supernatant and washes (800pl) comprise the non-adherent count
Adherent cells are lysed by 15min with 500pl 0.1% Non-Idet in distilled water, and
are then removed to a scintillation vial (adherent count)
The reserve cells are spun-out, and the supernatant (10% of the total supernatant
count) and cells (10% of the total cell count) counted separately.
Analysis.
Adherent and non-adherent samples for each well are counted sequentially by
gamma counter.
Results are calculated as adherent count / adherent + non- adherent count (%), and
the mean of triplicate wells is quoted.
Comparisons are made using paired or non-paired t test as appropriate.
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It was decided to study the adhesion of a representative group of human
haematopoietic cell lines to various proteins and proteoglycans, stromal and
endothelial cultures, in order to establish whether differences in lineage
differentiation or CAM expression could be correlated with differences in functional
adhesion. The cell lines KG la, K562, HL60, CEM and NALM-6 were studied. The
tissue culture of these cell lines in suspension is discussed in Section 2.2.2 and key
characteristics summarised in Table 2.1. Lineage marker and cell adhesion molecule
expression on these lines was characterised using single colour immunocytometry
(Chapter 3.4), employing the same panel ofmAbs used to characterise HPC in
Chapter 3.2. It is acknowledged that some or all of these cell lines may express
other CAMs, but this possibility could not be explored without the use of a very
broad panel of anti-CAM mAbs, and such an approach was outwith the financial
constraints of the study. Adhesion of these cell lines to a panel of extracellular
matrix components (ECM) was studied using the 5,Cr adhesion assay developed in
Chapter 4 (Sections 5.2 and 5.3). Commercial thrombospondin was found to be
prohibitively expensive and only KG la adhesion to this substrate could be
investigated. The nature of KG1 a binding to fibronectin was examined in more
depth in Section 5.4 using a combination of metabolic blockade, synthetic peptides,
monoclonal antibodies, and enzymatic treatment. The composite results of these
studies are discussed in Section 5.5.
5.2 Study of the Adhesion ofHuman Haematopoietic Cell Lines to
Extracellular Matrix Components.
The collagens, glycoproteins and proteoglycans studied were those identified by
other groups as expressed within the bone marrow stroma [Bentley, 1982; Keating,
Wright, Kinsell et al. 1984; Gordon, 1988a; Zuckerman, Prince & Gay, 1989;Clark,
Gallagher & Dexter, 1992; Morris, Turnbull, Riley et al. 1991; Chichester,
Fernandez & Minguell, 1993]. The study material was derived from commercial
sources (Table 5.1), and therefore was not itself of human bone marrow stromal
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Table 5.1 ExtracellularMatrix Components Studied.
collagen type I (human placenta)
collagen type III (human placenta)
collagen type IV (human placenta)
fibronectin (human plasma)




heparan sulphate (bovine kidney)
chondroitin sulphate (bovine trachea)
hyaluronic acid (human umbilical cord)
origin. No source of hemonectin could be found [Campbell, Wicha & Long, 1987],
Stock solutions of collagens were made up at a concentration of O.lmg/ml in
0.1% acetic acid in distilled water, and of fibronectin, vitronectin, thrombospondin,
laminin and proteoglycans at a concentration of 0.05mg/ml in distilled water. 24
well tissue culture plates (surface area 2cm2) were layered with lOOpl of test
solution, and incubated at 37°C for lhr. This gave a substrate concentration of 5pg /
50|_il / cm2 for collagens, and 2.5pg / 50pl / cm2 for other proteins and
proteoglycans. Triplicate wells were established for each test substrate, along with
triplicate pFn and denatured dBSA wells as positive and negative controls
respectively. The mean % adherence was derived and binding compared to negative
control by two-tailed paired t test over a series of 4 replicate experiments. In view of
the possibility that residual acetic acid in the collagen wells may alter the binding of
the test cells through alteration in the pH of the assay medium, all wells were
incubated with 400pi of assay medium for 5min prior to use, and this was removed
prior to addition of the cells. Although increased acidity was frequently observed
through change in the colour of this wash medium, no change was observed during
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the test incubation itself. With the exception of this modification, no other change
was made to the standardised protocol (Table 4.20).
Cells were 51Cr labelled using standard method, though the 5ICr uptake and
labelling index did vary to some extent between cell lines (Table 5.2).
The results of this large series of experiments are summarised in Tables 5.3 -
5.7. KGla appeared to bind to collagen type I, though this did not achieve statistical
significance. KGla bound significantly to fibronectin (p<0.02) and to
thrombospondin (p<0.001) but not to vitronectin, laminin or the proteoglycans
tested. K562 and HL-60 bound to fibronectin (p<0.01 and p<0.02 respectively) and
appeared to bind to vitronectin and laminin though this was not statistically
significant. These two lines did not adhere to the collagens or proteoglycans tested.
NALM-6 bound strongly to fibronectin (p<0.01) and also bound to heparan sulphate
(p<0.05), chondroitin sulphate (p<0.01) and to a lesser extent to hyaluronic acid
(ns). Vitronectin and laminin binding were once again apparent but not statistically
significant. CEM showed borderline binding to collagens type I (ns) and III (ns),
and significant binding to fibronectin (p<0.05) and laminin (p<0.01). Adhesion to
proteoglycans was also apparent, though the standard deviations were wide and the
data not statistically significant. Some cell lines appear to demonstrate less binding
to substrates than to dBSA e.g. KGla to collagen IV and proteoglycans, K562, HL-
60 and NALM-6 to collagens, although only in one case did this effect approach
significance (Table 5.5). Backgound binding to dBSA did not differ significantly
between cell lines (non-paired t test).
Clearly differences in functional binding of haematopoietic cell lines to ECM
components do occur and some correlations with cell adhesion molecule expression
are apparent (Figures 3.9 - 3.12 & Tables 5.3 - 5.7). For example, all five cell lines
express VLA-4 (CD49d) and VLA-5 (CD49e) and all demonstrated significant
binding to pFn. KGla express CD36 and bind markedly to thrombospondin.
Whether the lack of CD36 expression by the other cell lines correlated with absence
of thrombospondin binding is unknown. However, important areas of discordance
also occur. For example PECAM-1 (CD31) and CD45 expression by KGla did not
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Table 5.2 51Cr Labelling ofHaematopoietic Cell Lines.





KGla 0.31 ±0.11 35 ±7 2.6 ± 2.0% (6)
K562 0.48 ± 0.07 44 ± 13 6.0 ± 5.6% (4)
HL60 0.56 ±0.17 62 ±7 1.2 ±0.5% (4)
NALM-6 0.31 ±0.16 16 ± 3 10.1 ±6.6% (4)
CEM 0.28 ±0.18 13 ± 7 7.4 ± 8.3% (4)
Legend. Results presented are the mean ± standard deviation of 4 replicate
experiments.Some cell lines did appear to label more easily than others, e.g. HL
has a high labelling index and low supernatant contamination compared with
NALM-6.
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Table 5.3 Adhesion of KGla to Extracellular Matrix Components.
Collagens.
type I 25.8 ± 19.1% (ns)
type III 12.1 ± 7.6% (ns)
type IV 3.7 ± 1.9% (ns)
Glycoproteins.
plasma fibroneetin. 28.2 ± 6.0% (p<0.02)
vitronectin. 11.7 ± 11.7% (ns)
thrombospondin 76.2 ± 12.8% (p<0.001)
laminin. 12.6 ± 11.7% (ns)
Proteoglycans.
heparan sulphate 4.4 ± 1.0% (ns)
chondroitin sulphate 5.2 ± 1.7% (ns)
hyaluronic acid 6.8 ± 1.3% (ns)
Controls.
dBSA. 9.6 ± 4.8%
Legend. Results are quoted as mean % adherence ± standard deviation of 4 replicate
experiments. Substrates are compared with negative control (dBSA) by paired t test.
Within each experiment, test substrates and controls were assayed in triplicate, and
the mean % adherence used as the assay result. KGla were found to bind
significantly to plasma fibronectin and thrombospondin, and also bound to collagen
type I (though non-significant due to a wide standard deviation).
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Table 5.4 Adhesion of K562 to Extracellular Matrix Components.
Collagens.
type I 6.7 ± 1.4 (ns)
type III 7.6 ± 2.5 (ns)
type IV 5.0 ± 2.7 (ns)
Glycoproteins.
plasma fibronectin. 38.7 ± 4.1 (p<0.01)
vitronectin. 23.3 ± 3.1 (ns)
laminin. 38.1 ± 9.0 (ns)
Proteoglycans.
heparan sulphate 15.2 ± 15.0 (ns)
chondroitin sulphate 16.4 ± 17.1 (ns)
hyaluronic acid 12.3 ± 9.1 (ns)
Controls.
dBSA. 8.5 ± 3.0
Legend. Results are quoted as mean % adherence ± standard deviation of 4 replicate
experiments. Substrates are compared with negative control (dBSA) by paired t test.
Within each experiment, test substrates and controls were assayed in triplicate, and
the mean % adherence used as the assay result. K562 adhered significantly to
plasma fibronectin only. Vitronectin and laminin adherence occurred but did not
achieve statistical significance.
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Table 5.5 Adhesion of HL60 to Extracellular Matrix Components.
Collagens.
type I 3.6 ± 3.3 (ns)
type III 5.4 ± 3.0 (ns)
type IV 2.9 ± 1.9(p<0.05)
Glycoproteins.
plasma fibronectin. 30.7 ± 9.9 (p<0.02)
vitronectin. 41.8 ± 31.7 (ns)
laminin. 55.2 ± 20.3% (ns)
Proteoglycans.
heparan sulphate 8.4 ± 6.5 (ns)
chondroitin sulphate 7.6 ± 4.0 (ns)
hyaluronic acid 17.4 ± 9.8 (ns)
Controls.
dBSA. 12.1 ±6.3
Legend. Results are quoted as mean % adherence ± standard deviation of 4 replicate
experiments. Substrates are compared with negative control (dBSA) by paired t test.
Within each experiment, test substrates and controls were assayed in triplicate, and
the mean % adherence used as the assay result. HL-60 adhered significantly to
fibronectin, and also to vitronectin and laminin - though this was not statistically
significant due to the wide standard error of the results. Adhesion to collagen type
IV was significantly less than that to dBSA.
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Table 5.6 Adhesion ofNALM-6 to Extracellular Matrix Components.
Collagens.
type I 10.0 ± 5.5% (ns)
type III 11.6± 6.7% (ns)
type IV 8.4 ± 5.3% (ns)
Glycoproteins.
plasma fibroneetin. 82.1 ± 13.1% (p<0.01)
vitronectin. 37.0 ± 9.9 (ns)
laminin. 68.9 ± 20.7 (ns)
Proteoglycans.
heparan sulphate 41.6 ± 15.0% (p<0.05)
chondroitin sulphate 40.4 ± 7.9% (p<0.01)
hyaluronic acid 29.8 ±11.6% (ns)
Controls.
dBSA. 14.6 ±3.3
Legend. Results are quoted as mean % adherence ± standard deviation of 4 replicate
experiments. Substrates are compared with negative control (dBSA) by paired t test.
Within each experiment, test substrates and controls were assayed in triplicate, and
the mean % adherence used as the assay result. NALM-6 adhered significantly to
fibronectin, heparan sulphate and chondroitin sulphate, and also to vitronectin,
laminin and hyaluronic acid.
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Table 5.7 Adhesion of CEM to Extracellular Matrix Components.
Collagens.
type I 18.8 ± 5.1% (ns)
type III 21.9 ± 7.3% (ns)
type IV 12.0 ± 2.9% (ns)
Glycoproteins.
plasma fibronectin. 38.0 ± 13.3% (p<0.05)
vitronectin. 22.3 ± 2.8 (ns)
laminin. 72.4 ± 17.6% (p<0.005)
Proteoglycans.
heparan sulphate 29.8 ± 25.7% (ns)
chondroitin sulphate 30.7 ± 25.3% (ns)
hyaluronic acid 24.8 ± 19.1% (ns)
Controls.
dBSA. 9.6 ±1.1
Legend. Results are quoted as mean % adherence ± standard deviation of 4 replicate
experiments. Substrates are compared with negative control (dBSA) by paired t test.
Within each experiment, test substrates and controls were assayed in triplicate, and
the mean % adherence used as the assay result. CEM adhered significantly to
fibronectin and laminin and demonstrated borderline adhesion to collagens type I
and III.
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correlate with binding to heparan sulphate [Parish, Hogarth & McKenzie, 1988],
whereas CD31 CD45" NALM-6 did adhere to this proteoglycan. Similarly, KG la,
HL60 and CEM express HCAM (CD44) but adhere neither to collagens nor to
hyaluronic acid. K562 express VNR (CD51) though they do not appear to
significantly bind to vitronectin. The functional activity of some of the other
expressed CAMs could not be assessed because of the absence of the appropriate
purified ligand e.g. ICAM-1 (CD54) (ligand LFA-1), PECAM-1 (CD31) (ligand
PECAM-1), LFA-3 (CD58) (ligand LFA-2), LFA-1 (CD1 la) (ligand ICAM-1) and
VLA-4 (CD49d) (ligand VCAM-1).
The information required to correlate CAM expression and functional binding
activity is incomplete. Part of the problem is that a complete characterisation of
CAM expression by the cell lines studied has not been carried out and additional
molecules may therefore be participating in cell adhesion. For example the CAM or
CAMs which mediate CEM adhesion to laminin were not identified. In contrast,
CAM expression is not sufficient in itself to convey adhesion to an appropriate
ligand within the assay system. Some CAMs may be expressed in a non-activated
form or may mediate adhesion to other, as yet unidentified, ligands. Alternatively,
the purified ECM components used in this study may be comprised of the wrong
isoforms or glycosylation pattern, or may have been presented in an unacceptable
format. Finally some CAM-ligand binding is of low avidity and may be obscured by
the relatively high shear stress imparted during the washing procedures (Chapter 4.4
& 4.5). Two approaches were taken to extend these observations. First, a phorbol
ester and a calcium ionophore were used to attempt to "activate" cells in order to
establish whether some CAMs were expressed in a non-activated state (Section 5.3).
Second, a variety of approaches were used to attempt to blockade KG la adhesion to
pFn as a model system in which to establish whether a correlation between CAM
expression and functional binding to the appropriate ligand was sufficient to
conclude a causal link between the two (Section 5.4).
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5.3 Effects ofActivating Agents on KGla Adhesion to Extracellular Matrix
Components.
Integrin adhesiveness is known to be under tight regulatory control, with the
ability to switch rapidly between multiple adhesive states in response to appropriate
stimuli and intracellular signal transduction [Hogg, Bennett, Cabanas et al. 1992;
Matsumoto & Hemler, 1993; Diamond & Springer, 1994], For example, in T cells
integrin activation occurs in response to cross-linking (ligation) of specific surface
molecules (such as CD3 and CD7) or pharmacological agents such as the calcium
ionophore A23187, and the phorbol ester - phorbol myristate acetate (PMA),
through calcium mobilisation and protein kinase C activation respectively [Mobley,
Ennis & Shimizu, 1994], In these cells VLA-4 and VLA-5 mediated fibronectin
adhesion is enhanced without alteration in intensity of cell surface expression
[Ferreira, Valinsky, Sheridan et al. 1991; Uchiyama, Barut, Chauhan et al. 1992],
and is therefore a result of conformational change in the molecule and / or clustering
of integrins in the membrane. In HPC it is unknown whether CAMs are expressed in
a non-activated or partially-activated form and if so what the stimuli and
intracellular signalling mechanisms involved might be.
lpg/ml A23187 or lOng/ml PMA in IMDM 10% FCS were added to KGla
following 51Cr labelling, and incubated for 30min before aliquots were dispensed at
the same concentration into the test wells. KGla adherence to the panel of
extracellular matrix components was examined (Table 5.8 & 5.9) and the results
compared both to internal pFn and dBSA controls using a two-tailed paired t test,
and to the studies on non-activated cells using a two-tailed non-paired t test. The
results with A23187 were largely unremarkable, with no significant differences
from baseline. The results with PMA were very interesting in that there was an
apparent global increase in binding, with a non-significant increase in collagen
binding, augmentation of fibronectin binding (p<0.001), and significant increases in
vitronectin (p<0.05), laminin (p<0.01), proteoglycans (p<0.05) and dBSA binding
(p<0.01). Concomitant controls (not exposed to PMA) showed a small increase in
fibronectin binding (p<0.05) but no difference in dBSA binding comparative to the
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Type I 3.4 ± 1.2% ns(n=4) ns (n=4)
Type III 4.4 ± 2.7% ns (n=4) ns(n=4)
TypelV 1.9 ±0.2% p<0.05 (n=4) ns (n=4)
Glycoproteins
pFn 20.4 ± 14.0% ns(n=4) ns(n=4)
Vitronectin 9.1 ±2.1% (n=2) ns (n=2)
















7.0 ± 5.0% ns (n=4) ns(n=4)
Chondroitin
sulphate
8.8 ± 6.3% ns (n=4) ns (n=4)
Hyaluronic
acid
8.4 ±5.1% ns(n=4) ns (n=4)
dBSA 8.4 ± 7.0% ns (n=4) ns (n=4)
Controls.
pFn 30.6 ± 11.4% p<0.05 (n=4) ns(n=4)
dBSA 9.1 ±4.0% ns (n=4)
Legend. Results are reported as the mean ± standard deviation of 4 replicate
experiments. Adhesion of activated KGla to substrate is compared to that to dBSA
by paired t test*, and is compared to the adhesion of non-activated KGla to dBSA by
non-paired t test$. Activation of KGla with calcium ionophore A23187 had no effect
on adhesion to the panel of substrates.
229












Type I 34.6 ± 27.9% ns (n=3) ns (n=4)
Type III 34.1 ±21.4% ns (n=3) ns(n=4)
Type IV 11.8 ±8.1% ns (n=3) ns(n=4)
Glycoproteins
pFn 83.4 ± 14.0% p<0.05 (n=3) p<0.001 (n=4)
Vitronectin 59.6 ± 25.0% (n=2) p<0.05 (n=3)
















55.8 ± 28.2% ns (n=3) p<0.05 (n=3)
Chondroitin
sulphate
56.9 ±23.0% ns(n=3) p<0.05 (n=3)
Hyaluronic
acid
57.9 ± 22.7% ns (n=3) p<0.05 (n=3)
dBSA 60.4 ± 26.4% ns(n=3) p<0.01 (n=4)
Controls.
pFn 44.2 ± 9.9% p<0.05 (n=3) p<0.05 (n=4)
dBSA 7.9 ± 2.8% ns (n=3)
Legend. Results are reported as the mean ± standard deviation of 4 replicate
experiments. Adhesion of activated KG la to substrate is compared to that to dBSA
by paired t test*, and is compared to the adhesion of non-activated KGla to dBSA by
non-paired t tests. A global increase in KGla binding to substrates and dBSA
control occurs following activation with PMA.
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baseline investigation implying that overall technique in terms ofwashing
stringency and dBSA batch were similar.
This series of experiments and those preceding, generated two vexed questions:
First, is PMA having multiple effects on integrin and non-integrin CAMs, or is there
a negative global regulator of adhesion (such as ionic charge) which is reduced by
exposure to PMA? Second, is the assumption that dBSA comprises a "neutral"
backgound valid? How should the observations that binding to proteoglycans and
collagens (Tables 5.3 -5.7) is apparently less than that to dBSA, and the marked
increase in dBSA binding with PMA stimulation (Figure 5.9), be interpreted?
5.4 Detailed Studies of KGla Adhesion to Fibronectin.
5.4.1 Background.
Fibronectin fulfils a major role in maintaining the stability of the ECM in the
haematopoietic stroma, and long-term marrow cultures (vide infra) [Singer, Keating
& Wight, 1985]. It is a dimeric molecule, containing domains for binding of other
ECM proteins such as fibrin, collagens, and proteoglycans such as heparin and
heparan sulphate [Hynes, 1990; Schwarzbauer, 1991]. It contains at least two
discrete cell binding domains: an arginine-glycine-aspartic acid (RGD) containing
cell binding domain in the central part of the molecule - a ligand for VLA-5
(CD49e/CD29) [Ruoslahti & Pierschbacher, 1987], and a proline-gluamic acid-
isoleucine- leucine-aspartic acid-valine (PEILDV) containing domain at the
carboxy-terminal adjacent to the high-affinity heparin binding domain (the CS1
alternatively spliced domain) - which is a ligand for VLA-4 (CD49d/CD29). The
vitronectin receptor (CD51/CD61) and platelet glycoprotein Ilbllla (CD41a/CD61)
are also known to be fibronectin receptors [Uchiyama, Barut, Chauhan et al. 1992],
as are other integrin vitronectin receptors such as a 13 and a 13 _ (Table 1.9). In
addition, the integral membrane proteoglycan syndecan, binds to the heparin-
binding domain of fibronectin via its heparan sulphate side chains [Saunders &
Bernfield, 1988]. Fibronectin may play a pivotal role in the co-localisation of
proteoglycans, cytokines and haematopoietic cells within the stroma. At least 20
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variants have been described, which arise through alternative mRNA splicing
involving extra-domains a and b (EDa and EDb) and / or the carboxy-terminal
variable region. Too some extent, fxbronectin isoforms are cell type specific, and
may have different functions [Schwarzbauer, 1991]. Lerat, Lissitzky, Singer et al.
[1993] have shown that vascular smooth muscle-like stromal cells in human bone
marrow stromal cultures synthesise and secrete an EDa+ EDb" fibronectin variant,
which is incorporated into the ECM. Granulo-monocytic cells secreted an EDa"
EDb" variant, similar to that found in normal human and horse plasma [Tressel,
McCarthy, Calaycay et al. 1991], which shows poor ECM incorporation.
Both normal HPC, and the haematopoietic cell lines studied, express VLA-4
(CD49d/CD29) and VLA-5 (CD49e/CD29), though not the vitronectin receptor
(CD51/CD61) nor glycoprotein Ilbllla (CD41/CD61) (Figures 3.2 & 3.3, 3.5 -
3.12). Negligible binding to vitronectin makes a contribution from the alternative
receptors a B and a 1^ unlikely. Tavassoli et al. have demonstrated that membrane-
bound chondroitin sulphate can contribute to ElPC-fibronectin binding [Minguell,
Hardy & Tavassoli, 1992],
CAM blockade can be effected by non-specific mechanisms such as divalent
cation chelation (which abrogates integrin and selectin binding), by semi-specific
mechanisms such as synthetic RGD-containing peptides or enzymatic treatment, or
by highly-specific mechanisms such as mAbs which address the binding domain of
the CAM or alter the conformational structure of the molecule.
It was demonstrated in Chapter 4.3.3 that use of an assay medium free of
divalent cations (HBSS + lOmM EDTA) reduces KGla binding to pFn (Table 4.8).
suggesting that this process is predominanty integrin dependent. The effects of
divalent cations may be differential, studies on LFA-1 have suggested that leucocyte
integrin activity is augmented by Mn2+ and Mg2+ but inhibited by Ca2+ [Dransfield,
Cabanas, Craig et al. 1992], A series of studies was carried out to analyse the nature
ofKGla adhesion to Fn in more depth.
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5.4.2 A direct comparison ofKGla binding to plasma and tissue-derived
fibronectin.
KGla adhesion to both plasma-derived (pFn) and tissue-derived fibronectin
(tFn) was compared in a discrete series of experiments on the grounds that potential
differences in the balance of Fn isoforms may contribute to functional differences in
fibronectin derived from different sources [Lerat, Lissitzky, Singer et al. 1993], The
results are presented in Table 5.10. tFn displayed higher binding ofKGla than pFn
(p<0.05), and both displayed significant binding compared to dBSA background
(p<0.001 both). This suggested that tFn displayed more ligands or different kinds of
ligands compared to pFn.
5.4.3 Studies on the metabolic nature ofKGla adhesion to plasmafibronectin.
To assess the metabolic requirements of adhesion to fibronectin, KGla were
incubated with 51Cr in the usual manner, washed, distributed into appropriate
aliquots, and incubated for lhr at ambient temperature with 30mmol/l of sodium
fluoride, 10pg/ml of cytochalasin B, or 1 fig/ml of cycloheximide, in RPMI 10%
FCS. Cells were re-distributed to individual triplicate wells, and incubated with pFn
in medium containing the same concentration of the appropriate compound. Sodium
fluoride depletes cellular adenosine triphosphate [Narayanan, Su & Bedard, 1991],
cytochalasin B paralyses the cytoskeleton by blocking the assembly of actin
filaments, and cycloheximide inhibits protein synthesis [Majdic, Stockl, Pickl et al,
1994], The results of this study are summarised in Table 5.11. None of these
manipulations had any significant effect on KGla-pFn adhesion, suggesting that the
latter is a feature of constitutively expressed and activated cell adhesion molecules.
5.4.4 Blockade ofKG1a-fibronectin adhesion by RGD-containingpeptides.
The recognition of a number ofECM proteins by integrins is mediated through a
common arginine-glycine-aspartic acid (RGD) containing domain [Ruoslahti &
Pierschbacher, 1986 & 1987], VLA-4 (CD49d/CD29) recognition of fibronectin is
mediated through a separate domain, and is not RGD-blocked (vide supra). The
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pFn 68.1 ±9.2% pO.OOl (5)
tFn 74.0 ± 7.7% p<0.001 (5)
dBSA 28.8 ± 11.4% (5)
Legend. Data is presented as the mean ± standard deviation of 5 replicate
experiments. Statistical significance is calculated comparative to dBSA (paired t
test). Adhesion to tFn proved greater than that to pFn (p<0.05) (paired t test).
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44.4 ± 14.2% ns p<0.01
cytochalasin B
(pFn)
46.6 ± 24.0% ns p<0.05
cycloheximide
(pFn)
63.7 ± 11.0% ns p<0.001
RPMI 10% FCS
(pFn)




Legend. Data is presented as the mean ± standard deviation of 4 replicate
experiments. Adhesion ofKGla to pFn in the presence ofmetabolic inhibitors is
compared to that in normal medium* and to background5 by two-tailed paired t test.
No significant effect of the metabolic inhibitors studied could be demonstrated.
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importance ofVLA-5 in fibronectin adhesion can therefore be explored using
synthetic peptides.
KGla were 5lCr labelled using standard technique and washed twice in assay
medium. Aliquots containing 6x10s cells were re-suspended in IMDM containing 1-
1 OmM arginine-glycine-aspartic acid-serine (RGDS) peptide or arginine-glycine-
glutamic acid-serine (RGES) peptide as control. In two separate series of
experiments, adhesion to pFn and to tFn was studied in this way. The results are
summarised in Table 5.12. Inhibition of binding by RGES appeared to be
independent of peptide concentration. Inhibition by RGDS was highly concentration
dependent, and reached a plateau at 5mM. Significant differences between RGDS
and RGES inhibition were present at 2.5mM (p<0.05) and 5mM (p<0.01) only
(paired t test). Study of KG1 a binding to tFn was carried out in a separate series of
experiments, and a very similar pattern of inhibition was demonstrated. A two-tailed
non-paired t test showed no demonstrable difference between inhibition of adhesion
to pFn and tFn. A heptapeptide containing additional residues immmediately
adjacent to the RGD sequence in fibronectin (glycine-arginine-glycine-aspartic acid-
serine-proline-cysteine) has been shown to be better at inhibiting attachment of cells
to fibronectin and vitronectin [Gartner & Bennett, 1985; Pierschbacher & Ruoslahti,
1987; Hautanen, Gailit, Mann et al. 1989].
5.4.5 Blockade ofKG 1a-fibronectin adhesion by monoclonal antibodies.
A further analysis ofKGla adhesion to pFn was undertaken using mAbs of
known blockading ability. The anti-a4 mAb HP2/1 abrogates binding of human
myeloma cell lines and T-lymphocytes to the to CS1 domain of fibronectin
[Uchiyama, Barut, Chauhan et al, 1992; Nojima, Humphries, Mould et al. 1990).
The anti-a4 mAb L25.3 and has been shown to inhibit T lymphocyte interaction
with human endothelial cells, VCAM-1 transfected L cells, and Fn [Clayberger,
Krensky, Mclntyre et al. 1987], mAb 16 has anti-a5 chain specificity, and has been
shown to inhibit fibroblast attachment to Fn, but not to vitronectin or laminin
[Akiyama, Yamada, Chen et al. 1989].
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Table 5.12 Blockade ofKGla Adhesion to Fibronectin by RGD-Containing
Peptides.
Peptide RGDS cf: pFn RGES cf: pFn
nil 31.9 ±6.5%
5mM 8.1 ± 1.5% p<0.01 27.1 ±6.8% p<0.05
2.5mM 12.5 ± 1.2% p<0.02 24.7 ± 6.0% p<0.02
ImM 21.8 ±6.7% p<0.01 22.5 ±3.4% p<0.05
0.5mM 21.7 ±6.4% p<0.05 23.9 ±7.2% ns
dBSA 19.0 ± 11.3%
Legend. Results are presented as mean % adherence ± standard deviation. A paired t
test was used to compare % adhesion in the presence of synthetic peptides with
adhesion to the fibronectin in the media alone (IMDM 10% FCS). Both peptides
inhibited KGla adhesion to pFn, but RGDS blockade increased with concentration
and was more marked above 2.5mM.
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In order to determine the appropriate quantity of mAb to be used in blockading
experiments, 5x10s KG la were incubated with serial titrations of each mAb adjusted
such that lOpg, 5pg, lpg, 0.5pg, 0.1 pg and 0 pg was present in lOpl during the
incubation step. These were stained with SAM-FITC second step reagent using
standard immunocytometry protocol, and analysed by flow cytometry. The rationale
of this approach was to achieve saturation of appropriate CAM epitopes, without a
large excess ofmAb which could cross-link and activate the study population.
These titration experiments showed that lOpl containing lpg ofmAb (i.e. a
concentration of lOOpg/ml) was sufficient to achieve saturation binding, and is
consistent with accepted practice [Coligan, Kruisbeek, Margulies et al. 1994],
Some authors have commented that sodium azide used as a preservative in mAb
preparations is a metabolic inhibitor and membrane immobiliser and may interfere
with cell adhesion. It proved unfeasible to obtain mAbs without sodium azide
preservative, so a control was run with each series of experiments which included an
incubation step with lOpl of PBS, 0.01% sodium azide.
KGla were 5ICr labelled and washed using standard technique, and aliquots of
5x10s cells were pelleted and incubated with 1 pg of one of the three mAbs in 1 Opl
PBS for 30min at +4°C. Controls were established with the same concentration of
an IgG2a mAb of irrelevant specificity, with PBS 0.1% sodium azide, and without
an incubation phase. The cells were resuspended in 1.2ml of culture medium, and
triple aliquots of 400pl incubated with pFn for 2hrs in the standard manner. An
adherent percentage was calculated and compared to controls by two-tailed paired t
test.
The results of this series of experiments is presented in Table 5.13. Adhesion of
KGla was uniformly greater in those cell samples which had been incubated with
mAb, including those in which an IgG2a of irrelevant specificity had been used,
compared to those samples incubated without mAb (medium alone and with sodium
azide). There was no clear difference between mAbs, with none showing significant
reduction in adhesion compared to the IgG2a control. Adhesion in the presence of
the sodium azide containing medium was similar to that in the positive control. All
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Table 5.13 KGla Adhesion to Fibronectin in the Presence of Monoclonal
Antibodies.




pFn HP2/1 53.1 ±23.6% p<0.02 p<0.05 ns(n=3)
pFn L25.3 45.0 ± 20.4% p<0.05 ns ns (n=4)
pFn mAb16 51.9 ±22.4% p<0.01 p<0.05 ns(n=4)
pFn IgG2a 55.8 ± 18.5% p<0.001 p<0.01 (n=4)
pFn sodium
azide
35.6 ± 19.0% p<0.05 ns (n=4)
pFn nil 35.7 ± 16.7% p<0.01 (n=4)
dBSA nil 21.1 ± 15.9% (n-4)
Legend. Results are reported as mean ± standard deviation of 4 replicate
experiments. Statistical significance of observed values were compared to dBSA*,
pFn$ and pFn following incubation with IgG2a" using paired t test. The mAbs
studied did not effect blockade ofKGla-pFn adhesion, indeed a paradoxical
increase in adhesion was demonstrated, which was dependent on the presence but
not the specificity of a mAb, and could not be ascribed to sodium azide.
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samples were superior to the negative (dBSA) control. The results of this series of
experiments were unexpected, and not easy to interpret. It seemed clear that the
effect of the mAbs on KGla-pFn adhesion was not a feature of antibody specificity,
but nevertheless required the presence of the mAb since the presence of handling
medium containing sodium azide alone did not effect KGla-pFn adhesion. The
cause of this effect is unclear. Cell aggregation did not occur, but the presence of the
immunoglobulin could have caused CAM activation via Fc receptor occupancy or
cross-linking, or may have acted as a molecular bridge between pFn and the cell.
The absence of an expected blockading effect in the presence of relevant mAbs is
difficult to interpret in view of this artefact. A repeat series of experiments
following Fc blockade with Fab' or F(ab')2 fragments may help to resolve the
problem.
5.4.6 Blockade ofKGla-fibronectin adhesion by enzymatic treatment.
The groups based in Minneapolis [Verfaillie, Benis, Iida et al. 1994] and
Jackson [Minguell, Hardy & Tavassoli, 1992; Conget & Minguell, 1994] have
demonstrated cooperation between binding of a cell surface chondroitin sulphate
(the core protein of which is related to CD44), and VLA-4 (CD49d/CD29) in
binding to the heparin binding domain of Fn. To test the hypothesis that cell surface
proteoglycans may be involved in HPC-Fn adhesion, KGla were 5lCr labelled in the
usual manner and aliquots of 5x10s cells were incubated for lhr at 37°C in lOOpl of
IMDM containing 0.1 units of chondroitinase ABC [Verfaillie, Benis, Iida et al.
1994], 0.5 units of heparinase [Coombe, Watt & Parish, 1994], 100 units
hyaluronidase [Koshiishi, Shizari & Underhill, 1994] or with no added enzyme. A
titration was not carried out, but the enzymes were used at concentrations which
effectively blocked cell adhesion in the studies cited. The labelled cells were
resuspended in the appropriate volume ofmedium and plated into triplicate wells
with pFn (Table 5.14). KGla adhesion to pFn was partially blocked by incubation
with chondroitinase ABC, but not by heparinase or hyaluronidase.
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Table 5.14 Comparative Effects of Enzymatic Digestion of Proteoglycans on
KGla Adhesion to Fibronectin.
enzyme mean %
adhesion
cf: dBSA cf- pFn
Chondroitinase
ABC
32 ± 5% p<0.01 p<0.001
Heparinase 61 ±2 p<0.01 ns
Hyaluronidase 61 ±2 p<0.01 ns
pFn 59 ±4 p<0.01
dBSA 17 ± 6
Legend. Data presented as the mean ± standard deviation of 4 replicate experiments.
KGla adhesion to pFn following enzyme incubation compared to that without and




The objective of the studies reported in this Chapter was to establish the extent
to which phenotypic CAM expression could be correlated with functional cell
adhesion to purified putative ligands. In addition, the utility of activating and
blockading agents in modifying CAM function and cellular adhesion behaviour was
explored in order to establish whether a positive correlation between the two was
sufficient to infer a direct causal relationship.
It is clear that some correlations between CAM expression and ligand binding
do exist. For example, all 5 cell lines express VLA-4 (CD49d) and VLA-5 (CD49e)
and all demonstrated significant adhesion to pFn. However, there were also found to
be areas of discordance, for example PECAM-1 (CD31) and CD45 expression by
KGla did not correlate with adhesion to heparan sulphate. On the grounds that some
CAMs may therefore be expressed in a non- or partially-activated state, 2 reagents,
the calcium ionophore A23187 and phorbol myristate acetate, were used as
activating agents. Although A23187 had no effect, PMA caused an increase in
adhesion to virtually all the substrates studied, raising the possibilities of a
generalised activation of identified CAMs together with the presence of further, as
yet unidentified, CAMs, or the downregulation of a global negative regulator of
adhesion.
KGla adhesion to pFn was examined in more depth to establish whether a
positive correlation between CAM expression and adhesion behaviour could be
taken to imply causality. Both divalent cation chelation and RGDS-containing
peptides had a similar partial blockading effect on KGla adhesion to pFn,
confirming the involvement ofVLA-5 in this interaction. Neither mAbs to VLA-4
nor to VLA-5 blocked KGla-pFn adhesion suggesting either that there was an un-
addressed methodological problem with this series of experiments, or that the
antibodies used did not appropriately block this adhesion despite blockading VLA-4
and VLA-5 function in some other experimental systems. The involvement ofVLA-
4 in KGla-pFn adhesion therefore remains moot. Moreover, the data from Section
5.4.6 clearly supports a corollary role for chondroitin sulphate, which would not
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have been predicted from the immunofluorescence studies.
It is clear from these experiments, therefore, that CAM expression is an
insufficient basis in itself to conclude involvement in cellular adhesion to an
appropriate ligand, and moreover that the phenotypic characterisation of cellular
CAM expression is incomplete, with the involvement of other classes of molecules
such as proteoglycans. A variety of phenotypic and functional experiments are
necessary to build up a complete picture of a particular cell-ligand interaction.
Two further limitations are inherent in this reductionist approach of studying
haematopoietic cell line adhesion to purified ECM components: first that HPC
interaction with the bone marrow micoenvironment in vivo is likely to involve
multiple cell-cell and cell-substrate adhesive pathways, only some of which can be
replicated using purified components. Second, that the study population differs from
normal human HPC. It was therefore felt to be important to investigate whether the
adhesion assay could be extended to study cell adhesion to bone marrow stromal
and endothelial tissue cultures in vitro, and whether HPC from human sources could
be purified and s'Cr labelled in a satisfactory manner. These issues are addressed in
Chapter 6.
244
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6.1 Introduction.
To evaluate the relevance of the observations made using haematopoietic cell
lines and highly purified extracellular matrix components to the interaction ofHPC
with the complex bone marrow endothelial and stromal environment in vivo, it was
decided to extend the 5lCr adhesion assay in two ways: first to permit analysis of
cell adhesion to bone marow stromal culture layers in vitro, second to allow the
study ofHPC themselves.
Long-term tissue cultures allow the study of cell-cell interactions in vitro in a
system that incorporates an order of complexity close to that exhibited by
haematopoiesis in vivo. The preparation of adherent cell lines and bone marrow
stromal cultures is discussed in Section 6.2. Haematopoietic cell lines were used to
establish the feasibility of applying the 51Cr adhesion assay to stromal cultures for
the same reasons of availability, consistency and characterisation outlined in
Chapter 4.1 (Section 6.3). Comparative adhesion of haematopoietic cell lines to the
murine stromal cell line M210-B4 (Section 6.4) were carried out, and the feasibility
of carrying out blockading experiments within the assay system was explored
(Section 6.5). In collaboration with Dr John Sweetenham and Mrs Lisa Masek of the
CRC Medical Oncology Unit Southampton General Hospital, studies have been
carried out to examine the adhesion of haematopoietic cell lines to human bone
marrow endothelial cultures in vitro. The methodology and preliminary results of
this work are discussed in Appendix 4.
It was clear that the application of the 51Cr adhesion assay to HPC required the
use ofhighly enriched populations and a three stage enrichment protocol was
developed with this in mind (Section 6.6). There are both advantages and
disadvantages to the use of highly purified HPC in adhesion assays. To advantage,
potential interference or alteration ofHPC adhesion by accessory cells (for example:
by competition for available binding sites, steric hindrance, or cytokine secretion),
is avoided. To detriment, cell loss and functional alteration occurring during the
enrichment process may be profound, and difficult to assess. Limitations in the
number of purified HPC available for adhesion experiments made it desirable to
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explore the possibility of increasing the labelling intensity of the target population
(Section 6.7). The general applicability of the assay approach to HPC is constrained
by the large starting population required, the extended nature of the enrichment
protocol, and the intensity of the 5lCr-labelling procedure.
6.2 Preparation of in vitro Tissue Cultures.
6.2.1 Backgound.
Long term culture of bone marrow stromal layers (LTBMC) was first developed
from mice by Dexter, Allen & Lajtha [1977], and later adapted to human marrow by
Gartner and Kaplan [1980]. In this system, cells aspirated from bone marrow were
maintained in an osmotically balanced culture medium and serum, and incubated at
33°C, 5% CO and 100% humidity. An adherent layer formed over three to four
weeks, which supported haematopoiesis in the absence of exogenous growth factors.
Greenberger [1978] demonstrated that supplementation of the culture medium with
corticosteroids stimulated lipid accumulation in stromal cells, and long-term
proliferation of haematopoietic cells.
Stromal LTBMC preferentially support granulopoiesis, but it is clear that
manipulation of the culture environment can lead to substantial alteration in the
behaviour of the culture. For example,Whitlock and Witte [1982] have shown that B
lymphopoiesis can be supported in murine LTBMC by alteration in the culture
conditions. It is clear, therefore, that pluripotential haematopoietic stem and early
progenitor cells adhere to LTBMC, and that their proliferation and differentiation is
dependent on the culture environment.
In man it has been found that culturing bone marrow in a standard medium
supplemented with FCS, leads to outgrowth ofmarrow fibroblasts which
preferentially support lymphopoiesis, whilst supplementing the standard medium
with horse serum and hydrocortisone, leads to formation of a morphologically more
heterogeneous stromal population with adipocyte formation, which supports
myelopoiesis (Dexter-type long term bone marrow stromal cultures). Unfortunately
only 20-40% of horse sera will support adipocyte formation and these have to be
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checked on a batch-batch basis. The confluent adherent layer which forms in
LTBMC after 3-4 weeks is a complex cellular and extracellular environment, which
has only been partially characterised. Five stromal cell populations are identifiable:
monocyte-macrophages, fibroblasts / reticular cells, "blanket cells", adipocytes and
endothelial cells [Allen & Dexter, 1984; Riley & Gordon, 1987; Allen, Dexter &
Simmons, 1990; Quesenberry, Temeles, McGrath et al. 1991]. These form a three
dimensional structure with the endothelial cells forming an incomplete layer at the
stromal / fluid interface [Allen & Dexter, 1982]. The relationship between reticular
cells and fibroblasts is unclear. Fibroblasts in LTBMC may be derived from
adventitial reticular cells, from fibroblasts associated with vascular and nerve
structures, or free lying fibroblasts within the marrow cavity. Charbord et al. have
pointed out the phenotypic similarities between reticular cells and vascular smooth
muscle cells based on data on studies of cytoskeletal proteins and on secretion of
fibronectin isoforms [Charbord, Lerat, Newton et al. 1990; Galmiche, Koteliansky,
Briere et al. 1993; Lerat, Lissitzky, Singer et al. 1993]. The origin of cells
accumulating lipid in LTBMC systems is equally uncertain. Tavassoli [1989] has
pointed out that lipid accumulationper se does not warrant the classification of a
cell as an adipocyte, since many cell types, including fibroblasts, adventitial
reticular cells and macrophages, may accumulate lipid both in vivo and in vitro. In
the absence of objective criteria with which to identify pre-adipocytes, it is unclear
whether lipid accumulation in vitro reflects a culture phenomenon, or development
of true marrow adipocytes. Although Greenberger demonstrated that addition of
hydrocortisone to LTBMC potentiated both lipogenesis and granulopoiesis
[Greenberger, 1978], the interdependence of the two is debated [Allen & Dexter,
1982; Touw & Lowenberg, 1983], Recent evidence suggests that the addition of
steroids to LTBMC leads to a decrease in stromal hyaluronic acid and a higher
incorporation of sulphated glycosaminoglycans such as heparan sulphate. The extent
to which LTBMC can be said to be representative of bone marrow stromal structure
in vivo remains uncertain.
From a functional point of view, long-term granulopoiesis occurs in LTBMC in
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the absence of exogenous growth factors, and is dependent on the presence of the
confluent stromal layer [Allen & Dexter, 1982; Dexter, Coutinho, Spooncer et al.
1990; Verfaille, Blakolmer & McGlave, 1990]. It appears that primitive HPC are
preferentially integrated in the adherent layer, whereas with increasing maturity
cells migrate to the surface and are shed into the growth medium [Mauch,
Greenberger, Botnick et al. 1980; Toksoz, Dexter, Lord et al. 1980; Winton &
Colenda, 1987]. In murine cultures, the addition of erythropoietin with agitation of
the culture, leads to decreased lipid storage, regression of endothelial cells, and
augmentation of erythropoiesis [Eliason, Testa & Dexter, 1979], Similarly,
modification of murine LTBMC by use of low concentrations of FCS, addition of
mercaptoethanol, and incubation at 37°C, promotes lymphopoiesis [Kincade, 1987].
In summary, these culture systems are probably the least artefactual in vitro model
available for examining HPC-stromal adhesion mechanisms, but remain highly
dependent on culture conditions and are therefore difficult to standardise.
The murine stromal cell line M210-B4 [Sutherland, Eaves, Lansdorp et al. 1991]
was used as a convenient substrate for initial studies (Figure 6.1). No human stromal
cell line could be found for study, though some have recently been described by
Aizawa [Aizawa, Yaguchi, Nakano et al. 1991], The validity of using a murine
stromal cell line as representative of human bone marrow stroma is supported by
experiments in which early human HPC are maintained for several weeks following
infusion into immunodeficient mice [Zanjani, Pallavicini, Ascensao et al. 1992;
Lapidot, Pflumio, Doedens et al. 1992] or when cocultured in vitro with murine
stromal cells in the absence of added human growth factors [Sutherland, Eaves,
Lansdorp et al. 1991; Issaad, Croisille, Katz et al. 1993: Burroughs, Gupta, Blazar
et al. 1994].
6.2.2. Preparation ofadherent cell lines.
Adherent cell lines were cultured and passaged in 25 cm3 or 75 cm3 tissue culture
flasks as previously described (Chapter 2.2.2). To prepare a 24 well plate for an
adhesion assay, the adherent cells were removed from the primary culture flask and
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Figure 6.1 M210-B4 Murine Stromal Cell Line.
is













Legend. M210-B4 murine bone marrow fibroblast cell line at confluence,
(magnification x4 blue filter).
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disaggregated by removing the culture medium, washing twice with 10ml of
anticoagulant medium, and incubating with 5ml of trypsin / EDTA at 37°C. The
cells were resuspended in culture medium at a concentration of 2x10s cells / ml, and
0.5ml aliquots transferred to each well of the test plate. M210-B4 were found to
grow to confluence in 2cm2 wells within 48-72hrs, and thereafter were used as soon
as possible. Senescent cultures (> 7 days) were found to deteriorate rapidly with
fragmentation of the adherent layer. The morphology of a confluent adherent cell
line at 3 days is illustrated in Figure 6.1. The use of smaller volumes of culture
medium (especially less than 200pl) was found to lead to preferential growth of
cells around the perimeter of the wells, and central subconfluence. This was thought
to be a reflection of an unequal depth of culture medium in the well either due to a
central convexity of the well base or (more likely) the effects of surface tension
acting at the periphery (Chapter 4.4.3). A further technical problem was found to be
the stability of the adherent layer in the face of recurrent addition and removal of
media during the adhesion assay. M210-B4 were vulnerable to traumatic disruption,
leading to loss of attachment at the periphery of the well (rolling) (Figure 6.2), or
the development of lacunae (Figure 6.4a). These effects were particularly apparent
when HBSS with lOmM EDTA or IMDM with 5mM RGDS were used as media
during blockading experiments (Section 6.5.1), and indeed on occasion RGDS
caused complete detachment of the stroma from the plastic carrier. IMDM with
5mM RGES did not disrupt the stromal layer. The use of several substrates to
augment stromal adhesion was explored. Poly-L-Lysine was found to be particularly
toxic to cell growth, even after thorough washing of the plate with culture medium.
Coating of the plates with collagen under standard conditions (Chapter 4.3) prior to
introduction of the cells was found to improve the stability of the M210-B4 stroma
[Freshney, 1987] and to prevent disruption of the stroma during divalent cation
chelation or exposure to RGDS. Pre-coating with collagen type IV was used as
standard protocol in view of the low binding affinity of haematopoietic cell lines for
this protein under normal conditions (such that it could be considered non-
contributory to binding to the stromal substrate) (Tables 5.3-5.7).
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Figure 6.2 Disruption of M210-B4 Stroma.
Legend. Disruption ofM210-B4 cell line with rolling-back of the intact fibroblast
layer, (magnification x4).
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6.2.3 Preparation ofhuman fibroblast and stromal cultures.
The cellularity of a stromal culture is affected by several factors: the exposure of
the donor to prior chemotherapy, the volume of the aspirate, and the method of
erythrocyte separation. Bone marrow derived from clinical samples was found to be
unsatisfactory for stromal culture because of the small volumes available and
limited proliferation due to prior exposure to chemotherapy. Normal haematopoietic
bone marrow was derived from the posterior iliac crests of patients undergoing
general anaesthesia for an elective (non-malignant) surgical procedure, or from
volunteers under local anaesthesia. A maximum of 10-20ml was aspirated
specifically for culture purposes under sterile conditions. Larger volume aspirates
lead to greater dilution of the stromal elements by the haematopoietic elements,
which is undesirable in this context. Unless removed, erythrocyte contamination of
unseparated cultures leads to a persistant mass over the surface of the culture.
Several methods were explored to remove erythrocytes including gravity
sedimentation over 30min through 10ml of 1% Dextran [David Kilpatrick - personal
communication], or 10ml of 0.01% methylcellulose [Elaine Spooncer - personal
communication]. These approaches proved unsatisfactory due to high residual
erythrocyte contamination. Bone marrow samples were therefore fractionated by
discontinuous density centrifugation over Ficoll-Hypaque at 500g for 30 minutes,
and washed several times in sterile HBSS to remove residual Ficoll which may be
toxic. This was found to be the most effective approach for removing erythrocytes,
although the extent to which stromal elements are lost is unclear. The cells were
resuspended in culture medium at a concentration of 2x106 cells/ml, and 0.5ml
aliquots distributed to individual wells of the 24 well plate [Freshney, Pragnell &
Freshney, 1994].
Two forms of culture technique were used for bone marrow stromal culture
(LTBMC) [Dexter, Spooncer, Simmons et al. 1984], The first used standard culture
medium (Appendix 2) and was carried out at 37°C, 5% CO^ and 100% humidity -
conditions known to favour fibroblast outgrowth (Figure 6.3). The second used
specific LTBMC medium containing hydrocortisone and horse serum (Appendix 2),
253
and was carried out at 5% CO and 100% humidity for 3-4 days at 37°C, followed
by prolonged incubation at 33°C. The latter conditions have been found to favour
adipocyte formation and haematopoiesis (Figure 6.4) as discussed above (Section
6.2.1). Antifungal agents were not used in view of their toxicity to the cultured cells.
All preparative manipulation was carried out under aseptic conditions using a
laminar flow hood and sterile glassware or plastic passivated with 1% dBSA in PBS
to minimise the loss of adherent cells during cell preparation and manipulation.
Bone marrow was manipulated and plated as soon as possible after harvesting, and
stored at +4°C if delay was unavoidable. 50% of the supernatant was removed and
replaced at weekly intervals, and the cultures monitored by inverted microscopy.
It was found that the stromal layers were fragile, and easily disrupted by
enthusiastic medium change (Figures 6.2 & 6.4a), in much the same way as the
M210-B4 cell line. Precoating the wells with collagen IV was found to provide
more stability to the stromal layer. Precoating culture plates with ECM has been
reported to augment the rate of stromal development [Campbell, Long & Wicha,
1987], though this was not observed in this work.
6.3 Preparatory Experiments to Study the Adhesion of KGla to in vitro Tissue
Cultures.
s'Cr-labelling ofKGla and substrate adhesion was carried out using the standard
protocol (Chapter 4 and Table 4.20). Two concerns arose which were specific to the
study of cellular sustrates: that removal of the supernatant and washing may lead to
disruption of the substrate (discussed in Section 6.2.1 and 6.2.2) and that free 51Cr
present in the supernatant may be taken up by the cellular substrate leading to a
falsely high adherent count. Two modifications were therefore made to the standard
protocol. All wells were examined by microscopy at the outset and again following
supernatant removal and washing at the end of the distractive phase of the
experiment. In practice very little disruption of the adherent layer could be ascribed
to the washing procedures, especially with the use of collagen as a base substrate. It
is possible that a collagenous substrate may alter the structure of the culture in such
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Figure 6.3 Human Bone Marrow Fibroblast Cultures.
Legend. Human bone marrow fibroblasts grown to confluence in standard tissue
culture medium, (magnification xlO blue filter).
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Figure 6.4 Human Bone Marrow Stromal Cultures.
Legend. Human bone marrow stroma grown to confluence in long-term culture
medium. The stromal culture differs from a fibroblast culture in the formation of
adipocytes (A) (magnification x4) and marked proliferation ofprimitive 1 IPC to
form "cobblestone areas"(bottom left) (B) (magnification x20 blue filter).
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a way as to change adhesive interactions with HPC. No difference was apparent in
the gross structure of the culture on microscopy. In a further series of experiments a
triplicate series of control wells was established containing M210-B4, but exposed
only to the appropriate volume of supernatant and not to labelled cells. The adherent
and non-adherent counts were analysed in the usual fashion. It was found that
counts of the adherent layer were not significantly above backgound and represented
<0.5% of the cell count per well, suggesting that 51Cr uptake by the substrate was
negligible (Table 6.1).
An important further consideration in using stromal LTBMC as a substrate for
HPC adhesion experiments is whether endogenous haematopoietic activity can (or
should) be removed. It could be argued, for example, that autologous HPC may
occupy available microenvironmental niches and reduce stromal adhesion of the test
cells. It is theoretically possible to grow a stroma free of endogenous
haematopoiesis by sorting fibroblast progenitors on the basis ofCD34 and Stro-1
positivity. Simmons and Torok-Storb [1991b] have shown that a purified population
of CD34+ STRO- 1+ cells contains >95% of detectable CFU-F, and gives rise to a
complex mixture of adherent stromal cells in culture, including fibroblasts,
adipocytes, and smooth muscle cells, but not endothelial cells or monocyte-
macrophages. Commoner methods of eliminating endogenous haematopoiesis
include early or late passage, or irradiation of the stroma following confluence
[Moreau, Andreoni, Caux et al. 1992], Stroma treated in this way remains capable
of supporting exogenous HPC, but the effects on the stromal microenvironment are
uncertain. In a series of experiments, KG la adhesion to stromal LTBMC and
fibroblast LTBMC with and without collagen type IV as a substrate, were compared
directly with adhesion to M210-B4 (Tables 6.2 & 6.3). No significant differences
could be detected in KGla adhesion to stromal and fibroblast layers, and no effect
of collagen type IV could be demonstrated. Adhesion to human LTBMC was
however superior to that to M210-B4, and adherence to all cellular substrates was
markedly superior to that to pFn. It appears therefore that KG la adherence to stroma
is superior to that to purified ECM components suggesting that cellular binding
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Table 6.151Cr Uptake by the Adherent Stromal Layer.
Cells per well: 4 ± 1.6x10s
Counts per well: 10,974 ± 2,632 cpm
Counts per well (supernatant only): 234 ±163 cpm
Supernatant contamination: 2.3 ± 2.0%
M210-B4 layer: 44 ± 4 cpm
Blank: 40 ± 2 cpm
Legend. Stromal counts were not found to be significantly above those of blank
assays (p=ns: paired t test), and represented <0.5% of the total cell count in each
well.
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Table 6.2 Comparative Adhesion ofKGla to the M210-B4 Cell Line and to
Human Bone Marrow Fibroblast and Stromal Cultures.
mean± SD cf.dBSA* cf:pFn% (n)
M210-B4 76 ± 8% p<0.01 p<0.02 4
LTBMC-Stroma
(plastic)
92 ± 3% p<0.001 p<0.01 4
LTBMC-F ibroblast
(plastic)
92 ± 3% p<0.001 p<0.01 4
LTBMC-Stroma
(collagen)
91 ±4% p<0.01 p<0.02 3
LTBMC-F ibroblast
(collagen)
92 ± 1 p<0.01 p<0.02 3
pFn 39 ±9 p<0.02 4
dBSA 17 ± 8 4
Legend. Comparative adhesion of KGla to cellular substrates. Results presented
the mean ± standard deviation of 3 or 4 replicate experiments. Student's paired t
was used to compare results of fibroblast / stromal adhesion to dBSA* and pFn$
adhesion (vide supra) and between different cellular substrates (Table 6.3).
Substantial adhesion occurred to all cellular substrates. Adhesion to human
fibroblast and stromal layers was superior to that to M210-B4. There was little
difference in KGla adhesion to fibroblast and stromal with or with out collagen
precoating of the plastic.
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Table 6.3 Statistical Comparison of KGla Adhesion to Various Combinations
of Cellular Substrate.
fibroblast: stroma ns
fibroblast (collagen): stroma (collagen) ns
fibroblast: fibroblast (collagen) ns
stroma: stroma (collagen) p<0.05
fibroblast: M210-B4 p<0.05
stroma: M210-B4 p<0.05
fibroblast (collagen): M210-B4 p<0.05
stroma (collagen): M210-B4 p<0.05
Legend, see Table 6.2.
affinity is greater, perhaps due to the involvement ofmultiple adhesion pathways. In
addition, ongoing endogenous haematopoiesis does not seem to interfere with KGla
adherence.
6.4 Comparative Adhesion of Haematopoietic Cell Lines to M210-B4.
A comparative study of the adhesion of the haematopoietic cell lines KGla,
K562, HL60, CEM and NALM-6 to M210-B4 was carried out to establish whether
differences in CAM expression and adhesion to ECM components translated into
differences in adhesion to composite stromal layers. The results of these
experiments are summarised in Table 6.4. All the haematopoietic cell lines studied
adhered to M210-B4, though the lymphoblastic lines CEM and NALM-6
demonstrated significantly greater stromal adherence than KGla.
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Table 6.4 Comparative Adhesion of Haematopoietic Cell Lines to M210-B4.
Cell line. mean ± SD cf: KGla
KGla 64.3 ± 4.2%
K562 62.9 ± 1.3% ns
HL60 72.4 ± 13.5% ns
CEM 81.4 ±2.0% p<0.01
NALM-6 80.3 ± 2.4% p<0.02
Legend. Data presented as the mean ± standard deviation of 4 replicate experiments.
Adhesion to M210-B4 was compared to that ofKGla by non-paired t test. All cell
lines adhered to M210-B4, though the lymphoid cell lines NALM-6 and CEM
demonstrated significantly greater adhesion than KGla.
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6.5 Blockade ofKGla Adhesion to M210-B4.
6.5.1 Blockade ofKGla adhesion by divalent cation chelation and synthetic
peptides.
Experiments were carried out to study the adhesion of 51Cr-labelled KGla to
M210-B4 in the presence ofHBSS lOmM EDTA, 5mM RGDS or RGES peptides.
KGla were incubated with 51Cr and peptide as described (Chapter 5.4.4). As noted
previously the adherent layer was found to become completely distracted from the
plastic carrier in the presence of divalent cation chelation and RGDS peptides,
suggesting that the stromal layer secretes its own ECM to which it then adheres
through an RGD-dependent mechanism. Precoating the wells with collagen type IV
protected the stroma from disruption presumably through the involvement ofnon-
integrin-dependent adhesion mechanisms. The results are summarised in Table 6.5.
Divalent cation chelation significantly blocked KGla adhesion to M210-B4, but
5mM RGDS caused no significant blockade, and indeed there was no significant
difference between adhesion in the presence of RGDS compared to that in the
presence ofRGES (p=ns paired t test).
6.5.2 Blockade ofKGla adhesion by monoclonal antibodies.
Experiments were carried out to study the effects ofmAbs known to blockade
adhesion in other experimental systems. LB-2 (anti-ICAM-1 CD54) has been shown
to inhibit ICAM-1 mediated adhesion to LFA-1 [Makgoba, Sanders, Luce et al,
1988]. L133.1 (anti-PECAM-1 CD31) has been shown to inhibit homotypic-
mediated aggregation of PECAM-1 expressing L cells [Albelda, Muller, Buck et al,
1991], G25.2 (anti-LFA-la CD1 la) has been shown to inhibit LFA-1 :ICAM-1
interaction [Makgoba, Sanders, Luce et al, 1988], whilst LI78 (anti-HCAM CD44)
has been shown to inhibit lymphocyte adhesion to lymph node endothelial cells
[Jalkanen, Bargatze, de los Toyos et al, 1987]. L25.3 (anti-VLA-4a CD49d) and
mAb 16 (anti-VLA-5a CD49e) were also used as previously noted (Chapter 5.4.5).
Three adhesion molecules were not studied. It was thought unlikely that LFA-3 (a
counter-receptor for T lymphocyte expressed LFA-2) would play a major role in
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Table 6.5 Blockade ofKGla-M210-B4 Adhesion by Divalent Cation Chelation
and RGDS Peptides.
medium mean± SD cf: dBSA' cf: no blockades
IMDM + 10% FCS 73.1 ± 12.5% p<0.01
HBSS + lOmM EDTA 42.1 ± 10.8% p<0.05 p<0.05
IMDM + 5mM RGDS 65.6 ±8.0% p<0.01 ns
IMDM + 5mM RGES 61.0 ± 10.2% pO.OOl ns
dBSA 14.3 ± 8.7%
Legend. Data is presented as the mean ± standard deviation of 4 replicate
experiments.
Statistical comparisons to dBSA* and to M210-B4 without blockade5 by paired t
test. Divalent cation chelation blocked KGla adhesion to M210-B4, but 5mM
RGDS or RGES had no effect. There was no significant difference between
adhesion in the presence ofRGDS or RGES (p=ns).
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KG la adhesion to M210-B4 and so blockading studies with mAbs to this CAM
were not carried out. Blockading mAbs to CD36 were not avaliable at the time of
the study whilst L-Selectin is not expressed by KGla (Figure 3.8 - 3.10). mAbs
were titrated against KGla using indirect immunofluorescence as previously
described (Chapter 5.4.5) and were used at a final concentration of lpg / 5x10s cells.
The results of these experiments are summarised in Table 6.6. None of the mAbs
studied proved capable of blockading KGla adhesion to M210-B4.
6.5.3 Blockade ofKGla adhesion by enzymatic treatment.
A final group of experiments was carried out to study the effects of glycolytic
enzymes on KGla adhesion to M210-B4.51Cr-labelled KGla were incubated with
chondroitinase ABC, heparinase I or hyaluronidase prior to the adhesive phase of
the experiment as previously described (Chapter 5.4.6). The results are summarised
in Table 6.7. Once again no significant blockade ofKGla adhesion to stroma could
be demonstrated.
6.5.4 Discussion.
The series of experiments described in the preceding sections demonstrated that
the 5lCr adhesion assay is applicable to the study of haematopoietic cell line
adhesion to complex tissue culture layers in vitro. Unlike the situation where cell
line adhesion to ECM components was studied (Chapter 5), it proved impractical to
blockade KGla adhesion to stroma with selective blocking agents (synthetic
peptides, mAbs or enzymes). The relatively non-specific approach of divalent cation
chelation was partially effective, though stromal adhesion remained greater than that
to background (dBSA). This data suggests that multiple adhesive pathways (some of
them divalent cation dependent) are involved, leading to a degree of redundancy in
HPC-stromal adhesion.
It was clear that the application of the 5lCr adhesion assay to HPC required the
development of high-grade enrichment and 51Cr-labelling of the target population.
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Table 6.6 Blockade ofKGla-M210-B4 Adhesion by Monoclonal Antibodies.
mAb mean ± SE cf: dBSA * cf: no mAbs
nil 73.1 ± 12.5% P<0.005
ICAM-1 68.7 ± 12.9% P<0.005 ns
PECAM-1 76.9 ± 9.4% P0.005 ns
LFA-1 77.9 ± 11.2% P<0.005 ns
HCAM 77.1 ± 13.5% P<0.005 ns
VLA-4 58.8 ± 28.7% P<0.05 ns
VLA-5 62.7 ±26.8% p<0.05 ns
IgGl
(control)
69.1 ± 13.1% P<0.01 ns
dBSA 15.9 ± 11.6%
Legend. Data is presented as the mean ± standard error of 4 replicate experiments.
KG la adhesion to M210-B4 in the presence of the named mAbs is compared to that
in the absence ofmAbs or to dBSA* by paired t test. None of the mAbs tested
showed demonstrable effect on adhesion.
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Table 6.7 Blockade of KGla-M210-B4 Adhesion by Enzymes.
enzyme mean± SD cf: dBSA* cfnit
nil 79.0 ± 11.9% p<0.01
Chondroitinase
ABC
77.9 ± 16.9% p<0.01 ns
Heparinase I 75.1 ± 18.6% p<0.05 ns
Hyaluronidase 73.7 ± 14.7% p<0.02 ns
dBSA 24.3 ± 11.0%
Legend. Data is presented as the mean ± standard deviation of 4 replicate
experiments. KG la adhesion to M210-B4 in the presence of the named enzymes is
compared to that in the absence of enzyme5 or to dBSA* by paired t test. None of the
enzymes tested showed demonstrable effect on adhesion.
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6.6 Development of a Haematopoietic Progenitor Enrichment Protocol.
6.6.1 Background and definitions.
Several approaches can be taken to HPC enrichment, and these are outlined in
Table 6.8 [Visser & Van Bekkum, 1990; Wunder & de Wynter, 1994]. Physical
methods exploit differences in cell size (elutriation) or density (sedimentation,
density gradient centrifugation). These are often used as a preparatory step in order
to effect depletion of red cells and / or neutrophils. The effects of Ficoll-Hypaque
separation on HPC enrichment and loss were explored in Section 6.6.3.
A number of different approaches can be taken to negative selection. Initially
workers in the area utilised attributes ofmature cells such as rapid monocyte
adherence to plastic or T lymphocyte rosette formation with sheep erythrocytes, to
enrich for HPC. To avoid multiple sequential depletion steps, naturally occurring
lectins such as soybean agglutinin were used to deplete a broad spectrum ofmature
cells. Latterly, it has become feasible to remove mature cells on the basis of a panel
ofmAbs, associated with bead, column or complement-mediated effectors
[Bertoncello, Bradley & Watt, 1991], The problems with approaches based on
negative selection relate to poor enrichment, particularly when the target population
comprises only a small fraction of the initial population.
The CD34 antigen can be used along with a number of different effector systems
to provide a single parameter positive selection. Briefly, these can be categorised
into those in which the CD34 mAb is covalently attached to the surface of a plastic
flask (AIS system), those in which biotinylated CD34 mAbs adhere to a strepavidin
column (Cell-Pro), and those in which CD34 mAbs are linked to beads and removed
using a magnetic field (Dynal, Baxter, Miltenyi Biotec) (Table 6.8). These
approaches have relative advantages and disadvantages, but an important problem is
the nature of the residual label left on the surface of the cell. For example, the Class
II anti-CD34 mAb QBEND10, but not the Class III mAb 8G12, has recently been
shown to enhance adhesiveness through LFA-1 activation [Majdic, Stockl, Pickl et
al, 1994; Traore & Hirn, 1994], The cumulative effect of mAbs and beads on the
surface of a cell is unknown. Manufacturers of these systems claim CD34
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Table 6.8 Haematopoietic Progenitor Enrichment.
Physical methods
Sedimentation (eg. methylcellulose, dextran)
Density gradient centrifugation (eg. Ficoll, Percoll)
Centrifugal counterflow elutriation (eg. CCE, Beckman).
Negative immunological selection.
Single parameterpositive immunological selection.
Immune panning (eg. AIS)
Immunoadsorption columns (eg. CellPro)
Immunomagnetic beads
Large beads (near cell size) (eg. Dynal, Baxter)
Medium beads (eg. Immunotech)
Small beads (eg. Miltenyi Biotech)
Multiparameter positive immunological selection.
Fluorescence activated cell sorting.
enrichment of up to 98%, but in general laboratory practice a figure of around 30-
50% has proved more realistic amongst European research laboratories. Indeed in a
European workshop partially devoted to F1PC enrichment, manufacturers were
unable to replicate the levels of enrichment claimed in their own laboratories
[Silvestri, Wunder, Sovalat et al. 1993; Wunder, Sovalat, Henon et al, 1994], The
advantage of a single step immunoadsorption or immunomagnetic enrichment
method lies in the processing of large numbers of cells albeit to an intermediate
purity [Winslow, Liesveld, Ryan et al. 1994],
It was necessary to consider a third option to provide highly enriched (>98%)
CD34+ HPC populations, based on the multiparameter sorting capabilities of the
fluorescence activated cell sorter (FACSorter). This instrument operates on the
same principles as the FACScan (Chapter 2.4.1). Subpopulations of cells from a
heterogeneous population are identified on the basis of light scatter and fluorescence
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characteristics [Parks, Lanier & Herzenberg, 1986], The nozzle assembly of the
sorter is vibrated by an oscillator-driven piezoelectric crystal at a frequency close to
the natural drop break up frequency of the jet. This stabilises drop formation at that
frequency, resulting in a uniform drop size, and a well defined time delay between
characterisation of the cell, and incorporation in the free drop. If the cell is to be
sorted, a voltage of approximately 100 volts is applied to the fluid just inside the
nozzle, and a drop which breaks from the jet whilst the voltage is applied will carry
the corresponding charge. The train of drops passes between two deflection plates
charged at +/- several thousand volts, and the charged drops are deflected from the
uncharged, and collected separately. Sorting decisions are made by combining
acquisition gates on the signals, so that a cell is sorted if its light scatter properties
and each of its fluorescence signals falls within defined limits. Large numbers of
cells may need to be examined in order to sort a rare subpopulation, and multiple
parameters may have to be utilised.
The same generic problem occurs when sorting HPC on the basis of CD34+
fluorescence as has already been discussed in some depth a propos the definition of
the study population in two and three colour immunocytometry (Chapter 2.9.3 &
3.5) [Weichel, Irlenbusch, Kato et al. 1992]. The position of the discriminatory
marker is a trade off between the selectivity of the sorting process in favour of the
more primitive CD34hl population, and the extent of contamination of the study
population with false positive cells. Enrichment of a rare cell subpopulation by
immunomagnetic and immunocytometry will amplify the false positive population
pro rata with the true positive. The approach taken to FACSorting a CD34+
population was similar to that employed during three colour and light scatter
analysis (Chapter 3.5), namely that negative and positive controls were used to
establish an acquisition gate on the FSC / SSC dot-plot, and a negative control
population was used to establish a second acquisition gate on FL-2 at 0.1% false
positivity (nested acquisition gates can be established on the FACSorter) and to
calculate the percentage contamination of the acquired CD34+ positive population.
This data was used to correct the measured CD34%+ of the tertiary product to get a
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more accurate estimate of the true purity of the study population. An alternative
quality control over the enrichment process would have been to counterstain the
final product with an anti-CD34- FITC conjugate directed to a different epitope (e.g.
QBEND10-FITC).
In a sequential enrichment protocol such as this, the product of one enrichment
process acts as the source material for the next. Some clarification of the
nomenclature is required to avoid confusion. The starting material (e.g. bone
marrow, peripheral blood or cord blood) is referred to as the initiate. The product of
a density gradient centrifugation (mononuclear cells) or of leucapheresis (nucleated
cells) is termed the primaryproduct, the product of an immunoadsorbtive step is
termed the secondary product, and the product of a FACSort is termed the tertiary
or final product. Terms are maintained even if one or more steps are omitted e.g.
FACSorted leucapheresis cells are still referred to as a tertiaryproduct.
The enrichment protocol was evaluated by CD34 immunocytometry, cell
enumeration (by automated counter or haemocytometer) and viability by trypan blue
dye exclusion (haemocytometer) (Chapters 2.2.3 and 2.4).
The following derivative terms were defined:
enrichment: % CD34 positive cells in the product
% CD34 positive cells in the initiate
% recovery:
(%CD34 positive cells in the product) x (total number of cells in product) x 100.
(%CD34 positive cells in the initiate) x (total number of cells in initiate)
purity: %CD34+ of the product - % contamination of CD34+ population in
the initiate
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6.6.2 Preliminary experimental studies.
In a preliminary experiment, 108 cells from leucapheresis product were labelled
with lOOpl of 8G12-RPE using standard single colour staining technique. The cells
were sorted using nested acquisition gates established on FSC / SSC and on FL2 as
described above, to include <0.1% of the negative control population. The results
are summarised in Table 6.9. This preliminary experiment was sufficient to
establish that the staining procedure, purity and recovery were satisfactory, but that
the sorting time for populations of this kind was not. The FACSorter has a
maximum sort rate of 5,000 cells/sec, equating to theoretical sort of 75 CD34+
cells/sec or lxlO6 cells in 4hrs for this sample. In practice the CD34+ sort rate was
10-20 cells/sec, yielding lxlO6 CD34+ cells in 14hrs. This was not considered a
practical option, and clearly some form of pre-sort enrichment was necessary.
It was decided that Ficoll-Hypaque discontinuous density centrifugation would
be used to prepare mononuclear cells from PB or BM (but not LP) because red cell
contamination was found to swamp both the immunomagnetic selection and the
FACSorter. This was followed by a preparatory positive immunological selection
and a final high grade enrichment by FACSorter.
6.6.3 Effects ofFicoll-Hypaque gradient on CD34 quantitation.
The effects of discontinuous density gradient centrifugation on CD34
quantitation was examined in a series of four experiments. 4ml of Ficoll (density
1,077g/dl) was decanted into a 14ml test tube and 10ml of bone marrow was added
gently onto the top using a Pasteur pipette such as to preserve the integrity of the
Ficoll-BM interface. The samples were subject to centrifugation at 500g for 30min.
The mononuclear cell layer was removed carefully by pipette and the cells washed
twice in HBSS. Samples of BM prior to and following separation were
immunofluorescence labelled and subject to red cell lysis in the usual manner
(Chapters 2.4). Both samples were treated with red cell lysis to maintain
comparability. The results are summarised in Table 6.10. 15% of the leucocytes
from the initial sample were recovered from the Ficoll gradient, with a CD34%C
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Table 6.9 Pilot Cell-Sort of 108 Cells from Leucapheresis Product.
Initial CD34+ count: 1.52% (5x10s cells labelled).
Initial cell count: lxl08 cells
Initial CD34+ count on primary product: 1.59%
CD34+ count through the lymphoblastoid gate: 2.50%
Cell recovery in tertiary product: 1.5xl06 cells
CD34+ purity in the tertiary product: 95%
Enrichment: 59.7 fold Recovery: 98.7%





pre-separation 221±102xl06 1.25 ±0.62 3.24 ± 2.43xl06
post-separation 38 ±24xl06 6.11 ±2.94 2.57 ± 2.43xl06
Legend. Purity 6.1 ± 2.9%. Enrichment: 4.88 ± 0.50 fold. Recovery: 77 ± 25%.
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purity of 6.11%, a mean CD34 enrichment of 4.88 fold and a mean CD34 recovery
of 77.25%.
6.6.4 The use ofDynal anti-CD34 beads and bead detachment systems.
The use ofDynal beads as a method for positive selection ofHPC was
investigated. Cells were labelled with an anti-CD34 mAb 561 directly conjugated to
a Dynal bead [Egeland, Tjonnfjord, Steen et al. 1993; Egeland & Gaudernack,
1994], The bead diameter is >0.5pm and confers a relatively large magnetic
moment to the labelled cell, which can be easily separated from the unlabelled
population using a simple permanent magnet. Although this system was found to be
simple and cheap, several drawbacks limited its applicability as a preparatory
enrichment for FACSorting. Multiple cell-bead attachments occurred leading to
rosetting of and aggregation of the CD34+ cells with beads (Figure 6.5). In addition,
the beads were found to interfere with FACS analysis by changing the optical and
fluorescence properties of the cells (Figure 6.6). Finally, it seemed likely that the
beads may interfere with adhesive properties of the study population. It was clear,
therefore, that if the Dynal system were to be of value the beads would have to be
removed from the surface of the cells prior to FACSorting. Several groups have
reported that incubation of cells overnight would lead to spontaneous shedding of
the beads. Trial experiments demonstrated very little bead shedding from KGla
using this method.
Civin reported that populations of 50-90% purity, 40-60% recovery and 100%
viability could be achieved using My10 and SAM- immunomagnetic microbeads,
shed by incubation with chymopapain at a concentration of 200u/107 cells/ml for
lOmin at 37°C [Civin, Strauss, Fackler et al. 1990]. Although there was little effect
on the morphologic and light scatter characteristics of the enriched cells, selective
loss of CD34 epitopes was reported. This was confirmed in an experiment in which
chymopapain treated KG1A were found to stain with 8G12-RPE but not with
QBEND10-FITC demonstrating that the Class II but not the Class III epitopes of
CD34 are chymopapain-sensitive. Clearly, therefore, this is an unsuitable approach
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Figure 6.5 KGla Labelled with Dynal Beads.
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Legend. KG la-labelled with Dynal anti-CD34 beads. The beads are easily visible by
microscopy and lead to rosetting and aggregation of the CD34+ population,
(magnification x20).
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Figure 6.6 Physical and Fluorescence Characteristics ofKGla Labelled with
Dynal Beads.
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Legend. The FSC / SSC characteristics of unlabeiled KGla (A) and Dynai beads (B)
have a combined effect when KGla are labelled with the latter (C). Moreover, the
FL-1 /' FL-2 characteristics ofKGla (D) differ from those of the beads (E) giving
rise to a complex fluorescence population on the labelled sample (F). These
properties make Dynal beads somewhat unsatisfactory when used for fluorescence




for detailed studies ofmembrane antigen expression and function.
Egeland et al. have carried out a considerable amount of work in the
development of the Dynal system and have been able to detach the beads from the
target population using a polyclonal Rabbit anti-mouse serum (detachabead)
[Smeland, Funderud, Kvalheim et al. 1992]. A series of experiments was carried out
in collaboration with Janet Innes of the Scottish National Blood Transfusion Service
National Sciences Laboratory to investigate the efficacy of the Dynal detachabead
system. KGla were incubated with 561-Dynal beads at a ratio of 4 beads / cell, for 1
hour at ambient temperature. The number of cells present and the percentage
rosetted with beads was enumerated using a haemocytometer. The cells were
washed several times to remove unrosetted cells, by placing the tube within the
magnetic field, extracting the supernatant by pipette, removing the tube from the
field and resuspending the cells in handling medium. The rosetted cells were
enumerated and incubated in 10pi of detachabead / 106 beads for 1 hour at ambient
temperature. Unrosetted cells were removed from the beads and residual rosetted
cells using the same washing procedure as previously, and both populations were
enumerated. The results of these experiments is summarised in Table 6.11. More
than 90% ofKGla formed rosettes, comparable to the percentage of this population
which express CD34 (Chapter 2.4.6 and Figure 2.6). Approximately 30% were
recovered following bead detachment, with another 20% remaining rosetted. In two
experiments the rosetted cells were subject to a second incubation with detachabead
leading to recovery of a further 16% of the initial population with 5% of the initial
population remaining rosetted. Two problems were considered to be ofparticular
importance. First, up to 50% of the cells were lost from the system, suggesting
traumatic damage during the washing procedures. Second, the partition between
rosetted and non-rosetted cells by the magnet was not complete. In particular the
washed population following bead detachment still contained cells with single beads
attached, which interfered with further FACS analysis or sorting. Furthermore, test
experiments with LP and CB showed very little success in isolating the small
numbers of CD34+ cells present in these samples.
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Table 6.11 Results of Experiments Removing Dynal Beads from KGla using the
Detachabead System.
Cells harvested: 16 (7-40)xl06
Rosette fomation: 94 ± 4%
Cells recovered: 30 ± 13%
Residual rosettes: 21 ± 11%
6.6.5 The use ofMiltenyi MACS system.
The magnetic cell separation system devised by Stefan Miltenyi at Cologne
[Miltenyi, Muller, Weichel et al. 1990] uses a combination of supramagnetic
ferritin-dextran beads with a diameter of approximately 50nm and a high gradient
magnetic field to circumvent the small magnetic moment of the beads. The beads
are not visible by transmitted-light microscopy. Labelled cells are run through a
column containing plastic-coated steelwool, which works as an extremely sensitive
filter for magnetic particles when within a magnetic field, but rapidly de-magnetises
when removed from the field allowing the retained particles to be eluted. Flow
through the column is controlled by a disposable needle at the outlet.
In initial experiments 107-108 cells LP derived cells were labelled with 8G12-RPE
and with of a second step rat anti-mouse mAb supramagnetic bead conjugate, using
standard indirect immunofluorescence labelling technique (Chapter 2.4, Table 6.12).
It was clear that 8G12-RPE could not be used at standard concentration (20pl / 106
cells) otherwise 2ml ofmAb would have to be used to stain 100xl06 cells. The mAb
was therefore re-titrated on a representative LP sample (Figure 6.13). The mfi of the
CD34+ population declined as expected, but percentage CD34+ positivity could be
maintained down to a lower concentration of 1 pi / 106 cells by appropriate
adjustment of the discriminatory marker, albeit at the cost of increased
contamination of the CD34+ population. On the strength of this, the 8G12-RPE was
used at 10pl / 107 nucleated cells. This is commensurate with the staining of 5x105
CD34+ KGla with lOpl of 8G12-RPE (Chapter 2.4) because the target CD34+
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Table 6.12 Immunofluorescence Labelling Protocol for MACS and
FACSorting.
108 nucleated cells derived from a leucapheresis product or Ficoll-Hypaque density
centrifugation.
washed twice in handling medium
incubated for 15 min in 0.5% gamma globulin
incubated for 15 min with lOOpl 8G12-RPE
washed twice in handling medium
incubated for 15 min with lOOpl of RAM-microbead conjugate
washed once and resuspended in handling medium.
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Legend. Titration of the anti-CD34 mAb 8G12-RPE on 106 cells from a LP sample
revealed, as expected, a progressive fall in the mean fluorescence intensity of the
CD34+ population with reduction in the volume ofmAb (A - E). Use of
progressively more permissive discriminatory markers on the negative control (F)
allowed HPC discrimination down to 1 p.1 / 106 cells albeit at the cost of greater
contamination of the study population with false positive cells. (A) 20pl 8G12-RPE
%fT (M2)1.04% mfi 978, (B) lOpl 8G12-RPE %fl+ (M2) 1.15% mfi 750. (C) 5pl
8G12-RPE %ff (M3) 1.21% mfi 184. (D) lpl 8G12-RPE%ff (M4) 1.27% mfi 113.
(E) 0.5pl 8G12-RPE %fT (M5) 1.21% mfi 61. (F) negative control %ff (M2) 0.05%
(M3) 0.11% (M4) 0.42% (M5) 1.23%.
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population in LP rarely comprises more than 5% of the primary product. An aliquot
of the primary product was retained and labelled separately with 8G12-RPE using
the standard quantitative methodology (Chapter 2.4) to act as an internal control for
the adequacy of the reduced labelling volume, and to aid in satisfactory definition of
the CD34+ population during FACS analysis and sorting. The RAM-microbead
conjugate could not be titrated and was used at 20pl /107 cells according to the
manufacturers instructions.
MiniMACS columns (maximum capacity 107 magnetic-labelled cells) were
prepared by priming with 500pi of handling medium and discarding the effluent.
The column was placed in the magnetic field, a 22 gauge needle attached to the
outlet, 2ml of the cell suspension containing a maximum of 108 cells was added at
the top and the effluent allowed to run through. The needle was removed and a
further 2ml of handling medium added and allowed to wash through. The column
was removed entirely from the vicinity of the magnetic field, a further 2ml of
handling medium added and the retained cells flushed out using the plunger
supplied. The eluted cells were enumerated and the CD34+% quantitated in the usual
manner.
In practice it was found that residual erythrocyte contamination within the LP
led to problems in enumeration of the CD34+ cells because CD45 counterstaining
could not be carried out. The primary product was therefore subject to an
erythrocyte lysis step following labelling and was then resuspended in handling
medium. Inadequate dispersion of the leucocytes in the fluid prior to MACS sorting
led to blockage of the column. Apart from these preliminary problems the MACS
system was found to be satisfactory and the results of a series of four experiments
carried out on LP are summarised in Table 6.13. The labelled cells were found to
have similar physical and fluorescence characteristics to an unlabelled population
(Figure 6.8).
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Table 6.13 Results of the Effects of MACS Separation on Leucapheresis
Product.
Leucapheresis product.
Cell count: 82.4 ± 28.7x106
CD34%+: 1.24 ±0.12
CD34": 1.03 ± 0.38xl06
MACS eluate.
Cell count: 4.4 ± 2.4x106
CD34%+: 14.12 ±8.1
CD34": 0.51 ±0.24xl06
Enrichment: 11.7 ± 7.2 fold. Recovery: 55.1 ± 26.0%.
6.6.6 Sequential MACS and FACSorting enrichment protocol.
A series of experiments were carried out in which cells from LP were subject to
sequential MACS enrichment followed by FACSorting. The operating parameters on
the FACSorter were established and the performance monitored by Andrew
Sanderson of the Institute ofCell, Animal and Population Biology, University of
Edinburgh. Labelled cells were acquired through an open gate designed to exclude
debris and cell aggregates only. CD34+ cells were discriminated on the basis of a
0.1% marker established on a negative control sample as previously described.
CD34+ cells were enumerated during collection by the FACSorter, the percentage
positivity in the final product was assessed by passing an aliquot through the
FACScan, and viability of the final product was assessed by trypan blue dye
exclusion.The results of a series of 6 experiments are summarised in Table 6.14. .It
was not feasible to determine whether selective loss ofHPC subsets had occurred,
because of the difficulty in obtaining sufficient cells for secondary labelling with
lineage and activation markers. It is accepted that the enrichment process favoured
the retention of CD34hl HPC. Cells from the tertiary product displayed similar light
scatter characteristics to those from the primary product (Figure 6.8), and appeared
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Table 6.14 Results of Sequential MACS and FACSort Enrichment of
Haematopoietic Progenitors on the Basis of CD34 Positivity.
Leucapheresis product.
Cell count: 69.2 ± 24.8x106
CD34%+: 1.70 ±0.91
CD34": 1.18 ±0.79
Contamination: 4.3 ± 2.5%
Finalproduct.
Cell count: 0.32 ± 0.35x106
CD34%+: 86.6 ± 10.9%
CD34": 0.25 ± 0.24xl06
Enrichment: 64.6 ±32.1. Recovery: 18.8 ± 8.3% Purity: 82.4 ± 8.9%
Viability: >90%.
to be of primtive "blast" morphology when examined by transmitted light
microscopy.
In summary, a three-stage protocol was effective in achieving highly enriched
populations ofHPC, starting with LP or Ficoll-prepared mononuclear cells,
followed by a single parameter positive enrichment based on immunomagnetic or
immunocolumn technology, and leading to multiparameter selection by
FACSorting. The major problems are the high degree of associated cell loss and the
potential for alteration in cell function - both of which are currently poorly
characterised and may or may not be selective to certain HPC subsets. Since it was
clear that only small numbers ofHPC would be available for adhesion experiments,
the labelling intensity ofHPC became a critical issue in considering whether
the 51Cr adhesion assay was applicable to this cell population.
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Legend. Representative sequential enrichment of CD34" HPC from a leucapheresis
product. (A) negative control M2 0.1%. (B) CD34+ leucapheresis product M2 1.24%
(C) MACS eluate M2 14.5%. (D) FACSorted CD34+ cells M2 98.0%. (E) CD34+
sorted cells demonstrate fairly typical FSC / SSC characteristics.
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6.7 Application of the 5lCr Adhesion Radioassay to Highly Enriched HPC.
6.7.1 Pilot studies of"Cr labelling ofperipheral blood lymphocytes.
In the first instance the feasibility of increasing the 5lCr labelling index was
assessed using peripheral blood mononuclear cells. These cells were readily
available and the minimal preparation meant that the issues related to prolonged ex
vivo manipulation (preceding Section) could be temporarily ignored. An initial
series of experiments was carried out employing the same labelling protocol as for
the cell lines (i.e. 200kBq 51Cr in lOOpl) (Table 6.15). There were two major
problems: first, the lymphocytes labelled poorly compared to cell lines, leading to a
low labelling index and a high supernatant contamination. This phenomenon has
been observed by other groups [Coligan, Kruisbeek, Margulies et al, 1994]. Second,
cell recovery was poor even with an initial population of 107 cells. A second series
of experiments was carried out with modification of the labelling protocol such that
the lymphocytes were incubated with a higher concentration of 51Cr (37 MBq/ml).
Cells were exposed to 200kBq 51Cr in 5pl, and IMBq 51Cr in 25pl for lhr. Larger
volume washes (4ml) and a different centrifuge (lOmin at 200g) were used such
that the cell pellet formed at the base of the tube rather than slightly to one side, and
greater care was taken in aspirating the supernatant. Improvement in cell recovery
was highly variable, and did not achieve significance on non-paired t test. A parallel
set of cells subject to the same washing routine but without exposure to 51Cr
demonstrated similar recovery, and was not dissimilar to that identified during the
labelling of cell lines (Table 5.2), suggesting that cell trauma and loss of low
buoyant density cells occurring the washing steps was the main problem, rather than
toxicity due to the high concentrations of 51Cr in use. Labelling indices were
significantly improved by incubation with IMBq 5lCr in 25pi (p<0.01) though
problems with high supernatant contamination persisted. It was considered that
perhaps the high ambient 51Cr concentrations were leading to an intracellular 51Cr
concentration higher than the binding capacity of the cytoplasmic proteins, and
that 5'Cr was therefore leaching back out into the supernatant. To test this hypothesis
a series of experiments was carried out in which, following incubation with
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Table 6.15 CrSI Labelling ofPeripheral Blood Lymphocytes.
5,Cr 200kBq/100jul 200kBq/5gl lMBq/25gl lMBq/25jul~
global total 619,31 lcpm 598,285cpm 2,732,715cpm l,199,345cpm
cell recovery* 19.9 ±2.8% 47.2 ±25.5% 48.0 ± 18.3% 46.3 ±23.1%
51Cr uptake 4.8 ± 1.9% 23.7 ±9.1% 21.7 ±5.1% 35.0 ± 6.9%
labelling
index
11.8± 1.9 35.7 ±20.4 151.3 ±50.6 97.0 ±53.1
Supernatant
contamination
20.4 ± 9.0% 31.3 ± 16.8% 23.2 ± 13.8% 2.7 ± 1.1%
Legend. Data is expressed as the mean ± standard deviation of 3 experiments. "In the
absence of 51Cr the cell recovery was 44.5 ± 30.4%. "Modified washing procedure.
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IMBq 51Cr in 25pi, the supernatant was removed, and the cells incubated in 4ml of
IMDM + 10% FCS for lhr to achieve a more stable equilibrium, before being
subject to the routine washing steps. As proposed, this lead to a slight decrease in
labelling index (which was nevertheless superior to that of exposure to 200kBq
(p<0.05)), but a marked reduction in the supernatant contamination (column 5 Table
6.15).
6.7.2 ^Cr-labelling enriched haematopoietic progenitors.
The compound problems associated with high grade HPC enrichment, and
in 5lCr-labelling mononuclear cells did not auger well for the feasibility of applying
this approach to HPC. It was decided to optimise the labelling procedure using a
standard incubation with 200kBq of 5lCr. The small numbers of cells available
following CD34+ enrichment (range 5x104 to 5x105) (Section 6.6.6) made the
washing steps particularly problematic because the cell pellet was difficult to
visualise. Initial experiments demonstrated that the predominant problems were
those of poor cell recovery and viability and difficulty resolving cell labelling above
the supernatant contamination. Further experiments with larger volume washes in
IMDM + 10% FCS improved the level of supernatant contamination (Table 6.16)
allowing definition of the cell labelling index, but did little to improve the poor
recovery of viable cells. It seemed clear that a larger initial cell population and an
abbreviated enrichment protocol were the main requirements for an effective
HPC 51Cr-labelling protocol.
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Table 6.16 5lCr Labelling of Enriched Haematopoietic Progenitors.
Initial population: 436 ± 304xl03
Labelled population: 50 ± 87x103
Recovery: 16.4 ±23.4%
Viability: 62.5 ± 22.2%
Labelling index: 22.2 ± 22.3cpm/103 cells
Supernatant contamination: 16.4 ± 13.2%
6.8 Discussion.
The objective of the work in this Chapter was two fold: first to establish whether
the adhesion assay system could be extended to study cell adhesion to stromal tissue
cultures, and the extent to which alteration in the nature of the substrate or specific
blockading agents could be used to explore the more complex adhesive interactions
occurring in this system. Second, it was aimed to establish the feasibility of
applying the assay system to bone marrow or peripheral blood derived HPC and to
consider the extent to which the purification and Cr51 labelling ofHPC may intrude
on the identity and functional behaviour of the study population.
6.8.1 Long-term bone marrow culture as a model of in vivo events.
A fundamental question is the extent to which LTBMC can be said to resemble
the structure and function of the bone marrow in vivo. This aspect has been explored
to some extent Section 6.2.1 and only a partial answer can be offered. On the
positive side HPC clearly do adhere to marrow endothelium and stroma culture in
vitro, and stromal layers are capable of supporting sustained proliferation of
primitive progenitors over many weeks [Dexter, Wright, Krizsa et al, 1977], This
supports the contention that LTBMC at least supply the adhesive and regulatory
elements required for haematopoiesis. On the negative side, the individual elements
in LTBMC are poorly characterised, functional activity is dependent on culture
conditions, and the gross structure of the culture cannot be said to resemble normal
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bone marrow structure in vivo. Caution must therefore be exercised in induction
from observations based on LTBMC to possible mechanisms involved in HPC-
stromal interaction in vivo.
A second question of substantial import is the extent of redundancy in HPC-
stromal adhesion. The presence of a great many potential adhesion pathways and the
ineffectual blockade of adhesion to stromal layers using specific agents (as
compared to divalent cation chelation) implies that a combined approach to
blockade may be required in trying to tease-out the contribution of individual
CAMs.
6.8.2 Is the 5]Cr adhesion assay applicable to haematopoietic progenitors?
Two key limitations currently prevent the application of the 51Cr- labelling
adhesion assay to HPC. First, the specificity of labelling is entirely dependent on a
highly enriched study population. There is conflict between the purity of the CD34+
population achieved and the extent to which cell loss and functional alteration
degrades confidence that the study population continues to resemble the HPC
population in vivo. The combination of cell loss and destruction during multiple
sequential enrichment procedures and the prolonged duration of ex vivo
manipulation in the absence of cytokine support lead to loss and functional
alteration ofHPC which may or may not be selective to certain subsets. For
example, physical separation methods may lead to selective loss of large high
density HPC, whilst both immunomagnetic / adsorptive and immunocytometric
separations are dependent on the intensity ofCD34 staining and preferentially retain
CD341" cells. The recovered population may be activated by binding of the mAb and
or the bead complex, or cells may have entered apoptosis despite appearing viable
on the basis of trypan blue dye exclusion [Koury, 1992]. More subtle influences on
target cell proliferation, differentiation or adhesive function remain largely
unexplored. Clearly these areas require further detailed scrutiny. It is not easy to
achieve sufficient numbers ofhighly enriched CD34+ cells using this protocol. The
use of a larger amount of initial material such as an apheresis unit along with a
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single step enrichment with a large-volume column would provide a satisfactory
number of cells with improved viability albeit at lower final purity.
The second key limitation was the poor sensitivity of the detection system.
Peripheral blood mononuclear cells could be labelled to 50-150 cpm/103 cells by
using high concentrations of 5,Cr and modification of the washing procedure. The
central problems with HPC-labelling were related to cell loss rather than difficulty
in 51Cr-labelling per se. There are no published protocols successfully 51Cr labelling
enriched HPC. David Leavesley (personal communication) has achieved labelling
indices for FACS-sorted CD34+ cells in the order of l,000cpm/103 cells by using a
custom source of 51Cr with a specific activity of 740MBq/mg (ml). There is no
reason, therefore, that the assay system should not be applicable to HPC
populations, provided sufficiently large numbers of enriched cells can be provided
with satisfactory viability and functional characteristics.
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7.1 Definition and Analysis of the Haematopoietic Progenitor Population.
The accuracy and precision with which the HPC population can be defined was
considered to be a fundamental issue.The description of haematopoietic stem and
progenitor cells is contingent on their potentiality, i.e. on their capacity for self-
renewal, multilineage proliferation and differentiation, and long-term bone marrow
repopulation (Chapter 1.2). In man, semisolid clonogenic assays have proved an
invaluable tool for HPC identification and quantitation, but there are some
important limitations. First, these assays are retrospective in a formal sense i.e. the
initiating cell (or cells) are lost as part of the assay. Second, the assay is itself
intimately dependent on context. These are fundamental limitations to the
informative power of semisolid clonogenic assays when asking questions about cell
phenotype and adhesive behaviour. For example it is very difficult to identify and
phenotypically characterise the cell or cells which will form clones in a clonogenic
assay, and the efficiency with which they will do so may be partially dependent on
the presence and nature of substrate adhesion (Chapters 1.2.3 and 4.1)
The CD34 sialomucin demonstrates highly restricted cellular and tissue
expression, and is proving valuable as a surrogate marker of the HPC population.
The majority of in vitro colony forming cells are found within this population and
purified CD34+ populations have proved capable of long-term reconstitution of
haematopoiesis and immunity in primates and man in vivo [Berenson, Bensinger,
Hill et al, 1991]. Unfortunately, the small size of the study population and the low
density of antigen expression convey significant methodological problems. In this
study normal human bone marrow samples (BM) demonstrated a CD34%+ of 0.67
± 0.6% nucleated cells (Chapter 2.7) with a mean epitope density in the order of
50,000 / cell (Chapter 3.5.2). CD34+ cells proved undetectable in normal peripheral
blood samples (PB) (Chapter 3.2.2), but were present in samples of peripheral blood
following high dose chemotherapy and recombinant human granulocyte colony-
stimulating factor (PBm) at 2.26 ± 2.20% (n=8) and in cord blood (CB) at 0.69 ±
0.52% (n=4) (Chapter 2.7). These figures are comparable with those of other authors
[Bender, Unverzagt, Walker et al, 1991; Bender, Williams, Myers et al, 1992].
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Considerable effort was devoted to the development and optimisation of the
CD34 immunocytometry methodology and validation against the CFU-GM
clonogenic assay (Chapter 2). It became clear that although CD34
immunocytometry has a number of practical advantages over CFU-GM in terms of
generality, rapidity and standardisation, the difficulties in achieving an accurate and
reproducible assay remain substantial.The high coefficient of variation of replicate
assays, especially at low cell numbers (Chapter 2.7), implies that fundamental
technical limitations mitigate against the objective of achieving more reproducible
results within and between institutions, despite continued advances in methodology
and standardisation (Chapter 2.9.2). Nevertheless, CD34 immunocytometry was
considered sufficiently satisfactory to enable pursuit of the phenotypic and
functional studies described herein.
A further issue is of central importance to the F1PC phenotypic studies of
Chapter 3 and the enrichment work of Chapter 6.6, namely the purity and
comprehensiveness of the CD34+ population (discussed in depth in Chapter 2.9.3).
Fluorescence overlap between the target and background populations during
immunocytometry engenders a conflict between exclusion of false positive cells in
the study population and exclusion of true positive cells of low antigen density or
unusual light scatter characteristics. In the comparative cell adhesion molecule
studies described in Chapter 3.2, contamination of the study population with 10-
20% false positive cells was accepted. The availability of superior mAb-
fluorochrome conjugates and improvements in immunocytometry methodology in
subsequent studies (Chapters 3.3 and 3.5) led to a reduction in contamination to 1-
2% allowing more confidence in the validity of the data.
A similar problem was presented in seeking to establish the best method of
measuring antigen expression within the CD34+ population. Here the truism that
fluorescence positivity is not synonymous with antigen positivity became important.
Fluorescence positivity of the test sample is highly dependent on decisions with
regard to placement of discriminatory markers on the negative control, and stringent
markers proved to be particularly vulnerable to small numbers of high fluorescence
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negative control cells.(Chapter 2.9.3). During the phenotypic HPC studies (Chapter
3) judiciously chosen discriminatory markers and mean fluorescence intensity were
found to provide complementary information in clarification of subpopulations of
fluorescence positive cells and global shifts in the population fluorescence
respectively (Chapter 2.9.3). Studies with calibration beads demonstrated that a
linear relationship exists between antigen expression and fluorescence intensity
provided a direct labelling protocol is used, and this may prove a very useful
additional technique for quantitating antigen expression within the CD34+
population in the future (Chapter 3.5.2). Unfortunately this system did not give
satisfactory results with an indirect labelling protocol and could not be applied to
the quantitation ofCAM expression during the present study.
7.2 Phenotypic Studies on Haematopoietic Progenitors.
The first and second objectives of this study (Chapter 1.6) directed work to
characterise the pattern of cell adhesion molecule (CAM) expression by sessile and
circulating HPC, and to attempt to establish whether differences in CAM expression
were linked with more generalised differences in lineage and activation marker
expression (Chapter 3). The data presented in Chapter 3.2, corroborated the
observations of a variety of groups (cited in Chapter 1.6) that HPC express at least 9
cell adhesion molecules belonging to several molecular families. These include
immunoglobulin gene superfamily members ICAM-1 (CD54), PECAM-1 (CD31)
and LFA-3 (CD58), the B] integrins VLA-4 (CD49d/CD29) and VLA-5
(CD49e/CD29), the fi2 integrin LFA-1 (CD1 la/CD18), L-Selectin (CD62L), the
HCAM (CD44) family and CD36 (Chapter 3.2.3). In addition to these HPC express
the putative CAMs CD34, CD45, HLA-DR (Chapters 3.2 and 3.3),CD43, Sialyl
Lewis", Thy-1 and CD4, as well as cytokine receptors, cell membrane-associated
proteoglycans and other poorly characterised molecules such as that described by
Tavassoli et al. [Referenced in Chapter 1.6],
The differential expression of these molecules was studied on HPC from BM,
PBm and CB. It was not practical to study all the identified potential adhesion
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mechanisms and the study focused on those which are best characterised (Chapter
3.2 and Table 3.1). Equally, the study was not intended to be fully comprehensive
with regard to CAMs not normally expressed by BM HPC i. e. the possibility that
upregulation of one or more CAMs occurs during mobilisation was not studied.
The results of this study demonstrated clear reduction in LFA-3 (CD58) and VLA-5
(CD49e/CD29) expression by PBm HPC, and reduction in ICAM-1 (CD54), LFA-3
(CD58), VLA-5 (CD49e/CD29), LFA-1 (CDlla/CD18) and L-Selectin (CD62L) by
CB HPC. The interpretation of the CB data was complicated by the smaller size of
the study population and increased backgound binding of the second step reagent
compared to BM and PBm samples (Chapter 3.2.3), making conclusions difficult.
The comparative data from the BM and PBm work was however sufficiently valid to
warrant publication (Appendix 5).
Few studies have asked whether sessile and circulating HPC demonstrate
differences in CAM expression. Mohle, Haas & Hunstein, [1993] reported LFA-1
(CD1 la/CD18) to be significantly reduced in LP HPC but no difference in ICAM-1
(CD54) or HCAM (CD44) expression, whilst Leavesley, Oliver, Swart et al [1994]
reported reduced expression of LFA-1 (CD1 la/CD18) and VLA-4 (CD49d/CD29),
but not PECAM-1 (CD31) in cryopreserved LP HPC. Saeland, Duvert, Caux et al
[1992], found no difference in the expression of adhesion molecules between BM
and CB CD34+ cells using a semiquantitative reporting system. The discordance
between the results of these studies and those reported herein probably relate to
methodological differences and are discussed in some depth in Chapter 3.6.1.
The biological significance of the results of the CAM study remained unclear for
two reasons. First, it was uncertain whether differences in CAM expression were a
reflection of potential differences in the overall heterogeneity of the CD34+
population between study populations as a result of source differences or the effects
of in vivo exposure to chemotherapy or cytokines. Second, as previously recognised,
there were serious reservations about using phenotypic differences in CAM
expression to infer differences in functional binding behaviour.
It is clear from many immunological and clonogenic studies that the HPC
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population defined by CD34+ is heterogeneous in terms of the stage of
differentiation and lineage-committment. In Chapter 3.3 a study was carried out to
clarify whether differences in lineage and activation marker expression could be
detected between sessile and circulating HPC. The antigens studied were CD33 as a
marker of early myeloid differentiation, the transferrin receptor (CD71) - as a
marker of erythroid differentiation, CD41a (GpIIb) as a marker ofmegakaryocyte
differentiation, CD7 and CD19 as markers of early T and B lymphoid differentiation
respectively. HLA-DR and CD38 were studied as markers of cell "activation"
(Chapter 3.3). CD33 and CD19 were found to be expressed by subpopulations of
CD34+ cells within BM from at least some individuals, but not by circulating
populations. CD71 was expressed by 40% ofBM HPC and somewhat fewer
circulating cells. CD38 and HLA-DR were expressed by the majority ofHPC, but at
higher antigen density in BM compared to circulating populations. There was a
particularly marked difference in the expression of CD38 between CB and other
populations. In summary, therefore, differences in the state of activation and lineage
committment clearly do exist between HPC derived from different sources,
suggesting the presence ofmore mixed CD34+ population within the BM with more
activated cells and erythroid and B-lymphoid precursors (Chapter 3.3.2).
Considerable variation exists between reports from different groups on the
levels of antigen positivity or expression. For example the results presented here
suggest a very low level ofCD33 expression by HPC from all sources, comparable
with those of Fritsch, Buchinger, Printz et al [1993a], who found CD34+ cells to be
predominantly CD33" or CD33'0. Others have described significant percentages of
CD34+ CD33+ cells, albeit at low antigen density and with wide variance between
samples [Bender, Unverzagt, Walker et al, 1991; Bender, Williams, Myers et al,
1992; Saeland, Duvert & Caux 1992; Mohle, Haas & Hunstein 1993] The problem
appears to be poor standardisation between research groups with regard to the nature
of the study populations, methodology and analytical criteria, and also to expected
stochastic variation between studies. In addition, there are clear reservations about
interpreting the expression of a single antigen as indicative of a specific
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haematopoietic lineage (discussed in depth in Chapter 3.6.2).
It was decided to attempt to determine whether differences in CAM expression
occur between identifiable HPC subsets. If so, it was reasoned, differences in CAM
expression between sessile and circulating HPC may be explicable on the basis of
differences in lineage committment and activation rather than on the sessile or
circulatory origin of the cells. Few studies have attempted to discriminate whether
differences exist in CAM expression within CD34+ subsets. Gunji, Nakamura,
Hagiwara et al. [1992] have demonstrated differences in LFA-1 expression between
primitive and mature CD34+ cells, whilst Watt, Williamson, Genevier et al. [1993]
have shown restricted expression of PECAM-1 (CD31) by myeloid and B lymphoid
HPC subsets. Several groups have demonstrated lineage and stage specific variation
in functional HPC adhesion to cellular and non-cellular substrates using clonogenic
assays, supporting the likelihood that differences in HPC subset expression ofCAM
do exist (cited in Chapter 1.6). Two approaches were taken to address this issue:
immunocytometry studies on human haematopoietic cell lines (Chapter 3.4) and the
development of three colour immunocytometry of HPC (Chapter 3.5).
Single colour immunocytometry was used to study the expression of the CAMs,
lineage and activation markers detailed above, in a group of human haematopoietic
cell lines chosen to represent a variety of stages and lineages of differentiation: the
acute myeloblasts leukaemia line KGla, the chronic myeloid leukaemia line K562,
the acute promyelocytic leukaemia line HL60, the acute T lymphoblastic leukaemia
line CEM and the B lymphoblastic leukaemia line NALM-6. This simple study was
quite informative. It was clear that the expression of lineage and activation markers
did not correspond particularly well with the derivation of the lines (Chapter 3.4).
For example none of the myeloid lines expressed CD33, whereas both KGla and
CEM expressed CD7 and K562 and NALM-6 expressed CD 19. CD71 was
expressed by all lines except HL60, underlining its widespread expression on
proliferating cells, whilst CD38 was only expressed on the lymphoid cell lines.
Multiparameter immunocytometric analysis of peripheral blood leucocyte
populations has illustrated that antigen expression is rarely lineage-restricted and is
296
better described as lineage-associated [Terstappen, Hollander, Meiners et al, 1990],
This study served to emphasise that lineage marker associations deduced from
scrutiny of normal haematopoietic precursors and mature cells cannot be assumed to
be valid when applied to neoplastic haematopoietic cells, haematopoietic cell lines
and HPC [Greaves, Chan, Furley et al. 1986],
Whilst some CAMs were expressed on all lines (CD54, CD49d and CD49e),
others were differentially expressed (CD58, CD31, CDlla, CD51, CD44 and CD36)
or not at all (CD62L). Clustering ofCAMs and lineage / activation markers could be
demonstrated, but did not fall easily into a preconceived pattern. Of relevance, LFA-
3 was expressed by all lines except CEM, and VLA-5 by all lines, making it less
likely that expression of these antigens is affected by differences in lineage
heterogeneity.
The only way to resolve the issue of differential expression of CAM within HPC
lineage subsets is by three colour immunocytometry ofCD34+ subpopulations
(Chapter 3.5). This represents a formidable technical challenge because of the
composite problems described above. Several preliminary studies were carried out
to optimise the methodology. A comparative study of available third colour reagents
showed that both Quantum Red and PerCP provided reasonable discrimination
between positive and negative test populations,though the latter provided a simpler
labelling protocol (Chapter 3.5.1). The use of calibration beads allowed the amount
of antigen present on the cell surface to be quantified, provided that a direct
labelling technique was used. Indirect technique led to poor discrimination between
individual bead populations and degraded linearity in the relationship between
antigen density and fluorescence (Chapter 3.5.2). However it did prove reasonably
straightforward to acquire samples on the basis ofCD347FSC (Chapter 3.5.3), and
this proved the key to providing sufficient cells to enable three colour analysis and
the enrichment work discussed later (Chapter 6.6 and Section 7.4). Subanalysis of
CD33+, CD7+, CD19+ or CD41a+ HPC subsets either in terms of light scatter
characteristics (Chapter 3.5.4) or CAM expression was not a practical proposition
because of the very small numbers of cells involved. However, it was possible to
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discriminate CD71, HLA-DR and CD38 positive and negative subpopulations,
which were also the most relevant because these markers demonstrated the greatest
differences between sessile and circulating CD34+ populations (vide supra).
Expression of CD58 and CD49e was examined within CD34+ CD717", CD34+
HLA-DR7" and CD34+ CD387" subpopulations. Allowing for the technical
limitations of the study, LFA-3 (CD58) expression did not vary significantly
between subsets, whilst VLA-5 (CD49e) expression was greater in the CD34+
CD71+ and the CD34+ CD38+ populations. Since CD71 and CD38 were more highly
expressed by BM than PBra CD34+ cells, this data supports the proposition that the
reduced VLA-5 expression in the circulating CD34+ population is a reflection of
other changes in HPC activation or differential mobilisation of some subsets.
7.3 Functional Studies ofHaematopoietic Cell Line Adhesion.
Cell adhesion molecule expression is a necessary but insufficient criterion from
which to conclude participation in HPC adhesion, because expression does not
necessarily confer functional activity. Many CAM occur as multiple isoforms (e.g.
CD54 and CD44) or must undergo membrane redistribution or conformational
change to achieve maximum avidity (e.g. CD49d and CD49e). The development of
an assay to study functional HPC adhesion was therefore essential to evaluate the
potential role of the CAMs described above in HPC homing and engraftment, and to
consider whether reduction in CD49e expression in particular could be responsible
for HPC mobilisation (Chapter 1.6). Adhesion assays based on direct visualisation
and clonogenic assay suffer from similar limitations in accuracy namely the
statistical variation in the distribution of small numbers of cells (which conform
with a Poisson distribution) and high observer errors (Chapter 4.1). Clonogenic
assays are additionally dependent on the culture environment, making it sometimes
difficult to separate conditions affecting adhesion from those affecting cloning
efficiency (Chapters 1.2.3 and 4.1). The s'Cr adhesion assay offered the potential
advantages of larger numbers of cells, the correlation of phenotypic and functional
data, and applicability to the study of adhesion of HPC and haematopoietic cell lines
298
to a variety of cellular and non-cellular substrates (Chapter 4). This type of assay
was used by Hardy and Minguell (1993) to study murine haematopoietic cell line
adhesion to fibroblast cell lines. The 51Cr adhesion assay was developed using
human haematopoietic cell lines in the first instance, because these provided the
advantages of the availability of large numbers of cells, of a relativly consistent and
homogeneous population within which lineage differentiation and adhesion
molecule expression had already been partially defined (Chapter 3.4 and vide
supra). KGla and purified plasma fibronectin (pFn) were used to develop and
optimise the assay system. Briefly, 107 KGla were labelled by incubation with
200kBq of 51Cr for lhr at ambient temperature. The 51Cr was removed and the cells
washed twice, leading to a labelling index (LI) of around 40cpm/103 cells (Chapter
4.2). It was calculated that at this level of labelling a minimum of 105 cells could be
used per assay well to resolve down to 1% of the study population. In practice
approximately 2.5x105 cells were used per well. Optimal conditions for
coating the plastic carrier (i.e. a 24 well tissue culture plate) with fibronectin were
established: a lhr incubation at ambient temperature with 1 OOpil of 50pg/ml was
found to be satisfactory (Chapter 4.3). During the adhesive phase of the experiment,
labelled KGla were incubated in the substrate-coated wells for 2 hours at ambient
temperature. During the distractive phase, the supernatant was removed by pipette,
the well was washed twice with medium and the supernatant and washes were
pooled (Chapter 4.4). The adherent cells were lysed using a detergent in distilled
water. Both the adherent and the non-adherent fractions were then counted in a
gamma counter, and the total count and adherence percentage calculated. Denatured
bovine serum albumin (dBSA) coated wells were used as a negative control because
of the high backgound binding of cells to uncoated tissue culture plastic. Assays and
controls were established in triplicate within a particular 24 well plate and the mean
percentage adherence of the three wells was taken as the assay result. The extent of
cellular adherence was found to be particularly dependent on the stringency of the
washing procedure following the adhesion phase of the experiment and this was
standardised as far as possible. Monitoring of a series of experiments over 6-12
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months confirmed an acceptable degree of assay reproducibility (Chapter 4.4.6). In
addition, overall labelling and adhesion parameters were similar to those ofHardy
& Minguell [1993] and of John Sweetenham and Lisa Masek in Southampton who
have used the assay in collaborative work (vide infra and also Chapter 6.1 and
Appendix 4).
The 51Cr adhesion assay was used in a series of studies to examine the adhesion
of the haematopoietic cell lines detailed above to human extracellular matrix (ECM)
components (Chapter 5). The commercially purified components studied were
collagens types I, III and IV, fibronectin, vitronectin, thrombospondin and
vitronectin, and heparan sulphate, chondroitin sulphate and hyaluronic acid. These
proteins, glycoproteins and proteoglycans are known to be expressed within human
bone marrow stroma [Gordon, 1988a; Clark, Gallagher & Dexter, 1992],
Differences in the functional binding of haematopoietic cell lines to ECM
components were demonstrated (Chapter 5.2) and some correlations with cell line
CAM expression were apparent (Chapter 3.4). For example, all five cell lines
express VLA-4 (CD49d/CD29) and VLA-5 (CD49e/CD29) and all demonstrated
significant binding to pFn. KGla express CD36 and bound markedly to
thrombospondin. Important areas of discordance were also demonstrated. For
example CD31+ CD45+ KGla did not adhere to heparan sulphate, whereas CD31"
CD45 NALM-6 did. Similarly KGla, HL60 and CEM express HCAM (CD44) but
adhered neither to collagens nor to hyaluronic acid. K562 express VNR (CD51)
though they did not adhere to vitronectin.
The information required to predict functional adhesion behaviour on the basis
of CAM expression is necessarily incomplete. A full characterisation ofCAM
expression by the cell lines studied was not carried out and additional molecules
may therefore augment cell adhesion behavour. In addition, the functional activity
of some of the CAMs known to be expressed (Chapter 3.4) could not be fully
assessed in the assay system because the appropriate ligands are predominantly cell
surface bound and were not readily available in purified form. Finally, it is clear
that CAM expression is not sufficient in itself to convey adhesion to an appropriate
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ligand. Some CAMs may be expressed in a non-activated form, or may mediate low
avidity adhesion obscured by the relatively high shear stress imparted during the
distractive phase of the assay.
Several approaches were taken to extend these observations:
First, a phorbol ester and a calcium ionophore were used to "activate" KG la in
order to establish whether some CAMs were expressed in a non-activated state
(Section 5.3). Although the ionophore had little effect, the phorbol ester markedly
increased adhesion to glycoproteins and proteoglycans, and also background
binding to dBSA. This could be due to an increase in the expression or avidity of
multiple CAMs, or downregulation of a global negative regulator of adhesion in
response to phorbol ester. Background binding to dBSA was also found to be
variable during general experimentation (Chapter 4.4.6) - an observation confirmed
by other workers in the field (David Leavesley, personal communication). How one
should interpret these findings is not clear, but clearly KGla-pFn adhesion is not
simply dependent on CAM expression, but also on their state of "activation" and on
negative adhesion molecules i.e. molecules which function to control non-specific
cell adhesion.
Second, a variety of approaches were used to attempt to blockade KG la
adhesion to pFn as a model system in which to establish whether the correlation
between CAM expression and functional binding to the appropriate ligand was
sufficient to conclude a causal link between the two (Chapter 5.4). Several different
agents were used to explore this interaction including divalent cation chelation with
HBSS and EDTA, a synthetic tetrapeptide known to mimic the recognitionmotif on
fibronectin for VLA-5 (CD49e/CD29) (RGDS), mAbs known to blockade VLA-4
(CD49d/CD29) and VLA-5 (CD49e/CD29) activity in other experimental systems,
and a series of enzymes known to degrade proteoglycans. Partial blockade ofKGla-
pFn adhesion was achieved by divalent cation chelation, a 5mM solution ofRGDS
and by chondroitinase ABC, but not by the other agents examined. Clearly,
therefore KGla adhesion to pFn is partially dependent on VLA-5 but also on
chondroitin sulphate, and potentially also on other mechanisms (combination
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experiments were not carried out).
Third, the assay system was extended to examine the adhesion of
haematopoietic cell lines to bone marrow stromal and endothelial cultures in vitro in
order to mimic some of the complexity of HPC-stromal interaction occurring in vivo
and also to examine in more depth the proposition that reduction or blockade of
VLA-5 (CD49e/CD29) activity might alone be sufficient to explain HPC
mobilisation. To extend the assay system in this way further developmental work
was undertaken (Chapter 6). Long-term bone marrow stromal cultures were
prepared using the techniques first described for mice by Dexter, Allen & Lajtha
[1977], and later adapted to human marrow by Gartner and Kaplan [1980]. Aliquots
of sterile bone marow were cultured for 3 weeks in a medium containing foetal calf
and horse serum and hydrocortisone. The confluent stromal layer that forms over
this period is complex, containing monocytes, fibroblasts, adipocytes and
endothelial cells, and is capable of sustaining primitive haematopoietic progenitors
which proliferate to form large discrete colonies or "cobblestone areas" (Chapter
6.2). Preparatory experiments demonstrated the need to grow the cultures on
collagen to prevent disruption of the integrity of the stromal layer during the
distractive phase of the adhesion assay (Chapter 6.3). KGla adhesion to long-term
bone marrow stromal cultures, bone marrow fibroblast cultures (grown without
horse serum or hydrocortisone) and a murine bone marrow fibroblast cell line
(M210-B4) was examined and found to be similar to each cellular substrate and
significantly greater than that to pFn (Chapter 6.4). Blockade ofKGla adhesion to
M210-B4 was therefore examined using divalent cation chelation, synthetic
peptides, enzymes and a broadened panel of mAbs to ICAM-1 (CD54), PECAM-1
(CD31), LFA-1 (CD1 la) and HCAM (CD44) as well as those to VLA-4 (CD49d)
and VLA-5(CD49e). Only divalent cation chelation engendered any significant
degree of blockade in this system, suggesting that although integrins as a group
were essential to KGla-stromal adhesion, individual CAMs in the system were
redundant. Miyake et al [Miyake, Medina, Hayashi el al. 1990; Miyake, Weissman,
Greenberger et al. 1991] have demonstrated inhibition of lymphohaematopoiesis in
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murine long-term bone marrow stromal cultures by blockade of the VLA-4 /
VCAM-1 and the CD44 / hyaluronate pathways. However it is not clear whether
inhibition ofHPC adhesion to the stroma, or impediment of the survival or
proliferation ofHPC or their progeny was the mechanism responsible for these
observations.
The adhesion of human haematopoietic cell lines to human umbilical vein
endothelial and bone marrow endothelial cultures was studied in collaborative work
with John Sweetenham and Lisa Masek of the University of Southampton
(Appendix 4). All five cell lines adhered significantly to endothelial cultures in
vitro. Adherence ofKG la, HL60 and CEM was significantly greater to umbilical
vein endothelium (HUVEC) activated with tumour necrosis factor-a than to non-
activated, whilst K562 and NALM-6 demonstrated no difference. There was no
difference in the adherence of any of the cell lines between activated and non-
activated endothelial LTBMC, but adherence ofKGla, HL60 and CEM to
endothelial LTBMC was superior to that to non-activated HUVECS, and on a par
with that to activated HUVECS. It appears, therefore, that some cell lines (KGla,
HL60, CEM) but not others (K562, NALM-6) are capable of responding to
activation of endothelium by tumour necrosis factor a, and that bone marrow
endothelial cultures are constitutively activated. These differences may be helpful in
clarifying changes in ligand expression of functional importance during endothelial
activation. The study also demonstrates that the 51Cr adhesion assay is applicable not
just to examine the effects ofHPC activation and blockade on stromal and
endothelial adhesion, but also to examine the effects ofmanipulation of the cellular
substrate .
In summary of the functional adhesion work on haematopoietic cell lines, it can
be said that the 51Cr adhesion assay has been shown to provide a satisfactory method
for addressing questions about the relationship between HPC cell adhesion molecule
expression and functional adhesion behaviour, and that manipulation of the study
population and/or of the substrate by activation or blockade can help to dissect the
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composite mechanisms responsible for adhesion to the stromal microenvironment.
It has also been demonstrated that HPC adhesion to the bone marrow stroma in
vivo is unlikely to be wholely based on any individual cell adhesion molecule -
ligand pathway such as VLA-5 (CD49e/CD29) interaction with fibronectin. The
observed reduction in VLA-5 expression on circulating compared to sessile HPC is
not sufficient in itself to explain HPC mobilisation.
7.4 Functional Assay ofHaematopoietic Progenitor Adhesion.
In the final part of the thesis it was decided to examine whether the 51Cr assay
could be applied directly to the study of human HPC. This brought together the
developmental work on the immunocytometric definition and characterisation of
HPC (Chapters 2 and 3) with that on the Cr51 adhesion assay (Chapters 4-6).
As a first step it was clear that highly enriched populations ofHPC would have
to be prepared, and a three-step enrichment protocol was designed entailing the use
of leucapheresis or density-gradient prepared cells, a preparatory enrichment using
the miniMACS column and a final enrichment using a fluorescence activated cell
sorter (Chapter 6.6). Cells were labelled with an anti-CD34-RPE mAb and a RAM-
supraparamagnetic microbead second step reagent using established techniques
(Chapters 2.4 and 6.6). Up tolO8 cells were added to the top of a miniMACS column
in a powerful magnetic field and allowed to flow through under the influence of
gravity. The eluate was retrieved by removing the column from the magnetic field
and flushing with fresh medium. The MACS eluate was then FACSorted. CD34+
cells were acquired through an open gate designed to exclude debris and cell
aggregates only, and were discriminated on the basis of a 0.1% marker established
on a negative control sample (Chapter 3.5 & 3.6, and 6.6.). They were enumerated
during collection by the FACSorter, the percentage positivity in the final product
was assessed by passing an aliquot through the FACScan, and viability of the final
product was assessed by trypan blue dye exclusion. The composite results
demonstrated a final purity of 82% with a viability of>90% and an 65 fold
enrichment factor. The final yield of purified CD34+ cells from 69x106 LP was
304
0.25x106 cells, representing a recovery of 19%. It was not feasible to determine
whether selective loss ofHPC subsets had occurred, although both the MACS and
the FACSort favour the selective retention of CD34hl HPC. The enrichment protocol
took approximately 6hrs to complete, and although the cells looked normal on
microscopic examination and were mainly viable on trypan blue exclusion, there
was no way of knowing whether they may have undergone more subtle changes in
function.
As a second step the labelling of peripheral blood mononuclear cells with 5lCr
was examined prior to application to enriched HPC (Chapter 6.7.1). Peripheral
blood mononuclear cells labelled poorly with standard concentrations of 51Cr, but
satisfactory labelling could be achieved by using high concentrations of 51Cr and a
modified washing procedure. Additional problems were encountered in attempting
to 51Cr-label enriched HPC (Chapter 6.7.2). The small numbers of cells available
following CD34+ enrichment made the washing steps particularly difficult because
the cell pellet was difficult to visualise. The recovery from this procedure was 16%,
leading to a labelled population of 5.0x104, with a viability of 62% (trypan blue dye
exclusion), a labelling index of 22cpm/103 cells and a supernatant contamination of
16%. There are no published protocols successfully 51Cr labelling enriched HPC
though David Leavesley (personal communication) has achieved labelling indices
for FACS-sorted CD34+ cells in the order of l,000cpm/103 cells by using a custom
source of 5lCr with a specific activity of 740MBq/mg (ml).
In summary, therefore, it is feasible to prepare 5lCr-labelled HPC for adhesion
experiments but the use of a larger amount of initial material such as an apheresis
unit is required along with an abbreviated enrichment protocol. A single step
enrichment with a large-volume column should provide a satisfactory cell yield and
viability, albeit providing a product with lower final purity. Combining this
approach with a high intensity 51Cr labelling protocol should provide sufficient cells
for functional adhesion experiments. More work is required to establish the effects
of cell enrichment and labelling on CD34+ subsets and function.
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7.5 The Limitations ofCurrent Adhesion Assays and Their Possible Resolution.
The key problems and limitations of current HPC adhesion assays have been
discussed within the relevant sections of the text, and are summarised here as a focal
point for discussion of the direction of future research.
7.5.1 The nature of the carrier and ofthe test substrate.
The nature of the carrier is critical to satisfactory binding and presentation of the
substrate. Tissue culture plastics are thought to bind proteins and cells
predominantly through ionic and hydrophobic interactions, increasing the
background against which specific binding must be discriminated. Some companies
such as Costar now provide a range of 96 well plates with well characterised
surfaces. It is possible that some ligands will display preferential adsorption to
particular types of plastic, or that the orientation or binding avidity will be further
affected by the nature of the carrier. It is probably desirable to define the optimal
concentration and binding conditions for each ligand and carrier (Chapter 4.3.2).
The source and purity of the substrate is also of importance to the validity of the
assay. Contamination of the test substrate with other proteins or carbohydrates may
affect the result of the assay. Many ECM components occur in multiple isoforms
which vary depending on the source of the material. In the assays carried out in the
course of these studies, commercial human materials of defined purity were used
wherever possible, although some proteoglycans were of bovine origin (Appendix
1). Moreover, commercial preparations do show variation between companies, and
those derived from miscellaneous human tissues may differ structurally from those
present in human bone marrow stroma (see for example the discussion of Fn
isoforms in Chapter 5.4 and 5.5). The optimal policy would be to purify study
materials direct from the relevant tissue in house, such that contamination and
structural variation could be more closely defined.
Denatured BSA is a satisfactory control despite a significant amount of batch-to-
batch variation in cellular binding (Chapter 4.4 and 4.5). This problem has been also
reported by other workers in the field (David Leavesley, personal communication),
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and there is no easy resolution - the only clear alternative being to use a purified
protein to which one is confident the test cells will not bind (for example: collagen
type IV in the case of haematopoietic cell lines).
7.5.2 Differentiation ofadherent and non-adherent populations.
The critical issue in the measurement of cell-substrate adhesion is control over
the shear forces applied during the distractive phase of the adhesion assay. Removal
of non-adherent cells by pipette is difficult to control and may be of such magnitude
as to largely obscure low avidity binding interactions such as that between selectins
and proteoglycans, whilst preserving high avidity interactions such as those
involving integrin binding to ECM glycoproteins. One approach worthy of
exploration in future studies would be to reduce shear forces by converting the assay
to a 96 well plate system, in which case one could distract non-adherent cells by
inverting the plate for an hour. Gravity provides a uniform distraction force and the
fluid does not fall out of the wells due to surface tension. The top 50% of the
supernatant can then be removed with a multiwell pipette.
A related, though somewhat conceptual issue, is that there is often no clear way
of discriminating whether the results of a particular adhesion assay reflect the
overall adhesive affinity and capacity of a homogeneous cell population for a given
substrate, or the behaviour of two or more subpopulations with qualitatively
different adhesive properties. In many cases these complementary interpretations of
the data are equally valid ways of viewing the data (see the discussion of the
problems of formulating the results of adhesion assays in Chapter 4.5, and similar
problems with immunocytometry data in Chapter 2.9). A system in which serial
assays could be carried out at varying concentration may allow deduction of affinity
and adhesive capacity of the substrate for the study population as a whole through a
Scatchard analysis (Chapter 4.4.4).
307
7.5.3 The nature of the assay read-out.
Direct enumeration of the adherent population by normal light or phase contrast
microscopy can be applied to cell lines or highly enriched HPC populations on non-
cellular substrates. Fluorescence microscopy has wider applicability to non- or
partially-enriched HPC populations, on cellular and non-cellular substrates.
Although these approaches are the most direct, they suffer from several limitations
with regard to stochastic distribution and observer variation as discussed in Chapter
4.1. Semisolid clonogenic assays have been used by several groups to study HPC
adhesion mechanisms. This kind of assay is useful in that it yields information on
adhesive behaviour of functionally defined HPC subpopulations. The limitations are
firstly, that the clonogenic assay employed is not necessarily representative of the
adhesive behaviour of other HPC subpopulations, or ofHPC as a whole. It may be
necessary to combine a panel of clonogenic assays, or to focus on a functionally-
defined HPC subpopulation. Secondly, that the phenotypic identity of the cell giving
rise to a particular colony is unknown, making it difficult to correlate the behaviour
of the adhesive cells with their cell adhesion molecule expression. Thirdly, that
alteration ofHPC cloning efficiency may occur due to the presence of accessory
cells or as a direct result of substrate adhesion. Fourthly, that the assays are difficult
to standardise between laboratories, are labour intensive and time consuming.
Although the 51Cr-adhesion assay has proved satisfactory in the analysis of cell line
adhesion, where large numbers of cells of a fairly homogeneous phenotype are
available, it is clearly less easily applicable to the study ofHPC for the reasons
outlined above (Section 7.4). To reiterate, the problems are two-fold: the production
of sufficient numbers ofhighly purifed HPC and the achievement of a satisfactory
labelling index, with the addendum that the study population may undergo
physiologically significant functional alteration during the preparatory procedures.
Although the initial problems can be overcome given sufficiently large amounts of
harvest, resource and enthusiasm, it is by no means clear that the addendum can be
satisfied. There is some advantage in the use of highly purified HPC populations for
adhesion studies, namely the elimination of accessory cells which may inhibit HPC
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adhesion through competition for available binding sites, steric hindrance or
secretion of cytokines which alter the functional behaviour of the study population.
More detailed analysis of the product of intensive cell purification in terms of
pattern of differentiation, proliferation and apoptosis is clearly required. One
alternative might be to convey specificity within the labelling / read-out system
(rather than separating the two functions as in CD34-purification and 5lCr-labelling).
For example, if the study population were labelled with an anti-CD34 mAb and a
second step reagent before carrying out the adhesion phase of the assay, a read-out
could then be achieved using an enzymatic (colorimetric or chemiluminescence) or
fluorimetric method following separation of the adherent and non-adherent
populations. A potential advantage of this type of approach is that it may be easier
to amplify the detection system in order to improve the sensitivity into the 102 to 104
range. This would permit analysis of non- or partially-purified, as well as highly
purified CD34+ populations, and would permit conversion of the assay to a 96 well
plate system, with the consequent advantages in assay turnover, informative content
and standardised supernatant removal.
7.5.4 The potential development ofdynamic adhesion assays.
Up to this point, consideration has been resticted to adhesion assays which are
essentially static in nature. There are a number of important limitations in the
relevance of such assays, particularly a propos the interaction ofHPC with
endothelium under vascular flow conditions. In principle, vascular flow limits the
time available for an HPC to interact with an endothelial cells before moving-on,
and also provides a shear force which serves to distract low affinity adhesions. The
time taken for the cells to sediment to the test surface, and the absence of detailed
control over shear force are absolute limitations in most static assay systems.
A number of strategies have been developed to try to overcome these problems.
Leavesley, Oliver, Swart et al. [1994], have used a flow cytometry based assay to
study interaction ofCD34+ cells with CHO cells stably transfected with human
ICAM-1 and VCAM-1. The test cells are incubated together in suspension on a
309
roller, fixed following various periods, and analysed for the loss of single positive
cells due to formation ofCD34+-CHO doublets and higher aggregates. In a similar
approach, Aizawa et al. have studied formation of rosettes between stromal and
haematopoietic cells [Aizawa, Hojoh, Suda et al. 1991] The advantage of this kind
of approach is that the cell-cell interaction can be arrested at any stage, allowing
analysis of early events, and that the low shear forces invoked allow assessment of
low avidity binding. A disadvantage is that it is difficult to accurately quantitate the
shear force applied.
Nordon, Milthorpe, Schindhelm et al [1994] have developed a system to
examine the strength of cell-ligand affinity based on cell detachment at a critical
uniform shear stress generated by controlling flow rate through a 100pm parallel-
plate system. The narrow plate separation allowed complete cell sedimentation
within 30s, and permitted study of the early stages of bond formation. Flow
residence time, median critical shear stress, temperature and ligand density, were
found to influence cell attachment probability. Attachment strength was found to be
a heterogeneous property due to cellular heterogeneity and to the stochastic
fluctuation inherent in an adhesive bond dependent on small numbers [1,000-6,000]
ofmarker / ligand interactions. Lackie [1991] has developed a similar approach in
which cells in suspension pass over endothelium in a chamber with well defined
linear flow characteristics. The shear force is a combination of the velocity of flow
(controlled by a pump) and the viscosity of the medium. Cell adhesion over a
discrete area of the surface is recorded by video. These kind of distraction and flow
assays have not yet been applied to HPC studies.
7.5.5 Multistep adhesion cascades.
A further issue arises from these studies. Given that the majority of the CAMs
described are expressed by diverse cell types and the widespread distribution of
ECM molecules such as fibronectin and thrombospondin, how is tissue specificity
of adhesion conveyed? The concept ofmultistep adhesion cascades has been
advanced by several authors [Butcher, 1991 & 1993; Tanaka& Shaw, 1992;
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Tanaka, Albelda, Horgan et al. 1992; Springer, 1994], These authors suggest that
leucocyte-homing requires a highly specific (but low avidity) recognition system
which mediates initial interaction with vascular endothelial molecules (addressins)
imparting positional information. In lymphocyte homing a lectin has been described
which recognises phosphomannose residues displayed by high endothelial venules
[Gallatin, St John, Sieglemen et al. 1986], The HPC-marrow endothelium homing
receptor is unknown, though Tavassoli's group have demonstrated expression of a
lectin that recognises mannose / galactose residues [Aizawa & Tavassoli, 1987;
1988], and PECAM-1 (CD31), HCAM (CD44), CD45 and L-Selectin (CD62L) all
display carbohydrate specificities. The initial recognition event is postulated to
trigger amplification of the adhesive response through activation of high-avidity,
low specificity adhesion systems, such as those mediated by integrins. Leavesley et
al. have demonstrated that VLA-4 (CD49d/CD29) mediated adhesion of CD34+
cells to VCAM-1 (CD106), but not LFA-1 (CD1 la/CD18) mediated adhesion to
ICAM-1 (CD54), is enhanced by antibodies to co-expressed PECAM-1 (CD31)
[Leavesley, Oliver, Swart et al. 1994]. Majdic et al have demonstrated that mAbs to
O-sialoglycoprotease-sensitive epitopes of CD34 (Section 1.4) can activate the
LFA-1 :ICAM-1 adhesion system through protein tyrosine kinases, and that this
requires cellular energy and cytoskeletal reorganisation [Majdic, Stockl, Pickl et al.
1994], Low avidity interactions are difficult to study in current adhesion assays
because of poor control over the shear forces generated in distracting the non¬
adherent population as discussed above. Adhesion of cell lines to extracellular
matrix components is partially integrin mediated (Chapters 5.2 and 5.4) and is not
dependent on protein synthesis, metabolic energy or cytoskeletal reorganisation
(Chapter 5.4.3), suggesting that these molecules are expressed in a functionally
active form. The effects of PMA on the adhesive behaviour of cell lines (Chapter
5.3) suggests either that these molecules can be further activated, or that negative
regulators of adhesion exist which have hitherto been largely ignored. Clearly more
subtle adhesion assays are required if these sequential events are to be elucidated.
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7.5.6 The effects ofcell adhesion on proliferation, differentiation and survival.
Recently, it has become clear that adhesive interactions between HPC and
extracellular matrix components may in part be responsible for modulation of
cellular proliferation, differentiation or apoptosis. Catherine Verfaillie has
demonstrated that direct contact between HPC and stroma is not essential to HPC
survival, but in the absence of such contact excessive proliferation occurs
[Verfaillie, 1992]. More recently the group has provided evidence that adhesion of
HPC to fibronectin inhibits cellular proliferation [Hurley & Verfaillie, 1993] and
has further suggested that the stromal adhesion defect seen in chronic myeloid
leukaemia blasts may contribute to their uncontrolled proliferation [Verfaillie,
McCarthy & McGlave, 1992], Long-term maintenance ofprimitive human HPC in
culture requires unidentified stromal-derived factors in addition to known
stimulatory and inhibitory cytokines [Verfaille, 1994] probably including ECM
components like fibronectin, thrombospondin [Long & Dixit, 1990; Long, Briddell,
Walter et al. 1992] and proteoglycans [Spooncer, Gallagher, Krizsa el al. 1983;
Roberts, Gallagher, Spooncer et al. 1988; Gordon, Riley & Clarke, 1988; Bruno,
Guscar, Luikart et al. 1993; Gupta, McCarthy & Verfaillie, 1993]. Once again we
have barely scratched the surface in studying the effects of adhesion on HPC
kinetics.
7.6 Potential Clinical Applications.
Two potential applications of this study were thought to be worthy of further
consideration.
7.6.1 Development ofless toxic HPC mobilisation regimens.
It was considered possible that the intravenous use ofpeptide fragments or
blockading mAbs may permit development of less toxic regimens for mobilisation
of HPC from the bone marrow. Papayannopoulou & Nakamoto [1993] have recently
provided experimental evidence that an anti-VLA-4 (CD49d) mAb infused into
primates produced up to a 200 fold rise in HPC in the peripheral blood. The use of
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RGD-containing fragments was an attractive proposition because these can be easily
synthesised, and are likely to be non- immunogenic in vivo. There are two
limitations to the approach. First, the data from Chapters 5.4 and 6.5 mitigates
against the possibility of blockading HPC-stromal adhesion in vivo using a single
agents. Second, at concentrations high enough to blockade HPC-Fn adhesion,
synthetic peptides also interfere with other RGD-dependent adhesive interactions
such as that between platelet GpIIb/IIIa (CD41a/CD61) and fibrinogen. This
possibility was explored using a platelet aggregation assay. Briefly, platelet rich
plasma was prepared by centrifugation ofwhole blood at 10,000rpm for 10 min, and
platelet poor plasma by centrifugation at 30,000rpm for 10 min. These two solutions
were used to calibrate measurement ofminimum and maximum light transmission
by a spectrophotometer. Aliquots of platelet rich plasma were incubated for 30 min
in the presence or absence of 5mM RGDS, and then stimulated with 5pM ADP,
2.8pg/ml collagen, 0.5u/ml thrombin, 1.5mg/ml ristocetin or 500pg/ml arachadonic
acid. RGDS virtually abolished platelet aggregation in response to ADP, and
significantly inhibited that to thrombin and ristocetin [Gartner & Bennett, 1985].
This data suggests that RGDS would not be satisfactory as an in vivo mobilising
agent because the peptide would precipitate a haemorrhagic diathesis. Many toxic
snake venoms contain this same binding motif [Hutton & Warrell, 1993]. Slightly
longer peptides containing amino acids adjacent to the RGD sequence may convey
greater specificity to VLA-5 and may be of clinical utility if the specificity is
sufficiently discrete. [Pierschbacher & Ruoslahti, 1987; Hautanen, Gailit, Mann et
al. 1989].
7.6.2 Ex vivo manipulation ofhaematopoietic progenitors.
Stromal cultures have been used in the clinical setting to support HPC during ex
vivo manipulation, to augment HPC gene transfection and to purge neoplastic cells
from contaminated bone marrow or peripheral blood harvests [Gordon, Dowding,
Riley et al. 1987; Verfaillie, McCarthy & McGlave, 1992], There are a number of
practical disadvantages to this technique. First, autologous stroma can only be
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derived from bone marrow and so co-culture of peripheral blood or cord blood HPC
requires a preformed autologous or allogeneic stroma. Second, the stroma is fragile
and requires a rigid carrier. In effect, this restricts stromal culture to flasks in an
open system, increasing the environmental exposure of the harvest. Third, the
stromal cultures are poorly characterised and the system is therefore difficult to
standardise or control. One way ofmitigating these problems would be to construct
blood-bag plastics with an ECM coating. Flexible blood-bags provide an enclosed,
gas-permeable system with a non-adherent surface in which clinical harvests can be
handled, reducing environmental exposure but allowing ex vivo manipulation
including culture and cryopreservation. Judicious construction of a matrix may
allow selective retention ofHPC, controlled ex vivo culture with removal ofmature
cells, neoplastic cell purging, or HPC gene transfection. In addition, the work of
Verfaillie et al [Hurley & Verfaillie, 1993], suggests that ECM components which
until recently have been considered to be relatively inert, play an active role in
control of cell physiological functions. Preliminary work in this area has been
carried out and is currently the subject of a patent application.
7.7 Concluding Remarks.
The objective of the work presented within this thesis was the development of
assay techniques which would enable the study of human haematopoietic progenitor
adhesive interactions with the bone marrow microenvironment, and to investigate
the mechanisms involved in HPC migration, mobilisaton and homing.
Immunocytometry has provided valuable information on the range of cell adhesion
molecules expressed by HPC, and has suggested that differences exist between
sessile and circulating progenitors both in terms of activation and lineage
committment and CAM expression. Advanced immunocytometry holds the promise
of being able to dissect CAM expression within very low frequency subpopulations
of HPC and of being able to purify those subpopulations for functional studies.
Functional adhesion assays are essential to a fuller understanding of the relevance of
phenotypic studies. The 51Cr assay presented here represents a step in the direction
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of drawing causal links between CAM expression and functional cellular binding
behaviour. Clearly much technical work is required in the development of this and
other approaches to the study ofHPC adhesion, and the dissection of individual
adhesion pathways by activation and blockade. The difficulty in identifying discrete
HPC subpopulations within what appears to be a continuum, the plethora of
adhesion mechanisms, the categorical overlap between adhesion and
communication mechanisms, and the dependence ofHPC identity on environmental
conditions, suggests a depth of physiological complexity which a homeostatic
metaphor ill-equips us to understand [Bernard, 1865]. The challenge presented is to
put the individual pieces together, not simply as a study in bone marrow
transplantation, but as an amenable model system with which to develop a fuller
understanding of human morphogenesis [Thompson, 1961].
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Appendix 1 Equipment, Materials, Monoclonal Antibodies and Cell Lines.
1.1 Equipment.
1.1.1 Specific Equipment.
ZF. Coulter Electronics, Dunstable, UK.
T-890. Coulter Electronics, Dunstable, UK.
FACScan Flow Cytometer (FACS). Becton Dickinson, California, USA.
Dynal system. Gift ofDr Torstein Egeland, University of Oslo, Norway.
miniMACS system. Miltenyi Biotec, Cologne, Germany.
FACStar Plus Flow Sorter. Becton Dickinson, California, USA.
Gamma Counter. Auto-Gamma 500. Packard Instruments, Reading, UK.
Micro-Osmometer. Advanced Instruments Inc., Massachusettes, USA.
pH meter. Ciba Corning Diagnostic Ltd.,Sudbury, UK.
12 & 24 well tissue culture grade plates. Costar UK Ltd., High Wycombe, UK.
25cm2 and 75cm2 canted neck tissue culture flasks. Greiner, Dursley, UK..
1.1.2 Computer software.
Consort 30. Becton Dickinson, California, USA.
Lysis II. Becton Dickinson, California, USA.
Paint-A-Gate. Becton Dickinson, California, USA.
1.2 Materials.
A23187 Calcium ionophore. Sigma Chemical Co. Poole, UK.
Acetic acid. BDH Laboratory Supplies, Poole, UK.
Ammonium chloride. BDH Laboratory Supplies, Poole, UK.
Arginine-Glycine-Asparagine-Serine [RGDS] (synthetic peptide). Sigma Chemical
Co. Poole, UK.
Arginine-Glycine-Glutamine-Serine [RGES] (synthetic peptide). Sigma Chemical
Co. Poole, UK.
Bovine serum albumin (BSA). Sigma Chemical Co. Poole, UK.
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Chondroitin Sulphate A (sodium salt from bovine trachea). Sigma Chemical Co.
Poole, UK.
Chondroitinase ABC (from Proteus vulgaris). Sigma Chemical Co. Poole, UK.
Collagen Type I (acid soluble from human placenta). Sigma Chemical Co. Poole,
UK.
Collagen Type III (acid soluble from human placenta). Sigma Chemical Co. Poole,
UK.
Collagen Type IV (acid soluble from human placenta) Sigma Chemical Co. Poole,
UK.
Dimethylsulfoxide (DMSO). Sigma Chemical Co. Poole, UK.
Deoxyribonuclease I. Sigma Chemical Co. Poole, UK.
Ethylenediaminetetra-acetic acid (EDTA). BDH Laboratory Supplies, Poole, UK.
Fibronectin (from human plasma). Sigma Chemical Co. Poole, UK.
Fibronectin (from human foreskin fibroblasts). Sigma Chemical Co. Poole, UK.
Ficoll-Hypaque (density 1.077g/dl) Lymphoprep. Nycomed Pharma, Oslo, Norway.
Foetal calf serum (FCS). Sigma Chemical Co. Poole, UK.
Gentamycin 5mg/ml. Sigma Chemical Co. Poole, UK.
Glutamax-1. Gibco BRL., Paisley, UK.
Hanks' Balanced Salts Solution (HBSS).without Ca or Mg, sodium bicarbonate
added. Northumbria Biologicals. Cramlington UK.
Heparan Sulphate (sodium salt from bovine kidney). Sigma Chemical Co. Poole,
UK.
Heparin (mucous) Inj BP. Leo Laboratories Ltd, Princes Risborough, UK.
Heparinase I (from Flavobacterium heparinum). Sigma Chemical Company, Poole,
UK.
Horse Serum. Sigma Chemical Company, Poole, UK.
Human gamma globulin (Cohn fractions II and III). Sigma Chemical Company,
Poole, UK.
Hyaluronic Acid (from human umbilical cord). Sigma Chemical Co. Poole, UK.
Hyaluronidase (from bovine testes). Sigma Chemical Company, Poole, UK.
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Iscove's Modified Dulbecco's Medium (IMDM) with L Glutamine and 25mM
HEPES. Sodium bicarbonate added. Gibco BRL. Paisley, UK.
Laminin (from human placenta). Sigma Chemical Co. Poole, UK.
Lyzerglobin. JT Baker BV. Deventer, Holland.
Magnesium Sulphate. Sigma Chemical Co. Poole, UK.
Methylcellulose. Sigma Chemical Co. Poole, UK.
Mouse Serum. Prepared by Kay Samuel.
Non-Idet P40 (non-ionic detergent). Sigma Chemical Co. Poole, UK.
Paraformaldehyde. BDH Laboratory Supplies, Poole, UK.
Penicillin 10,000u/ml, Streptomycin lOmg/ml. Sigma Chemical Co. Poole, UK.
Phosphate buffered saline (PBS). Sigma Chemical Company, Poole, UK.
Quantum simply cellular beads. Sigma Chemical Co. Poole, UK.
Rabbit Serum. Scottish Antibody Production Unit. Carluke. UK.
RPMI 1640. Scottish National Reagents Unit.
Sodium azide. Sigma Chemical Co. Poole, UK.
Sodium chromate (51Cr). Amersham International PLC. Amersham, UK.
Sodium hydrogen carbonate. BDH Laboratory Supplies, Poole, UK.
Thrombospondin (from human platelets). Sigma Chemical Co. Poole, UK.
Trypan blue stain (0.4%). Sigma Chemical Co. Poole, UK.
«
Trypsin/EDTA (0.25%). Sigma Chemical Co. Poole, UK.
Vitronectin (from human placenta). Sigma Chemical Co. Poole, UK.




8H8.1 (FITC), IgG2a (murine). Immunotech, Marseille, France.
CD19:
J4.119 (FITC), IgGl (murine). Immunotech, Marseille, France.
359
CDlla (LFA-lct chain):
I0T16 (Purified), IgGl (murine). Immunotech, Marseille, France.
CD31 (PECAM-1, GpIIa):
5.6E (Purified), IgGl (murine). Immunotech, Marseille, France.
L133.1 (Purified), IgGl (murine). Becton Dickinson, Oxford, UK.
CDS3:
D3HL60 (FITC), IgGl (mouse). Immunotech, Marseille, France.
CD34:
MylO [HPCA-1] (Purified), IgGl (murine). Becton Dickinson, Oxford, UK.
8G12 [HPCA-2] (RPE), IgGl (murine) Becton Dickinson, Oxford, UK.
QBEND10 (Purified), IgGl (murine). Immunotech, Marseille, France.
QBEND-10 (FITC), IgGl (murine). Immunotech, Marseille, France.
BI-3C5 (Purified), IgGl (murine) Sera-Lab, Sussex, UK.
Tiik-3 (Purified), IgG3 (murine) Dako, High Wycombe, UK.
12.8 (Purified), IgM (murine) a gift ofDr ID Bernstein, Seattle.
CD36:
FA6-152 (Purified), IgGl (murine). Immunotech, Marseille, France.
CD38:
T16 (FITC), IgGl (murine). Immunotech, Marseille, France.
CD41a (Gp lib) :
P2 (FITC), IgGl (murine). Immunotech, Marseille, France.
CD44 (HCAM):
F10-44-2 (Purified), IgG2a (murine). Serotec, Oxford, UK.
L178 (Purified), IgGl (murine). Becton Dickinson, Oxford, UK.
CD45 (Leucocyte common antigen):
IOLla (Purified), IgGl (murine). Immunotech, Marseille, France.
IOLlc (FITC), IgGl (murine). Immunotech, Marseille, France.
CD49d (VLA-4a -chain,a
^ ):
HP2/1 (Purified), IgGl (murine). Immunotech, Marseille, France.
L25.3 (Purified), IgG2b (murine). Becton Dickinson, Oxford.
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CD49e (VLA-5 a-chain, aJ:
SAM1 (Purified), IgG2a (murine). Immunotech, Marseille, France.
mAb 16 (purified), IgG2a (murine). Becton Dickinson, Oxford, UK.
CD51 (VNR a-chain):
AMF7 (Purified), IgGl (murine). Immunotech, Marseille, France.
CD54 (ICAM-1):
84HIO (Purified), IgGl (murine). Immunotech, Marseille, France.
LB-2 (purified), IgG2b (murine). Becton Dickinson, Oxford, UK.
CD58 (LFA-3):
AMF7 (Purified), IgG2a (murine). Immunotech, Marseille, France.
CD62L (L-Selectin):.
Dreg56 (Purified), IgGl (murine). Immunotech, Marseille, France.
CD71 (transferrin receptor):
YDJ1.2.2 (FITC), IgGl (murine).Immunotech, Marseille, France..
1.3.2 Unclassified.
HLA-DR:
B8.12.2 (FITC). IgG2b (murine). Immunotech, Marseille, France.
1.3.3 Irrelevant specificity.
IgGl (Purified), (murine), Immunotech, Marseille, France.
IgG2a (Purified), (murine), Immunotech, Marseille, France.
IgGl (FITC), (murine), Immunotech, Marseille, France.
IgGl (RPE), (murine), Immunotech, Marseille, France.
1.3.4 Second and third-step reagents.
Sheep F(ab') anti-mouse IgG -FITC conjugate (adsorbed with human serum).
Sigma Chemical Co. Poole, UK.
Sheep F(ab') anti-mouse IgG -RPE conjugate (adsorbed with human serum).
Sigma Chemical Co. Poole, UK
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Goat F(ab')2 anti-mouse IgG - Red 613. Gibco BRL. Paisley, UK.
Goat anti-mouse IgG (Fab specific) -biotin conjugate. Sigma Chemical Co. Poole,
UK.
Streptavidin-Quantum Red conjugate. Sigma Chemical Co. Poole, UK.
Rat anti-mouse IgG2a -PerCP conjugate. (Peridinin Chlorophyll Protein). Becton
Dickinson, Oxford, UK.
Rat anti-mouse IgGl -microbead conjugate. Miltenyi Biotec Inc, Cologne,
Germany.
1.4 Cell lines.
M210-B4 murine stromal cell line. A gift ofDr Connie Eaves, Terry Fox
Laboratory, University of British Columbia, Vancouver.
5637 human bladder carcinoma cell line. American Tissue Culture Collection,
Rockville MD, USA.
KG la human acute myelogenous leukaemia cell line. American Tissue Culture
Collection, Rockville MD, USA.
K562. human chronic myelogenous leukaemia. A gift ofDr David Flavell,
Department of Pathology, University of Southampton.
HL60. human promyelocytic leukaemia. A gift ofDr David Flavell, Department of
Pathology, University of Southampton.
CEM human acute T lymphoblastic leukaemia. A gift ofDr David Flavell,
Department of Pathology, University of Southampton.
NALM-6 human B cell lymphoma line. A gift ofDr David Flavell, Department of
Pathology, University of Southampton.
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Appendix 2 Preparation of Solutions and Media.
2.1 Tissue Culture Solutions.
Antibiotic stock (20ml):
penicillin 10,000u/ml, streptomycin lOmg/ml 7.0ml
gentamycin 5mg/ml 1,4ml
distilled water 11,6ml
Standard tissue culture medium (500ml):
Iscove's modified Dulbecco's medium (IMDM) 440ml.
foetal calf serum (FCS). 50ml
glutamax-1 5ml
antibiotic stock 5ml
CFU-GM assay medium (Stock 1.8ml):
9% methylcellulose 800pl
foetal calf serum (FCS) 600pl
5637 conditioned medium 200pl
Iscove's modified Dulbecco's medium (IMDM) 170pl
antibiotic stock 30pi
LTBMC medium (500ml):
Iscove's modified Dulbecco's medium [IMDM] 400ml






Immunocytometry handling medium (100ml).
phosphate buffered saline (PBS) 100ml
bovine serum albumin (BSA) lg
sodium azide O.lg
ethylenediaminetetra-acetic acid (EDTA) 0.02g
Human gamma-globulin solution (100ml).
phosphate buffered saline (PBS) 100ml
human gamma globulin (Cohn fraction II and III) 0.5g











Appendix 3. Additional Tables.
Table A1 Overall Accuracy of CD34+ Quantitation.




PB 1.08 ±0.16% cv=14.8%
BM 1.36 ±0.07% cv=5.3%
LP 1.51 ±0.09% cv=6.0%
LP 0.18 ±0.02% cv=l 1.5%
LP 0.17 ±0.02% cv=12.1%
LP 0.41 ±0.10% cv=23.8%
CB 1.40 ±0.27% cv=19.3%
BM 0.13 ±0.05% cv=33.4%
PB 6.70 ± 0.22% cv=3.2%
PB 2.78 ± 0.20% cv=1.4%
LP 1.73 ±0.55% cv-31.7%
CB 0.76 ± 0.08% cv=l 1.1%
CB 0.28 ±0.12% cv=43.5%
CB 0.34 ± 0.06% cv=17.6%
LP 3.96 ±0.72% cv=18.1%
Legend. Refer to Figure 2.9. PB: Peripheral Blood. LP: Leucapheresis Product.
BM: Bone Marrow. CB: Cord Blood.
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Table A2 Correlation between CFU-GM and CD34+ Cells in 14 Leucapheresis
Product Samples. {Legend. Refer to Figure 2.10).
sample CD34%+ CFU-GM/105 Cloning Efficiency
#1 0.1% 3 3.5%
#2 0.2% 1 0.75%
#3 0.0% 1
#4 0.5% 2 0.4%
#5 0.2% 1 0.5%
#6 0.8% 17 2.1%
#7 1.9% 175 9.2%
#8 0.4% 7 1.7%
#9 0.1% 6 6.0%
#10 0.3% 10 3.3%
#11 0.0% 2
#12 0.0% 3
#13 3.0% 613 20.0%
#14 2.0% 650 32.5%
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Legend. Refer to pages 102.
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Table A4 Percentage Positivity Cell Adhesion Molecule Expression within
CD34+ Populations from Bone Marrow, Mobilised Peripheral Blood and
Umbilical Cord Blood.
































































Legend. Refer to Figure 3.2 and overpage.
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Table A4 continued.



































































Legend. Refer to Figure 3.2. Results are quoted as the mean ± standard deviation of
(n) replicate experiments. Comparisons are made to the appropriate negative
controls by 2 tailed paired t test.
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Table A5 Mean Fluorescence Intensity of Cell Adhesion Molecule Expression
within CD34+ Populations from Bone Marrow, Mobilised Peripheral Blood and
Umbilical Cord Blood.








































































Legend. Refer to Figure 3.3 and overpage.
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Table A5 continued.
CD BM PBm#l PBm#2 CB
FITC controls
IgGl 12 ± 3 13 ± 9 10 ± 6 14 ± 8
RPE controls
IgGl 9 ± 3 10 ± 4 9 ± 3 23 ± 15
IgG2a 10± 3 12 ± 3 12 ± 5 32± 19
Legend. Refer to Figure 3.3. Results are quoted as the mean ± standard deviation of
(n) replicate experiments. Comparisons are made to the appropriate negative
controls by 2 tailed paired t test.
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Table A6 Percentage Positive Lineage Marker Expression within the CD34+
Populations of Bone Marrow, Mobilised Peripheral Blood and Cord Blood.
CD BM (n=5) PS" (n=4) LP (n=4) CB (n=4)
CD34% 4.13 ± 1.69 3.10 ± 3.40 4.81 ± 1.56 0.57 ±0.40
CD34n 1,232 ±512 553 ± 264 1.423 ±429 86 ±73
IgGl 0.06 ±0.01 0.03 ± 0.02 0.07 ±0.05 0.05 ±0.01
Contam (%) 1.5 ±0.6% 0.8 ± 0.6% 1.5 ± 1.0% 12.2 ±6.5%
CD33% 11 ± 11 ns 6 ± 4 ns 2 ± 2 ns 7 ± 7 ns
CD7% 8 ± 8 ns 5 ± 2 ns 2 ± 1 ns 14 ± 7 p<0.05
CD19% 16 ± 21 ns 4 ± 2 ns 1 ± 1 ns 7 ± 6 ns
CD71% 40 ± 27 p<0.05 33 ±21 ns 24 ± 9 ns 44 ± 20 p<0.05
CD41a% 8 ± 6 p<0.05 5 ± 3 ns 7 ± 5 ns 10 ± 3 ns
CD38% 68 ±31 p<0.01 63 ±21 p<0.01 63 ± 13 p<0.01 22 ±5 p<0.01
HLA-DR% 76 ± 17 p<0.001 85 ± 6 p<0.001 88 ± 8 p<0.001 77 ±18 p<0.01
IgGl% 2 ± 3 2 ± 1 2 ± 2 4 ± 6
CD45% 76 ± 35 p<0.01 97 ± 5 p<0.001 99 ± 1 p<0.01 96 ± 3 p<0.001
Legend. Refer to Figure 3.6. Results are quoted as the mean ± standard deviation of
(n) experiments. Comparisons are made to the negative controls by paired t test.
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Table A7 Mean Fluorescence Intensity of Lineage Marker Expression within
CD34+ Populations from Bone Marrow, Mobilised Peripheral Blood and
Umbilical Cord Blood.
CD BM PET LP CB
CD33 30 ± 34 ns 12 ± 7 ns 3 ± 3 ns 7 ± 4 ns
CD7 29 ±31 ns 11 ± 8 ns 3 ± 1 ns 4 ± 4 ns
CD19 29 ±31 p<0.05 8 ± 5 ns 3 ± 1 ns 9 ± 3 ns
CD71 53 ± 29 p<0.01 23 ± 9 ns 16 ± 7 p<0.05 495 ± 502 ns
CD41a 34 ± 32 ns 12 ± 7 ns 17 ± 19 ns 43 ± 60 ns
CD38 83 ± 14 p<0.001 35 ± 5 p<0.01 24 ± 6 p<0.01 14 ± 6 ns
HLA-DR 166 ±26 p<0.01 85 ± 43 p<0.05 50 ± 18 ns 96 ± 32 p<0.05
FITC controls









Legend: Refer to Figure 3.7. Results are quoted as the mean ± standard deviation of
(n) replicate experiments. Comparisons are made to the appropriate negative
controls by 2 tailed paired t test.
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Table A8 Cell Adhesion Molecules Expressed by KGla.




CD54 99 ± 3% p<0.001 56 ± 18 p<0.05 n=3
CD31 30 ± 13% p<0.05 18 ± 7 p<0.01 n=3
CD58 98 ± 1% p<0.001 44 ± 13 p<0.05 n=3
CD49d 99 ± 1% p<0.001 58 ± 11 p<0.05 n=3
CD49e 99 ± 1% p<0.001 52 ± 16 p<0.05 n=3
CDlla 99 ± 0% p<0.001 168 ±61 p<0.05 n=3
CD51 7 ± 3% ns 5 ± 0 n=3
CD62L 5 ± 4% ns 5 ± 1 ns n=3
CD44 99 ± 0% p<0.001 307 ± 24 p<0.01 n=3
CD36 56 ± 39% ns 157 ±252 ns n=3
Controls.
IgGl SAM-FITC 2± 1% 4 ± 0 n=3
IgG2a SAM-FITC 2 ± 3% 4 ± 1 n=3
CD45 SAM-FITC 99 ± 1% p<0.01 113 ± 5 p<0.01 n=2
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Table A8 continued. Lineage and Activation Markers Expressed by KGla.




CD34 70 ± 19% n=4
CD33 11 ± 8% ns 8 ± 6 ns n=4
CD7 48 ± 27% p<0.05 42 ± 15 p<0.01 n=4
CD19 4 ± 1% ns 4 ± 2 ns n=4
CD71 84 ± 8% p<0.001 128 ±25 p<0.05 n=4
CD41a 3 ± 1% ns 3 ± 1 ns n=4
CD38 9 ± 4% p<0.05 7 ± 4 ns n=4
HLA-DR 3 ± 1% ns 3 ± 1 ns n=4
Controls.
IgGl-FITC 3± 1% 3 ± 1 n=4
CD45-FITC 93 ± 4% p<0.001 113 ±46 p<0.01 n=4
Legend. Refer to Figures 3.9-3.12. Results are quoted as the mean ± standard
deviation of (n) replicate experiments. Comparisons are made to the appropriate
negative controls by 2 tailed paired t test.
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Table A.9 Cell Adhesion Molecule Expression by K562.




CD54 66 ± 10% p<0.01 50 ± 6 p<0.001 n=4
CD31 24 ± 26% ns 22 ± 12 ns n=4
CD58 60 ± 8% p<0.01 37 ± 9 p<0.01 n=4
CD49d 44 ± 8% p<0.01 31 ± 7 p<0.01 n=4
CD49e 74 ± 6% p<0.001 55 ± 16 p<0.05 n=4
CDlla 19 ± 14% ns 21 ± 2 ns n=4
CD51 58 ± 13% p<0.01 47 ± 8 p<0.01 n=4
CD62L 11 ± 17% ns 11 ± 4 ns n=4
CD44 21 ±3%ns 25 ± 6 ns n=3
CD36 17 ± 3% ns 23 ± 3 ns n=4
Controls.
IgGl SAM-FITC 16 ± 4 19 ± 5 n=4
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Table A.9 continued: Lineage and Activation Markers Expressed by K562.




CD34 3 ± 1% ns 9 ± 4 ns n=3
CD33 12 ± 8% ns 12 ± 7 ns n=4
CD7 13 ± 18% ns 14 ± 3 ns n=4
CD19 19 ± 4% p<0.01 19 ± 4 p<0.05 n=4
CD71 65 ± 16% p<0.05 38 ± 21 ns n=4
CD41a 10 ± 3% ns 11 ± 4 ns n=4
CD38+ 10 ± 4% ns 11 ± 4 ns n=4
HLA-DR 12 =f= 2% ns 12 ± 7 ns n=4
Controls.
IgGl-FITC 10 ±4% 10 ± 4 n=4
CD45-FITC 90 ± 5% pO.OOl 69 ± 35 p<0.05 n=4
Legend. Refer to Figures 3.9-3.12. Results are quoted as the mean ± standard
deviation of (n) replicate experiments. Comparisons are made to the appropriate
negative controls by 2 tailed paired t test.
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Table A.10 Cell Adhesion Molecule Expression by HL60.




CD54 81 ± 14% p<0.01 72 ± 35 p<0.05 n=4
CD31 47 ± 27% ns 61 ± 36 ns n=4
CD58 68 ± 16% p<0.01 57 ± 54 ns n=4
CD49d 82 ± 22% p<0.01 83 ± 40 p<0.05 n=4
CD49e 73 ± 26% p<0.01 61 ± 28 p<0.05 n=4
CDlla 79 ± 25% p<0.01 67 ± 19 p<0.01 n=4
CD51 30 ± 45 ns 26 ± 1 ns n-4
CD62L 3 ± 2% ns 19 ± 9 p<0.05 n=4
CD44 74 ± 1% 311 ±390 n=2
CD36 18 ± 17% ns 28 ± 13 ns n=4
Controls.
IgGl SAM-FITC 5 ± 5% 19 ± 8 n=4
IgG2a SAM-FITC 5 ± 5% 4 ±0.1 n=4
CD45 SAM-FITC 87 ± 9% p<0.001 103 ±46 p<0.05 n=4
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Table A.10 continued: Lineage and Activation Marker Expression by HL60.




CD34 5 ± 2% ns 9 ± 4 ns n=4
CD33 27 ± 27% ns 14 ± 9 ns n=4
CD7 32 ± 20% ns 15 ± 3 ns n=4
CD19 22 ± 9% p<0.05 14 ± 5 ns n=4
CD71 30 ± 16% ns 21 ± 21 ns n=4
CD41a 9 ± 7% ns 10 ± 8 ns n=4
CD38 26 ± 27% ns 15 ± 13 ns n=4
HLA-DR 31 ± 18% p<0.05 15 ± 6 p<0.05 n=4
Controls.
IgGl-FITC 5 ± 2% 9 ± 4 n=4
CD45-FITC 95 ± 3% p<0.001 105 ± 82 ns n=4
Legend. Refer to Figures 3.9-3.12. Results are quoted as the mean ± standard
deviation of (n) replicate experiments. Comparisons are made to the appropriate
negative controls by 2 tailed paired t test.
379
Table A.ll Cell Adhesion Molecule Expression by NALM-6.




CD54 82 ± 5% p<0.001 40 ± 7 p<0.01 n=4
CD31 1 ± 0.5% ns 4 ± 0.4 ns n=2
CD58 84 ± 9% p<0.001 36 ± 3 p<0.001 n=4
CD49d 79 ± 14% p<0.01 35 ± 9 p<0.01 n=4
CD49e 68 ± 25% p<0.02 43 ±21 p<0.05 n=4
CDlla 2 ± 2.5% ns 7 ± 4 ns n=4
CD51 4 ± 4% ns 9 ± 4 ns n=4
CD62L 0.4 ± 0.2% ns 4 ± 1 ns n=4
CD44 0.7 ± 0.3% ns 5 ± 4 ns n=4
CD36 1 ± 0.6% ns 4 ± 2 ns n=4
Controls.
IgGl SAM-FITC 0.8 ± 0.6% 4 ± 1 n=4
IgG2a SAM-FITC 0.9 ± 0.9% 5 ± 1 n=4
CD45 SAM-FITC 0.7 ± 0.5% ns 4 ± 1 ns n=4
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Table A.ll continued: Lineage and Activation Marker expression by NALM-6.




CD34 0.6 ± 0.4% ns 2 ± 1 ns n=4
CD33 0.4 ± 0.2% ns 2 ± 0.3 ns n=4
CD7 3 ± 2% ns 3 ± 2 ns n=4
CD19 80 ± 22% p<0.01 21 ± 5 p<0.01 n=4
CD71 83 ± 17% p<0.01 34 ± 10 p<0.01 n=4
CD41a 2 ± 1% ns 2 ± 0.3 ns n=4
CD38 85 ± 13% p<0.001 23 ± 2 p<0.001 n=4
HLA-DR 96 ± 4% p<0.001 64 ± 19 p<0.01 n=4
Controls.
IgGl-FITC 2 ± 2% 3 ±0.5 n=4
CD45-FITC 3 ± 2% ns 3 ± 0.4 ns n=4
Legend. Refer to Figures 3.9-3.12. Results are quoted as the mean ± standard
deviation of (n) replicate experiments. Comparisons are made to the appropriate
negative controls by 2 tailed paired t test.
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Table A.12 Cell Adhesion Molecule Expression by CEM.




CD54 56 ± 28% p<0.05 41 ±24 p<0.05 n=4
CD31 19 ±22% 27 ± 12 n=2
CD58 30 ± 29% ns 20 ± 3 p<0.02 n=4
CD49d 63 ± 31% p<0.05 44 ± 19 p<0.02 n=4
CD49e 23 ± 31% ns 20 ± 6 p<0.02 n=4
CDlla 61 ±39%ns 40 ± 8 p<0.01 n=3
CD51 6 ± 6% ns 14 ± 16 ns n=4
CD62L 6 ± 8% ns 9 ± 4 ns n=4
CD44 84 ± 15% p<0.01 129 ± 35 p<0.01 n=4
CD36 2 ± 1% ns 8 ± 9 ns n=4
Controls.
IgGl SAM-FITC 0.75 ±0.5 7 ± 8 n=4
IgG2a SAM-FITC 1.2 ±0.8 8 ± 7 n=4
CD45 SAM-FITC 87 ± 17 p<0.01 94 ±15 p<0.01 n=4
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Table A.12 continued: Lineage and ActivationMarker Expression by CEM.




CD34 1 ± 2% ns 3 ± 1 ns n=3
CD33 0.3 ± 0.3% ns 2 ± 1 ns n=3
CD7 90 ± 6% p<0.001 52 ± 5 p<0.001 n=4
CD19 5 ± 2% ns 5 ± 2 ns n=4
CD71 92 ± 5% p<0.001 86 ± 11 p<0.001 n=4
CD41a 1 ± 1% ns 3 ± 1 ns n=4
CD38 74 ± 28% p<0.02 31 ± 11 p<0.02 n=4
HLA-DR 2 ± 1% ns 4 ± 1 ns n=4
Controls.
IgGl-FITC 2 ± 2% 3 ± 1 n=4
CD45 91 ± 12% p<0.001 69 ± 23 p<0.02 n=4
Legend. Refer to Figures 3.9-3.12. Results are quoted as the mean ± standard
deviation of (n) replicate experiments. Comparisons are made to the appropriate
negative controls by 2 tailed paired t test.
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Bead #1 4 095 10
Bead #2 15 493 31
Bead #3 35 340 60
Bead #4 134 309 220
Legend. Results are quoted as mean ± standard error (number of replicate
experiments). %+ fluorescence and mfi is compared to isotype and fluorochrome-
specific control by two-tailed t test. Refer to Figure 3.15.
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Appendix 4 Human Bone Marrow Endothelial Cultures.
Human bone marrow endothelial cell cultures were prepared by John
Sweetenham and Lisa Masek of the CRC Wessex Medical Oncology Unit,
University of Southampton, as part of the collaborative work undertaken under a
grant from the Leukaemia Research Fund.
Briefly, the method was as follows: a mononuclear cell preparation derived from
normal human bone marrow was subject to positive selection using magnetic beads
coated with the plant lectin Ulex europeaus agglutinin-1 (UEA-1). The cells were
grown on tissue culture plates coated with ECM derived from human umbilical vein
endothelial cells. Positive staining with several endothelial markers was observed
including FVIII related antigen, BMA 120, CD31, ELAM-1, ICAM-1 (CD54) and
E-Selectin (CD62E). Electron microscopy confirmed the presence ofWeibel-Palade
bodies. The cells have been cultured through up to 8 passages with no apparent
change in their growth characteristics [Masek & Sweetenham, 1993; Masek,
Sweetenham, Whitehouse et al. 1994], A similar approach has recently been
described by Rafii, Shapiro, Rimarachin et al. [1994],
A series of experiments was carried out to study the comparative adhesion of
human haematopoietic cell lines to human umbilical vein endothelial cell cultures
and endothelial LTBMC using the 51Cr adhesion assay. lOng/ml of recombinant
human tumour necrosis factor a was used to study the effects of an activating agent
on the endothelial cultures. The use of the same methodological protocol and a
series of parallel experiments on adhesion of 51Cr-labelled KGla to pFn and dBSA,
were sufficient to establish that the assay results were comparable between the
Edinburgh and Southampton centres. The results of these experiments are presented
in Table A.M. All five cell lines adhered significantly to endothelial cultures in
vitro. Adherence ofKGla, HL60 and CEM was significantly greater to activated
than to non-activated HUVECS (P<0.001), whilst K562 and NALM-6 demonstrated
no difference. Adherence ofKGla, HL60 and CEM was significantly greater to
non-activated endothelial LTBMC than to non-activated HUVECS (P<0.001),
whilst that of K562 and NALM-6 was similar. Adherence of all cell lines to
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activated HUVECS was similar to that to activated endothelial LTBMC. There was
no difference in the adherence of any of the cell lines between activated and non-
activated endothelial LTBMC.
In summary of this data, it appears that some cell lines (KGla, HL60, CEM) but
not others (K562, NALM-6) are capable of responding to activation ofHUVECS by
tumour necrosis factor a. Endothelial LTBMC appear to be constitutively activated.
These differences may be helpful in clarifying changes in ligand expression of
functional importance during endothelial activation. This study demonstrates the
reproducibility of the 5lCr adhesion assay between centres and the applicability of
the method to examine the effects ofmanipulation of the substrate on HPC-stromal
and -endothelial adhesion. In particular it may allow us to examine the proposition
that chemotherapy , radiotherapy and cytokines give rise to HPC mobilisation
through a diresct effect on the bone marrow stroma or endothelium [Greenberger,
1991; Uhlman, Verfaillie, Jones et al. 1991; Shirota& Tavassoli, 1991 & 1992;
Srour, 1994],
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Table A.14 Adhesion of Human Haematopoietic Cell Lines to Human
Umbilical Vein and Bone Marrow Endothelial Cultures.
















































dBSA 2.9 ±1.1 1.0 ±0.3% 3.0 ±0.8% 2.8 ± 1.5% 7.2 ± 2.8%
Legend. Results are quoted as the mean ± standard deviation of 4 replicate
experiments. Comparison to dBSA by paired t test.
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Haematology Oncology
Peripheral Blood Stem Cell
Transplantation
J. I. O. Craig, M. L. Turner, A. C. Parker
S UMMA R Y. Haematopoietic stem cells are usually sessile within the bone marrow
microenvironment. However, small numbers do circulate in the peripheral blood of normal individuals,
and following chemotherapy and/or intravenous growth factors, a substantial transient rise in
circulating stem cells occurs. Leukocytes harvested by cytapheresis at this time can be used for
autologous reconstitution of the haematopoietic and lymphoid systems following high dosage chemo/
radiotherapy for the treatment of malignant disease. Peripheral blood stem cell transplants give rise
to similar disease response rates as autologous bone marrow transplants, but have the advantage of
more rapid haematopoietic reconstitution, and in addition can be offered to patients in whom marrow
harvest is not feasible due to bone marrow damage or infiltration.
This article reviews the theoretical and historical background to haematopoietic stem cell research,
current clinical practice in peripheral blood stem cell mobilisation and harvesting, addresses the
potential advantages and disadvantages compared to bone marrow transplantation, and assesses
current experience of comparative efficacy.
Haematopoietic stem cells are the progenitors of the
haematopoietic and lymphoid systems. They are
defined by their facility to give rise to cells of myelo-
monocytic, erythroid, megakaryocytic and lymphoid
lineage by a process of proliferation and differen¬
tiation, and possess the capacity to maintain long
term haematopoiesis by a process of self renewal.1
The rarity of stem cells has led to problems of
identification, which have been partially solved by
the development of functional assays and immuno-
phenotyping.
Functional Haematopoietic Stem Cell Assays
The murine spleen colony assay was the first animal
model to be developed and is based on the observation
J. I. O. Craig, M. L. Turner, A. C. Parker, Department of
Haematology, Royal Infirmary of Edinburgh, Lauriston Place,
Edinburgh EH3 9YW. Tel: 031 229 2477 Ext 3030, Fax: 031 228
2189.
Correspondence to: M. L. Turner.
that intravenous injection of bone marrow cells into
irradiated mice leads to the development of multiline-
age colonies in the spleen.2 These colonies are con¬
sidered to be the progeny of single clonogenic cells,
and are termed colony forming units—spleen (CFU-
S). CFU-S can be removed, and re-injected into a
second irradiated mouse, where splenic colonies again
develop, implying a capacity for self renewal. CFU-
S have proved to be heterogeneous in their ability to
sustain long term haematopoiesis: CFU-S generated
at day+ 12 after infusion appear to be more primitive
than those generated at day+ 8, and those CFU-S
that generate colonies in secondary recipients may be
more closely related to pluripotential haematopoietic
stem cells with long term repopulating ability.3
In man, of course, the CFU-S is not an acceptable
assay technique, and several in vitro clonogenic test
systems have been developed for the quantitation of
haematopoietic progenitors. Lineage-committed stem
cells can be assayed in semisolid culture media, and
by variation of culture environment, colonies can be
Blood Reviews (1992) 6, 59-67
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induced to form from multipotent cells (colony form¬
ing unit—granulocyte, erythroid, monocyte, mega¬
karyocyte, CFU-GEMM) or unipotent cells (colony
forming unit—granulocyte, monocyte, CFU-GM;
burst forming unit—erythroid, BFU-E; colony form¬
ing unit—megakaryocyte, CFEl-Meg; colony form¬
ing unit—eosinophilic, CFEf-Eo). Studies on highly
purified populations have suggested that most cells
capable of long term repopulation in vivo, may not
be detected by these kinds of clonogenic assay.4
Several assays for more primitive stem cells have been
developed,5 these include the human blast cell assay,6
the human high proliferative potential colony assay7
and the xenogeneic murine bone marrow transplant
model.8 However, the stem cells giving rise to colonies
under these conditions remain poorly characterised.
Recent work suggests that cells capable of forming
multilineage colonies on coculture with irradiated
long term marrow stromal layers (long term culture—
initiating cells),9 or of surviving in vitro 4 hydroper-
oxycyclophosphamide exposure (pre CFU-GM
assay),10 may be more closely related to the pluripot-
ent haematopoietic stem cell.
At present, the CFU-GM assay is the most widely
used measure of the haematopoietic progenitor
viability of a bone marrow or PBSC harvest. The
number of CFU-GM has been shown to correlate
well with restoration of haematopoiesis after bone
marrow transplantation in dogs.11 In man, CFU-GM
have been shown to correlate well with neutrophil
recovery after bone marrow transplantation, but to
a lesser degree with platelet recovery.12
Immunophenotyping of Haematopoietic Stem Cells
The time delay inherent in semisolid culture assays,
along with the difficulties in standardisation and
reproducibility engendered by variation in culture
media, environment and observer error, has led to
the application of immunophenotyping and flow cyto¬
metry to the problem of stem cell identification. CD34
is a highly glycosylated membrane glycoprotein of
unknown function. In man, expression is confined to
haematopoietic precursors and vascular endothelial
cells. Around 1.5% of low density bone marrow cells
are CD34 + , and virtually all unipotent and multipot¬
ent colony forming cells fall within this population.13
The CD34+ cell population is heterogeneous. CD34
expression is highest in the earliest progenitors, and
is progressively reduced with maturation, such that
some of the later progenitors may be operationally
defined within the CD34" population during analysis
by flow cytometry. Pluripotential stem cells capable
of forming colonies in long term stromal co-culture
and the pre CFU-GM assay, fall within the top 2%
of the CD34 fluorescence profile,9 display low reten¬
tion of the mitochondrial dye rhodamine 123,14,15
and lack expression of lineage specific markers.10,16
Lineage committed stem cells display higher rhoda¬
mine 123 retention, and coexpress myeloid (HLA-
DR + , CD33 + ),17 T cell (HLA-DR + , TdT + , CD7 + )
or B cell (HLA-DR + , TdT + , CD10 + , CD19 + )18
surface antigens. All subpopulations of CD34+ cells
may be important for rapid and sustained lymphohae-
matopoietic reconstitution. Several groups have dem¬
onstrated a correlation between CD34 +% and CFU-
GM,19,20 which may allow this antigen to be used as
a marker for assessing the viability of a harvest, or
to predict peripheral blood stem cell rebound follow¬
ing chemotherapy.21
Peripheral Blood Stem Cells
Under normal circumstances, the majority of haema¬
topoietic stem cells are sessile within the bone mar¬
row, and will preferentially home to the marrow if
given by intravenous infusion. Homing mechanisms
are, as yet, imperfectly understood, but involve mut¬
ual recognition and binding by cell surface adhesion
molecules expressed by stem cells, and ligands or
counter-receptors expressed in a tissue specific man¬
ner by vascular endothelial cells, stromal cells, and
the extracellular matrix.22 Small numbers of haemato¬
poietic stem cells circulate in the peripheral blood in
normal individuals. Larger numbers of PBSC can be
found under certain pathological and iatrogenic
induced conditions discussed below, though whether
this arises due to perturbation of the bone marrow
microenvironment, or alteration of stem cell adhesion
molecule profile, is at present unclear.
Animal Studies and Early Studies in Man
The observation that buffy coat cells could protect
irradiated mice from bone marrow failure was first
made in 1951.23 Transplantation experiments showed
that irradiated mice given blood derived allogeneic
leukocytes displayed haematopoietic chimerism for
several months.24 At an early stage, the importance
of dose of transfused leukocytes was shown in dogs,25
in which 10 times the number of cells had to be given
in order to establish haematological recovery, when
compared to bone marrow. When the properties of
circulating stem cells were compared to marrow
derived stem cells, they were found to have a lower
radiosensitivity, with more cells in S phase, and a
higher seeding efficiency.26 Micklem et al.27 found
that peripheral blood and bone marrow stem cells
differed markedly in their capacity for self renewal,
and the size of descendant populations, suggesting
that PBSC represent a selected population with lower
long term repopulating ability. However, Northdurft
et al.28 were able to demonstrate long term reconsti¬
tution of haematopoiesis in dogs after peripheral
blood leukocyte infusion, and showed that colony
formation in semisolid culture was a good predictor
of engraftment. Harvesting in dogs was facilitated by
treatment with cyclophosphamide, which increased
the circulating CFU-GM 11-fold, and augmented
haematopoietic recovery 12.5-fold after transplan-
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tation.11 These encouraging results in animals led to
preliminary work in man.
The presence of colony forming cells in the periph¬
eral blood of man was demonstrated by Chervenick
and Boggs in 1971.29 Kurnick and Robinson30 cul¬
tured peripheral blood leukocytes from patients with
viral illnesses with increased numbers of large lym¬
phocytes, and displayed higher levels of granulocytic
colonies than the normal population. Barr31 showed
that colony forming activity was displayed predomi¬
nantly by cells of large lymphocyte morphology.
Peripheral Blood Stem Cell Mobilisation
Steady state peripheral blood contains approximately
0.2% ±0.1% CD34+ cells, about one tenth the level
in normal bone marrow (1.8% +0.9%).17 Several
factors have been shown to increase circulating levels
of stem cells 2 to 4-fold, including exercise, ACTH,32
hydrocortisone,33 and endotoxin.34 In certain disease
states, particularly myeloproliferative disorders such
as myelofibrosis and chronic myeloid leukaemia,
greatly increased numbers of circulating progenitors
are found.35-37 The effect of chemotherapy on periph¬
eral blood stem cell levels was first demonstrated by
Richman in 1976,38 who observed a 20-fold increase
in circulating CFU-GM over baseline following inter¬
mittent chemotherapy for solid tumours. She postu¬
lated that it should be possible to obtain sufficient
numbers of stem cells for transplantation by
judiciously timed leukapheresis. To et al.39 studied
patients with acute myeloid leukaemia (AML) in
1984, and found a 10 to 100-fold increase in CFU-
GM in those patients entering remission, which
coincided with platelet recovery. Similar increases
have been reported in other groups of patients with
AML, and also in a small number of patients with
acute lymphoblastic leukaemia (ALL).40'41 We have
demonstrated42 a 5-fold increase in peripheral blood
CFU-GM in patients with high grade non Hodgkin's
lymphoma (NHL) after routine chemotherapy
regimes, and a 16-fold increase following ALL-type
therapy. The majority of patients with Hodgkin's
disease (HD) receiving routine chemotherapy dis¬
played little or no rise in CFU-GM, though an
intensive regime precipitated a 16-fold increase. Bone
marrow involvement significantly reduced the peak
levels of CFU-GM, as did second or subsequent line
chemotherapy. Wunder et al.43 have demonstrated
elevated levels of PBSC after high dose chemotherapy
for myeloma.
To et al44,45 pioneered the use of single infusions
of high dose cyclophosphamide (4g/m2) for mobilis¬
ation of haematopoietic stem cells in patients with
lymphoma, myeloma, and solid tumours. Peak levels
of circulating stem cells are reached 16 days after
chemotherapy, with mean peak CFU-GM elevated
14-fold above baseline, generally coinciding with the
time at which the neutrophil count in the peripheral
blood reached 1 x 109/1. More recently, several groups
have used cyclophosphamide at doses of up to 7g/
m2, to achieve greater elevation of CFU-GM.46'47
Various interrelated factors influence the CFU-GM
yield, including the use of higher cyclophosphamide
mobilisation doses, higher pre-mobilisation CFU-
GM levels, degree of bone marrow involvement,
timing and amount of previous chemotherapy, and
speed of leukocyte recovery. Unfortunately, such high
doses of cyclophosphamide lead to a prolonged per¬
iod ofmarrow hypoplasia, with significant associated
morbidity and mortality.
In view of the significant toxicity of high dosage
cyclophosphamide, and the variable levels of PBSC
following standard chemotherapy, several groups
have explored the use of recombinant growth factors
to mobilise PBSC. In primates, increased numbers of
peripheral blood CFU-GM can be induced by recom¬
binant human granulocyte-monocyte colony stimulat¬
ing factor (rhGM-CSF), interleukin-3 (rhIL-3),48 and
stem cell factor (rhSCF).49 In man, rhG-CSF used
alone produced a 56-fold increase in CFU-GM over
baseline,50 and a 278-fold increase when used in
conjunction with standard chemotherapy.51 rhGM-
CSF given alone, or subsequent to chemotherapy,
has been shown to increase PBSC levels by a factor
of 20 and 60-fold respectively.52 Gianni et al have
demonstrated up to 1000-fold elevation in circulating
CFU-GM by the use of high dose cyclophosphamide
(7g/m2) with rhGM-CSF.53'54 In phase 1 studies the
use of rhIL-3 alone has proved to be disappointing,
with only a 10-fold increase in CFU-GM,55'56 but
recent study has suggested that the sequential use of
rhIL-3 and rhGM-CSF may be more effective.57
Though recombinant growth factors are generally
well tolerated, the potential for stimulation of malig¬
nant cells remains a concern.58 On the basis of current
experience, we recommend that patients who are
potential candidates for PBSCT are identified at
presentation, and harvested on first line chemo¬
therapy with growth factor support. We harvest after
each of at least the first three pulses of chemotherapy,
because the yield of PBSC is better early in the course
of treatment. Relapsed patients, or those who have
failed to achieve good yields of PBSC on standard
chemotherapy, can be given high dose cyclophos¬
phamide (4g/m2) with growth factors. In patients
with residual tumour, the use of cyclophosphamide
allows assessment of disease responsiveness before
progress to transplantation.
PBSC Harvesting Techniques
As haematopoietic stem cell activity is found in the
'lymphocyte' fraction of peripheral blood, leukapher¬
esis can be used to harvest progenitors. Many cell
separators employing continuous and discontinuous
flow have been used successfully such as the Aminco
centrifuge,59 the Hemonetics Model V50,6° the Cobe
Spectra61 and the Fenwall CS3000.62 The more recent
modifications to protocols, and use of computer
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controlled separators have improved the ease and
efficiency of the procedure.63 We employ a Cobe
Spectra or a Fenwall CS3000 with a small volume
collection chamber, which allows direct cryopreserv-
ation of the harvest without further manipulation to
reduce the volume or red cell contamination.
Harvests have been cryopreserved with and without
further manipulation, mainly with the use of 10%
DMSO as a cryoprotectant, and controlled rate freez¬
ing with storage in liquid nitrogen at —135°C.64,65
It has been suggested that the use of 6% hydroxyethyl
starch with 5% dimethyl sulfoxide would reduce stem
cell toxicity, whilst allowing direct freezing and stor¬
age in a — 80°C freezer.66
Timing of Leukapheresis
The timing and extent of PBSC rebound is difficult
to predict on an individual patient basis, and depends
upon several factors including the amount of previous
chemotherapy or radiotherapy, and the nature of the
mobilising agent. The CFU-GM assay requires a
2-week incubation period, which makes day to day
monitoring of PBSC levels impossible. Indirect indi¬
cators of PBSC mobilisation such as synchronous
monocyte and platelet recovery41 or a rapid rise in
white cell count67 have been advocated by some
groups. We currently use a recovering peripheral
blood leukocyte count of 1 x 103/pl as a surrogate
marker to initiate leukapheresis, and carry out 4 or
5 procedures over subsequent days. Reports from
groups finding a close correlation between CD34%
and CFU-GM19,20 raise the possibility of using rapid
immunophenotyping to identify early PBSC rebound,
allowing early and much more accurate timing of
leukapheresis.
Complications of Bone Marrow Transplantation, and
the Potential Advantages of PBSC Transplantation
Bone marrow transplantation (BMT) has found wide¬
spread utility in the management of haematological
and solid tumours.68 Allogeneic bone marrow trans¬
plantation (AlloBMT) is a major procedure with an
overall mortality of 20-50%,69 related to the compli¬
cations of prolonged marrow hypoplasia, drug tox¬
icity, and graft versus host disease.70 A significant
limitation is the availability of HLA identical sibling
donors in only 35% of the population, and the higher
mortality associated with HLA matched unrelated
donor transplants.71
The use of autologous bone marrow (AutoBMT)
overcomes the problem of haematopoietic rescue
following high dose chemo-radiotherapy, has more
widespread application, and is associated with low
risk of graft failure or graft versus host disease.
Complications associated with marrow hypoplasia
remain a significant cause of morbidity, and are
responsible for 10-20% mortality in some reports.
Significant disadvantages of AutoBMT include the
potential reinfusion of malignant cells with the har¬
vest, and the loss of a graft versus leukaemia effect,
both of which may contribute to a higher rate of
disease relapse. Marrow harvest from the posterior
iliac crests may not be possible in patients with disease
at this site, or in those who have previously received
pelvic radiotherapy.
Peripheral Blood Stem Cell Transplantation
The potential advantages of PBSCT over bone mar¬
row autologous transplantation are 3-fold.
Firstly, PBSC can be harvested without the pre¬
requisite of a healthy pelvic bone marrow, and with¬
out a general anaesthetic, facilitating this as a
therapeutic option for patients with damage to the
marrow due to previous disease or radiotherapy.
Secondly, rapid haematopoietic reconstitution is seen
in those patients transplanted with PBSC collected
after mobilisation.65,72,73 The number of CFU-
GM infused needs to be substantially higher
(80-100 x 104/kgBW) than in a bone marrow harvest
(10-20 x 104/kgBW), and correlates well with the rate
of granulocyte recovery.74,75 When adequate num¬
bers of PBSC are infused, a neutrophil count of
0.5 x 103/pl is achieved on average by day +11, and
a platelet count of 50xl03/[il by day+13.76 This
compares favourably with AutoBMT, where neutro¬
phil engraftment occurs at day+ 22, and platelet
engraftment at day+ 32; and also with AutoBMT
augmented by G-CSF, where neutrophil engraftment
occurs at day+11, and platelet engraftment at
day+ 39.50 This translates into a reduction in patient
morbidity and resource utilisation.76 Stem cells col¬
lected from peripheral blood in steady state, show
recovery rates similar to AutoBMT.77 Differences in
speed of haematopoietic reconstitution may be related
to a greater proportion of myeloid-committed stem
cells in mobilised PBSC harvests. A recent study by
Bender et al17 has shown a higher coexpression of
the myeloid associated antigen CD33 by CD34+ cells
from peripheral blood comparative to those from
bone marrow (89 v 43% respectively).
Concern has been voiced from the outset, that
PBSC may not contain pluripotential haematopoietic
stem cells necessary for long term engraftment. Mick-
lem et al27 were unable to demonstrate long term
repopulating capacity in circulating haematopoietic
stem cells in mice. Studies in genetically disparate
dogs and primates have confirmed short term
engraftment, but the animals usually succumb to
graft versus host disease. Most PBSC transplants in
man have been autotransplants, and unless the trans¬
planted haematopoietic stem cells are artificially gen¬
etically marked, it is impossible to determine the
origin of long term post-transplant haematopoiesis.
No such studies have yet been reported.78 Long term
recovery of haematopoiesis has been demonstrated
in several studies in man,79,80 but is not necessarily
proof of sustained engraftment, because at least some
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endogenous haematopoietic stem cells survive chemo-
radiotherapy,81 and because initial transient PBSC
generated haematopoiesis may be superseded by
endogenous recovery. Some support for this thesis
comes from the transient fall in granulocytes and
platelets sometimes observed about 6 weeks after
transplantation,82 though this can be overcome by
infusing larger numbers of CFU-GM. More recently
a number of groups have provided support for the
presence of pluripotential PBSC on the basis of
immunophenotypic characteristics, colony formation
in long term stromal cultures,83 and resistance to
5-Fluorouracil.84 The timing of leukapheresis may be
important in this regard, some studies suggesting that
early PBSC recovery is enriched in pluripotent cells,
whilst the later phase of mobilisation contains more
mature progenitors. These points are important to
resolve if PBSC are to be used in an allogeneic setting,
or for gene transfer in the future.
A third potential advantage of PBSC transplan¬
tation is the differential risk of tumour contamination
of the harvest. Several techniques can be used to
assess minimal residual disease present in bone mar¬
row or PBSC harvest; these include morphological
and cytogenetic analysis,85 analysis of gene rearrange¬
ments by Southern blot and polymerase chain reac¬
tion,86,87 immunological analysis of differentiation
antigens,88 and clonogenic assay.89 The risk of bone
marrow harvest contamination is highest in acute and
chronic leukaemias and myeloma, and relatively com¬
mon in low grade NHL. Marrow involvement occurs
less commonly in high grade NHL, HD, and several
solid tumours including breast and small cell lung
cancer. Several groups have exploited the limited
expression of CD34 to explore positive selection of
haematopoietic stem cells from contaminated har¬
vest.90 Such an approach may be expected to effect
a 2-4 log removal of neoplastic cells, which may not
be sufficient for contaminated bone marrow, but
could be sufficient for a PBSC harvest, if contami¬
nation is less common or less severe in the latter.91
Preliminary results do suggest that PBSC are less
likely to be contaminated by residual neoplastic cells
than bone marrow, but large studies are not yet
available, and no consensus has yet been reached as
to whether, or how many, infused neoplastic cells
may engender relapse. The most common source of
relapse after autologous transplantation is likely to
be endogenous residual disease which has survived
cytotoxic therapy.
Comparative Assessment of PBSC and Autologous
Bone Marrow Transplantation
Acute and Chronic Leukaemia
The role of autologous transplantation in the acute
leukaemias has yet to be clearly defined,92 though in
patients without an HLA matched donor, AutoBMT
gives an advantage over chemotherapy alone93 in
poor prognosis disease, or second or subsequent
remission.
Adequate reconstitution of haematopoiesis by
PBSC in acute myeloid leukaemia (AML) has been
demonstrated, Reiffers94 found a 33% disease free
survival 3 years after PBSCT, which is similar to the
results of AutoBMT. The European Bone Marrow
Transplant Group has not been able to detect any
difference in disease free survival between patients
receiving PBSCT and AutoBMT.95'96
Very few PBSC transplants have been reported in
ALL, but two case studies found good engraftment
with remission continuing up to 6 months.97,98
AlloBMT is the treatment of choice for young
patients with chronic myeloid leukaemia (CML).99
In those patients without a suitable donor, autologous
bone marrow harvested in chronic phase can success¬
fully re-establish this phase at the time of acceleration
or transformation. However, the duration of second
chronic phase is usually short, and the benefit to long
term survival is uncertain. Peripheral blood from
patients with CML prior to treatment contains large
numbers of stem cells, which can be used for
transplantation. Some groups have successfully pro¬
longed second chronic phase by double
PBSCT ± recombinant alpha interferon.100 Other
groups have successfully restored Philadelphia nega¬
tive haematopoiesis by collecting Philadelphia nega¬
tive cells following high dose chemotherapy,101,102 or
by purging the harvest of Philadelphia positive cells
by in vitro co-culture with marrow stromal layers.
Further work is necessary to establish the durability
of such treatments.
Hodgkin's Disease and the Non Hodgkin's
Lymphomas
AutoBMT is used for patients with lymphoma who
have proved refractory to front line therapy, or who
are in early relapse, or second or subsequent
remission.103
Kessinger104 has reported the results of PBSC
transplantation in the largest series of patients with
lymphoma. 16 patients with NHL and 24 with HD
were studied. All had refractory disease and had
received much previous therapy. Many had marrow
involvement or had received pelvic radiotherapy. The
clinical response compared favourably with autolog¬
ous BMT, with a 2-year event free survival of 49%
for those with NHL and an 18 month event free
survival of 15% in HD. PBSCT has been successfully
used in patients in whom marrow harvest was not
possible, in both HD105"107 and NHL108-110, with
comparable outcome to AutoBMT.
Multiple Myeloma and Solid Tumours
AutoBMT has produced some promising results in
the management of multiple myeloma, with complete
remission of median duration 24 months, though
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there is no plateau to the relapse free survival 3-
curve,111 PBSCT has proved to be feasible and effi¬
cacious in this setting,112-114 and several groups are
evaluating this procedure in the setting of a two phase
intensive therapy.115'116 Experience obtained in
breast cancer, soft tissue sarcomas, stage IV neuro¬
blastoma, and recurrent or bulky germ line tumours,
suggests that high dose therapy with AutoBMT 5
improves disease free survival.117118 Occasional
PBSC transplants have been carried out successfully,
and are being used increasingly,119'120 the results of
comparative studies are awaited.
7.
Concluding Remarks
Approximately 500 peripheral blood stem cell trans- 8-
plants have been reported over the last decade, almost
all as autotransplants in patients with acute or chronic 9.
leukaemia, lymphoma, myeloma or solid tumours.
This procedure offers advantages over bone marrow
transplantation in patients with marrow disease, and io.
significantly enhances the speed of haematopoietic
reconstitution, with less procedure related morbidity ,,
and mortality. Despite early worries about the secur¬
ity of long term haematopoietic reconstitution, this
does not seem to be a problem in clinical practice, n
though to what extent this is supported by infused
pluripotential stem cells, or by endogenous stem cells
which have survived the conditioning regime, is
unclear at present. More detailed characterisation of
haematopoietic stem cells from different sources, less
toxic and more effective mobilising regimes, and more
accurate timing of leukapheresis, are areas of prime 14
importance to further improve PBSC transplantation,
and to expand it's use to the allogeneic setting or for
gene therapy. Preliminary evidence of differential
levels of minimal residual disease in bone marrow 15.
and PBSC harvest, may make this the procedure of
choice in some neoplastic diseases. Small trials have
shown comparable results between PBSC transplan- 16.
tation and autologous BMT in terms of long term
disease free survival. Large scale comparative trials
are now necessary to establish the place of this
technology in routine clinical practice. It is possible
that PBSC transplantation will come to supersede 17
autologous BMT in view of the superior engraftment
kinetics, and the ensuing clinical and financial benefit.
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I. INTRODUCTION
Protozoan organisms exist as discrete entities, or as primitive multicellular aggregates
bound together in a non-specific manner (Shapiro, 1988). Metazoan organisms are
complex multicellular systems in which tissue structure arises as an emergent property
of the interplay between cell differentiation and cell position. A cell's position in the
body of the organism is actively determined by the expression of cell surface molecules
capable of highly specific binding to molecular ligands on the surface of other cells, or
within the extracellular matrix. The pattern of cell adhesion molecule (CAM)
expression determines the range of microenvironments within the organism which a
particular cell can occupy. Conversely, occupation of such a site through CAM-ligand
binding, has a regulatory effect on differential gene expression. A two way process of
cell differentiation and cell position is therefore established through cell adhesion
molecules, which are pivotal to the development and maintenance of tissue structure in
all metazoan organisms.
This article reviews current knowledge of the molecular biology of human cell
adhesion molecules, and attempts to provide some illustration of the way in which
advances in this field are influencing thinking in human physiology and pathology.
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ii. background remarks
Close cell-cell contact between mammalian cells is opposed by the negative entropy
required for interdigitation of their surface glycocalyces, and mutual negative charge
conveyed by sialic acid residues (Bell, Dembo & Bongrand, 1984). Cell-cell and
cell-matrix adhesion is therefore an active functional process which involves specific
surface membrane proteins termed cell adhesion molecules (CAMs).
Individual CAMs are highly specific in the ligands or counter-receptors to which
they bind, in much the same way as cell surface receptors are highly specific in the
soluble mediators to which they bind. The mutual binding affinity of a CAM and a
particular ligand can be theoretically modelled, and the effects of changes in molecular
charge, conformation or surface density assessed (Tozeren, 1990).
Three types of CAM-ligand binding have been described (Alberts et al., 1989).
Homophilic binding involves binding of a cell surface molecule to a similar molecule
on an apposing cell {trans-binding), or sometimes on the adjacent membrane of the
same cell (cA-binding). Members of the Cadherin family involved in the assembly of
adherens and desmosomal junctions, and the Immunoglobulin gene superfamily
member NCAM, bind in this way.
Most CAMs, such as Integrin family members, are involved in heterophilic binding,
i.e. bind to a counter-receptor of different structure on another cell, or to an
extracellular ligand such as fibronectin. Members of the Selectin family and HCAM
bind to carbohydrate moieties on other cells or within the extracellular matrix.
Occasionally, CAMs bind via a multivalent link molecule, for example, the binding of
platelet gpIIb/IIIa complex to dimeric fibrinogen, which is thought to mediate platelet
aggregation.
Most CAMs are transmembrane proteins, consisting of an extracellular domain
which is involved in ligand or counter-receptor binding, a hydrophobic transmembrane
domain, and an intracellular domain which is often linked to the cytoskeleton. Signal
transduction by these molecules is usually bidirectional. The functional differentiation
of a cell determines the pattern of CAM expression, but in turn, CAM binding can elicit
changes in gene expression and cell phenotype. This property of CAMs, has imbued
them with a pivotal role in the development and maintenance of three-dimensional
tissue structure in multicellular organisms.
Changes in CAM expression are achieved through alteration in surface expression,
or modulation of the binding affinity of a molecule by modification of its chemical
structure in situ.
During the development of an individual cell lineage the pattern of CAM expression
changes allowing association with a variety of other cells and tissues. Individual mature
cells may alter expression of CAMs as part of a change in functional status, for example,
during activation. Finally, cells may undergo changes in CAM expression patterns
during pathological processes such as neoplasia or viral infection. Such changes are not
merely passive markers of altered cell phenotype, but a central facet of the physiology
of normal and diseased tissue.
iii. molecular biology
There are at least five families of cell surface proteins involved in cell adhesion
(Table 1).
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The Cadherin family includes at least three related molecules involved in calcium
dependent, cell—cell homophilic binding (Takaichi, 1988; Takaichi, 1990; Flemming,
1990): E-cadherin (uvomorulin), P-cadherin, and N-cadherin.
Members of the family show similar overall structure, with MT 124000, 723—748
amino acids, and 43—58% mutual homology. They exist as single pass transmembrane
glycoproteins, with large extracellular domains which are responsible for homophilic
binding. Calcium depletion markedly increases the sensitivity of the molecule to
protease degradation. The intracellular domain is linked to the cortical actin
cytoskeleton, and is essential to the function of the molecule, allowing concentration of
cadherins at junctional complexes. The molecule as a whole links cytoskeletal structures
in adjacent cells.
Cadherins are fundamental in establishing and maintaining multicellular structures,
especially in the embryonic stages of vertebrate development. Differential expression of
these, and other primary CAMs (such as NCAM, see below), allow creation of
boundaries between cell collectives destined for different paths of differentiation.
Interference in cadherin binding, for example by monoclonal antibody (mAb), gives
rise to severe distortion of embryonic topology. In adult tissues, cadherin expression is
highest in epithelial derived tissues. Infusion of an anti-E-cadherin mAb over a
monolayer culture of epithelial cells, leads to disruption of cell-cell cohesion,
breakdown in epithelial sheet, and morphological changes in the epithelial cells, with
adoption of a more fibroblastic appearance. It seems very likely that further members
of the family will be identified (Goodwin et al., 1990).
(2) Immunoglobulin gene superfamily
Members of the Ig gene superfamily (Williams, 1987; Williams, 1988) include
receptors which bind counter-receptors or structural ligands, and antigen-specific
receptors such as the T-cell receptor (TCR) and surface immunoglobulin (Ig), (Table
2). The molecules of this family are characterized by variable numbers of
immunoglobulin domains, which consist of two sheets of anti-parallel /J-pleated
strands, each containing 90-100 amino acids, and an interdomain disulphide bond.
Ligand binding is calcium independent.
The neural cell adhesion molecule (NCAM) was the first member of this family to
be isolated and characterized (Cunningham et al., 1987). Structurally it consists of a
single pass transmembrane glycoprotein of 1000 amino acids, with five extracellular
binding domains which are homologous with those of other members of the
immunoglobulin gene superfamily. A single gene codes for NCAM, but differential
RNA splicing leads to three major polypeptides which differ in carboxy-terminal
structure (transmembrane and cytoplasmic domains). NCAM binding is homophilic,
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Table 2. Major members of the immunoglobulin gene superfamily
Receptor
Neural cell adhesion molecule
NCAM
VCAM-i
















































and is highly cooperative, i.e. nonlinearly affected by local cell surface density. Indeed
at high surface densities m-binding (NCAM—NCAM on the same cell) occurs, leading
to a multivalent CAM structure. Modulation of NCAM binding affinity is effected by
changes in sialic acid content. Embryonic (E)NCAM has a Mr 200-250000, and about
30% sialic acid, Adult (A)NCAM has a Mr 140-180000, and about 10% sialic acid.
The high negative charge conveyed by sialic acid opposes binding, and it is thought that
(E)NCAM has about half the binding affinity of (A)NCAM. The conversion of
(E)NCAM to (A)NCAM is thought to be effected by in situ enzymatic cleavage, and has
major implications in the development of the nervous system (Edelman, 1984).
Like E-cadherin, NCAM is a primary cell adhesion molecule, appearing very early
in development, and can be seen at various times on derivatives of all three germ
lineages, playing an important role in the development of the central nervous system.
Most members of the immunoglobulin gene superfamily are involved in heterophilic
binding. Some are mutual counter-receptors, for example the leukocyte function-
associated antigens, LFA-2 (CD2) and LFA-3 (CD58) (which, like NCAM, has
anchoring isoforms). Others bind to integrin counter-receptors. Intercellular cell
adhesion molecule, ICAM-i (CD54), has five immunoglobulin domains, and is
expressed by a wide variety of cells in response to inflammatory mediators. ICAM-2 is
structurally very similar, but with only two extracellular immunoglobulin domains, and
is constitutively expressed by endothelial cells. Both bind the leukocyte /?2 integrin
LFA-i. Similarly, vascular cell adhesion molecule, VCAM-i is expressed on
endothelial cells in response to inflammatory stimuli, binding to a monocyte expressed
integrin, VLA-4.
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Several members of the family play a critical role in the immune system. The
Immunoglobulin (Ig) (Tonegawa, 1983) and T-cell receptor (TCR) (Davis &
Bjorkman, 1988) genes are unique in that they undergo a process of somatic gene
rearrangement in order to generate the vast range of receptor specificity necessary for
antigen-specific recognition.
Other members of the family are involved in antigen non-specific immune regulation,
these include Major Histocompatibility Complex (MHC) class I and class II molecules
(which show a very high degree of genetic polymorphism), /?2 microglobulin, CD4 and
CD8, poly-Ig receptor, and the Fey receptor.
Three members of the superfamily are predominantly expressed in the nervous
system: NCAM, myelin-associated glycoprotein (MAG), and peripheral myelin
glycoprotein (Po). In addition Thy-i antigen, OX-2, and CD4 are co-expressed both
by lymphocytes, and by nervous system tissues. The significance of this is not clearly
understood (Parnes & Hunkapiller, 1987; Quarles, Hammer & Trapp, 1990).
Other members of the superfamily include the platelet-derived growth factor
receptor (PDGF-R), monocyte colony-stimulating factor receptor (M-CSF R),
carcinoembryonic antigen (CEA) (Lance, 1990; Zhou, Fuks & Stanners, 1990) and
proteoglycan link proteins.
Proteins with immunoglobulin superfamily homology and cell adhesion functions
occur in invertebrates, and it is postulated that an ancient CAM diversified to form the
contemporary superfamily, including the molecules responsible for antigen-specific
binding within the vertebrate immune systems (Ohno, 1987; Edelman, 1987).
(3) Integrin family
The integrins comprise a large family of transmembrane glycoproteins with
widespread tissue distribution, and involvement in both cell-cell and cell-matrix
interaction (Hynes, 1987; Hemler, 1988; Albelda & Buck, 1990). Molecules of this
family are heterodimers, with unique a-subunits, and a small number of /Lsubunits
from which three subfamilies are defined. Subunits are Mr 100—200000 in size, and
considerable structural homology is evident; the various chains are 25—65%
homologous, and the/?-chains 37-45 % homologous. The a- and /^-chains of a molecule
are non-covalently bound, and both contribute to ligand specificity. a-Chains
demonstrate a highly conserved binding domain to the amino-acid sequence
arginine-glycine-aspargine (RGD) (Ruoslahti & Pierschbacher, 1987) which allows
many of this family to bind to extracellular matrix (ECM) proteins such as collagen,
fibronectin, and laminin. In addition, the a-chain contains 3—4 repeats of a divalent
cation binding site (Ca2+ or Mg2+). Changes in extracellular calcium concentration
affect the topology and functional activity of the in situ molecule (Graham & Brown,
1991).
The /^-chains are common to subfamilies of receptors, and are bound to the actin-
based intracellular cytoskeleton by a series of link proteins which include talin, vinculin
and actinin (Alberts et al., 1989). Three main subfamilies are differentiated on the basis
of a common /9-chain (Table 3).
The /?! subfamily (Hemler, 1990) are termed 'very late activation' because two
members (VLA-i and VLA-2) are expressed on T lymphocytes 2—4 weeks after in vitro
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Table 3. Integrin family
Receptor Tissue distribution Ligand
Pi 1(CD29) - VLA (very late activation) family
VLA-i (CDw49a) Fibroblasts, basement membrane Collagen, laminin
*201 VLA-2 (CDw49b) Fibroblasts, epithelial and endothelial Collagen, laminin
cells platelets, T lymphocytes
<*aA VLA-3 (cdw49c) Fibroblasts, epithelial cells Collagen, laminin, fibronectin
<x4/?i VLA-4 (CDw49d) Fibroblasts, monocytes, lymphocytes Fibronectin, VCAM-i
a5A VLA-s (CDw49e) Fibroblasts, epithelial and endothelial Fibronectin
cells
T lymphocytes
a6^1 VLA-6 (CDw49f) Platelets, T lymphocytes Laminin
aVfix (CD51) Fibroblasts Fibronectin
(CD 1 8) - LEU-CAM (leucocyte cell adhesion) family
ab/i2 LFA-i (CDua) All leucocytes ICAM-i
am/?2 MAC-i (CDub) Monocytes, granulocytes iC3b (inactivated
complement 3b)
ax/?2 pi5°, 95 (CDiic) Monocytes, granulocytes ic3b
/?3 (CD61) - cytoadhesion family
aIIb/?3 gpIIb/IIIa (CD41) Platelets vWF, fibrinogen, fibronectin
aV/?3 VNR (CDS1) Endothelial cells, B lymphocytes, Vitronectin
monocytes
The complexity of the family has been increased by the development of novel /? subunits which can form alterna¬
tive complexes with a4, a6 and aV
activation. The /?, subfamily is widely expressed, and mainly involved in binding to
ECM proteins. VLA-4 appears to have dual specificity due to alternative RNA splicing,
to the matrix protein fibronectin, and to VCAM-i, an immunoglobulin gene
superfamily member expressed by endothelial cells in response to inflammatory
mediators.
The /?2 subfamily (Larson & Springer, 1990; Arnaout, 1990 a) are termed leukocyte
cell adhesion molecules, and comprise three members with a common /?2 chain (CD 18).
LFA-i (CDna/CDi8) is expressed on all leucocytes, and is a counter-receptor for
ICAM-i. MAC-1 (CDnb/CDi8) and pi5o,95 (CDiic/CDi8) are expressed on
phagocytes and large granular lymphocytes, and are receptors for inactivated
complement C3b. Genetic deficiency of these molecules leads to poor response to
inflammation, and a syndrome of recurrent infections.
The/?3 (cytoadhesin) subfamily comprises gpIIb/IIIa, an important platelet adhesion
molecule for Fibrinogen, Fibronectin, and von Willebrand Factor (vWF); and the
vitronectin receptor (VNR) expressed on endothelial cells and macrophages.
The a-chains of /?, integrins VLA-i and VLA-2, and of y?2 integrins LFA-i, MAC-
1 and pi50,95, show homology within binding domains to a number of other proteins,
including von Willebrand Factor (vWF), complement components C2 and Factor B,
and ECM proteins such as cartilage matrix protein and type VI collagen. These
proteins are considered part of a type-A domain superfamily of molecules involved in
cell adhesion and extracellular structure (Colombatti & Bonaldo, 1991).
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(4) Selectin family
The Selectin family are C-type lectins, i.e. carbohydrate-binding proteins (Rosen,
1990; Watson et al., 1990; Springer & Lasky, 1991). The N-terminal domain is
homologous with a variety of animal lectins, including hepatic galactose receptors,
soluble mannose binding lectins, invertebrate lectins, and also the low affinity receptor
for IgE (CD23). They are temperature insensitive, and Ca2+ dependent, though Mg2+
independent.
There are three members of the family. LECAM-i (MEL-14/LAM-1) plays a
central role in the regulation of lymphocyte traffic. ELAM-1 is expressed on endothelial
cells in response to inflammatory stimuli. GMP-140/PADGEM (CD62), is stored in
the a. granules of platelets, and in Weibel-Palade bodies in endothelial cells, from where
it can be rapidly mobilized after stimulation by products of the clotting cascade.
(5) HCAM (CD44)
The homing-associated cell adhesion molecule (HCAM) (Haynes et al., 1989;
Lewisohn et al., 1989), is a lectin with galactosyl and mannosyl specificity, and is
apparently unrelated to other cell adhesion molecules. It displays features related to
proteoglycan core proteins, including potential chondroitin sulphate linkage, O-
glycosylation sites, and an N-terminal domain homologous to cartilage proteoglycan
core and link protein domains involved in glycosaminoglycan interaction. Specificity of
binding is achieved through differential splicing of nascent RNA or differential
glycosylation of the CD44 molecule. Tissue expression is widespread: the molecule has
been identified as of key importance in the recirculation of lymphocytes between blood
and lymphoid organs, from which it derives its name.
Carbohydrates are capable of a high degree of structural diversity, and specific
protein or lipid bound carbohydrate moieties are expressed on the luminal aspect of
endothelial cell surface membrane, often in a tissue specific manner. Such molecules are
termed mucosal vascular addressins, and are ligands for leukocyte-expressed lectins (in
particular LECAM-i and HCAM), and provide a molecular mechanism for tissue
specific traffic of lymphocytes and some neoplastic cells (Berg et al., 1989; Weir, 1989;
Brandley, Swiedler & Robbins, 1990).
IV. ILLUSTRATIONS
(1) Developmental biology
The development, maintenance and repair of tissue structure (Edelman, 1984;
Edelman, 1988; Anderson, 1990; Cunningham, 1991) is dependent on tension between
primary cellular driving forces, such as cell growth and proliferation, and cell
migration; and primary cell regulatory processes, such as cell adhesion, differential
gene expression (differentiation), and programmed cell death (apoptosis) (Wyllie, Kerr
& Currie, 1980).
Three-dimensional tissue structure is not directly encoded at the level of the genome,
but is an emergent property of interactions occurring at the cellular level, albeit
operating under local genetic and epigenetic rules. During the process of embryonic
induction (Gordon, 1987), cells of different ontogeny are brought together by
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morphogenetic movements with reciprocal effect on cell differentiation, mediated
through cell adhesion molecules or receptors for diffusible factors.
Embryonic induction operates mainly on and between cell collectives rather than
individual cells, and is a stochastic process. Induction is not necessarily symmetric, for
example one cell collective may be primarily induced to differentiate, the other (or
several others) acting principally as inducing agents. The central interplay of cell
adhesion and cell differentiation during topographic development will be exemplified
by two examples: the early processes of gastrulation and neurulation, and the later
development of cerebellar mapping.
Following fertilization (Moore, 1988), the zygote undergoes a series of symmetrical
mitotic divisions leading to a 12- to 16-cell morula at 3 days. After the morula enters
the uterus, a fluid-filled cavity develops inside it, converting the morula into a
blastocyst. The centrally localized cells form an inner cell mass, which will form the
embryo. From the 1st to the 3rd weeks, the inner cell mass (embryonic disk) is
converted into a trilaminar embryonic disk by the process of gastrulation. A groove
forms on the dorsal aspect of the embryonic disk (termed the primitive streak). Cells
from the superficial layer of the disk migrate through the primitive streak to form a
second layer below the first, and a third layer between the first two. From these three
primitive germ layers all further tissues will develop. The ectoderm gives rise to the
epidermis and nervous systems, the mesoderm: muscles, skeletal structures, the
vascular system and urogenital tract, and the endoderm: the primitive gut and its
derivatives, including the intra-abdominal organs and lungs.
The process of gastrulation is permitted by the interconversion of cell collectives
between two global structural states: epithelium, in which contiguous cells are bound
in sheets, with defined polarity and a basement membrane, and mesenchyme, in which
the cells are more loosely associated (either stationary or migrating), and with a loose
ECM structure (McNeill et al., 1990; Crossin et al., 1990). Interconversion occurs in
both directions many times during embryogenesis, and is termed epithelial—
mesenchymal transformation.
Between the 3rd and 4th weeks, the embryo undergoes a process of neurulation.
Ectodermal tissue anterior to the primitive streak is induced to differentiate by the
underlying dorsal mesoderm. A thickened neural plate forms, rolls up on itself and
pinches off to form the neural tube, from which the central nervous system will develop.
In the middle of the dorsal mesoderm a rod of specialized cells form the notochord,
which acts as the central axis of the embryo. On either side of the notochord, lateral
segmentation of the mesoderm occurs, with the formation of somites, from which the
vertebrae and skeletal muscles develop. Two CAMs have been found to be involved
during the earliest stages of embryogenesis: NCAM (Ig gene superfamily), and E-
cadherin.
Much of the work on the expression of these two CAMs has been done in chick
embryos. Just before gastrulation, cells throughout the embryo express both CAMs
fairly uniformly. As the primitive streak develops, cells migrating to form the
mesoderm do not express either. As neurulation proceeds, the situation becomes more
complex. Cells destined to form the neural plate, notochord, and somites, express
NCAM intensely, but stop expressing E-cadherin; the surrounding non-neural
ectoderm, and endoderm do the opposite. A border forms between neural and non-
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neural ectoderm, which is a direct reflection of the pattern of CAM expression.
Furthermore there is a gradient of NCAM expression. Expression is most intense in the
region of the neural plate, and less so in underlying mesodermal structures. The pattern
of expression is dynamic, for example the notochord at first expresses no CAMs, then
expresses NCAM intensely, and finally switches off expression again.
Two generalizations can be made:
(1) CAMs undergo dynamic changes in sequence of appearance, disappearance, and
distribution, and permit border formation between different cell collectives.
(2) During mesenchymal to epithelial transformation (condensation), CAM ex¬
pression is increased, during epithelial to mesenchymal transformation (dispersion),
CAM expression is reduced.
Studies at later stages of embryonic development are more restricted. During
development of the central nervous system, neurites from peripheral neurons may have
to grow substantial distances to form synaptic connection with central neurons. How
does a specific peripheral neuron address itself to a specific central neuron ?
Early studies on mice (Edelman, 1984) have demonstrated widespread expression of
NCAM in the brain, and distinctive patterns of conversion of (E)NCAM to (A)NCAM
during development. It appears that NCAM is essential to normal cerebellar
development. If NCAM binding is blocked by infusion of monoclonal antibody (mAb)
in vivo, the mouse develops a markedly hypoplastic cerebellar structure. Moreover, a
mutant 'staggerer' mouse has been described, in which the principal abnormality
appears to be an inability to convert the E form of NCAM to the more adhesive A form.
Failure to form adhesive synapses with incoming neurites, leads to death of cerebellar
granule cells, a small and histologically disordered cerebellum, and a severely ataxic
mouse.
One can therefore propose a thesis: during cerebellar development (Yamaguchi,
1989; Takaichi et al., 1990) the granule cells form a more or less homogeneous
population. Contact with, and adhesion to incoming neurites leads to synapse formation
(Yamaguchi, 1989) and differentiation of the granule cell. Cells which do not form such
connections undergo apoptosis. The process is instructive, with a high degree of
stochastic redundancy, but permits the development of a central cerebellar map without
the need for specific molecular addressing of individual cells at the genomic level.
(2) Haemostasis, inflammation, and wound repair
In cybernetic terms, the control of these three processes provides similar and
overlapping problems related to the maintenance of tissue integrity. Individual cells
exist predominantly in a quiescent state, but need to be activated in response to
appropriate stimuli, with changes in cell function, motility, and adhesion. A high
degree of stochastic redundancy is usually apparent, in order to provide a rapidly
effective response which is not vulnerable to minor component breakdown. Negative
control is essential to provide spatial and temporal limitation of the activated response.
Maintenance of the integrity of the vascular system demands rapid and effective
control of blood leakage (haemostasis), balanced by the need to maintain vascular
patency. Haemostasis is achieved through the combination of vasoconstriction, platelet
adhesion, activation and aggregation to form a primary haemostatic 'plug', and
activation of the coagulation cascade with generation of polymeric fibrin. This is
368 M. L. Turner
followed by tissue remodelling. A complex set of negative feedback systems act to
prevent inappropriate platelet activation, to localize coagulation factor activity, and to
lyse intravascular thrombus (Kay, 1988).
Circulating platelets do not adhere to intact vascular endothelium under normal
circumstances. When a blood vessel is damaged, the endothelial barrier is disrupted,
and platelets adhere to the exposed subendothelial surface. The platelet surface
membrane has adhesion molecules which bind to specific matrix proteins. These
receptors include gpIb/IX complex, a receptor for von Willebrand's Factor (vWF), and
several integrin receptors including gpla/lla (VLA-2: a collagen receptor), gplc/lla
(VLA-5: a fibronectin receptor), and gplc/llb (VLA-6: a laminin receptor) (Andrews
& Fox, 1990; Parmentier et al., 1990). Many components of the matrix such as
von Willebrand Factor, thrombospondin, fibronectin and collagen, bind to each
other, augmenting the adhesive response, and providing a high degree of redundancy
within the system.
Adhesion leads to platelet activation, producing changes in platelet metabolism and
morphology, and release of granule contents. These changes act to effect recruitment
of more platelets to the haemostatic plug, and to create a local procoagulant
microenvironment. The membrane integrin gpIIb/IIIa (Plow & Ginsberg, 1989) is
expressed by activated platelets, and binds to fibrinogen and other proteins containing
the arginine-glycine-aspargine (RGD) motif. Dimeric fibrinogen molecules probably
mediate the aggregation of activated platelets, in association with multimeric vWF.
Platelet procoagulant activity is markedly increased by activation, and the surface
membrane expresses binding sites for coagulation proteins. Triggering of the
coagulation enzyme cascade leads to formation of multicomponent enzyme complexes
on the surface of the developing platelet plug, responsible for the activation of factor X
and prothrombin.
Negative control is essential to prevent dissemination of platelet and coagulation
cascade activation, and to ensure termination of the response at a suitable juncture.
Intact endothelium does not express platelet adhesion counter-receptors, and produces
prostacyclin (PGI2), a potent anti-aggregant. Unbound activated coagulation proteins
are opposed by circulating serine proteinase inhibitors such as antithrombin III,
heparin cofactor II, Cx esterase inhibitor, antiprotease, and oc2 macroglobulin.
Endothelium also expresses surface thrombomodulin, which is activated by thrombin,
and binds protein C/S enzyme complex, augmenting the inactivation of coagulation
factors V and VIII. In addition endothelium releases tissue plasminogen activator,
responsible for activation of circulating plasminogen to form fibrinolytic plasmin.
These mechanisms serve to contain the area of thrombus formation.
Genetic deficiencies in platelet adhesion receptors can occur (George & Shattil,
1991): these include Bernard-Soulier disease (gpIb/IX deficiency), and Glanzmann's
Thrombasthenia (gpIIb/IIIa deficiency). Clinically these manifest as a bleeding
diathesis similar to that caused by thrombocytopenia.
Neutrophils and monocytes circulate in the peripheral blood in a quiescent state. In
response to tissue injury, inflammatory mediators are released which cause priming and
activation, not only of circulating phagocytes, but also of adjacent endothelium. One or
both cell types phenotypically alter to become mutually adhesive (Ward & Marks, 1989 ;
Carlos & Harlan, 1990; Albelda, 1991).
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In order to migrate to an inflammatory site, circulating phagocytes must undertake
several steps: adherence to the luminal aspect of the endothelium (Patarroyo et al.,
1990; Yong & Khwaja, 1990), diapedesis between endothelial cell junctions, migration
through the subendothelial extracellular matrix, functional participation in the
inflammatory reaction, and programmed senescence.
The primary mediator of activated neutrophil binding to endothelium appears to be
CDiia/CDi8, though CDiib/CDi8 also contributes. In monocytes all three
heterodimers of the /?2 integrin subfamily are expressed. Constitutive surface expression
of these molecules is held at low level. Stimulatory agonists (such as calcium
ionophores, phorbol esters, GM-CSF, C^a, tumour necrosis factor (TNF), and an
increase in ambient temperature) leads to upregulated surface expression, due to release
from intracellular stores. Upregulation is not sufficient in itself to explain the rapid
changes in adherence characteristics which occur with phagocyte activation, and it is
thought that additional alteration in the biochemical conformation of the surface
molecule occurs through phosphorylation, or proteolytic cleavage.
The central role of leukocyte adhesion molecules in the inflammatory response is
exemplified by Leukocyte Adhesion Deficiency (LAD) (Fisher et al., 1988; Arnaout,
19906) in which reduced or absent expression of the CD11/CD18 subfamily on
phagocytes, results in an inability to adhere and orientate to the endothelium when
stimulated, and failure of emigration in response to inflammatory stimuli. Such patients
suffer recurrent severe bacterial infections.
Endothelium constitutively expresses ICAM-i, the counter-receptor for CDiia/
CD 18 at low level. Upregulation occurs in vitro in response to inflammatory mediators
such as tumour necrosis factor (TNF-), interleukin 1 (IL-i), y-interferon (ylF),
phorbol ester and lipopolysaccharide (LPS), and is effected at the mRNA level, being
first apparent at 4 h after stimulation, and maximal at about 24 h.
Phagocyte adherence to activated endothelium can be blocked by anti-CD 18 mAb in
vitro, and differences in neutrophil and monocyte adherence can be demonstrated.
Other CAMs involved in phagocyte-endothelial cell interactions include ELAM-i,
which is not constitutively expressed by endothelial cells, but is rapidly induced by
inflammatory stimuli, and which mediates neutrophil binding - though the counter-
receptor is unknown. VCAM-i is expressed in a similar manner, and binds to VLA-4
on monocytes.
Thrombin and leucotriene stimulation also induces endothelial cells to increase
ICAM-i and ELAM-i expression by increased protein synthesis, and to release GMP-
140. The role of these molecules in phagocyte adherence is unknown.
Preliminary studies demonstrate differential sensitivity of phagocytic cells to
stimulating agents, and different patterns of CAM expression, which may contribute to
differences in kinetic response to inflammatory reaction. Resolution of the inflammatory
response involves neutrophil senescence and apoptosis, with aggregation of nuclear
chromatin, nucleolar prominence, and cytoplasmic vacuolation. Apoptotic neutrophils
are recognized and engulfed by tissue macrophages (Savill et al., 1989), employing the
/?3 integrin, VNR (Savill et al., 1990).
Although phagocyte activation is an essential mechanism of host defence and tissue
repair, it can also contribute significantly to tissue damage through a number of
mechanisms, including homotypic intravascular aggregation leading to microvascular
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occlusion and ischaemia, release of inflammatory mediators, and neutrophil protease
and oxidant release (Editorial, 1990). Neutrophils are thought to play an important role
in the pathogenesis of a number of clinical syndromes, including adult respiratory
distress syndrome, ischaemia-reperfusion injury following myocardial and cerebral
infarction, tissue rejection following transplantation, and vasculitic disorders (Weiss,
1989).
Immunohistological staining for adhesion molecules may prove a useful adjunct to
conventional histology in monitoring inflammatory disease. Increased ICAM-i
expression has been demonstrated in a number of conditions including acute and
chronic hepatitis (Volpes, van den Oord & Desmet, 1990), allograft rejection (Faull &
Russ, 1989), and inflammatory skin conditions (Nickloff, Griffiths & Barker, 1990).
Techniques for the assay of circulating ICAM-i isoforms have also been developed
(Seth, Raymond & Makgoba, 1991).
Limited studies have been carried out on the therapeutic use of anti-CAM mAb.
Anti-CDi 1/CD18 mAbs inhibit neutrophil migration in animal models of acute
inflammation (Editorial, 1990; Watson, Fennie & Lasky, 1991), and ischaemia-
reperfusion injury (Arnaout, 1990 a).
The repair process in damaged skin also appears to be mediated by changes in cellular
CAM expression and functional phenotype. In normal skin, keratinocytes are relatively
static, in wounded skin they undergo changes in cell attachment, with upregulation of
a5 integrin subunits, and structural alteration in ^-subunit (Grinnel, 1990). Activated
keratinocytes undergo spreading and migration in areas of tissue damage and can be
cultured in vitro for use as wound dressings (Hancock & Leigh, 1989). Fibroblasts
similarly undergo changes in CAM expression patterns during wound healing in
connective tissues (Chuong & Chen, 1991).
(3) The immune system : T-cell ontogeny, traffic and function
T lymphocytes (Springer, 1990 a; Robertson, 1990; Klein, 1991) are derived from
pluripotential haematopoietic stem cells (PHSC), which migrate to the embryonic
thymus at about 10-14 days' gestation. The thymic stroma, is derived from the
embryonic pharyngeal pouch, and is comprised principally of epithelial cells, dendritic
cells, and macrophages. Adhesion of PHSC to the thymic microenvironment (Haynes,
1984) induces proliferation and differentiation, with rearrangement of T-cell receptor
(TCR) yS genes, followed by TCR a/?-gene rearrangement (Finkel, Kubo & Cambier,
1991). This is a process unique to TCR and immunoglobulin (Ig) genes in vertebrates,
and is responsible for generating the vast repertoire of binding specificity, characteristic
of the immune system. At this stage in development, T cells express both CD4 and
CD8 coreceptors. In addition, they express LFA-2, which facilitates binding to thymic
epithelial cells, elaborate Interleukin-2 (IL-2), and express LFA-i, which permits
binding to ICAM 1 on macrophages, which elaborate IL-i. Other thymic hormones
such as IL-4, IL-6, and IL-7, are also elaborated by the thymic stromal cells.
Following generation of large numbers of T cells, with diverse TCR specificity,
stringent selection occurs, with both negative and positive selection procedures. Close
contact with MHC molecules expressed on thymic epithelial and dendritic cells, leads
to apoptosis of those cells incapable of recognizing self MHC, and later, suppression or
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elimination of T cells recognizing self antigens in conjunction with self MHC. In the
final analysis, T cells capable of recognizing foreign antigen in the presence of self
MHC molecules, are selected formaturation into single positive cells (i.e. CD4 + CD8 —
or CD4—CD8 + ), and leave the thymus. Apoptotic cells are recognized and removed
by tissue macrophages.
Newly emigrated T lymphocytes are considered 'naive' until they encounter and are
stimulated by contact with specific antigen, when they are activated, and differentiate
into 'memory' cells. The transition from naive to memory phenotype makes the cell
more sensitive to TCR binding, and effects permanent changes in surface CAM
expression, with alteration in LFA-i, LFA-2, VLA family and HCAM levels. T cells
recirculate between blood and lymph, tissues, and secondary lymphoid organs such as
lymph nodes and mucosal associated lymphoid tissue (MALT) (Stoolman, 1989;
Springer, 19906; Yednock & Rosen, 1990). Naive and memory T cells display different
recirculation patterns (Mackay, Marston & Dudler, 1990), and occupy distinct
microenvironments within secondary lymphoid tissues (Janossy et al., 1989). Naive T
cells enter lymph nodes from the blood at specialized high endothelial venules (HEV).
Memory T cells emigrate from blood through tissue endothelium, and enter local
lymph nodes through efferent lymphatics. Memory T cells appear to specifically
recognize tissue endothelium similar to that where they first contacted antigen. Such
specificity appears to be conveyed by selective expression of carbohydrate based
mucosal addressins by endothelial cells from different tissues, recognized and bound by
T-cell surface lectins (selectins and HCAM).
As outlined above, the T-cell receptor (TCR) recognizes antigen as peptide fragment
bound to Major Histocompatibility Complex (MHC)-coded proteins on the surface of
antigen presenting cells. MHC class I molecules are expressed by virtually all nucleated
cells, and selectively bind endogenously synthesized peptides. The peptide-MHC class
I complex is bound by CD8, expressed on the surface of T suppressor/cytotoxic cells.
Cells synthesizing abnormal peptides, e.g. as a result of viral infection, are destroyed.
MHC class II molecules are selectively expressed, in particular by B lymphocytes, and
monocytes/macrophages, and bind exogenous peptide fragments derived during
endocytosis. Peptide-MHC class II complex is bound by CD4, expressed by T helper
cells, and leads to the proliferation and maturation of other T cells, and of B cells.
The interaction of T cells with other immune system cells is therefore dependent on
two types of cell adhesion molecule, those responsible for antigen specific recognition
(i.e. principally TCR/CD3 complex), and those which are antigen non-specific. TCR
and its coreceptors (CD4 or CD8) diffuse independently in the plane of the T-cell
membrane, and are brought together by corecognition of the same peptide-MHC
molecular complex. At physiological densities, no adhesion of T cells will occur.
Recognition of peptide—MHC complex, or in vitro cross-linking of TCR by mAb,
causes T-cell activation, production of amplifying factors — such as IL-2, and
upregulation of non antigen specific adhesion molecules. These include LFA-
i(CDna/i8), LFA-2(CD2), and a series of VLA integrins. The counter-receptors for
these molecules (ICAM-i and LFA-3 respectively), are expressed by a wide variety of
cells. T-cell adhesion and detachment needs to occur rapidly, average cycle time is
estimated as 1-3 min. Regulation of CAM receptor surface density at the DNA or RNA
level, release from intracellular storage, or alteration of surface charge by changes in
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sialylation, all occur, but require glycoprotein turnover and de novo synthesis and take
place over relatively long time scales of 12-24 h. Qualitative changes in CAM function
can be achieved over a much shorter time scale. LFA-i can be converted from a low to
a high avidity state by conformational change, controlled by TCR binding via the
intracellular cytoskeleton (Dustin & Springer, 1989). Avidity peaks at 5—10 min after
TCR binding or cross-linking, and returns to rest over a period of 30 min. In cybernetic
terms, LFA-i acts as a servomotor, under TCR control (Dustin, 1990).
(4) Neoplasia : tumour metastasis and invasion
In 1889, Stephen Paget published a paper (Paget, 1889) in which he theorized that
particular tumours were predisposed to spread to particular sites in the body on the
basis of the tissue's ability to support the growth of that tissue. This was known as the
'seed and soil' hypothesis, and seems to have presaged current insight.
Five steps appear critical for successful metastatic spread of a tumour (Zetter, 1990):
neoplastic proliferation at the primary site, recruitment of blood vessels (angio-
neogenesis) and intravasation of neoplastic cells, adherence to the endothelium or
subendothelial basement membrane at the secondary site, invasion of parenchymal
tissue at the secondary site, and proliferation at the secondary site, which is dependent
on a favourable microenvironment including growth and mitogenic factors.
The passive trapping of neoplastic cells in pre-capillary vessels is insufficient in itself
to permit metastatic spread to a secondary site, site-specific adherence of neoplastic
cells to the luminal aspect of the endothelium, or to subendothelial basement membrane
is essential (Antonia et al., 1989; Pauli et al., 1990). Experimental studies demonstrate
that tumour cells with specific metastatic site preferences, selectively adhere in tissue
culture to endothelial cells derived from those preferred sites. Such specificity depends
on CAM expression by endothelial cells - presumably mainly carbohydrate addressins,
and also adhesive elements of the subendothelial basement membrane (ECM).
Evidence suggests that the expression of CAMs by endothelial cells is modulated not
only by cytokines, but also by tissue specific components of the ECM (Liotta, 1986;
Sher et al., 1988).
Several studies have attempted to correlate alterations in CAM expression with
invasive phenotype (Hart, 1990; Mareel, Van Roy & De Baetselier, 1990). Epithelial
tumours have proved particularly useful in this regard, because motility of normal
epithelial cells is restricted by E-cadherin expression. Well differentiated epithelial
tumours, with low invasive potential (I—), show high E-cadherin expression; poorly
differentiated tumour with high invasive potential (I + ), show low expression.
Moreover, invasive phenotype can be converted in vitro from I + to I — by plasmid
transfection of cDNA encoding E-cadherin, and from I — to I + by mAb to E-cadherin,
or by plasmid transfection of E-cadherin-specific antisense RNA (Vleminckx et al.,
1991). Jouanneau (Thiery et al., 1990) has demonstrated I— to 1+ conversion of
neoplastic epithelial cells by growth on collagen matrices in vitro. The cells undergo
downregulation of E-cadherin, with dissolution of desmosomes and intermediary
junctions, and assumption of a more motile, fibroblastic appearance, reminiscent of the
changes occurring during embryonic epithelial—mesenchymal dispersion.
Immunohistochemical study of CAM expression by neoplastic tissues, promises
further insight into tumour classification, management and prognosis (Maio et al.,
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1990; Horst et al., 1990). It appears clear that normal tissue development and repair
processes, and homing mechanisms, provide strong parallels with neoplastic cell
behaviour (Pierce & Speers, 1988).
V. CONCLUDING REMARKS
This review has attempted to illustrate the way in which advances in our
understanding of CAMs are proving a unifying theme in seemingly disparate areas of
physiology and pathology. This is not a trivial unification.
The evolutionary emergence of cell-cell adhesion and signalling by way of cell
surface molecules, has resulted in place-dependent mechanisms for the control of gene
expression. Cell position, as defined by cell adhesion profile, and cell function, as
defined by differential gene expression, are interdependent variables. The development
and maintenance of tissue structure in metazoan organisms is not directly encoded at
the genomic level, but is an emergent property of multicellular interaction. Emergent
processes occur when simple agents are connected to each other in complex ways, and
are a common feature of many systems — both biological and non-biological (Stein,
1990). All cells are capable of primary driving forces: growth, proliferation, and
motility. Metazoan cells are tightly regulated by an interplay between cell dif¬
ferentiation, and cell adhesion/detachment. The rules which govern these processes at
the local cellular level, permit the establishment of topology at the level of the cell
collective or tissue. The close structural relationship between antigen specific
recognition molecules and cell adhesion molecules of the immunoglobulin gene
superfamily, is worthy of particular note. The suggestion of a common ancestral origin
(Ohno, 1987), implies a close relationship between the immune system and other
systems devoted to the maintenance of morphological integrity: haemostasis,
inflammation and tissue repair and remodelling. The classic view of the immune system
as a defence against foreign invasion may itself be a limited scenario for a system which
has evolved in response to a broader imperative — the discrimination of self from
aberrant self — cellular morphoregulation.
VI. SUMMARY
Cell adhesion molecules are pivotal to the development and maintenance of tissue
structure in metazoan organisms. In mammals, several families of proteins are involved
in cell—cell and cell-matrix adhesion. The cadherins are homophilic, primary CAMs,
involved in the establishment of boundaries between cell collectives early in
embryogenesis. The Ig gene superfamily have diversified widely, with homophilic and
heterophilic CAMs and antigen recognition molecules amongst the members. The
Integrin family play an important role in binding to extracellular matrix, as well as
counter-receptors on the surface of other cells. The Selectin family and HCAM are
carbohydrate-binding proteins, and play a prominent role in the circulation of
lymphocytes and neoplastic cells.
CAMs are fundamental to development of tissue structure in metazoan organisms.
Cellular differentiation dictates adherence to a specific microenvironment, through the
pattern of surface CAM expression. Conversely, CAM binding can affect gene
expression within the cell itself. Cell differentiation and cell adhesion are interdependent
processes. In the adult, CAM are crucial to tissue maintenance. Cells frequently change
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their adhesive properties in response to physiological or pathological processes. The
integrity of the vascular system is maintained by circulating platelets which are capable
of rapid upregulation of cell adhesion and profound changes in metabolism, on contact
with subendothelial matrix. Both endothelial cells and neutrophils undergo changes in
CAM expression in response to inflammatory mediators, permitting rapid and
appropriate recruitment of phagocytes to damaged tissue. Tissue repair is dependent on
phenotypic changes in normally static cells, allowing increased motility and replication.
The immune system requires constitutive cells to undergo multiple complex adhesion
and detachment events over short periods of time, and is capable of discriminating
normal self from aberrant-self or non-self, through antigen specific recognition and
adhesion molecules. The pathophysiology of processes such as infection and neoplasia
are profoundly affected by cellular CAM expression.
CAMs and related molecules are fundamental to the development, maintenance and
surveillance of tissue structure.
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HUMAN HAEMATOPOIETIC PROGENITORS
AS A TARGET FOR GENE THERAPY
IN JANUARY of this year the Committee on the Ethics of
Gene Therapy, chaired by Sir Cecil Clothier, approved the first
proposal for the use of gene therapy in the UK, to treat a child
with adenosine deaminase deficiency (ADA) by transfection
of a normal ADA gene into haematopoietic progenitors.1 This
has been hailed as a ground-breaking therapy, but what are the
advantages and pitfalls of haematopoietic progenitors as a
target for gene transfection, and what diseases may be amen¬
able to this kind of therapeutic intervention?
Haematopoietic progenitor cells.
The haematopoietic and lymphoid systems are continuously
generated by the proliferation andmultilineage differentiation
of haematopoietic progenitor cells (HPC). Stem cells form the
most primitive subpopulation within the progenitor compart¬
ment, capable of extensive self-renewal, pluripotential
differentiation and long-term generation of the lymphoid and
haematopoietic systems.2 HPC comprise 1-2% of bone mar¬
rownucleated cells, and a smallerpercentageofnucleated cells
in adult peripheral blood3 and umbilical co^d blood.4
Autologous or allogeneic bone marrow, adult or cord blood
can be harvested and stored, and can be used later for "bone
marrow" transplantation. Autochthonous lympho-
haematopoiesis is usually ablated by high dose
chemo-radiotherapy, and die harvest is administered by
intravenous infusion. The homing and engraftment of HPC to
the marrow stroma is pivotal to the success of this procedure,
since the moremature precursors and terminally differentiated
cells are short lived. HPC are therefore an attractive target for
gene therapy, because they are relatively straightforward to
harvest, can bemanipulated in vitro for gene inserdon, and can
be returned to the patient by intravenous infusion. Moreover,
successful transfecuon of HPC may lead to the generadon of
a large self-perpetuadng transfected cellmass, theoretically for
the life of the recipient.
Problems with gene transfer into haematopoietic
progenitors.
There are several obstacles to the clinical application of gene
transfer into HPC. The first is the scarcity of the target cells.
Several techniques are now available for in vitro production of
Correspondence and requests for reprints to: M L Turner, Department of
Haematology, Royal Infirmary, Lauriston Place, Edinburgh EH3 9YW
enriched HPC populations,5 including physical methods such
as discontinuous density centrifugation and counterflow elu-
triation, and immunological methods such as panning,
immunoaffinity columns, immunomagnedc beads and fluo¬
rescence activated cell sordng. Parallel enrichment with
physical methods or immunological columns or beads allows
preparation of large numbers of cells on the basis of a single
parameter. The product is of relatively low purity, but can be
used as a platform for multiparameter fluorescence activated
cell sorting.6 A serial protocol of this kind can lead to popula¬
tions containing >95% HPC, with sadsfactory yield and cell
viability.
Pluripotent stem cells are a particularly problematic target in
that they comprise only 1-2% of the HPC compartment, and
are predominantly in quiescent phase.7 Moreover, stem cells
are thought to support lymphohaematopoiesis on the basis of
oligoclonal succession; that is, at any one time only a few stem
cells actively contribute to the generation of progeny,
sequential acdvation and exhaustion occurs, and effete stem
cells are replaced from the quiescent pool.8 It may therefore
be necessary to transfect a high percentage of quiescent stem
cells to achieve long-term morphological stability of the
derivative population. Quiescent haematopoietic stem cells
can be sorted from the progenitor compartment on die basis of
high CD34 expression, low rhodamine retention, and low
expression of lineage-specific antigens.
Several techniques for cell dansfection9'10 have been
developed including physical methods such as calcium
phosphate precipitadon, lipofusion and electroporadon, and
viral transfecdon by retrovirus, SV40, adenovirus, herpes
simplex, and adeno-associated virus. Most current protocols
employ retroviral vectors11 which have proved more efficient
than other viral or physical methods, but which require target
cells to be in cycle to achieve transfection.12 Considerable
progress has been made over the last few years in the in vitro
manipulation of haematopoiedc cells through posidve and
1 ^
negative cytokines. Several groups have now provided
evidence that incubadon of HPC in vitro with a combination
of cytokines preserves HPC viability and function, and
improves retroviral dansfection efficiency by recruiting
quiescent cells into active proliferation. HPC mobilised to the
peripheral blood by the use of in vivo chemotherapy and/or
growth factors have a particularly high cycling fracdon, and
may be the optimal source of HPC for redoviral dansfer.3'14
Concerns remain about the possibility of recombinadon of the
retroviral vector, leading to generation of replication
competent virus in vivo}5 An alternative approach may be to
use a physical method such as lipofusion,16 which is not
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dependent on the cycling status of the target cells, and which
avoids the risks associated with biological vectors.
Stable transfection of reporter genes and of several
therapeutically relevant human genes into murine and human
HPC has now been reported.11'17 Achieving high levels of
sustained expression in vivo has proved problematic, however,
due to downregulation of gene transcription and competition
from autochthonous HPC. Vector constructs containing
promotor/enhancer sequences may circumvent this problem,
and allow better control over lineage restriction of expression.
Candidate diseases for HPC transfection
Parkman has proposed a classification of genetic disorders
which may be correctable by HPC transplantation, based on
the differential expression of the defective gene, and die clini¬
cal manifestations of the disorder (Table I).18 The best
candidates for genetic correction are those diseases in which
expression of the defective gene is limited to the lymphoid or
haematopoietic systems (Classes I-III), or the clinicalmanifes¬
tations are limited to these systems (Class IV) (Table I). HPC
transfection may only partially correct the clinical phenotype
in Class V diseases such as Lesch-Nyhan syndrome, in which
genetic expression and clinical manifestations are generalised.
Other Class V defectsmay be fully correctable if treated early.
For example, animal models of Krabbe's disease and fucosi-
dosis can be cured by allogeneic bone marrow transplant, as
long as the procedure is carried out within the first few weeks
of birth. In man it is now feasible to carry out allogeneic HPC
transpl antation in utero,19 orwithin a few weeks ofbirth, using
HPC derived from umbilical cord blood.4
Finally, lymphohaematopoielic cells may be engineered to
express proteins normally expressed by other tissues (Class
VI). HPC may prove a convenient vehicle for gene therapy of
some of these disorders, where the clinical manifestations can
be corrected by systemic secretion of a normal protein.
Experience in adult allogeneic transplantation has previously
suggested that clearance ofendogenous HPC by chemotherapy
or radiotherapy is a prerequisite for successful engraftment by
exogenous HPC. This view has recently been challenged by
murine and human studies 19,20 which suggest that partial
engraftment can occur in the absence of a preparatory regimen.
In many diseases a mixed chimaeric lymphohaematopoietic
system may be sufficient to ameliorate the clinical problem.
The clinical and technical skills necessary for harvest, in vitro
manipulation, and reinfusion of genetically manipulated
autologous HPC are largely established.
Three therapeutically relevant genes have been transfered
into human HPC: the human genes for ADA, p globin, and
glucocerebrosidase. The first gene therapy protocols were
introduced in September 1990, and involved transfection of
peripheral blood T lymphocytes with an ADA gene, in three
patients with ADA deficiency.21 Satisfactory correction of the
immune defect has been achieved, but it is unclear how long
the effect will last, and infusions of transfected lymphocytes
Table I
Candidate diseases for gene replacement therapy by gene transfer
into haematopoietic progenitors
Class I: expression of genetic defect restricted to lymphoid cells
non-ADA deficient severe combined immune deficiency
X-linked agammaglobulinaemia
Class II: expression restricted to lymphoid and haematopoietic cells.
Wiskott-Aldrich syndrome
Chediak-Higashi syndrome
Class III: expression restricted to haematopoietic cells
a and (5 thalassemia
sickle cell disease and other haemaglobinopathies
chronic granulomatous disease
platelet storage pool disorders
osteopetrosis
Class IV: generalised expression of genetic defect, clinical manifestations
restricted to lymphohaematopoietic cells
adenosine deaminase deficiency
purine nucleoside phosphorylase deficiency
Fanconi's anaemia
Class V: generalised expression with generalised clinical manifestations
Lesch-Nyhan syndrome




eg: Gaucher's disease (glucocerebrosidase deficiency)
Neimann Pick disease (sphingomyelinase deficiency)
Krabbe's disease (galactoccrebrosidase deficiency)
Class VI: defective gene not normally expressed by
lymphohaematopoietic cells,
haemophilia A and B (Factor VIII and factor IX deficiency)
vonWillebrand's disease
CL\ antitrypsin deficiency.
are to be repeated at yearly intervals. The ADA gene was
always expected to be the first candidate for gene therapy
because of the relatively small size of the cDNA, and because
relatively low levels of expression are sufficient to correct the
immune defect. The first clinical studies of ADA transfected
HPC have been initiated in Great Ormond Street, London.
Sickle cell anaemia and P thalassaemia are common diseases
characterised by defective structure or expression of the p
globin gene. Treatment of sickle cell anaemia may require
selective removal of the defective P sickle gene, and
replacement with a normal P globin gene by homologous
recombination.11 This is not a practical proposition at present,
p thalassaemiamay be corrected by gene addition, and several
reports have described successful transfection of HPC with
human p globin gene in mice, though expression has proved
to be poor. Inclusion of promoter/enhancer regions may solve
this problem, but these elements are large, and their inclusion
in retroviral vectors inhibits vims production.
In view of these problems, it is unlikely that the P globin
disorders will be the next diseases to be tackled with gene
therapy, despite their clinical importance. A more likely
candidate is one of the enzyme deficiencies such as Gaucher's
disease or the haemophilias, in which lineage restricted
expression is not necessarily required, and 10-50% of normal
levels of expression should be sufficient to correct the clinical
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phenotype. The genefor human glucocerebrosidase9 has been
successfully transfected into HPC, but long term expression
has not yet been demonstrated. The factor IX gene has been
successfully transfected into and expressed by skin
fibroblasts,9 suggesting that appropriate post-translational
modification and secretion of a protein can occur in cells other
than those normally responsible for production. HPC may
prove to be a suitable vehicle for control of the systemic
manifestations of these kinds of disease.
Within the next decade, gene therapy is likely to emerge as
an important therapeutic modality to correct or modify
inherited defects in haematopoiesis, immunity and
metabolism.
Haematopoietic progenitors are an obvious target for such
intervention, in view of their self-renewing and proliferative
potential. Bringing this technology from tire laboratory to the
clinic is likely to teach us a great deal about the regulation of
cellular proliferation and differentiation, the control of gene








1 Beecham L. Green light for gene therapy. Medicopolitical Digest. Br Med J
1993; 306: 658.
2 Spangrade GJ. Hematopoietic stem-cell differentiation. Current Opinion in
Immunology 1991; 3: 171-178.
3 Craig JID, TurnerML, Parker AC. Peripheral blood stem cell transplantation.
Blood Reviews 1992; 6: 59-67.
4 Broxmeyer HE, Kurtzberg J, Gluckman F, et at. Umbilical cord blood hema¬
topoietic stem and rcpopulating cells in human clinical transplantation. Blood
Cells 1991; 17:313-329.
5 VisserJWM, Van Bekkum DW. Purification ofpluripotent hemopoietic stem
cells: past and present. Experimental Hematology 1990; 18: 248-256.
6 Weichel W, Irlenbusch S, Kalo K, Radbruch A. Sorting of rare cells. In:
Radbruch A. Flow Cytometry and Cell Sorting. Berlin: Springer-Verlag
1992: 159-167.
7 Suda T, Suda J, Ogawa M. Proliferation kinetics and differentiation ofmurine
blast cell colonies in culture: evidence for variable GO periods and constant
doubling rates of early pluripotent hematopoietic progenitors. Journal of Cell
Physiology 1983; 117:308-318.
8 Abkowitz JL, LinebargerML, Newton MA, Shelton GH, Ott RL, Guttorp P.
Evidence for the maintenance of hematopoiesis in a large animal by the
sequential activation of stem cell clones. Proceedings of the National
Academy of Sciences USA 1990; 87: 9062-9066.
9 Miller AD. Progress toward human gene therapy. Blood 1990; 76: 271-278.
10 Larrick JW, Burck KL. Gene therapy: application ofmolecular biology. New
York: Elsevier. 1991.
11 Karlsson S. Treatment of genetic defects in hematopoietic cell function by
gene transfer. Blood 1991; 78: 2481-2492.
12 Miller DG, Adam MA,Miller AD. Gene transfer by retrovirus vectors occurs
only in cells that are actively replicating at the time of infection. Molecular
Cell Biology 1990; 10: 4239-4242.
13 Moore MAS. Clinical implications of positive and negative hematopoietic
stem cell regulators. Blood 1991; 78: 1-19.
14 Bregni M, Magni M, Siena S, Di Nicola M, Bonadonna G, Gianni AM.
Human peripheral blood hematopoietic progenitors are optimal targets of
retroviral-mediated gene transfer. Blood 1992; 80: 1418-1422.
15 Tolstoshev P. Retroviral-mediated gene therapy— safety considerations and
preclinical studies. Bone Marrow Transplantation 1992; 9: 148-150 (Supp. 1)
16 Wu GY, Wu CII. Delivery systems for gene therapy. Biotherapy 1991; 3:
87-95.
17 Dick JE, Kamel-Reid S, Murdoch B, Doedens M. Gene transfer into normal
human hematopoietic cells using in vitro and in vivo assays. Blood 1991; 78:
624-634.
18 Parkman R. The application of bonemarrow transplantation to the treatment
of genetic diseases. Science 1986: 232: 1373-1378.
19 Raudrant D, Touraine JL, Rebaud A. In utero transplantation of stem cells in
humans: technical aspects and clinical experience during pregnancy. Bone
Marrow Transplantation 1992; 9: 98-100 (Supp 1)
20 Wu DD, Keating A. Hematopoietic stem cells engraft in untreated transplant
recipients. Experimental Hematology 1993; 21:251-256.
21 Anderson WF. Cautious optimism. (Editorial) Human Gene Therapy 1991;
2: 1.
Reprintedfrom the Scottish Medical Journal Volume 38 No 5 October 1993
133
Stem Cells
Volume 12, Number 2, 1994
Regulation of Hematopoietic Progenitor Cell Migration,
Mobilization and Homing
Marc L. Turner
Department of Haematology, Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom
STEM CELLS 1994;12:227-229
Copyright ©1994 AlphaMed Press. All rights of reproduction in any form
Ej AlphaMed Press
4100 South Kettering Boulevard
Dayton, OH 45439-2092 (USA)
S+513 293-8508
Fax: +513 293-7652
Regulation of Hematopoietic Progenitor Cell Migration,
Mobilization and Homing
Marc L. Turner
Department of Haematology, Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom
Key Words. Hematopoietic progenitor cells • Cell adhesion
Hematopoietic progenitor cells (HPC) are
predominantly sessile within the bone marrow
extravascular compartment. During human
embryonic and fetal ontogeny, HPC migrate
from yolk sac blood islands to the fetal liver
and spleen between 15 days and 6 weeks, and to
the bone marrow from 20 weeks onwards [1],
Occasionally, HPC migration can occur between
dizygotic twins in utero through placental vas¬
cular anastamoses, leading to chimeric hemato-
poiesis [2]. The mechanisms underlying this
sequential migration are not understood [3]. At
birth significant numbers of HPC are present
in umbilical cord blood and these can be har¬
vested and used for allogenic transplantation [4].
In healthy adults, HPC migrate from the bone
marrow to other tissues including the spleen, thy¬
mus and areas of mast cell development in the
stomach, cecum, mesentery and skin [5]. Areas of
the bone marrow which have been naturally or
artificially damaged can be recolonized by migra¬
tion from healthy marrow [6]. Low levels of HPC
circulate in the peripheral blood of adults, but a
substantial rise can occur under a variety of phys¬
iological, pathological, and iatrogenic conditions.
These cells can be harvested by leukapheresis
and are finding widespread use in clinical trans¬
plantation [7]. Following high dose chemother¬
apy with or without radiotherapy, ablated marrow
can be recolonized by intravenous infusion of
HPC from autologous or allogenic bone marrow,
cord blood or peripheral blood. Homing and
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engraftment of HPC to the bone marrow are
thought to be mediated through HPC expression
of cytoadhesion molecules with high specificity
recognition of, and adhesion to, iigands or
counter-receptors expressed by the luminal
aspect of the sinusoidal endothelium and stro¬
mal cells and extracellular matrix [8]. HPC
migration, mobilization and homing are related
phenomena, and although considerable progress
has been made in our understanding of cytoad¬
hesion mechanisms at the molecular level, a uni¬
fied theory of the regulation of these processes
has yet to be established. Two approaches may
be used to construct such a theory.
A Deterministic Model of HPC Migration
and Mobilization
A deterministic model proposes that prog¬
enitor migration and mobilization are instructed
at the cellular level by an intrinsic program or an
extrinsic cybernetic system. Migration is under¬
stood as a teleoiogical phenomenon [9], HPC
egress the marrow in response to a specific stim¬
ulus, possibly a homeostatic feedback signal,
and are directed to a specific target tissue.
During fetal ontogeny HPC undergo
sequential migration. A deterministic model of
migration postulates developmental stage-spe¬
cific modulation of cytoadhesion molecule
expression to permit sequential detachment, cir¬
culation and homing to a new hematopoietic
environment. Modulation of cytoadhesion mol¬
ecule expression must coincide with maturation
of the appropriate environment, implying pre¬
cise developmental timing or signaling from the




In the normal adult, HPC undergo migra¬
tion from the bone marrow to various tissues,
including the thymus and spleen. Partial body
irradiation experiments in mice have shown that
damaged marrow can be repopulated by HPC
migrating from a protected area [6], and that this
is accompanied by a decline in HPC in the
shielded marrow [10]. It is unclear as to whether
this is a reflection of migration of HPC in
response to humoral feedback communication
between depleted and normal marrow, or an
increased rate of HPC differentiation in response
to depletion of committed precursors [10, 11].
If HPC do undergo tissue-specific migration in
response to humoral feedback, then similar cyber¬
netic mechanisms may be necessary to regulate
migration to other lymphohematopoietic tissues.
The interpretation of HPC mobilization
proves difficult within this theoretical frame¬
work. A wide variety of agents can cause eleva¬
tion of peripheral blood HPC levels [7], including
exercise, adrenocorticotropic hormore (ACTH),
hydrocortisone, endotoxin, dextran sulphate,
chemotherapy and recombinant growth factors.
Two possible explanations may be offered:
first, that HPC downregulate cytoadhesion mol¬
ecule expression in response to a wide variety of
stimuli, through mechanisms which have yet to
be elucidated. If so, it becomes difficult to explain
the rapid engraftment of peripheral blood and
umbilical cord blood derived progenitors fol¬
lowing transplantation. Second, damage to the
blood/marrow interface or elements of the marrow
stroma may allow uncontrolled egress of normal
HPC. Tavassoli has provided evidence of break¬
down in the functional integrity of the marrow
endothelium in response to irradiation, and has
suggested that this preempts endothelial recog¬
nition and permits unregulated transmigration
post-transplant [12], However, one has to argue
for a preferential sensitivity ofmarrow endothe¬
lium to chemo/radiotherapy, or a generalized
breakdown in endothelial function which may
lead to indiscriminate homing. It seems unlikely
that endothelial or stromal damage can be held
responsible for the rapid HPC mobilization
observed following exercise or administration of
dextran sulphate, or for the delayed mobilization
seen during recovery from high-dose chemother¬
apy. Different mechanisms of homing and mobi¬
lization may, of course, predominate under
different circumstances.
A Stochastic Model of HPC Migration and
Mobilization
A stochastic model proposes that HPC
migration and mobilization are emergent fea¬
tures of HPC population dynamics and are a con¬
sequence of physical rather than teleological
causation [8]. The pattern of tissue migration and
homing is understood to be the result of selec¬
tion of circulating HPC through competitive bind¬
ing to available niches. This model proposes that
constitutive overproduction of HPC leads to the
presence of homeless cells, which "wander"
within the bone marrow and egress into the
peripheral blood. If adherence of HPC to stroma
is a reversible process, the relative avidity of
which is determined by the pattern of cellular
cytoadhesion molecule expression, then there
may be ongoing competition for available niches
and a dynamic equilibrium between incumbent
and circulating HPC. Recent work has demon¬
strated that infused HPC can engraft bone mar¬
row in the absence of a conditioning regimen in
immune deficient mice [13], and also in the
immunologically immature human fetus [14],
Crittenden et al. [15] have demonstrated that
repeated marrow transfusion in non-myeloab-
lated mice gives rise to sequential incremental
increases in the percentage of allogenic engrafted
HPC and have suggested that approximately 10%
of incumbent (host) HPC may be replaced fol¬
lowing each infusion. Modest overproduction
provides an explanation for the presence of HPC
in the peripheral blood of healthy individuals,
and colonization of new microenvironmental
niches in developing fetal hematopoietic tissues,
and local and remote niches in adult spleen, thy¬
mus or gastrointestinal hematopoietic tissues, or
in damaged bone marrow. Moreover, the pool of
circulating HPC may act as a buffer, ensuring
engraftment of all potential microenvironmen¬
tal niches and maintaining consistent support of
the hematopoietic and lymphoid systems. HPC
unable to find a suitable microenvironmental
home probably undergo apoptosis due to a lack of
growth factor support [16], leading to a selec¬
tive but redundant method ofmaintaining a stable
HPC population.
Elevation of peripheral blood HPC may
arise within this framework through several
mechanisms. The size of the circulating HPC
population can be postulated to be dependent on
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the proliferative rate of HPC, the extent of
dynamic interchange between incumbent and cir¬
culating cells, and the survival capacity of HPC in
the absence of stromal support. Different
hematopoietic tissues may provide a different
proliferative stimulus, or different adhesion kinet¬
ics. For example, individuals in whom the spleen
is a major organ of hematopoiesis (e.g., neonates),
have elevated levels of circulating HPC which
may be due to a more rapid dynamic interchange
between sessile and circulating cells, allowing
support of a larger circulating population.
In adults, "mobilization" may occur in
response to demargination (e.g., exercise,
ACTH, hydrocortisone or endotoxin), block¬
age of HPC-endothelial adhesion (e.g., dex-
tran sulphate), rebound overproduction of HPC
in response to temporary marrow aplasia (e.g.,
high dose chemotherapy), or protection against
apoptosis (e.g., growth factors [14]). Different
mechanisms acting contemporaneously (e.g.,
chemotherapy and growth factors) may act syn-
ergistically, giving rise to a particularly high
and sustained level of circulating HPC.
Neither of these theoretical approaches cur¬
rently provides a comprehensive explanation of
hematopoietic progenitor migration and mobi¬
lization, nor are they necessarily mutually incom¬
patible. Areas of confrontation should prove
informative fields for experimental scrutiny.
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Abstract. The mechanisms responsible for mobi¬
lization of hematopoietic progenitor cells (HPC)
from the bone marrow into the circulation are
unknown. One possibility is that HPC downregu-
late cell adhesion molecule expression. We studied
normal human bone marrow and adult peripheral
blood following 4g/m2 cyclophosphamide and
recombinant human granulocyte colony-stimulat¬
ing factor (rHuG-CSF). Each sample was studied
for the coexpression of CD34 and a panel of cell
adhesion molecules by dual immunocytometry.
Bone marrow HPC express the immunoglobulin
gene superfamily members ICAM-1 (CD54),
PECAM-1 (CD31) and LFA-3 (CD58), the inte-
grins VLA-4 (CD49d/CD29), VLA-5 (CD49e/CD29)
and LFA-1 (CDlla/CD18), L-Selectin (CD62L),
HCAM (CD44) and CD36. Mobilized peripheral
blood HPC display less expression of LFA-3 (CD54)
and VLA-5 (CD49e). Significant differences in cell
adhesion molecule expression do exist between ses¬
sile and circulating HPC, but the biological rele¬
vance of these observations is currently unclear.
Introduction
Hematopoietic progenitor cells (HPC) are
predominantly sessile within the bone marrow
but also circulate at low levels in the peripheral
blood, migrate between hematopoietic tissues
during fetal development and adult life [1],
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and home to the marrow following intravenous
infusion [2]. Elevation of peripheral blood
HPC occurs under a variety of physiological,
pathological and iatrogenic conditions. HPC
harvested by leukapheresis from the periph¬
eral blood of patients with neoplastic disease
during the recovery phase following chemo¬
therapy and/or recombinant growth factors can
be used for transplantation [3]. The mecha¬
nisms by which HPC are released into the
peripheral blood, circulate and home to spe¬
cific tissues are poorly understood [1, 4]. One
of several possibilities [5] is that alteration in
HPC cell adhesion molecule expression or
function is responsible for HPC egress from
the marrow.
We have used dual immunocytometry to
study the comparative expression of cell adhe¬
sion molecules by the CD34+ HPC population
from normal human bone marrow and from adult
peripheral blood following high dose cyclophos¬
phamide and recombinant human granulocyte
colony-stimulating factor (rHuG-CSF). We
focused on those cell adhesion molecules which
other groups have described as expressed by bone
marrow HPC: the immunoglobulin gene super-
family members ICAM-1 [6, 7] (CD54),
PECAM-1 [8, 13] (CD31) and LFA-3 [7] (CD58),
the integrins VLA-4 (CD49d/CD29), VLA-5
(CD49e/CD29), LFA-1 (CD1 la/CD 18) and VNR
[7, 9-12] (CD51/CD61), L-Selectin [13] (CD62L),
HCAM [7, 11, 14] (CD44) and CD36 [15, 16]
(Table I). There is little evidence that other adhe¬
sion molecules of the immunoglobulin, integrin or
selectin families are expressed by bone marrow
HPC [7,9, 10],
STEM CELLS 1995;13:311-316
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Materials and Methods
Source and Preparation of Cells
Bone marrow aspirates (n = 8) were obtained
from normal volunteers undergoing a general
anesthetic for routine surgical procedures.
Peripheral blood samples were obtained from
patients with Hodgkin's disease (n = 2), non-
Hodgkin's lymphoma (n = 3) or breast carcinoma
(n = 3), undergoing treatment with cyclophos¬
phamide 4 g/m2 and rHuG-CSF 5pg/kg intra¬
venously as previously described [17]. Peripheral
blood samples were taken twice during the recov¬
ery phase following hypoplasia, as the peripheral
blood leukocyte count rose above 1 x 109/1, and
48 h later. These time points correspond to the
rise and subsequent fall in the levels of circu¬
lating progenitors in the peripheral blood [17].
These procedures were carried out with informed
consent and approved by the Lothian Health
Board Ethics of Medical Research Subcommittee
for Medicine and Clinical Oncology.
Samples were prepared by discontinuous den¬
sity centrifugation over Ficoll Hypaque at
1.077g/ml (Lymphoprep, Nycomed Pharma AS,
Oslo, Norway). Low buoyant-density cells from
the interface were collected, and the viability was
assessed by trypan blue dye exclusion (Sigma
Chemical Co., Poole, UK). Cells were washed
three times in a handling medium consisting of
phosphate buffered saline containing 1 % bovine
serum albumin (Sigma) and 0.1% sodium azide
(Sigma). In order to block Fc receptor uptake of
the monoclonal antibody, 5 x 105 cells/test were
incubated with rabbit serum for 15 min, washed,
then incubated for 30 min with 10 pi of a pretitered
purified monoclonal antibody addressed to a cell
adhesion molecule (Table I). After incubation, the
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cells were washed three times and incubated for
30 min with a sheep antimouse IgG:R-phyco-
erythrin conjugate (Sigma) diluted to 1/40. The
cells were washed three times and incubated for
15 min with mouse serum in order to block
uptake of the anti-CD34 monoclonal antibody
by the bound sheep anti-mouse reagent. The cells
were washed again and incubated for 30 min with
10 pi of anti-CD34 monoclonal antibody directly
conjugated to fluorescein isothiocyanate (FITC)
(8G12; Becton Dickinson Immunocytometry
Systems, San Jose, CA). Finally the cells were
washed and resuspended in 2% paraformaldehyde
(Merck BDH. Poole, UK). Positive controls were
established using purified and FITC-conjugated
monoclonal antibodies addressed to CD45 (J33;
IT). Negative controls were established using
irrelevant isotype-specific purified and conju¬
gated monoclonal antibodies as appropriate. All
incubation, washing, centrifugation and storage
were carried out at +4°C.
Flow Cytometry
Flow cytometric analysis was performed
on a fluorescence-activated cell sorter
(FACScan. Becton Dickinson) equipped with
an argon laser tuned at 488 nm, power 14.8 mW.
Compensation was set in the two fluorescence
channels using the positive controls. Data acqui¬
sition was carried out with Consort 30 Data
Management System. An initial acquisition on
an ungated sample was used to define the dis¬
tribution of the CD34+ population on the for¬
ward and side scatter dot-plot and to establish a
lymphoblastoid acquisition gate. This was found
to reduce background fluorescence and enrich
for HPC permitting better definition and less
contamination of the CD34+ population.
Forward and side scatter and two fluorescence
signals were determined for 10,000 events and
stored in listmode data files. Analysis of the
data was performed with Consort 30 software.
Data Analysis
Results are reported as mean ± standard
error of the mean of 8 replicate experiments.
Statistical analyses were performed using a
two-tailed Student's r-test for paired or
unpaired samples as appropriate, p values
were not formally corrected for the effects of
multiple comparisons, but we have only rec¬
ognized statistical significance at a p value
of <0.01.
Results
Definition of the CD34+ Population
A marker established at 0.5% on the FL-1
histogram of the negative control was used to
define the CD34+ population. These comprised
5.1 ± 4.8% of cells within the lymphoblastoid
acquisition gate from bone marrow (n = 8). Adult
peripheral blood taken at day 10 ± 1 post-
cyclophosphamide showed a white count of 1.9
± 0.6 x 1CP/1, and contained 6.8 ± 4.3% CD34+
cells (n = 7). Paired samples taken at day 12 ± 1
showed a white count of 16.7 ±3.1 x 109/1, and
contained 5.3 ± 5.3% CD34+ cells (n = 8).
Determination of Cell Adhesion Molecule
Expression
A marker established at the point of mini¬
mal inflection on the FL-2 histogram of the
appropriate negative control was used to define
adhesion molecule positivity. The mean fluores¬
cence intensity of the CD34+ population was cal¬
culated from the quadrant statistics. CD34+ HPC
expressed 9 out of the 10 cell adhesion mole¬
cules studied (Figs. 1-3). Virtually all bone mar¬
row HPC expressed HCAM (CD44). ICAM-1
(CD54), PECAM-1 (CD31) and LFA-1 (CD1 la)
were also expressed by a high proportion of HPC,
while intermediate to low percentages expressed
LFA-3 (CD58), VLA-4 (CD49d), VLA-5
(CD49e), L-Selectin (CD62L) and CD36 (Fig. 1).
When the mean fluorescence intensity of the
CD34+ population was analyzed, HCAM (CD44)
displayed very high intensity fluorescence, while
those of the other adhesion molecules were sub¬
stantially lower (Fig. 2).
Peripheral blood HPC expressed less LFA-3
(p < 0.01) and VLA- 5 (p < 0.01) than bone mar¬
row HPC when compared by percentage expres¬
sion, but not when compared by mean
fluorescence intensity. There was no significant
difference in cell adhesion molecule expression
by paired peripheral blood HPC samples col¬
lected at two time points.
Discussion
We have confirmed the observations of a
number of other groups that bone marrow HPC
express at least nine cell adhesion molecules
belonging to several molecular families (Table I,
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M Bone Marrow
■ Peripheral Blood day >10
B3 Peripheral Blood day +12
H Bone Marrow
■ Peripheral Blood day +10
E3 Peripheral Blood day +12
Fig. 1. Percentage cell adhesion molecule positivity
within the CD34+ population. Data are presented as
the mean ± standard error of eight replicate experi¬
ments, and CD45 and IgGl are reported for compar¬
ison as positive and negative controls.
Figs. 1-3). In addition to these, CD34 may itself
act as a ligand for L-Selectin [18] (CD62L),
while CD45 and Thy-1 (CDw90) are known to
mediate adhesion to heparan sulphate [19], and
cell membrane-associated proteoglycans may
mediate adhesion to fibronectin [20]. The way in
which these various molecular pathways con¬
tribute to HPC homing and engraftment is com¬
plex and currently poorly understood.
The mechanisms responsible for HPC
release from the marrow during migration and
mobilization are similarly uncertain. We have
investigated one hypothesis—that HPC egress
may result from downregulation of cell adhe¬
sion molecule expression. Other possibilities
include downregulation of HPC adhesion mol¬
ecule function without alteration in expression,
upregulation of adhesion molecules not nor¬
mally expressed, or alteration in marrow
endothelial function.
Mobilized peripheral blood HPC demon¬
strate less expression of LFA-3 (CD58) and
VLA-5 (CD49e) than bone marrow HPC. The
discordance between results calculated by per¬
centage positivity and by mean fluorescence
intensity may reflect the greater sensitivity of the
former to loss of expression by a subpopulation of
CD34+ cells, as averse to a global reduction in
expression by the CD34+ population as a whole.
LFA-3 is a counter-receptor for LFA-2, and may
mediate regulatory interactions between T lym¬
phocytes and HPC [21]. VLA-5 recognizes the
cell binding domain of fibronectin, and modifi¬
cation of expression may contribute to the
Fig. 2. Mean fluorescence intensity of the CD34+
population. Data are presented as the mean ± stan¬
dard error of eight replicate experiments. CD45 and
IgGl are reported for comparison as positive and
negative controls.
observed lineage and stage-specific binding of
HPC to fibronectin [22, 23], and to the release of
cells from the marrow.
The overall physiological relevance of this
data remains unclear for two principal reasons:
1) differential adhesion molecule expression
between HPC subsets [24] and source-dependent
differences in the heterogeneity of the CD34+
population [25, 26] may contribute to the
observed differences in adhesion molecule expres¬
sion by the CD34+ population as a whole and 2)
the functional role of various cell adhesion
molecule—ligand pathways in HPC—stromal
interaction remains to be fully established,
and it is unclear whether observed phenotypic
differences are reflected by functional differ¬
ences in the adhesion behavior of sessile and
circulating HPC.
Finally, we considered the possibility that
differences in cell adhesion molecule expres¬
sion may be detectable between circulating
HPC during the early phase of mobilization,
when marrow egression predominates, and the
later phase, when HPC may be returning to the
marrow. We demonstrated no such differences
and offer two possible explanations. Return of
HPC cell adhesion molecule expression to
"normal" may lead to rapid clearance of these
cells from the circulating population, or lev¬
els of circulating HPC may fall through apop-
tosis of nonengrafted cells rather than through
return to the marrow. The fate of mobilized
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K: CD45 (pos control)
C: LFA-3 (CD58)
F: LFA-1 (CD 1 la)
I: HCAM (CD44)
L: IgG (neg control)
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